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Abstract 
This study focused on biochemical and structural characterisation of two lipid binding 
proteins: human phosphatidylinositol transfer protein (PITP) Nir2 and American 
hookworm fatty acid and retinol binding protein (FAR) Na-FAR-1.  
Nir2 is a large multi-domain PITP that has recently been implicated in phosphoinositide 
signalling, where it was demonstrated to regulate phosphatidylinositol-4,5-bisphosphate 
[PI(4,5)P2] homeostasis. Nir2 acts by reciprocally transporting phosphatidylinositol (PI) 
and phosphatidic acid (PA) between the plasma membrane (PM) and the endoplasmic 
reticulum (ER), which allows PI(4,5)P2 to be re-synthesised at the PM. Upon cell 
stimulation, Nir2 translocates to the ER-PM contact sites and is believed to associate with 
the PM by binding to PA via its C-terminal LNS2 domain. Due to the proposed role of 
LNS2-PA binding in Nir2 targeting, a detailed investigation of the binding mechanism is 
desirable, which could help to reveal more details about Nir2 function in the cell. 
Expression screening of the difficult-to-express Nir2 LNS2 domain yielded a highly-
expressed construct that was employed for characterisation of LNS2-PA binding. The data 
suggested that Nir2 LNS2 binds PA in a specific manner, interacts with both the polar and 
apolar regions of PA and might associate with the membrane via both hydrophobic and 
polar interactions. Although the structure of the LNS2 domain could not be determined, 
several assays are proposed for the identification of LNS2-PA interaction inhibitors that 
could be used as tool compounds in the investigation of Nir2 and its homologs. 
Na-FAR-1 is a small lipid binding protein secreted by the human hookworm Necator 
americanus that infects hundreds of millions of people globally. Na-FAR-1 is known to 
bind a range of lipid ligands including fatty acids, retinoids and phospholipids, and was 
proposed to play a role in parasite-host interactions by facilitating nutrient uptake or 
sequestering lipid signalling molecules in the host tissues. The structure of Na-FAR-1 has 
been determined previously, but the molecular details of ligand binding by Na-FAR-1 
remained unclear. In this study, the high-resolution structure of Na-FAR-1 in complex with 
its natural ligand oleic acid was determined, and the ligand binding sites were mapped. 
Furthermore, phospholipid binding by Na-FAR-1 was investigated, and resonance 
assignment of Na-FAR-1 in complex with PA was carried out, which can be used to obtain 
the structure of the complex. In addition, Na-FAR-1’s interaction with lysophosphatidic 
acid was demonstrated in vitro. As lysophosphatidic acid is a mediator of inflammation, 
the interaction might have important biological implications if it also occurs in vivo. 
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  CTP  Cytidine triphosphate 
  DAG  Diacylglycerol 
  DAGK  Diacylglycerol kinase 
  DAUDA  11-(Dansylamino)undecanoic acid 
  DD-coupling Dipole-dipole coupling 
  DHPA   Dihexanoyl phosphatidic acid 
  DHPC  Dihexanoyl phosphatidylcholine 
  DIPSI  Decoupling in the presence of scalar interactions 
  DMSO  Dimethyl sulphoxide 
  DNA  Deoxyribonucleic acid 
  DOPA   Dioleoyl phosphatidic acid 
  DOPC  Dioleoyl phosphatidylcholine 
  DPH  1,6-Diphenyl-1,3,5-hexatriene 
  DTT  Dithiothreitol 
  EEA1  Early endosome antigen 1 
  ER   Endoplasmic reticulum 
  FABP  Fatty acid binding protein 
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  FAR  Fatty acid and retinol binding protein  
  FID  Free induction decay 
  FPR2/ALX Formyl peptide receptor 2/lipoxin A4 receptor 
  FRET  Fluorescence resonance energy transfer 
  FYVE  Fab1/YOTB/Vac1/EEA1 
  G3P  sn-Glycerol 3-phosphate 
  GRAM  Glucosyltransferases, Rab-like GTPase activators and myotubularins 
  GST  Glutathione S-transferase 
  H6/His6  Hexahistidine tag 
  HMQC  Heteronuclear multiple quantum coherence 
  HPLC  High pressure liquid chromatography 
  HRV  Human rhinovirus 
  HSA  Human serum albumin 
  HSQC  Heteronuclear single quantum coherence 
  I(1,3)P2  Inositol 1,3-bisphosphate 
  INEPT  Insensitive nuclei enhanced by polarization transfer 
  IP3/I(1,4,5)P3 Inositol 1,4,5-trisphosphate 
  IPTG  Isopropyl β-D-1-thiogalactopyranoside 
  IRF  Instrument response function 
  ITC  Isothermal titration calorimetry 
  IUBMB  International Union of Biochemistry and Molecular Biology  
  IUPAC  International Union of Pure and Applied Chemistry 
  LB   Lysogeny broth 
  LNS2  Lipin/Ned1/Smp2 
  LPA  Lysophosphatidic acid 
  LPC  Lysophosphatidylcholine 
  LPL  Lysophospholipid 
  LSA  Liposome co-sedimentation assay 
  LUV  Large unilamellar vesicles 
  MAD  Multiple wavelength anomalous dispersion 
  MALS  Multi-angle X-ray scattering 
  MBP  Maltose-binding protein 
  MIR  Multiple isomorphous replacement 
  MLV  Multilamellar vesicle 
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  MOPS  3-(N-morpholino)propanesulfonic acid 
  MR  Molecular replacement 
  MW  Molecular weight 
  NaPi  Sodium phosphate 
  NBD  Nitrobenzoxadiazole   
  NBT  Nitro-blue tetrazolium chloride 
  NMR   Nuclear magnetic resonance 
  NOE  Nuclear Overhauser effect 
  NOESY  Nuclear Overhauser effect spectroscopy 
  NPA  Nematode polyprotein allergen 
  NTA  Nitrilotriacetic acid 
  NUS  Non-uniform sampling 
  NusA  N-utilisation substance A 
  OD  Optical density 
  OLA  Oleic acid 
  OLPA  Oleoyl lysophosphatidic acid 
  OPPF  Oxford Protein Production Facility 
  PA   Phosphatidic acid  
  PAGE  Polyacrylamide gel electrophoresis 
  PC   Phosphatidylcholine 
  PCR  Polymerase chain reaction 
  PDB  Protein Data Bank 
  PDI  Polydispersity index 
  PE   Phosphatidylethanolamine 
  PG   Phosphatidylglycerol 
  PH   Pleckstrin homology 
  PI   Phosphatidylinositol 
  PI(3,4,5)P3  Phosphatidylinositol 3,4,5-triphosphate 
  PI(3,4)P2   Phosphatidylinositol 3,4-bisphosphate 
  PI(3,5)P2   Phosphatidylinositol 3,5-bisphosphate 
  PI(3)P  Phosphatidylinositol 3-phosphate 
  PI(4,5)P2   Phosphatidylinositol 4,5-bisphosphate 
  PI(4)P   Phosphatidylinositol 4-phosphate 
  PI(5)P  Phosphatidylinositol 5-phosphate 
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  PIS  Phosphatidylinositol synthase 
  PKC  Protein kinase C 
  PKD  Protein kinase D 
  PLC  Phospholipase C 
  PLD  Phospholipase D 
  PM  Plasma membrane 
  PPAR  Peroxisome proliferator-activated receptor 
  PPI  Polyphosphoinositide 
  ppm  Parts per million  
  PRE  Paramagnetic relaxation enhancement 
  PS   Phosphatidylserine 
  PX   Phox homology 
  RDC  Residual dipolar coupling 
  RMSD  Root mean squared deviation 
  RNA  Ribonucleic acid 
  rpm  Rounds per minute 
  S1P  Sphingosine-1-phosphate 
  SAD  Single wavelength anomalous dispersion 
  SDS  Sodium dodecyl sulphate 
  SEC  Size-exclusion chromatography 
  SPR  Surface plasmon resonance 
  STD  Saturation transfer difference 
  SUMO  Small ubiquitin-like modifier 
  SUV  Small unilamellar vesicle 
  TB   Terrific broth 
  TCEP  Tris(2-carboxyethyl)phosphine 
  TCSPC  Time-correlated single photon counting 
  TF   Trigger factor 
  TLC  Thin-layer chromatography 
  TOCSY  Total correlation spectroscopy 
  Tris  Tris(hydroxymethyl)aminomethane 
  TROSY  Transverse relaxation optimised spectroscopy 
  Trx  Thioredoxin 
  UDP  Uridine diphosphate 
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  UV  Ultraviolet 
  VAP  Vesicle-associated membrane protein-associated protein 
  waterLOGSY Water-ligand observed by gradient spectroscopy 
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1. Introduction  
1.1 Lipids and their biological functions 
Along with proteins, carbohydrates and nuclei acids, lipids are a major class of biological 
molecules. The distinguishing feature of lipids is their high hydrophobicity compared to 
other biomolecules. Although all lipids contain hydrophobic groups, they also display great 
structural diversity. A systematic classification of lipids has been developed, according to 
which lipids are broadly divided into eight categories: 1) fatty acyls, 2) glycerolipids, 3) 
glycerophospholipids, 4) sterol lipids, 5) sphingolipids, 6) prenol lipids, 7) saccharolipids 
and 8) polyketides  (Fahy et al., 2011, 2005). The categories are primarily characterised by 
the presence of certain functional groups or moieties in the lipid structure and/or the 
common biosynthetic pathway. For instance, glycerophospholipids are characterised by the 
presence of a phosphate or phosphonate group covalently linked to their glycerol backbone 
which distinguishes them from glycerolipids. The structures of the representative examples 
of the eight lipid categories are given in Table 1-1. With the information obtained from the 
recent large-scale lipidomics studies, several online databases containing the structures of 
known biological lipids have been created. To date, the most extensive lipid database is the 
LIPID MAPS Structure Database (http://www.lipidmaps.org/data/structure/) which is a 
product of the Lipid Metabolites and Pathways Strategy (LIPID MAPS), an international 
collaboratory project that aims to characterise all lipid species and lipid metabolic 
pathways in mammalian cells (Fahy et al., 2009; Sud et al., 2007).  
As well having diverse structures, lipids also possess diverse functions in living organisms. 
The three major functions of lipids are their energetic, structural and signalling functions.  
It is widely known that lipids are a major source and reservoir of energy in many 
organisms. In aerobes, breakdown of fatty acids in the β-oxidation process leads to 
generation of acetyl-CoA, which is utilised in the Krebs cycle. Total oxidation of fatty 
acids produces ~ 9 kcal g-1 which is more than twice the amount of energy produced from 
the oxidation of sugars and proteins. Typically, triacylglycerides, which contain three fatty 
acyl residues attached to their glycerol backbone, are the preferred lipids for energy storage 
in eukaryotes.  
The primary structural function of lipids is in the biological membranes that serve as the 
boundaries of the cell and the subcellular compartments such as the endoplasmic reticulum 
(ER), Golgi complex, endosomes and lysosomes. Glycerophospholipids are the major 
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structural units of the membranes that form the membrane bilayer. The ability of 
membrane glycerophospholipids to self-assemble into the bilayer structure is dictated by 
their physicochemical properties. Like the majority of lipids, glycerophospholipids are 
amphipathic molecules that possess both hydrophobic and hydrophilic groups. In an 
aqueous solution, it is energetically favourable for lipids to form aggregates in which their 
apolar regions are excluded from the interaction with the solvent (Tanford, 1980). 
Depending on the geometric shape of the molecule, lipids have propensity to form either 
bilayer or non-bilayer polymorphisms (superstructures), such as micelles and inverted 
cubic phases. Although biological membranes are complex mixtures of lipids that also 
contain non-bilayer lipids such as phosphatidylethanolamine and cardiolipin (Kruijff, 
1997), the majority of glycerophospholipids in the membrane are bilayer-preferring lipids 
that facilitate the formation of the bilayer structure. It is widely accepted that the ability of 
lipids to self-assemble into superstructures has been central to the emergence of life. 
The roles of lipids in cell signalling are diverse. Lipids can act as signalling molecules in 
their own right (Balla, 2013; Di Paolo and De Camilli, 2006; Fernandis and Wenk, 2007; 
Rivera and Chun, 2008), be involved in post-translational modification of proteins that can 
affect their signalling functions (Ahearn et al., 2012; Paulick and Bertozzi, 2008; Resh, 
2013) or participate in formation of plasma membrane subdomains called lipid rafts which 
can serve as cell signalling platforms (Hancock, 2006; Lingwood and Simons, 2009; 
Simons and Sampaio, 2011). Lipid signalling molecules regulate numerous crucial 
biological processes including cell proliferation and migration, membrane trafficking, 
metabolism, and inflammation. In accordance with their roles in normal cellular and 
organismal functions, signalling lipids have also been implicated in pathogenesis of major 
diseases such as cancer, diabetes, neurodegenerative and infectious diseases (Wymann and 
Schneiter, 2008). Membrane-embedded glycerophospholipids are the major players in lipid 
signalling, in which they can participate by directly interacting with signalling proteins or 
by serving as precursors for other signalling lipids such as soluble lysophospholipids and 
eicosanoids.  
A review of all lipid types and their functions is by far beyond the scope of this thesis. 
Only the functions of certain glycerophospholipids and fatty acyls that have relevance to 
the proteins investigated in this study will be discussed in the following sections of this 
chapter.  
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Lipid category Representative example 
Fatty acyls 
 
Octadec-9Z-enoic acid 
Glycerolipids 
 
1,2-Dihexadecanoyl-sn-glycerol 
Glycerophospholipids 
 
1,2-Dihexadecanoyl-sn-glycero-3-phosphate 
Sphingolipids 
 
Tetradecasphing-4E-enine 
Saccharolipids 
 
UDP-3-(3R-hydroxy-tetradecanoyl)-N-acetyl-αD-glucosamine 
Sterol lipids 
 
Cholest-5-en-3β-ol 
Prenol lipids 
 
(Z)-3,7-dimethylocta-2,6-dienal 
Polyketides 
 
Trichostatin A 
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Table 1-1. Lipid categories and their representative examples. 
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1.1.1 Glycerophospholipids 
1.1.1.1 Structure and nomenclature 
Glycerophospholipids consist of a glycerol backbone to which two fatty acyl residues and 
a polar head group are attached via ester linkages. The head group is attached at the sn-3 
position in the glycerol backbone, whereas the fatty acyl tails are attached at the sn-1 and 
sn-2. The three sn positions correspond to the stereospecifically numbered carbon atoms in 
the glycerol molecule, according to the IUPAC-IUBMB nomenclature for lipids 
(International Union of Biochemistry and Molecular Biology, 1992). In the representative 
glycerolipid and glycerophospholipid structures shown in Table 1-1, the molecules are 
oriented such that their sn-1, sn-2 and sn-3 are shown from left to right. 
Numerous glycerophospholipid species are found in nature, which can be distinguished by 
the type of fatty acyl residues and the head group that they contain. In biological and 
biochemical literature, lipids with identical head groups are typically grouped together and 
referred to by a single name, which is usually abbreviated. For example, if the head group 
of a glycerophospholipid (further, simply phospholipid) is a phosphate group, the lipid is 
referred to as phosphatidic acid (abbreviated as PA), if the head group is a phosphocholine 
moiety, the lipid is referred to as phosphatidylcholine (PC), if the head group is a 
phosphoinositol moiety, the lipid is referred to as phosphatidylinositol (PI), and so on. To 
distinguish between phospholipids that have identical head groups but different fatty acyl 
residues, the fatty acyl tail types can also be specified. For instance, 1,2-dioleoyl-PA (or 
simply dioleoyl PA or DOPA) refers to a PA species that has two oleic acid residues at 
sn-1 and sn-2 positions. Instead of the common fatty acid names, C:D nomenclature can be 
used to specify the number of carbon atoms and the number, position and stereochemistry 
of double bonds in the acyl chain of a fatty acid. Using C:D nomenclature, oleic acid can 
represented as 18:1 cis-9, as it contains 18 carbon atoms and a single cis-double bond at 
position ω-9 (i.e., ninth carbon-carbon bond counting from the terminal methyl group) in 
the acyl chain. The standard two-letter phospholipid nomenclature will be used henceforth, 
and the fatty acyl residues (also called fatty acyl tails) will only be specified where 
relevant. 
1.1.1.2 Phosphatidylinositol and polyphosphoinositides 
PI is one of the key phospholipids in the plasma membrane that is a parent lipid of 
polyphosphoinositides (PPIs), a class of versatile cellular signalling lipids. PPIs are the 
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phosphorylated species of PI that are produced by phosphorylation of the PI myo-inositol 
ring at positions 3, 4 and 5 by the action of specific PI kinases. Depending on the pattern of 
the myo-inositol ring phosphorylation, seven different PPIs can be distinguished: PI(3)P, 
PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2 and PI(3,4,5)P3. The numbers in the 
parentheses correspond to the identifiers of the carbons in the PI inositol ring to which a 
phosphate group is covalently attached, not counting the phosphate group at carbon 1 via 
which the ring is attached to the glycerol backbone. Importantly, different PPI species can 
be rapidly interconverted into one another by the action of PPI kinases and phosphatases, 
which makes PPI signalling plastic and adaptable. In mammals, at least 19 PPI kinases and 
28 PPI phosphatases have been identified, which catalyse 18 different reactions (Sasaki et 
al., 2009). The levels of PPIs vary in different cell types and membrane compartments, but 
are typically very low (< 1% of total cellular phospholipids). 
PPIs can regulate cell signalling in at least two ways: by acting as substrates for production 
of signalling molecules and by engaging in direct interactions with effector proteins. A 
textbook example of the former function of PPIs in cell signalling is the hydrolysis of 
PI(4,5,)P2 by phospholipase C (PLC) and the resulting generation of diacylglycerol (DAG) 
and inositol-1,4,5-phosphate (IP3), which act as secondary messengers in the cell. The 
generation of IP3 leads to release of Ca2+ from the ER, which in turn activates Ca2+-
calmodulin signalling and other Ca2+ signalling pathways (Clapham, 2007). DAG acts by 
binding to DAG effectors, such as the serine/threonine kinases of the protein kinase C 
(PKC) and protein kinase D (PKD) family, which regulate the activity of a variety of 
downstream signalling effectors. The role of PI(4,5,)P2 and PLC in secondary messenger 
production was first discovered in the eighties (Berridge, 1983; Creba et al., 1983) and is 
well documented in the literature (Balla, 2013; Irvine, 2003; Katan, 2005; Rebecchi and 
Pentyala, 2000).  
As well as being the substrates of PLCs, PPIs also regulate cell signalling processes by 
participating in direct protein-lipid interactions. PPI head groups are recognised by a 
number of phospholipid binding protein domain families that transiently interact with the 
membrane. Such membrane-interacting domains include the pleckstrin homology (PH) 
domain, PKC conserved-region 2 (C2) domain, Fab1/YOTB/Vac1/EEA1 (FYVE) domain, 
Phox homology (PX) domain, glucosyltransferases, Rab-like GTPase activators and 
myotubularins (GRAM) domain and others (Lemmon, 2008, 2003). In addition, 
unstructured domains containing basic and apolar residues are also known to bind certain 
PPIs (McLaughlin and Murray, 2005). Protein-PPI interactions can regulate signalling by 
modulating the activity and localisation of PPI effector proteins. Recognition of a specific 
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PPI by an effector allows its targeting to a specific membrane compartment, as separate 
membrane compartments in the cell have distinct PPI profiles. In this way, signalling 
partners can be brought together at a specific location to facilitate the signalling process or 
specific effectors can be recruited to the membrane to perform membrane-associated 
functions, such as the initiation of exocytosis or cytoskeleton remodelling. The dynamism 
of PPI generation and interconversion and the ability of PPIs to target effectors to specific 
subcellular compartments allows fine-tuning of cell signalling in a spatiotemporal manner. 
Numerous effectors can be recruited to the membrane through interaction with PPIs. 
Several examples of important signalling proteins controlled by PPIs in this way include 
protein kinases Akt (Watton and Downward, 1999), PDK1 (Mora et al., 2004) and BTK 
(Várnai et al., 1999), regulators of G-proteins Cdc24 (Gulli and Peter, 2001) and Sos 
(Rojas et al., 2011), several isoforms of PLC (Williams, 1999), and SARA (Itoh et al., 
2002), a regulator of Smad-mediated signalling. By influencing the localisation of PPI 
effectors, PPIs and PPI-modifying enzymes regulate a number of central pathways that 
control cell proliferation, survival and migration (Ooms et al., 2009; Vanhaesebroeck et 
al., 2005; Wymann and Pirola, 1998). Hence, it is not surprising that PPI signalling has 
been implicated in diseases where these crucial cellular processes are disrupted, the most 
prominent example of which is cancer (Bunney and Katan, 2010; Park et al., 2012). In 
addition to cancer, the role of PPIs in Type 2 diabetes, bacterial infections as well as 
several congenital disorders including Lowe syndrome and Charcot–Marie–Tooth disease 
has also been documented (Majerus and York, 2009; Pendaries et al., 2003). 
In Section 1.2, several of the largest families of PPI binding domains will be discussed in 
more detail. 
1.1.1.3 Phosphatidic acid 
Phosphatidic acid (PA) is an anionic phospholipid whose head group consists of a single 
phosphate group attached to the glycerol backbone via a phosphoester linkage. The basic 
structure of PA dictates its role as a key intermediate in de novo phospholipid biosynthesis. 
In mammals, PA is as a precursor of DAG and CDP-DAG, which are used as substrates for 
the synthesis of all membrane glycerophospholipids in mammalian cells (Vance, 2015). 
DAG is produced through PA dephosphorylation by phosphatidic acid phosphatase-1 
(PAP-1), and CDP-DAG is generated from PA and CTP by CDP-DAG synthase. DAG is 
then used as a precursor for the synthesis of PC and PE, and CDP-DAG for the synthesis of 
PI and cardiolipin. In turn, PC and PE can be converted into phosphatidylserine (PS). PA 
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can be generated de novo from lysophosphatidic acid by the activity of lysophosphatidic 
acid acyltransferase. Alternatively, phospholipase D (PLD)-catalysed hydrolysis of PC and 
phosphorylation of DAG by DAG kinase also result in PA production. Due to the rapid 
turnover of PA, its levels in the membrane are typically low (~ 1-2% of total cellular 
phospholipids). 
As well as functioning in phospholipid biosynthesis, PA also acts as a signalling lipid by 
directly interacting with PA binding proteins and facilitating their membrane recruitment. 
Examples of signalling proteins regulated by PA binding include Raf-1 (Ghosh et al., 
1996), mTOR (Fang et al., 2001), Sos (Zhao et al., 2007), Rho (Kurooka et al., 2011) and 
PKCε (Jose Lopez-Andreo et al., 2003). It is thus not a surprise that similar to PPI 
signalling, PA signalling is known to regulate a breadth of cellular processes including 
vesicular trafficking, cell proliferation, migration and survival, and was shown to play a 
role in cancer (Wang et al., 2006). 
Usually, PA effectors employ basic residues such as arginine and lysine for binding of the 
anionic phosphomonoester head group of PA via electrostatic interactions (Ghosh et al., 
1996; Nakanishi et al., 2004; Stace and Ktistakis, 2006). The ionisation state of PA plays 
an important role in protein-PA binding and PA signalling. This is because the 
phosphomonoester group of PA (and lysophosphatidic acid) has two pKas, unlike the 
phosphodiester groups of other phospholipids. As one of the pKas is in the physiological 
pH range (Kooijman et al., 2005a), PA is particularly sensitive to small pH changes in the 
cell and has been demonstrated to have a pH sensing function in yeast (Young et al., 
2010). 
Importantly, deprotonation of PA can be facilitated by hydrogen bonding between the 
basic residues in the protein and the head group of PA. This effect contributes to the so-
called electrostatic/hydrogen-bond switch mechanism that allows specific recognition of 
PA by PA binding proteins (Kooijman et al., 2007). In the first step of the switch 
mechanism, a PA binding protein is electrostatically attracted to partially-protonated PA in 
the membrane that carries a single negative charge. Basic residues in the ligand binding 
site of the protein form hydrogen bonds to the phosphate group of PA, leading to full 
deprotonation of the PA head group and formation of the second negative charge. As a 
result, the protein is able to make additional electrostatic interactions with PA, which 
increases its binding affinity to PA (Kooijman et al., 2007). 
In addition to participating in direct protein-lipid interactions, PA can influence the activity 
of membrane-associated proteins indirectly by affecting the membrane structure. The 
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reason for this is the cone-shape shaped structure of PA which is unique among membrane 
phospholipids at physiological conditions (Kooijman et al., 2005b, 2003). The cone-shaped 
structure of PA affects the packing of the phospholipid head groups and allows the apolar 
layer of the membrane to be partially exposed. As a result, the presence of PA in the 
membrane can enhance membrane insertion of membrane-binding proteins such as 
dynamin (Burger et al., 2000).  
1.1.2 Lysophospholipids  
Lysophospholipids (LPLs) are a class of bioactive phospholipids that contain a single acyl 
chain in their structure. Depending on the nature of the LPL backbone, LPLs can be 
divided into glyceroLPLs and lysosphingolipids that belong to the glycerophospholipid and 
sphingolipid categories, respectively. Most prominent types of LPLs include 
lysophosphatidylcholine (LPC), lysophosphatidic acid (LPA) and sphingosine-1-phosphate 
(S1P). Due to the lack of the second fatty acyl residue, LPLs are considerably more soluble 
in water than diacylphospholipids. GlyceroLPLs are produced as a result of 
diacylglycerophospholipid hydrolysis catalysed by phospholipases A (PLAs). LPA can 
also be synthesised de novo from glycerol-3-phosphate or 1-acyl-dihydroxyacetone-
phosphate (Vance, 2015), or generated via lysoPLD-mediated hydrolysis of LPC. De novo 
LPA biosynthesis is of large importance in phospholipid metabolism, as LPA is a precursor 
of PA. S1P is produced by phosphorylation of sphingoid bases by sphingosine kinases 
(Vance, 2015).  
LPA and S1P are well-characterised cellular signalling lipids, which act through a set of 
specific G-protein coupled receptors. Six distinct LPA receptors (LPA1-6) and five distinct 
S1P receptors (S1P1-5) have been characterised to date (Yung et al., 2014). Importantly, 
LPL binding to distinct LPL receptors elicits different signalling responses in the cell. Due 
to their solubility, LPLs can act as both extracellular and intracellular signalling mediators, 
and are abundant in various biological fluids including serum, saliva and follicular fluid 
(Rivera and Chun, 2008). Specifically, LPA signalling has been implicated in pro-, anti-
inflammatory and immune responses (Choi et al., 2010; Gobeil et al., 2003; Palmetshofer 
et al., 1999; Rubenfeld et al., 2005; Zheng et al., 2000), wound healing (Khurana et al., 
2008), the pathogenesis of cancer (Bian et al., 2004; Fishman et al., 2001; Stracke et al., 
1992), and in inflammatory (Zhao et al., 2009; Zhao and Natarajan, 2013) and 
cardiovascular diseases (Rother et al., 2003; Siess, 2002; Tigyi et al., 1995). S1P signalling 
has been found to regulate processes similar to LPA including inflammation and immune 
cell trafficking (Huang et al., 2013; Pyne et al., 2016; Spiegel and Milstien, 2011). 
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1.1.3 Fatty acyls 
Fatty acyls are a diverse class of lipids that comprises fatty acids, fatty esters, fatty amides, 
eicosanoids, docosanoids and other lipids. Fatty acyls are characterised by a common 
biosynthetic pathway, in which fatty acyl carbon chains are produced by sequential 
condensation of malonyl- or methylmanonyl-CoA on the acetyl-CoA primer. In this 
section, attention will be given primarily to polyunsaturated fatty acyls involved in cell 
signalling.  
1.1.3.1 Fatty acids 
Fatty acids are the most prominent group of fatty acyls. Naturally occurring fatty acids 
have diverse chemical structures, and include saturated, monounsaturated, polyunsaturated, 
branched, carbocyclic, oxo, amino and other fatty acids. Fatty acids play a central role in 
metabolism, where they can act as precursors of other lipid classes, such as 
glycerophospholipids, sphingolipids, tri- and diacylglycerides, eicosanoids, or can be 
broken down in the β-oxidation pathway to produce acetyl-CoA for cellular respiration. In 
lipid biosynthesis, fatty acids can be esterified to the glycerol backbone by the action of 
acyltransferases to produce fatty acyl chains of glycerolipids and glycerophospholipids, or 
can be oxidised by cyclooxygenases or lipoxygenases to yield eicosanoids. Furthermore, 
palmitic acid is a key precursor of sphinganine, a central intermediate in the de novo 
synthesis of all sphingolipids. As lipid biosynthetic pathways differ between species, so do 
nutritional requirements of organisms. An example of a class of organisms with restricted 
fatty acid biosynthesis are parasitic nematodes, which heavily rely on acquisition of 
essential lipids from the host. 
As well as being precursors of major signalling lipids in the cells, fatty acids can act 
directly as intracellular and extracellular signalling molecules (Papackova and Cahova, 
2015). In the cell, fatty acids are stored in the form of triacylglycerol and phospholipid 
fatty acyl tails, and are released by the action of intracellular lipases. Due to their low 
water solubility, fatty acids are carried from their release site to their cognate receptors by 
the cytosolic fatty acid transport proteins including those of the fatty acid binding protein 
(FABP) family (Chmurzyńska, 2006; Smathers and Petersen, 2011). Intracellular fatty acid 
receptors include peroxisome proliferator-activated receptors (PPARs), which bind to a 
range of saturated and unsaturated fatty acids, and sterol-regulatory element binding 
protein 1 (SREBP1), which binds only polyunsaturated fatty acids. PPARs and SREBP1 
are transcription factors that control the expression of genes involved in lipid transport and 
  
30 
metabolism and are regulated by fatty acid binding (Kersten et al., 2000). Importantly, 
extracellular fatty acids are also known to participate in cell signalling by binding to Toll-
like receptors in the plasma membrane (Fessler et al., 2009; Guo and Friedman, 2010). 
Specifically, dietary saturated fatty acids have been shown to elicit pro-inflammatory 
responses by activating Toll-like receptors 2 and 4 (Huang et al., 2012). 
1.1.3.2 Eicosanoids 
Eicosanoids are a group of bioactive lipids produced from the oxidation of arachidonic 
acid and other polyunsaturated fatty acids through enzymatic and non-enzymatic 
mechanisms. The major classes of eicosanoids include prostaglandins, leukotrienes and 
thromboxanes, which are generated by cyclooxygenases, lipoxygenases and cytochrome 
P450 enzymes, respectively. Eicosanoid production is initiated after the release of 
arachidonic acid from internal lipid stores by PLA2, which is activated in response to 
external stimuli.  
Eicosanoids are key regulators of inflammatory responses in the cell. They bind a variety 
of cognate receptors including PPARs, formyl peptide receptor 2 (FPR2, also known as 
lipoxin A4 receptor or ALX) and prostaglandin D, E, F receptors (Dennis and Norris, 
2015). Eicosanoids can act as pro- or anti-inflammatory agents depending on the type of 
receptors they activate and the cell type in which the signalling occurs. Prostaglandins 
control classical inflammatory responses such as redness, pain, tissue swelling, heat and 
loss of function. Correspondingly, prostaglandins and other eicosanoids have been 
implicated in acute infection and injury, as well as chronic inflammatory diseases such as 
allergy, asthma and arthritis (Dennis and Norris, 2015; Ricciotti and FitzGerald, 2011). 
Interestingly, prostaglandin E2 has been found to be secreted by filarial worms during 
infection, where it is believed to be involved in immunomodulation of the host (Liu et al., 
1990). 
1.1.4 Retinol and retinoic acid 
Retinoic acid is a prenol lipid that is involved in a variety of cellular and organismal 
processes. Similar to many other lipid signalling mediators, retinoic acid is an important 
regulator of inflammation and immunity. It is a metabolite of retinol (vitamin A), an 
essential component of human diet. In the cell, retinoic acid signalling is mediated via 
intracellular retinoic acid receptors RAR and RXR (Altucci et al., 2007), which form 
heterodimers on ligand binding and act as transcription factors. Retinoic acid signalling has 
  
31 
a well-established role in gut inflammation and regulation of immune cells (Mora et al., 
2008), and appears to be important in gastrointestinal parasitic nematode infections (Hurst 
and Else, 2012). Although the exact role of retinoic acid signalling in parasitic infections is 
unclear, it has been implicated in several immunological processes. For instance, retinoic 
acid signalling was found to regulate Th1, Th2 and Treg responses during pig infection by 
Ascaris suum (Dawson et al., 2009), and vitamin A-deficient mice have been shown to 
have lower Trichinella spiralis expulsion rates compared to non-deficient mice, as well as 
lower frequency of IgG1-secreting B lymphocytes (Carman et al., 1992). Moreover, 
vitamin A deficiency has been associated with an increase in Th1 responses and reduction 
in Th2 responses in T. spiralis-infected mice (Cantorna et al., 1994). In addition, retinoic 
acid signalling has been demonstrated to play a role in the maintenance of gut epithelium 
integrity (Osanai et al., 2006), which acts as a natural barrier for gut-inhabiting parasites. 
Interestingly, many species of parasitic nematodes secrete several distinct classes of 
retinoic acid binding proteins, at least some of which are believed to participate in 
immunomodulation of the host by sequestration of retinoic acid or its precursors from the 
host tissues. The lipid binding proteins of nematodes will be discussed below in Section 
1.2. 
1.2 Lipid binding proteins 
In the previous section, diverse signalling functions of lipids were introduced. From the 
various examples presented, a common pattern can be observed where lipid signalling is 
mediated and regulated via the action of lipid binding proteins. Proteins can participate in 
lipid signalling directly by binding to signalling lipids. In turn, lipid binding can aid protein 
recruitment to biological membranes or lead to conformational changes in proteins that 
allow them to engage in interactions with their signalling partners and initiate downstream 
signal transduction. Proteins can also maintain lipid-dependent signalling pathways and 
control the levels of specific bioactive lipids available for protein-lipid interactions by 
acting as lipid transporters. In addition, plasma lipid binding proteins such as albumin 
transport nutrient lipids for energy metabolism and substrates for biosynthesis of lipids 
across the tissues. Intracellular counterparts of albumin are FABPs, which distribute fatty 
acids in the cytoplasm.  
A review of all lipid binding protein types is beyond the scope of this thesis. Only the 
structure and functions of several phospholipid binding domains and fatty acid binding 
proteins will be briefly discussed below, with primary attention given to mammalian 
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phosphatidylinositol transfer proteins (PITPs) and nematode fatty acid and retinol binding 
proteins (FARs). 
1.2.1 Phospholipid binding domains and proteins 
Phospholipid signalling is mediated through the activity of phospholipid binding proteins. 
Many phospholipids, examples of which include several types of PPIs, bind to a number of 
conserved modular phospholipid binding domains shared between a large variety of 
phospholipid binding proteins (Cullen et al., 2001; Hurley et al., 2000). In contrast, no 
conserved common PA binding domain has been identified, and each family of PA binding 
proteins has a unique sequence typically containing basic and hydrophobic residues that 
interact with PA (Stace and Ktistakis, 2006). It is important to note that protein-
phospholipid binding typically occurs at the membrane (binding to lysophospholipids 
being the exception). Hence, interactions between the phospholipid binding proteins and 
the bilayer lipids neighbouring the ligand often also play a role in the interaction. 
Furthermore, several types of lipid binding domains interact with the membrane non-
specifically, recognising general membrane properties such as charge and amphiphilicity. 
Below, several proteins and protein domains that demonstrate specific phospholipid 
binding will be described. 
1.2.1.1 PH domain 
The PH domain is one of the most widespread protein domains in the cell. Several variants 
of PH domain are known, which have been demonstrated to interact with PI(3,4,5)P3, 
PI(3,4)P2, PI(4,5)P2, as well as PA and PS (Lemmon, 2008). Different PH domain variants 
have different phospholipid specificity, with several variants displaying dual specificity. 
Structures of several PH domains have been determined, including those of PLCδ 
(Ferguson et al., 1995), pleckstrin (Yoon et al., 1994), Sos1 (Zheng et al., 1997) and 
ceramide trafficking protein (Sugiki et al., 2012). Structural studies revealed that PH 
domains share a common fold consisting of a β-sandwich motif capped at one end by an α-
helix (Fig 1-1A). The phospholipid-interacting face of PH domains carries a net positive 
charge, which is believed to facilitate the interaction with the anionic head group of its 
ligands (Lemmon and Ferguson, 2000). PH domains interact with PPIs via a set of basic 
residues in the β1–β2 loop that form hydrogen bonds to the polar head group of their 
ligands. Although PH domains have been shown to insert into the membrane under certain 
conditions (Flesch et al., 2005), typically, PH binding to membrane PPIs does not require 
membrane insertion. Indeed, it has been demonstrated that certain PH domains interact 
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with soluble inositol phosphates with higher affinity than with intact PPIs (Lemmon, 2008; 
Lemmon et al., 1995). In addition to phospholipid binding, PH domains have been 
implicated in protein-protein interactions (Lemmon, 2004; Scheffzek and Welti, 2012), 
suggesting than the functions of PH domains are much more diverse than simple 
membrane targeting of proteins. 
1.2.1.2 FYVE domain 
FYVE domains constitute another class of modular phospholipid binding domains. Unlike 
PH domains, FYVE domains are only known to recognise one phospholipid species: 
PI(3)P (Gaullier et al., 1998; Patki et al., 1998). FYVE domains are Zinc finger proteins, 
and consist of two antiparallel β-sheets and an α-helix stabilised by two Zn2+ ions 
(Fig 1-1B). Binding of FYVE domains to PI(3)P is mediated by the basic 
(R/K)(R/K)HHCR motif in their β1-strand, the residues in which interact with the 
phosphoinositol head group of PI(3)P via hydrogen bonding (Kutateladze and Overduin, 
2001; Misra and Hurley, 1999; Saio et al., 2014). FYVE domains display a different mode 
of membrane association to PH domains. In contrast to PH domains, FYVE domains insert 
a loop into the lipid bilayer upon membrane binding (Kutateladze and Overduin, 2001), 
which allows them to enhance the affinity of PI(3)P binding. Correspondingly, FYVE 
domains have been demonstrated to interact with membrane-embedded PI(3)P with at least 
20-fold higher affinity than with short-chain PI(3)P or the soluble IP2 head group of PI(3)P 
(Gaullier et al., 2000; Kutateladze et al., 1999). Unlike the monomeric PH domains, FYVE 
domains have been shown to dimerise on membrane binding. The major function of FYVE 
domains is believed to be protein targeting to endosomes, which are enriched in PI(3)P 
(Raiborg et al., 2013).  
1.2.1.3 PX domain 
PX domains were first identified in the p40phox and p47phox subunits of phagocyte NADPH 
oxidase, from which they take their name (Ponting, 1996). Similar to FYVE domains, PX 
domains are known to interact predominantly with PI(3)P, and regulate the endosomal 
localisation of proteins involved in membrane trafficking. PX domains comprise a 
subdomain consisting of three β-sheets and a subdomain consisting of three α-helices. The 
pocket formed between the two subdomains serves as the binding site for the PI(3)P head 
group (Bravo et al., 2001; Cheever et al., 2001). Like in the case of FYVE domains, PX 
domain binding to PI(3)P-containing membranes is achieved through a combination of 
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specific hydrogen bonding to PI(3)P head group and insertion of a hydrophobic loop into 
the membrane bilayer (Kutateladze, 2007; Lemmon, 2003).  
 
 
 
 
 
1.2.1.4 PA binding proteins 
Although several PH domains (Bullen et al., 2016; Zhao et al., 2007) and at least one PX 
domain (Karathanassis et al., 2002) were reported to bind PA, no common well-defined 
globular protein domain that specifically recognises PA has been identified to date. 
Typically, proteins interact with PA via a number of hydrophobic and basic residues which 
are often conserved between related proteins (Stace and Ktistakis, 2006). For instance, in 
mammalian Raf-1, two neighbouring arginines and a lysine in the highly conserved Raf-1 
PA binding region have been shown to be directly involved in PA recognition (Rizzo et al., 
2000). Similarly, in the yeast SNARE protein Spo21p, three lysines, an arginine and a 
leucine in the RLHVKLKSLRNKIHKQLH sequence have been directly implicated in PA 
binding (Nakanishi et al., 2004). The lack of a defined PA binding domain makes 
identification of PA effectors difficult. Nevertheless, the importance of PA signalling in 
crucial cellular processes is becoming more and more clear and novel PA binding proteins 
are continued to be discovered. As described in Section 1.1.1.3, electrostatic/hydrogen 
bond switch mechanism has been proposed to explain how PA effectors achieve PA 
Figure 1-1. Structures of PH, FYVE and PX domains in complex with ligands. The structures 
are depicted in cartoon representation. Helices are coloured in red, β-strands in yellow and loops 
in green. The ligands are shown in teal. A. Crystal structure of the PH domain of PLCδ in complex 
with I(1,4,5)P3, the free head group of PI(4,5,)P2 (PDB ID 1MAI) (Ferguson et al., 1995). Protein 
interaction with the ligand is mediated via basic residues in the β1-β2 loop. B. Solution structure 
of the FYVE domain of early endosome antigen 1 (EEA1) in complex with I(1,3)P2, the free head 
group of PI(3)P (PDB ID 1HYI) (Kutateladze and Overduin, 2001). Zn2+ ions are shown as grey 
spheres. The protein forms polar contacts with the ligand via basic residues in its β1-strand. C. 
Crystal structure of the PX domain of p40phox in complex with di-butyl (di-4:0) PI(3)P (PDB ID 
1H6H) (Bravo et al., 2001). The ligand binding pocket is formed by three α-helices and three 
β-strands.
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specificity (Kooijman et al., 2007). However, since few PA effectors have been well-
characterised to date, the understanding of PA binding is far from complete.  
1.2.2 Nematode lipid binding proteins 
Nematodes or roundworms are a diverse class of organisms which include free-living 
species such as the model organism Caenorhabditis elegans, as well as important human, 
animal and plant parasites. Human parasitic nematodes, such as Ascaris lumbricoides and 
Necator americanus, infect more than 1.6 billion people globally (de Silva et al., 2003; 
Pullan et al., 2014), causing considerable human suffering and a profound deleterious 
impact on the society (Stephenson et al., 2000) in many developing regions of the world.  
Parasitic nematodes have restricted lipid metabolism (Smyth and Wakelin, 1994) and rely 
on acquisition of lipids essential for their survival from the environment. In order to 
transport, store and protect lipids from degradation, nematodes produce a range of lipid 
binding proteins. Due to their functions in nematode survival and parasitism, lipid binding 
proteins have been suggested as potential therapeutic or vaccine targets in the fight against 
nematode infections. To date, several classes of nematode lipid binding proteins have been 
identified and characterised, which include nematode fatty acid binding proteins 
(nemFABPs), nematode polyprotein allergens (NPAs) and fatty acid and retinol binding 
proteins (FARs).  
1.2.2.1 Nematode FABPs 
FABPs are ~14 kDa proteins widespread in animals, including mammals. Although the 
primary sequence of FABPs can vary considerably, all known FABP structures contain a 
conserved β-barrel fold with a water-filled internal cavity that contains the ligand binding 
sites (Sacchettini et al., 1989; Thompson et al., 1997; Zimmerman and Veerkamp, 2002). 
In mammals, FABPs are cytosolic proteins involved in cell growth (Sorof, 1994), 
signalling (Wolfrum et al., 2001), differentiation (Veerkamp and Zimmerman, 2001) and 
pathogenesis (Baier et al., 1995). Unlike mammalian FABPs, nemFABPs are extracellular 
proteins that are secreted by the parasite. While the definite biological function of 
nemFABPs is yet to be discovered, they have been implicated in the maintenance of the 
worm egg lipid layer (Mei et al., 1997; Michalski et al., 2002), and have been proposed to 
play a role in nutrient acquisition by the parasites (Franchini et al., 2015). No empirical 
structures of nemFABPs have been published to date. 
  
36 
1.2.2.2 NPAs 
In contrast to FABPs, NPAs are found exclusively in nematodes. NPAs are produced as 
protein polymers, which are proteolytically cleaved into functional monomeric units and 
secreted by the parasite. NPAs have been identified from the strong IgE-type response that 
they elicit in the hosts (Tomlinson et al., 1989). They have been demonstrated to bind fatty 
acids and retinol and are believed to be involved in the transport or sequestration of small 
lipids (Kennedy, 2011; Kennedy et al., 1995). The structure of the repeated unit of Ascaris 
suum NPA ABA-1 has been solved, revealing an α-helical fold with two lipid binding 
pockets (Fig 1-2) (Meenan et al., 2011). 
 
1.2.2.3 FARs 
FARs are another distinct family of nematode lipid binding proteins. Like FABPs and NPA 
monomers, FARs are small and soluble proteins, with the average molecular weight equal 
to 14-20 kDa. FARs have been identified in C. elegans (Ce-FAR-1 to -8) and in a variety 
of parasitic nematodes, including human parasites Onchocerca volvulus (Ov-FAR-1), 
Brugia malayi (Bm-FAR-1) and Necator americanus (Na-FAR-1), as well as several 
animal and plant parasites. FARs demonstrate high expression levels in the worm tissues 
(Basavaraju et al., 2003; Popeijus et al., 2000; Ranjit et al., 2006) and some FARs, 
including Na-FAR-1, are secreted into the host. The ligand repertoire of FARs is wide and 
includes fatty acids, retinoids and phospholipids (Basavaraju et al., 2003; Garofalo et al., 
2003, 2002; Iberkleid et al., 2013; Jordanova et al., 2009; Rey-Burusco et al., 2015). In 
addition, Ov-FAR-1 has been shown to bind ivermectin, an antihelmintic drug (Lal and 
James, 1996; Sani and Vaid, 1988). Although the exact function of FARs in parasitic 
nematodes remains unclear, they were proposed to play a role in nutrient acquisition and/or 
sequestration of lipid signalling molecules to modulate the host’s response to the parasitic 
infection (Garofalo et al., 2002; Rey-Burusco et al., 2015). To date, the only FAR that has 
Figure 1-2. Solution-state structure of the repeated subunit 
of ABA-1, a nematode polyprotein allergen from Ascaris 
suum (PDB ID 2XV9). The structure is shown in cartoon 
representation. The locations of the two ligand binding pockets 
are shown. (Meenan et al., 2011).
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been directly implicated in the host immunomodulation is Meloidogyne javanica FAR-1 
(Mj-FAR-1), which has been shown to increase tomato susceptibility to root-knot 
nematode infections (Iberkleid et al., 2015, 2013).  
Na-FAR-1, which is the focus of this study and has potential biomedical importance due to 
its presence in a widespread human parasite, will be discussed in more detail in Section 
1.4. 
1.3 Phosphatidylinositol transfer proteins 
Phosphatidylinositol transfer proteins (PITPs) are phospholipid binding proteins involved 
in a wide range of biological processes including cytokinesis (Giansanti et al., 2006; 
Litvak et al., 2004), cell proliferation (Cockcroft and Garner, 2013; Schenning et al., 2008; 
Snoek, 2004), vesicular transport (Cockcroft, 1999; Jones et al., 1998; Simon et al., 1998), 
neurodevelopment (Cosker et al., 2008; Xie et al., 2005) and phototransduction (Harris and 
Stark, 1977; Kohn et al., 2007; Trivedi and Padinjat, 2007). The defining biochemical 
characteristic of PITPs is their ability to bind and transport phospholipids between lipid 
membranes. Consistently, they were shown to be key players in the non-vesicular 
phospholipid transport in the cell (Cockcroft and Garner, 2011).  
Based on their phospholipid binding properties and protein domain composition, PITPs are 
commonly divided into three classes: class I, class IIA and class IIB PITPs. Class I and IIB 
PITPs comprise a single PITP domain, whereas class IIA PITPs also contain additional 
domains (Cockcroft and Garner, 2011). In humans, five PITPs are present: two class I 
PITPs: PITPα and PITPβ; two class IIA PITPs: Nir2 (also known as RdgBαI or PITPNM1) 
and Nir3 (RdgBαII or PITPNM2); and one class IIB PITP: RdgBβ (PITPNC1). 
Furthermore, Nir1 (RdgBαIII or PITPNM3), a homolog of Nir2 and Nir3 lacking the PITP 
domain, is also found in the genome of humans. PITPs are highly conserved between 
mammals, and are also found in other classes of eukaryotes. All PITPs bind PI with high 
affinity and transfer it between cellular membranes. In addition, PITPα and PITPβ have 
been demonstrated to bind and transfer PC, and Nir2, Nir3 and RdgBβ have been shown to 
bind and transfer PA.  
PITPα and PITPβ are small ~ 35 kDa proteins. The structures of the apo (Schouten et al., 
2002), PI- (Tilley et al., 2007) and PC-bound (Yoder et al., 2001) PITPα, as well as the 
structure of PC-bound PITPβ (Vordtriede et al., 2005) have been determined using X-ray 
crystallography. Structural analysis revealed that the proteins share a common fold, 
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featuring a large concave β-sheet and seven α-helices (Fig 1-3). PITPα and PITPβ 
comprise three structural-functional units: 1) the lipid binding core, 2) the regulatory loop 
and 3) the C-terminal region (Cockcroft and Carvou, 2007). The lipid binding core forms 
the largest part of the proteins and can accommodate a single PI or PC molecule. The 
regulatory loop contains a PKC phosphorylation site, and has been proposed to act as an 
interface for interactions with protein- and lipid modifying enzymes (Yoder et al., 2001). 
The C-terminal region contains helix G and eleven C-terminal amino acids, which cap the 
entrance to the lipid binding core upon PI or PC binding. The phospholipid exchange 
happens in the open protein conformation when helix G is shifted outward and the cavity is 
open to the membrane interface. In the closed conformation, class I PITPs travel through 
the cytosol between subcellular compartments carrying PI or PC for the exchange 
(Cockcroft and Carvou, 2007). While the mammalian class I PITPs have been reasonably 
well-characterised, less is known about class II PITPs, especially in regard to the structure 
and function of domains absent in other PITPs. Below, the current knowledge about human 
class IIA PITPs will be briefly summarised. 
 
 
 
1.3.1 Class IIA PITPs 
Compared to PITPα and PITPβ, class IIA are much larger proteins with molecular masses 
of ~ 150-170 kDa. The founding member of the IIA sub-class of PITPs is RdgB (PITPNM) 
protein that was identified from the rdgB (retinal degeneration B) mutation in Drosophila 
(Vihtelic et al., 1993). The PITP domain of class IIA PITPs is located at the N-terminal 
end of the proteins. In addition, class IIA PITPs contain a FFAT motif, a DDHD domain 
and an Lipin/Ned1/Smp2 (LNS2) domain. The schematic domain composition of class IIA 
Figure 1-3. The crystal structure of human PITPα in complex with PI (PDB ID 1UW5). Two 
views of the structure are shown in cartoon representation. Protein α-helices are coloured in red, β-
strands in yellow and loops in green. The ligand (teal) is shown inside the structure. (Tilley et al., 
2007).
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PITPs Nir2, Nir3 and RdgB is depicted in Fig 1-4. Although Nir1 does not contain a PITP 
domain, it was included in Fig 1-4 with class IIA PITPs due to the shared domain 
composition and relatively high sequence homology with the PITPs.  
 
 
 
 
The FFAT motif is a short peptide (EFFDAxE, where x is any amino acid) that binds to 
VAPs [vesicle-associated membrane protein (VAMP)-associated proteins] (Loewen et al., 
2003; Loewen and Levine, 2005), which are integral membrane proteins localised at the 
cytoplasmic face of the ER. Correspondingly, Nir1-3 have been shown to interact with 
VAP-B via their FFAT motifs (Amarilio et al., 2005), which is consistent with the 
proposed function of class IIA PITPs in the PI(4,5)P2 cycle (see below). The acidic 
residues surrounding the FFAT motif have also been shown to bind Ca2+ in vitro (Lev et 
al., 1999; Vihtelic et al., 1993), however, it is unclear whether this interaction occurs or 
plays any role in the regulation of class IIA PITPs and Nir1 in vivo. 
The DDHD domain comprises 195 amino acids and is found in class IIA PITPs and several 
phospholipases (Lev, 2004). It is named after the four residues (DDHD) that are conserved 
between all DDHD domains. Although the function of the DDHD domain is unknown, the 
DDHD peptide may form a metal ion binding site (Lev, 2004). The DDHD domain is a 
part of the larger C-terminal region of Nir1-3 that was found to interact with PYK2 
tyrosine kinase in the study by Lev et al. (Lev et al., 1999), in which Nirs (PYK2 N-
terminal domain-interacting receptors) were identified. Recently, the DDHD domain was 
shown to interact with PI(4)P and PA in vitro (Klinkenberg et al., 2014). 
Figure 1-4. Schematic representation of the Nir1-3 and RdgB domain composition. Nir1-3 
and RdgB comprise a VAP-interacting FFAT motif, a putative metal binding DDHD domain and a 
phosphatidic acid binding haloacid dehalogenase-like LNS2 domain. Nir2, Nir3 and RdgB contain 
a PITP domain at their N-terminus, which is absent in Nir1. 
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The LNS2 domain is composed of ~ 130 amino acids and is proposed to belong to the 
haloacid dehalogenase (HAD) protein superfamily. Apart from class IIA PITPs and Nir1, 
the LNS2 domain is also found in mammalian lipins and yeast lipins orthologs Smp2 and 
Ned1. In lipins, Smp2 and Ned1, the LNS2 domain has a Mg2+-dependent phosphatidic 
acid phosphatase (PAP) activity (Donkor et al., 2007; Han et al., 2006). In contrast, in 
class IIA PITPs, LNS2 domain lacks the catalytic function and simply binds PA (Kim et 
al., 2013). The lack of PAP function is attributed to an aspartate to alanine change in the 
catalytic DxDxT motif that is critical for the PAP activity in lipins (Mietkiewska et al., 
2011; Reue and Dwyer, 2009). Crucially, PA binding by the LNS2 domain is believed to 
be required for the plasma membrane targeting of Nir2 and Nir3 (Chang and Liou, 2015; 
Kim et al., 2013).  
Nir2, Nir3 and RdgB have been directly implicated in PLC-mediated signalling, where 
their PI-PA exchange function is believed to be required for the maintenance of PI(4,5)P2 
cycle (Chang and Liou, 2015; Cockcroft et al., 2016; Kim et al., 2013, 2015; Yadav et al., 
2015). The PI(4,5)P2 cycle is a series of biochemical reactions that lead to generation of 
PI(4,5)P2 in the plasma membrane (PM) (Fig 1-5) (Cockcroft and Raghu, 2016). In the 
PI(4,5)P2 cycle, PI(4,5)P2 hydrolysis in response to PLC activation by external stimuli 
leads to production of DAG and IP3, of which DAG can be phosphorylated to generate PA. 
In order to maintain PLC-mediated signalling, re-synthesis of PI(4,5)P2 from PI is 
required. Since only a limited pool of PI is available at the PM for PI(4,5)P2 synthesis, PI 
needs to be transported from its de novo synthesis site in the ER to replenish PI(4,5)P2 
levels at the PM and maintain the signalling processes. Conversely, the PA that has 
accumulated at the PM as a result of PLC-mediated signalling needs to be transported to 
the ER to maintain the supply of PI required for the production of PI(4,5)P2. By 
reciprocally transferring PI and PA between the ER and PM, class IIA PITPs provide the 
substrate for PI(4,5)P2 synthesis in PM and PI synthesis in ER. The reported localisation of 
Nir2, Nir3 and RdgB at the ER-PM junctions (Chang et al., 2013; Chang and Liou, 2015; 
Cockcroft et al., 2016; Kim et al., 2013), which are the narrow (< 40 nm) contact sites 
between the two membranes, is in agreement with this putative function.  
Below, human class IIA PITPs Nir2 and Nir3, as well as their sister protein Nir1 will be 
described in more detail. 
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1.3.1.1 Nir2 
Although Nir2 is the most well-characterised human class IIA PITP to date, its cellular 
functions are only beginning to be elucidated. As mentioned above, Nir2 was isolated as a 
PYK2-binding protein together with other Nirs in 1999 (Lev et al., 1999). Several studies 
in cultured mammalian cells have followed, which revealed that Nir2 is a regulator of 
cellular morphogenesis (Tian et al., 2002) and cytokinesis (Litvak et al., 2004, 2002). In 
the study by Tian et al., co-expression of RhoA and Nir2 in human cerebellar 
medulloblastoma cells resulted in inhibition of RhoA-mediated neurite retraction, whereas 
injection of anti-Nir2 antibodies lead to a reduced neurite extension, suggesting that Nir2 
plays a role in cytoskeleton remodelling and controls cell shape (Tian et al., 2002). 
Consistent with this function, overexpression of different truncated Nir2 mutants resulted 
in morphological changes in a range of mammalian cell lines (Tian et al., 2002). Similar 
results were obtained by Litvak et al. who demonstrated that injection of anti-Nir2 
antibodies into HeLa cells resulted in aberrant cytokinesis (Litvak et al., 2002) and that 
phosphorylation of Nir2 was required for the completion of cytokinesis in mitotic cells 
(Litvak et al., 2004), confirming that Nir2 plays a role in cytoskeletal regulation. 
Figure 1-5. Schematic depiction of Nir2 and Nir3 function in the PI(4,5)P2 cycle. During PLC-
mediated signalling, PI(4,5)P2 (PIP2) is hydrolysed at the plasma membrane (PM) to produce DAG 
that is converted into PA. To maintain PLC-medicated signalling, PI is consumed at PM for the 
synthesis of PIP2. As PI is synthesised from PA in the endoplasmic reticulum (ER), the ER-PM 
transport of PI and the PM-ER transport of PA is required to maintain the levels of PI, and, 
correspondingly, PIP2 at the plasma membrane. The PI and PA transfer function of Nir2, Nir3 and 
RdgB is required to transport the lipids between the ER and PM. PI4K = PI 4-kinase, PI4P5K = PI 
4-phosphate 5-kinase, PLC = phospholipase C, DAGK = DAG kinase, CDS = CDP-DAG synthase, 
PIS = PI synthase. 
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In another study by Litvak et al., Nir2 was found to be involved in Golgi secretion function 
through regulation of DAG levels in the Golgi apparatus (Litvak et al., 2005). Here, 
downregulation of Nir2 expression by RNAi resulted in reduced DAG levels in the Golgi 
membrane and lead to impaired Golgi secretion function, which was rescued by inhibition 
of the CDP-DAG pathway (Litvak et al., 2005).  
Even more striking is Nir2 function in PI(4,5)P2 homeostasis, which has been investigated 
by multiple groups (Chang et al., 2013; Chang and Liou, 2015; Kim et al., 2013, 2015). 
The ability of Nir2 to regulate PI(4,5)P2 levels at the PM was first reported by Kim et al. 
(Kim et al., 2013). Kim et al. overexpressed a Myc-tagged Nir2 in HeLa cells and 
observed that Nir2 translocates to PM upon EGF stimulation of the serum-starved cells. 
The addition of PA to the cells lead to a similar effect, whereas inhibition of PA production 
by 1-butanol resulted in decreased Nir2 translocation to the PM, suggesting that Nir2 
translocation is mediated via PLD activation by EGF signalling (Kim et al., 2013). The 
following investigation of truncated Nir2 mutants revealed that the C-terminal portion of 
the protein containing the LNS2 domain was responsible for the PA-dependent PM 
targeting of Nir2. This was evident from the fact that the Nir2 mutant lacking the C-
terminal region failed to translocate to the PM upon EGF stimulation, whereas the mutant 
consisting of only the C-terminal region was detected at the PM after the addition of EGF. 
The ability of the C-terminal domain to bind PA with high specificity was demonstrated in 
vitro (Kim et al., 2013). Crucially, overexpression of Nir2 was found to cause an increase 
in PI(4,5)P2 and PI(3,4,5)P3 levels at the PM and depletion of Nir2 lead to a remarkable 
reduction in the levels of the two phospholipids. The regulation of PI(4,5)P2  appeared to 
be dependent on both the lipid transfer function of Nir2 and its PA-dependent PM 
translocation, as both PITP- and C-terminal domain truncated Nir2 mutants failed to 
restore the PI(4,5)P2 and PI(3,4,5)P3 levels in Nir2-depleted cells  (Kim et al., 2013). 
Furthermore, Kim et al. have generated a Nir2 mutant containing the D1128A mutation in 
the LNS2 domain, which has demonstrated reduced PA binding in vitro and reduced PM 
translocation in vivo (Kim et al., 2013). Although Kim et al. claimed that the mutation site 
was chosen based on the analysis of conserved motifs in HAD proteins, it is unclear 
whether the mutation caused a specific reduction in PA binding affinity of Nir2 LNS2 or 
whether the PA binding was affected due to a structural change in the domain caused by 
the mutation, as structural analysis of the mutant was not carried out. 
Further studies by Chang et al. and Kim at al. have confirmed the role of Nir2 in positive 
regulation of PI(4,5)P2 levels in the PM. Chang et al. demonstrated that Nir2 translocates to 
ER-PM junctions in response to histamine stimulation and replenishes PI(4,5)P2 levels 
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during PLC-mediated signalling (Chang et al., 2013). Consistent with the previously 
described results by Kim et al., Chang et al. observed that the PITP domain is not required 
for PM translocation of Nir2. Interestingly, Chang et al. also showed that receptor 
stimulation enhanced both PM targeting of Nir2 and co-localisation of Nir2 with VAP-A 
and VAP-B. Consistently, cultured mammalian cells overexpressing Nir2 with a functional 
mutation in the FFAT motif displayed reduced PI(4,5)P2 levels compared to the cells 
overexpressing wild-type Nir2, suggesting that VAP binding is important for Nir2 function 
in PI(4,5)P2 homeostasis (Chang et al., 2013). In another study, Chang and Liou have 
shown that PA plays a central role in PM targeting of Nir2 (Chang and Liou, 2015). 
Addition of PLD and DAGK inhibitors to HeLa cells inhibited PM translocation of Nir2, 
whereas addition of PA alone was able to initiate the translocation (Chang and Liou, 2015). 
By studying the chimeras of Nir2 and Nir3, Chang and Liou were able to show that 
translocation of Nir2 and Nir3 to the PM was dependent on their C-terminal domains 
(Chang and Liou, 2015). 
A more recent study by Kim et al. has provided further insight into the role of Nir2 in 
PI(4,5)P2 regulation (Kim et al., 2015). Kim et al. were able to monitor the PI(4,5)P2, PA, 
and DAG pools at the PM by using specific phospholipid binding domains coupled to two 
fluorescent probes that can act as a donor and acceptor in fluorescence resonance energy 
transfer (FRET). Consistent with previous results, Kim et al. observed that PM PI(4,5)P2 
and DAG levels were reduced in Nir2-depleted cells. Surprisingly, an increase in PA levels 
was observed, which was believed to be due to decreased consumption of PA in Nir2-
deficient cells (Kim et al., 2015). As in the previous studies, Nir2 was found to translocate 
from the cytoplasm to the ER-PM junctions on receptor stimulation. By using a 
fluorescently-labelled PA binding motif from yeast sporulation protein Spo20 and a GFP-
Nir2 fusion, Kim et al. demonstrated that Nir2 overexpression facilitates PA removal from 
PM in angiotensin II-stimulated cells, and that PA transported by Nir2 is utilised in the ER 
membrane for PI synthesis (Kim et al., 2015). Interestingly, the kinetics of Nir2-GFP 
membrane translocation upon receptor stimulation were faster than those of the Spo20 PA 
binding motif, which suggests that an interaction between Nir2 and a membrane lipid other 
than PA might also be involved in PM targeting of Nir2. A short putative DAG binding 
sequence preceding the LNS2 domain was identified by Kim et al., the absence of which 
from Nir2 prevented PM recruitment (Kim et al., 2015). These data suggest that DAG 
might also be a regulator of Nir2 localisation along with PA. However, the putative DAG 
binding function of Nir2 C-terminal region was not directly demonstrated by Kim et al. 
and is yet to be confirmed by other groups. 
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Remarkably, overexpression of Nir2 was shown to enhance epithelial-to-mesenchymal 
transition in cultured breast cancer cells and injection of Nir2-overexpressing cells into 
mice was found to promote lung metastasis in mice metastasis models (Keinan et al., 
2014).  Furthermore, high Nir2 expression levels were associated with poor prognosis in 
breast cancer patients (Keinan et al., 2014), pointing to its potential as a target for cancer 
therapies. 
1.3.1.2 Nir3 
Nir3 is much less studied than Nir2. Analogously to Nir2, Nir3 was identified as a PYK2 
binding protein (Lev et al., 1999) and was shown to bind VAP-B through its FFAT domain 
(Amarilio et al., 2005). The predominant source of information about the cellular function 
of Nir3 is the study by Chang and Liou referenced in the Nir2 section above (Chang and 
Liou, 2015). In the study, Nir3 was found to be involved in PI(4,5)P2 homeostasis together 
with Nir2. Interestingly, Nir3 appeared to be less efficient at PI(4,5)P2 replenishment than 
Nir2 in response to receptor stimulation, which was believed to be due to the difference in 
the activity of the PITP domains of Nir3 and Nir2. However, in contrast to Nir2, Nir3 was 
found to play a clear role in the maintenance of basal PI(4,5)P2 levels and was shown to be 
more important than Nir2 in PI(4,5)P2 homeostasis during low levels of receptor activation 
(Chang and Liou, 2015). These results indicate that Nir2 and Nir3 have complementary 
functions in PI(4,5)P2 cycle. Further studies are required to better understand the role of 
Nir3 in cell signalling and lipid metabolism. 
1.3.1.3 Nir1 
Nir1 is an even more mysterious RdgB-like protein. It shares the PYK2 and VAP-B 
binding function with Nir2 and Nir3 (Amarilio et al., 2005; Lev et al., 1999), but lacks the 
PITP domain and thus is not believed to transport lipids. Knowledge about the cellular 
function of Nir1 is scarce. A mutation in Nir1 was documented to cause autosomal 
dominant cone dystrophy, a rare congenital vision disorder, indicating a role for Nir1 in 
mammalian phototransduction (Kohn et al., 2007). This putative function of Nir1 is similar 
to the function of its Drosophila ortholog RdgB, which is a known player in 
phototransduction (Harris and Stark, 1977; Vihtelic et al., 1993). Recently, Nir1 was also 
proposed to be a receptor of chemokine (C-C motif) ligand 18 (CCL18) (Chen et al., 2011; 
Zhang et al., 2013). However, evidence obtained by a different group has shed doubt on 
this notion (Krohn et al., 2013). Furthermore, like Nir2 and Nir3, Nir1 is not believed to be 
an integral membrane protein (Cockcroft and Raghu, 2016), and hence it is unlikely to act 
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as a cell-surface receptor of CCL18. Further research will be required to obtain a clearer 
picture of Nir1 function in the cell. 
1.4 Na-FAR-1 
Na-FAR-1 is one of the most well-studied FARs to date. As it is one of the six FARs 
identified in an important intestinal human parasite, American hookworm Necator 
americanus (Tang et al., 2014), Na-FAR-1 is of interest as a potential drug or vaccine 
target. Importantly, Na-FAR-1 contains a secretion signal and is highly expressed in the 
blood-feeding, adult stage of the parasite (Tang et al., 2014), which suggests that it may 
play a role in parasitism. Among FARs, the closest relatives of Na-FAR-1 are other 
parasite-specific FARs, such as Ov-FAR-1 and Bm-FAR-1 from human parasites, Ace-
FAR-1 and Hp-FAR-1 from animal parasites and Gp-FAR-1 from a plant parasite (Rey-
Burusco et al., 2015), some of which also have high expression levels in the parasitic 
stages of the worms (Jones et al., 2009; Popeijus et al., 2000; Ranjit et al., 2006). Similar 
to many other FARs, Na-FAR-1 has been demonstrated to bind retinoic acid and different 
fatty acids, displaying a preference for the long-chain fatty acids (Rey-Burusco et al., 
2015). Interestingly, Na-FAR-1 has also been shown to bind PG and PE (Rey-Burusco et 
al., 2015), which is the first documented evidence of phospholipid binding by a FAR. 
The structure of Na-FAR-1 has been determined by both solution-state NMR spectroscopy 
and X-ray crystallography in an apo (ligand-free) and holo (ligand-bound) forms, 
respectively (Gabrielsen et al., 2012; Rey-Burusco et al., 2015, 2014). It was found that 
Na-FAR-1 has an α-helical fold, which is largely similar to the previously determined fold 
of Ce-FAR-7 (Jordanova et al., 2009), the only other FAR whose three-dimensional 
structure is known. The fact that Na-FAR-1 and Ce-FAR-7 share a common fold despite 
their low sequence similarity suggests that the α-helical fold observed in the two proteins is 
a common feature of the FAR family.  
Na-FAR-1 comprises eleven α-helices (α1-11) of varying lengths that form a wedge-like 
structure (Rey-Burusco et al., 2015) (Fig 1-6). Helices α1-3, α6 and α9-11, of which α6, α9 
and α10 are the largest, form one face of the wedge, whereas α5, α7 and α8 form the 
opposite face. A cavity lined with predominantly hydrophobic residues is located at the 
centre of Na-FAR-1. Helix α4 is out of plane with the other helices, obstructing the cavity 
at one side of Na-FAR-1 (Rey-Burusco et al., 2015). The central cavity of Na-FAR-1 was 
shown to act as a ligand binding pocket, which is consistent with its hydrophobicity. 
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The structures of the apo and holo forms of Na-FAR-1 are largely similar. The most 
remarkable difference between the apo and the holo Na-FAR-1 is that the volume of the 
cavity of the holo protein is more than double the size of the apo protein cavity, indicating 
Na-FAR-1 expansion upon ligand binding (Rey-Burusco et al., 2015).  
 
 
 
In the study by Rey-Burusco et al., recombinant Na-FAR-1 expressed in E. coli was found 
to co-purify with endogenous E. coli lipids. In order to determine the structure of holo Na-
FAR-1, Rey-Burusco et al. crystallised the E. coli lipid bound Na-FAR-1 without further 
purification steps. As the protein contained a heterogeneous mixture of lipids, 
identification of ligands in the structure was difficult, and only one ligand binding site was 
mapped with confidence (Rey-Burusco et al., 2015). The ligand was identified as palmitic 
acid, which appeared to interact with the side-chain amine group of K96 via its carboxylic 
acid head group (Rey-Burusco et al., 2015). In addition, the fatty acyl tail of the ligand 
contacted eleven hydrophobic residues in the internal cavity of Na-FAR-1 (Rey-Burusco et 
al., 2015). Importantly, other electron density peaks were observed in the central cavity of 
Na-FAR-1 which could not be filled with water molecules alone, suggesting the presence 
of unidentified ligands at alternative binding sites. 
Furthermore, chemical shift perturbation analysis by NMR spectroscopy using oleic acid 
revealed that Na-FAR-1 forms four distinct complex with oleic acid during the ligand 
titration that were assumed to contain one, two, three and at least four ligand molecules. 
Figure 1-6. The structure of the ligand-free (apo) and E. coli lipid bound (holo) Na-FAR-1. 
A. Cartoon representation of the solution structure of apo Na-FAR-1 (PDB ID 4UET) (Rey-
Burusco et al., 2015). B. Cartoon representation of the crystal structure of holo Na-FAR-1 
(PDB ID 4XCP) (Rey-Burusco et al., 2015). No ligands are shown in the structure. The protein 
is coloured from blue (N-terminus) to red (C-terminus). The α-helices are numbered (α1-11).  
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From the chemical exchange regimes observed in the experiment, it was found that Na-
FAR-1 binds three oleic acid molecules with a higher affinity than the fourth oleic acid 
molecule (Rey-Burusco et al., 2015).  
1.5 Aims of this study 
The two primary aims of this study were to: a) determine the phosphatidic acid binding 
mechanism and the structure of the LNS2 domain of Nir2 and b) determine the fatty acid 
and phospholipid binding mechanism of Na-FAR-1 and map the previously unidentified 
fatty acid and phospholipid binding sites of Na-FAR-1. The rationale behind the study is 
described below. 
1.5.1 The structure and phosphatidic acid binding mechanism of the Nir2 
LNS2 domain 
The LNS2 domain of Nir2 has been proven to be a pivotal regulator of Nir2 PITP 
localisation, where the LNS2-PA interaction appears to play a central role. It is thus 
surprising that little to nothing is known about the PA binding mechanism of the LNS2 
domain and its three-dimensional structure. The structural and functional analysis of the 
LNS2-PA interaction will shed light on the mechanism of PA binding by the LNS2, and 
will help to better understand the role of the LNS2 domain in Nir2 PM targeting.  
Furthermore, determination of the atomic level details of the LNS2-PA binding could 
inform the development of an LNS2-PA interaction inhibitor tool compound, which could 
be used to obtain further insights into the cellular function of Nir2. Importantly, since the 
LNS2-PA interaction has been implicated in maintaining the signalling through MAP 
kinase and PI3K/Akt pathways (Kim et al., 2013), it is a possibility that PA recognition by 
Nir2 might play a role in cancer, where these key pathways are very often disrupted 
(Altomare and Testa, 2005; Martin, 2003; Sever and Brugge, 2015; Spiegel and Milstien, 
2003). Hence, structure determination of the LNS2 domain and/or the LNS2-PA complex 
and characterisation of PA binding by the LNS2 domain might aid the assessment of the 
potential of the Nir2 LNS2 as a drug target in cancer.  
To obtain the structural and functional information on LNS2-PA binding, this study aimed 
to: a) produce the LNS2 domain of Nir2 by recombinant expression, b) characterise the 
LNS2 domain binding to PA to determine what mechanisms are at play in the interaction 
and estimate the binding affinity, c) determine the three-dimensional structure of the LNS2 
domain in the PA-free and/or PA-bound form and map the PA binding site, d) use the 
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structural information to guide the development of the LNS2-PA inhibitor by in silico drug 
screening. 
1.5.2 The lipid binding mechanism of Na-FAR-1 
Although the structure of Na-FAR-1 has been determined and it was demonstrated that Na-
FAR-1 is able to form four distinct complexes with oleic acid, little else is known about its 
fatty acid binding mechanism. This includes the location of the putative long-chain fatty 
acid binding sites of Na-FAR-1, of which only one was identified. The recently discovered 
ability of Na-FAR-1 to interact with phospholipids also needs to be explored, and it is 
desirable to know whether Na-FAR-1 interacts with lysophospholipids, which are 
important extracellular mediators of inflammation. Furthermore, a better understanding of 
the mechanisms that underlie the relatively broad ligand specificity of Na-FAR-1 is also 
required. Answers to these questions may help to elucidate the biological function of Na-
FAR-1 and enhance our understanding of its role in parasitism.  
To obtain mechanistic details about the lipid binding by Na-FAR-1, this study aimed to: a) 
produce Na-FAR-1 by recombinant expression, b) confirm the phospholipid binding 
function of Na-FAR-1 in vitro, c) investigate whether Na-FAR-1 binds lysophospholipids, 
and d) determine the structure of Na-FAR-1 in complex with a fatty acid and in complex 
with a phospholipid, and compare the binding mechanisms. 
The experimental approaches used to achieve the aims stated in this section and in Section 
1.5.1 are described at the beginning of each relevant chapter of this thesis. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Protein accession numbers 
Protein sequences of Nir1-3 and RdgB were obtained from GenBank. Accession numbers 
are given in brackets: Nir1 (AAK01446), Nir2 (AAK01444), Nir3 (AAK01445), RdgB 
(CAA69291). Na-FAR-1 sequence was obtained from the Nematode Transcriptome 
Database (NEMBASE4; sequence ID NAC00128). 
2.1.2 Synthetic DNA 
Synthetic DNA fragments encoding the C-terminal domain portions of Nir1-3 and RdgB 
were purchased from GenScript (China). The DNA fragments were codon optimized for 
expression in E. coli. Synthetic DNA fragment encoding Na-FAR-1 was purchased from 
GeneArt AG (Germany), as described previously (Gabrielsen et al., 2012). 
2.1.3 Ligands 
Dihexanoyl (di-6:0), dioleoyl (di-18:1 cis-9) and egg yolk phosphatidic acid sodium salt 
and phosphatidylcholine were purchased from Avanti Polar Lipids. Oleic acid sodium salt, 
lysophosphatidic acid sodium salt, sn-glycerol 3-phosphate bis(cyclohexylammonium) salt 
and hexanoic acid were purchased from Sigma-Aldrich.  
2.1.4 Media recipes 
2.1.4.1 Lysogeny broth (LB) 
For 1 L: 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
dH2O to 1 L 
Autoclaved. 
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2.1.4.2 Autoinduction medium 
For 1 L: 
Tryptone 20 g 
Yeast extract 5 g 
NaCl 5 g 
dH2O to 1 L 
Autoclaved. 
60% glycerol (v/v), f.s. 10 ml 
10% glucose (w/v), f.s. 5 ml 
8% lactose (w/v), f.s. 25 ml 
Added to the autoclaved medium. f.s. = filter-sterilised. 
2.1.4.3 Terrific broth (TB) 
For 1 L: 
Tryptone 12 g 
Yeast extract 24 g 
80% glycerol (v/v) 5 ml 
dH2O to 900 ml 
Autoclaved.   
Hundred milliliters of 0.17 M KH2PO4, 0.72 M K2HPO4 filter-sterilised solution was added 
to the autoclaved medium. 
2.1.4.4 2x YT medium 
For 1 L: 
Tryptone 16 g 
Yeast extract 10 g 
dH2O to 1 L 
Autoclaved.   
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2.1.4.5 M9 minimal medium 
5x M9 salt solution, for 1 L: 
Na2HPO4 34 g 
KH2PO4 15 g 
NaCl 2.5 g 
dH2O to 1 L 
Autoclaved.  
 
M9 minimal medium, for 1 L: 
5x M9 salt solution 200 ml 
1 M MgSO4a 1 ml 
50 mM CaCl2a 1 ml 
20% (w/v) glucosea,b 15 ml 
NH4Clc 1 g 
50 mg/ml thiaminea 0.4 ml 
dH2O to 1 L 
a.  Filter-sterilised. 
b. 13C6-glucose for 13C labelling. 
c. 15NH4Cl for 15N labelling. 
 
 
2.2 Protein high-throughput expression screening at OPPF-UK 
Protein expression screening in E. coli and insect cells was carried out at Oxford Protein 
Production Facility-UK (OPPF-UK), as per the protocols given on the OPPF-UK website 
(www.oppf.rc-harwell.ac.uk, accessed on 02/07/2017) (Bird, 2016; Nettleship, 2016). The 
process is briefly described below. 
2.2.1 Molecular cloning  
Nir2, Nir3 and RdgB LNS2 domain fragments were amplified by PCR using a set of 
primers designed for ligation independent cloning. Forward primers contained 
AAGTTCTGTTTCAGGGCCCG adaptor sequence added to their 5’ end, reverse primers 
contained ATGGTCTAGAAAGCTTTA adaptor sequence added to their 5’ end. The 
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PCR-amplified fragments were cloned into 12 vectors of the pOPIN vector suite (Bird, 
2011) (pOPINE-3C-HALO7, pOPINEneo, pOPINF, pOPINHALO7, pOPINJ, pOPINM, 
pOPINTF, pOPINTRX) by using In-Fusion® Cloning Kit (Takara). Prior to InFusion® 
reaction, vectors were digested with KpnI and HindIII restriction endonucleases by the 
OPPF-UK staff. After cloning, the plasmids were transformed into OmniMaxII competent 
cells (Invitrogen) by heat-shock. The presence of the insert was validated by PCR and, in 
some cases, by Sanger sequencing (Source Bioscience, UK). For protein expression, the 
plasmids were transformed into Lemo21 (DE3) competent cells or Rosetta™ 2 (DE3) 
pLacI competent cells (NEB) or used to construct a recombinant baculovirus by using a 
bacmid produced by Ian Jones (University of Reading) for protein expression in insect Sf9 
cells (Thermo Fisher Scientific).  
2.2.2 Expression in E. coli 
Expression screening was carried out in a 96-well plate format. Individual colonies were 
picked from Lemo21 (DE3) and Rosetta™ 2 (DE3) pLacI agar plates and each was used to 
inoculate 0.7 ml of PowerBroth™ medium (Molecular Dimensions). The cultures were 
incubated overnight at 37 °C. The next day, 150 µl of Lemo21 (DE3) and 250 µl of 
Rosetta™ 2 (DE3) pLacI overnight culture were used to inoculate 3 ml aliquots of 
PowerBroth™ for IPTG-induced expression and 3 ml aliquots of OvernightExpress™ 
medium (Novagen) for expression with autoinduction.  
For IPTG induction, cultures in PowerBroth™ were shaken at 220-225 rpm, 37 °C for 
~ 4 hours, and cooled down to 20 °C whilst shaking at 220-225 rpm for 20 min. IPTG was 
added to the final concentration of 1 mM, and the cultures were incubated for ~ 18 hours at 
20 °C, shaking at 220-225 rpm.  
For autoinduction, cultures in the OvernightExpress™ medium were shaken at 220-225 
rpm, 37 °C for ~ 4 hours. The temperature of the shaker was then reduced to 25 °C and the 
cultures were shaken at 220-225 rpm for 24 hours.  
The cells were harvested by centrifugation at 6000 x g for 15 min. 
2.2.3 Purification from E. coli 
Cell pellets were briefly frozen at -80 °C, thawed and resuspended in lysis buffer (50 mM 
sodium phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 1% Tween 20) supplemented 
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with 1 mg/ml lysozyme and 3 units of Benzonase® nuclease (EMD Millipore). Cells were 
lysed by shaking on an orbital microplate shaker (30 min, ~ 1000 rpm) and lysates were 
centrifuged at 6000 x g for 30 min. Cleared lysates were used for Ni2+-affinity purification, 
which was carried out on QIAGEN BioRobot 8000. Lysates were mixed with 20 µl of 
QIAGEN Ni-NTA magnetic beads and shaken on an orbital microplate shaker for 30 min. 
Beads were separated from the supernatant using a QIAGEN magnet and the supernatant 
was discarded. Beads were washed with the wash buffer (50 mM sodium phosphate pH 
8.0, 300 mM NaCl, 20 mM imidazole, 0.05% Tween 20), and protein elution was carried 
out by the addition of 50 µl elution buffer (50 mM sodium phosphate pH 8.0, 300 mM 
NaCl, 250 mM imidazole, 0.05% Tween 20).  
2.2.4 Small-scale expression testing in insect cells 
Expression screening was carried out in a 24-well plate format. Sf9 cells were cultured in 
Sf-900 II serum-free medium (Thermo Fisher Scientific). For transfection with the bacmid 
and the plasmid encoding the protein constructs of interest, cells were grown to 
~ 5 x 105 cells/ml, and 0.5 ml of cells was added to each well. A mixture of bacmid 
(250 ng, 2.5 µl), recombinant plasmid (100 – 500 ng), transfection reagent FuGENE® HD 
(1.5 µl, Promega) and Sf-900 II medium (50 µl) was prepared and added to the cells. The 
plate was slowly swirled to allow the transfection mixture to disperse in the well. Cells 
were incubated for 6 days at 27 °C. After 6 days, the supernatant was removed from the 
cells and used as the P0 viral stock. Viral stocks were stored in the dark at 4 °C. 
Virus amplification, expression testing and virus scale-up was carried out by Mr Valtteri 
Järvinen (OPPF-UK). 
For production of P1 viral stock, 5 µl of P0 stock was added to 0.5 ml Sf9 cells 
(1.0 x 106 cells/ml) in each well. The cells were incubated for 6 days at 27 °C to allow viral 
amplification. The supernatant was then harvested and used as P1 stock.  
For expression testing, 3 or 30 µl of P1 stock was added to 3 ml of Sf9 cells 
(1.0 x 106 cells/ml) in each well. The cells were incubated at 27 °C for 3 days, shaking at 
250 rpm. After 3 days, 1 ml of cells was transferred from each well to a well in a 96-well 
plate. The plate was centrifuged for 15 min at 6000 x g to pellet the cells. Supernatant was 
discarded, and the cells were frozen at -80 °C. Protein purification was carried out as 
described above for E. coli. 
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2.2.5 Baculovirus scale-up and large-scale expression testing in insect cells 
P2 viral stock used for large-scale expression screening was produced as follows. Fifty-
milliliter suspension culture of Sf9 cells (1.0 x 106 cells/ml) was infected with 400 µl of P1 
virus. The culture was incubated at 27 °C for 6-7 days, shaking at 250 rpm, and the cells 
were then pelleted for 10 min at 1000 x g. The supernatant was harvested and used as P2 
virus stock.  
Large-scale protein expression was tested by infecting 2.5 L of Sf9 cells (1 x 106 cells/ml) 
in a Thomson flask with either 2.5 ml (1:1000 dilution) or 25 ml (1:100 dilution) of P2 
viral stock. The infected cultures were incubated at 27 °C for 3 days, shaking at 250 rpm. 
Samples (2 ml) were taken and used for Ni2+-affinity purification to assess the protein yield 
as described above. The remaining cultures were centrifuged at 6000 x g, frozen at -80 °C 
and used for large-scale protein purification. 
2.3 Molecular biology, protein expression and purification 
2.3.1 Molecular cloning into pNIC28-Bsa4 vector 
For cloning into pNIC28-Bsa4 vector, DNA fragments were amplified by PCR with a set 
of primers containing adaptor sequences for ligation independent cloning. Forward primers 
contained TACTTCCAATCCATG adaptor sequence added to their 5’ end, reverse primers 
contained TATCCACCTTTACTG adaptor sequence added to their 5’ end. Cloning was 
carried out using InFusion® Cloning Kit (Takara), as per manufacturer’s protocol. DNA 
sequence was confirmed by Sanger sequencing (service was provided by Source 
Bioscience, UK). 
2.3.2 Plasmid extraction 
Plasmids for cloning and protein expression were purified from 10 ml LB culture of 
E. coli. The culture was inoculated with a single bacterial colony and grown at 37 °C 
overnight, shaking at 225 rpm. Cells were harvested by centrifugation at 3000 x g. Plasmid 
purification was carried out using Wizard® Plus SV Miniprep DNA Purification System 
(Promega), as per manufacturer’s protocol. DNA was eluted by addition of 20-30 µl of 
nuclease free water supplied with the kit. Plasmid solutions were stored at -20 °C until 
required. 
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2.3.3 Large-scale protein expression in E. coli 
2.3.3.1 Production of proteins with natural isotope abundance 
Tuner (DE3) pLysS cells (Novagen) or T7 Express lysY/Iq cells (New England Biolabs) 
were used for large-scale protein expression. For expression, inoculation cultures (10 ml) 
were prepared in LB the day before and grown at 37 °C, 225 rpm overnight. The cultures 
were used to inoculate the expression media (typically, LB or TB), with 10 ml inoculation 
culture used per 0.5 L media. Expression cultures were grown until OD600 reached ~ 0.5-
0.7 in LB or ~ 1.0-1.4 in TB. All media were supplemented with an appropriate antibiotic, 
depending on the plasmid and the cell strain used. The antibiotics were used at the 
following concentrations: 100 µg/ml ampicillin, 30 µg/ml kanamycin or 25 µg/ml 
chloramphenicol. Protein expression was induced by addition of 0.4 mM IPTG, followed 
by an overnight incubation at 16 °C or 20 °C for expression of Nir2 and RdgB fragments, 
or by a 3-hour incubation at 37 °C for expression of Na-FAR-1, shaking at 225 rpm. Cells 
were harvested by centrifugation at 9000 rpm in Beckman J2-21 centrifuge using JA-21 
rotor. Cells were lysed by sonication (15 sec on/off pulses, 50% intensity) on a MSE 
Soniprep 150 (Sanyo) sonicator or by using a French press cell disruptor and purified by 
Ni2+-affinity chromatography (Ni-Superflow resin, Generon, UK).  
2.3.3.2 Production of isotope-labelled proteins for NMR spectroscopy 
For production of isotope-labelled Na-FAR-1 for NMR experiments, an alternative growth 
strategy was used. Expression cultures were initially grown in 2x YT medium until OD600 
reached ~ 1.5-2.0. After this, the cultures were centrifuged as described above, 
resuspended in M9 minimal medium (without nitrogen and carbon sources) and 
centrifuged again to remove any nutrients retained in the pellet after growth in 2x YT. The 
medium was then decanted and replaced with fresh M9 medium supplemented with 1 g/L 
15NH4Cl and 3 g/L glucose or 13C6-glucose (Sigma-Aldrich). The cultures were incubated 
for 1 hour at 20 °C, and protein expression was induced by addition of 0.4 mM IPTG, 
followed by overnight incubation at 20 °C. The cells were harvested the next day and lysed 
as described above.  
2.3.4 Large-scale protein expression in insect cells (adherent culture) 
Protein large-scale expression was carried out using P2 stock of the recombinant 
baculovirus produced by Mr Valtteri Järvinen at OPPF-UK. Sf9 cells (Thermo Fisher 
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Scientific) were grown at 27-28 °C in TC-100 Insect medium (Thermo Fisher Scientific) 
supplemented with 10% FBS (Thermo Fisher Scientific), which was heat-inactivated by 
30 min incubation at 56 °C in a water bath. Corning® 150 cm2 cell culture flasks with a 
plug seal cap were used for cell growth. Cells were infected at ~ 90% confluency with 
1:1000 dilution of the P2 stock, which was determined to be an optimal ratio of the virus to 
the culture in the small-scale expression trials carried out at OPPF-UK. After infection, 
cells were incubated for 72 hours at 27-28 °C, harvested by centrifugation at 1000 x g, and 
stored at -80 °C until required. Cells were lysed by a ~ 15 min incubation with the lysis 
buffer (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, 1 % Tween 20), 
gently rocking. The lysate was used for protein purification. 
2.3.5 Ni2+-affinity chromatography 
Ni2+-affinity chromatography was performed using Ni-Superflow resin (Generon, UK). 
Typically, ~ 0.5-1 ml of resin was used for protein purification from 1 L of LB culture or 
0.5 L of TB culture. Purification was carried out essentially as per manufacturer’s protocol. 
Typical chromatography buffers contained 50 mM Tris-HCl or NaPi pH 7.5, 300 mM 
NaCl, 1 mM TCEP, with 10 mM, 30 mM and 300 mM imidazole used in the binding, wash 
and elution buffer, respectively. After protein binding, the column was washed with 10-20 
CV of the wash buffer and protein was eluted with 3 CV of the elution buffer. All fractions 
were collected into 20 ml universal tubes and stored on ice or at 4 °C until required. 
2.3.6 Size-exclusion chromatography (SEC)  
Size-exclusion chromatography was carried out on ÄKTA explorer chromatography 
system (GE Healthcare) equipped with a Superdex 75 10/300 GL column (GE Healthcare) 
or Superdex 200 Increase 10/300 GL column (GE Healthcare) at 8 °C. Typical buffer 
solution contained 20 mM sodium phosphate or Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
TCEP and 0.01% NaN3. Buffer components were varied depending on the nature and 
downstream applications of the protein sample. Normally, 0.5 ml of sample was loaded 
onto the column at a concentration of ~ 1-15 mg/ml. Protein elution was carried out with 
2 CV of buffer, with the typical flow rate set to 0.4 ml/min. 
2.3.7 SEC coupled with multi-angle light scattering (SEC-MALS) 
Analysis by SEC-multi-angle light scattering (SEC-MALS) was carried out on an Alliance 
HPLC system (Waters) equipped with a BEH SEC 200 Å, 3.5 µm column (Waters). The 
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HPLC system was connected to Viscotek SEC-MALS 20 multi-angle scattering detector 
(Malvern) and Viscotek VE 3589 refractive index detector (Malvern). The protein sample 
was prepared in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM TCEP buffer, which was 
also used as a running buffer. The column was calibrated by using human serum albumin 
standards prior to each run.  
2.3.8 SDS-PAGE 
SDS-PAGE was carried out using RunBlue 4-20% SDS Precast Gels (Expedeon). Prior to 
electrophoresis, protein samples were mixed with NuPage® LDS Sample Buffer (Novex) 
with β-mercaptoethanol added to a final 5% (v/v) concentration and heated at 85 °C for 
5 min. Protein bands were resolved in RunBlue running buffer (60 mM Tris, 30 mM 
MOPS, 0.1% SDS). Electrophoresis was performed at 180-200 V (constant voltage) for 
~ 45 min. The gels were stained with InstantBlue™ (Expedeon) protein stain and images 
were acquired using Kodak Image Station 440CF. 
2.3.9 Protein digestion with HRV 3C protease  
Proteolytic digests were carried out using His6-tagged HRV 3C produced in our home lab. 
The activity of the protease was confirmed by comparison with a commercial GST-tagged 
HRV 3C PreScission Protease (GE Healthcare). The digests were performed in a 20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT, 10 mM EDTA buffer at 4 °C for 24-48 
hours. Approximately 1 µg of the protease was used for the cleavage of 10 µg of protein. 
2.3.10 Western blotting 
Protein samples were resolved by SDS-PAGE and transferred from polyacrylamide gels 
onto nitrocellulose membrane (Whatman Protran BA-83, pore size 0.2 µm) in 25 mM Tris, 
1.9 mM glycine, 20% methanol at 400 mA (constant current) for 45 min. The membrane 
was blocked by a 1 hour incubation with 5% fat-free milk solution in 20 mM Tris-HCl 
pH 7.6, 140 mM NaCl, 0.1% Tween-20 (TBST) at room temperature on a rocking 
platform. Membrane was washed three times with 5 ml TBST and incubated with a 
solution of a primary anti-His-tag mouse antibody (Abcam) in TBST for 2 hours at room 
temperature, gently rocking. After that, the membrane was washed again three times with 
TBST and incubated with a secondary anti-mouse ALP-conjugated antibody (Promega) in 
TBST for 1 hour at room temperature, gently shaking. After three final washes, the 
membrane was incubated with BCIP/NBT solution (Sigma-Aldrich) for 10 minutes at 
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room temperature to develop the protein bands. 
2.3.11 Reverse-phase high pressure liquid chromatography (HPLC) 
Reverse-phase HPLC (RP-HPLC) was carried out using a Supelco Discovery® BIO wide-
pore C18 column (Sigma-Aldrich) on an ÄKTA purifier (GE Healthcare) chromatography 
system. The column was pre-equilibrated with 10% acetonitrile solution in dH2O (10% 
ACN) containing 0.01% trifluoroacetic acid. The sample was prepared in 10% ACN before 
loading into the injection loop. The elution program consisted of four steps: 1) washing 
step with 10% ACN (0.5 CV), 2) increase in ACN concentration to 50% (0.5 CV), 3) 
increase in ACN concentration to 60% (2 CV) and 4) increase in ACN concentration to 
100% (1 CV). The flow rate was set to 4 ml/min. The fractions were collected during each 
elution step and stored at 4 °C, covered.  
2.3.12 Protein lyophilisation 
Protein lyophilisation was carried out on a Heto PowerDry LL1500 freeze dryer for ~ 16 
hours with the cold trap cooled to -110 °C. Prior to lyophilisation, protein samples were 
frozen in liquid nitrogen. The samples were monitored during first 10 minutes of 
lyophilisation. If any thawing of the sample was observed, it was refrozen. Dry protein was 
stored at -20 °C, and redissolved in a buffer of interest. 
2.3.13 Lipid extraction 
Lipid extraction for TLC was carried out essentially as described previously (Obal et al., 
2012). Three milligrams of protein were added to 5 ml chloroform and the mixture was 
vigorously shaken on ice for 10 min. The extract was washed with 200 µl of 3 M NaCl 
solution and centrifuged at 5000 x g for 15 minutes. The aqueous phase was removed by 
pipetting and chloroform was evaporated under a stream of dry N2. The dry lipids were 
redissolved in 200 µl chloroform and stored at -20 °C under a layer of N2 until required. 
2.3.14 Thin-layer chromatography 
Thin-layer chromatography was carried out on TLC Silica gel 60 plates (EMD Millipore). 
The plates were pre-washed with methanol/chloroform 1:2 mixture by volume and 
activated at 100 °C for 30 minutes. Approximately 5 µl lipid extract was spotted onto the 
plate and the lipids were allowed to dry under a stream of N2. The lipids were resolved in 
hexane/diethyl ether/acetic acid 80:20:1 mixture by volume, sprayed with 8% (w/v) CuSO4 
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solution in 10% (v/v) phosphoric acid and charred at 150 °C for 10 minutes until black 
spots appeared. 
2.4 Characterisation of protein-ligand binding 
2.4.1 Lipid overlay assay 
Phospholipids in chloroform were spotted onto nitrocellulose membrane (Whatman 
Protran BA-83, pore size 0.2 µm), ~ 10 µg of lipid per dot. Lipids were dried under a 
stream of N2 and the membrane was blocked with 1% fatty acid free BSA in 20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20 (TBST) buffer for 1 hour at room 
temperature. The membrane was incubated with ~ 20-30 nM protein overnight at 4 °C and 
washed three times with TBST. In the next step, the membrane was incubated with anti-
His tag primary mouse antibody (Abgent) in TBST (1:1000 dilution) for 2 hours at room 
temperature and again washed three times with TBST. Secondary anti-mouse antibody 
conjugated to alkaline phosphatase (Promega) in TBST was added to the membrane 
(1:2500 dilution). The membrane was incubated for 1 hour at room temperature, and was 
washed three times with TBST for the last time. The signal was obtained by incubating the 
membrane with NBT-BCIP solution (Sigma-Aldrich) for 10 minutes at room temperature. 
2.4.2 Liposome co-sedimentation assay (LSA) 
2.4.2.1 LSA using MLVs 
The protocol was essentially as described previously (Kim et al., 2013). Lipid films 
containing either egg yolk PC or a mixture of egg yolk PC and PA in 2:1 (w/w) ratio were 
prepared in glass vials by mixing the phospholipid solutions in chloroform and drying 
them under nitrogen gas stream for 15 minutes. Tris buffer (20 mM Tris-HCl pH 7.5, 
150 mM NaCl) was added to the lipid films to a total lipid concentration of 1 mg/ml. The 
films were allowed to hydrate at room temperature for 20 min, after which the vials were 
vigorously vortexed for 2 min to produce the multilamellar vesicle (MLV) suspension. The 
TF fusion of Nir2 LNS2 (5 µg in 50 µl Tris buffer) was mixed with 16.5 µl of MLV 
suspension. The mixture was incubated at room temperature for 20 minutes and 
centrifuged at 16000 x g, 4 °C for 30 minutes. The supernatant was separated from the 
pellet, and the pellet was resuspended in 21.5 µl of Tris buffer. Both fractions were used 
for analysis by SDS-PAGE. 
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2.4.2.2 Semi-quantitative LSA using LUVs 
Ten millimolar stock of LUVs in Tris buffer was prepared by extrusion as described in 
Section 2.4.4 below. Protein was prepared in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 
1 mM TCEP buffer, and centrifuged at 150,000 x g, 16 °C for 10 minutes to pellet any 
aggregated material. Protein solution and LUVs were mixed to prepare a series of samples 
with varying concentration of LUVs for analysis of PA binding affinity. Protein 
concentration was 2 µM in all samples. The samples were incubated for 20 minutes at 
room temperature and centrifuged at 150,000 x g, 16 °C for 30 minutes.  
2.4.3 Time-resolved fluorescence lifetime measurements  
Fluorescence lifetime measurements were carried out on a PicoQuant FluoTime 300 
fluorescence spectrometer by using time-correlated single photon counting (TCSPC) 
technology. The excitation source was a super continuum laser (WL-SC-400-4-PP, 
Fianium) with tunable wavelength filter and multimode fibre (Superchrome-Vis-FDS-MM, 
Fianium). The ligands and the protein were prepared in 20 mM Tris-HCl pH 7.5, 100 mM 
NaCl, 1 mM DTT. The DHPA-NBD concentration was 3 µM in the fluorescence lifetime 
measurement in the absence of the protein, and 2 µM in the measurements in the presence 
of the protein (8 µM). The concentrations of the ligand and the protein were determined by 
UV-Vis spectrophotometry using the reported NBD molar extinction coefficient of 
25,000 M-1cm-1 at 480 nm (Ladokhin et al., 2002) and the TF Nir2 LNS2 molar extinction 
coefficient of 37,550 M-1 cm-1 at 280 nm calculated from the protein amino acid sequence 
in CLC Genomics Workbench (QIAGEN). The decays were measured at 534 nm and the 
fluorophore was excited at 460 nm. Fitting of fluorescence decay data was carried out with 
FluoFit software (PiqoQuant) using the exponential model with reconvolution. The quality 
of the fits was assessed by χ2 values and the randomness of residuals.  
2.4.4 Preparation of large unilamellar vesicles (LUVs) by extrusion  
Dioleoyl PA and PC dissolved in chloroform were used for LUV preparation. Lipids were 
mixed in glass vials in 70:30 PC:PA ratio for use in the liposome co-sedimentation assay 
and CD spectroscopy. Lipids were dried under a stream of dry N2 for 15 minutes to obtain 
lipid films. The lipid films were hydrated by the addition of buffer containing 20 mM 
Tris-HCl pH 7.5, 150 mM NaCl and 1 mM DTT or 1 mM TCEP to yield a total lipid 
concentration of 10 mM. The lipid films were incubated in the buffer for 1 hour. After the 
incubation, the liposome suspension was vortexed to dissociate the liposomes from the 
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glass and subjected to 4 freeze-thaw cycles using a dry ice/ethanol bath and a 37 °C water 
bath. The liposomes were downsized by extrusion through a nitrocellulose membrane 
(0.1 µm pore size, Avanti Polar Lipids) with a mini-extruder (Avanti Polar Lipids) to yield 
a transparent LUV suspension.  
2.4.5 Steady-state fluorescence spectroscopy 
Steady-state fluorescence spectroscopy experiments were carried out using Perkin Elmer 
LS 50B fluorimeter.  
Stocks of 11-[5-(Dimethylamino)-1-naphthalenesulfonylamino]undecanoic acid (DAUDA, 
1.4 mM), dioleoyl PA (DOPA, 10 mM) and oleoyl lysoPA (OLPA, 10 mM) were prepared 
in methanol for use in the assay. DAUDA stock concentration was calculated using the 
molar extinction coefficient of 4800 M-1 cm-1 at 335 nm in methanol (Haugland and 
Spence, 1996). DAUDA was diluted with 20 mM sodium phosphate pH 7.2 buffer in a 
quartz-glass cuvette to a concentration of ~ 1.5 µM. Na-FAR-1 (0.5 µM) was added to 
DAUDA, followed by DOPA or OLPA titration. Fluorescence emission intensity 
(λex = 345 nm) was recorded after each step to monitor DAUDA displacement. Na-FAR-1 
concentration was calculated using molar extinction coefficient of 7680 M-1 cm-1 at 280 nm 
estimated from the protein primary sequence. 
2.4.6 NMR spectroscopy  
All NMR experiments were carried out on a Bruker 600 MHz Avance IIIHD NMR 
spectrometer fitted with a TCI cryoprobe. Protein and ligand samples were prepared in 
5 mm thin-walled NMR sample tubes (Wilmad). 
2.4.6.1 Ligand-observed NMR experiments 
For the analysis of LNS2 ligand binding, CPMG (Carr and Purcell, 1954; Meiboom and 
Gill, 1958), waterLOGSY (Dalvit et al., 2001) and standard 1H spectra with water 
suppression were recorded out at 288 K. Protein samples (~ 10 µM) were prepared in 20 
mM sodium phosphate pH 7.5, 5% D2O. Dihexanoyl PA in d6-DMSO or dH2O were 
titrated into the protein samples in a series of steps. Dihexanoyl PC, hexanoic acid, oleic 
acid sodium salt and sn-glycerol 3-phosphate bis(cyclohexylammonium) salt were used at 
a concentration of 100 µM. 
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2.4.6.2 Chemical shift perturbation analysis 
Chemical shift perturbation caused by dioleoyl PA (DOPA) binding to 15N-labelled 
Na-FAR-1 was analysed in a series of 1H-15N heternonuclear single quantum coherence 
(HSQC) and SOFAST heternonuclear multiple quantum coherence (HMQC) (Schanda and 
Brutscher, 2005) experiments. For the analysis, DOPA sodium salt was prepared in 
methanol-d4 at ~ 10 mM concentration. DOPA was added to the protein sample in a series 
of titration steps until the apparent saturation of binding was reached.  
2.4.6.3 Double- and triple-resonance experiments for structure determination 
In order to prepare the complex of Na-FAR-1 with DOPA, DOPA in chloroform was 
added to a clean NMR tube, the solvent was evaporated in the stream of dry N2 and the dry 
lipid film was hydrated by the addition of Na-FAR-1 solution (0.5 mM) in 20 mM sodium 
phosphate pH 7.2, 0.01% NaN3 buffer to the final ligand concentration of 3.5 mM (7-fold 
excess of ligand to the protein). The phospholipids were mixed into the protein solution by 
gentle pipetting and the mixture was incubated at 35 °C for 2-4 hours until the sample 
became transparent and the phospholipid binding to the protein had equilibrated. 
The backbone resonances of Na-FAR-1 complex with DOPA were assigned with the help 
of 2D 1H, 15N HSQC and 3D HNCA, HNCO, HNcoCA, HBHANH, HBHAcoNH, 
CBCAcoNH, CBCANH (Grzesiek and Bax, 1993, 1992a; Kay et al., 1993; Muhandiram 
and Kay, 1994) and 15N NOESY-HSQC (Marion et al., 1989a, 1989b; Zuiderweg and 
Fesik, 1989) experiments. Side-chain resonance assignment was carried out using 2D 1H, 
13C HSQC, and 3D HCccoNH-TOCSY (Montelione et al., 1992), HCcH-,  hCCH-TOCSY 
(Bax et al., 1990) and 13C NOESY-HSQC experiments. The acquisition parameters of the 
protein NMR experiments are summarised in Table 2-1. Resonance assignments were 
performed using CcpNmr Analysis software (Vranken et al., 2005). Distance restraints 
were obtained from 15N and 13C NOESY-HSQC spectra. Dihedral restraints were obtained 
from the chemical shifts of assigned backbone resonances using DANGLE (Cheung et al., 
2010).  
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 F1 F2 F3   
 
Experiment 
 
Na 
ATb  
(s) 
SWc 
(ppm) 
Od 
(ppm) 
 
N 
AT  
(s) 
SW 
(ppm) 
O 
(ppm) 
 
N 
AT  
(s) 
SW 
(ppm) 
O 
(ppm) 
NUSe 
(%) 
 
Solvent 
 
Pulse seq.f 
1H, 15N HSQC 15N 0.1065 21.00 116.0 1H 0.1003 16.03 4.702      H2O/D2O fhsqcf3gpph 
1H, 15N HMQC 15N 0.0702 30.00 115.0 1H 0.1024 16.67 4.698      H2O sfhmqcf3gpph 
hbCBcgcdHD 13C 0.0106 40.00 39.00 1H 0.1065 16.03 4.702      D2O hbcbcgcdhdgp 
hbCBcgcdceHE 13C 0.0038 40.00 39.00 1H 0.1065 16.03 4.702      D2O hbcbcgcdcehegp 
aro 1H, 13C TROSY 13C 0.0106 40.16 120.0 1H 0.1217 14.03 4.702      D2O trosyargpphwg 
13C-filtered NOESY 1H 0.0640 4.702 4.702 1H 0.1024 16.67 4.702      D2O noesygpphwgx1 
HNCA 13C 0.0067 75.00 54.00 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 20 H2O hncagpwg3d 
CBCANH 13C 0.0067 75.00 39.40 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 20 H2O hncacbgpwg3d 
CBCAcoNH 13C 0.0067 75.00 43.00 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 20 H2O cbcaconhgpwg3d 
HNCO 13C 0.0193 22.00 176.0 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 25 H2O hncogpwg3d 
HNcaCO 13C 0.0193 22.00 176.0 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 25 H2O hncacogpwg3d 
HBHANH 1H 0.0133 8.00 4.702 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 25 H2O hbhanhgpwg3d 
HBHAcoNH 1H 0.0133 8.00 4.702 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 25 H2O hbhaconhgpwg3d 
HCcH-TOCSY 1H 0.0260 8.33 4.702 13C 0.0080 33.00 29.50 1H 0.1024 16.67 4.702 40 H2O hcchdigp3d 
hCCH-TOCSY 13C 0.0092 75.00 29.50 13C 0.0080 33.00 29.50 1H 0.1065 16.02 4.702  D2O hcchdigp3d2 
hCCcoNH-TOCSY 13C 0.0113 75.00 39.00 15N 0.0235 21.00 116.0 1H 0.1024 16.67 4.702 33 H2O hccconhgpwg3d3 
13C NOESY-HSQC 1H 0.0267 12.50 4.702 13C 0.0080 33.00 62.50 1H 0.1024 16.67 4.702 25 H2O noesyhsqcetgp3d 
15N NOESY-HSQC 1H 0.0267 12.50 4.702 15N 0.0256 20.50 116.0 1H 0.1024 16.67 4.702 25 H2O noesyhsqcf3gp193d 
a. Nucleus. 
b. Acquisition time. In NOESY-HSQC, acquisition in F2 was carried in the Echo-Antiecho mode. In all other experiments, acquisition in the indirect dimensions was carried in the States-TPPI 
mode. 
c. Spectral width.  
d. Transmitter frequency offset. 
e. Amount of non-uniform sampling. 
f. The noesyhsqcf3gp193d pulse sequence was modified to improve water suppression. In all other experiments, standard Bruker pulse sequences were used. 
Table 2-1. Acquisition parameters of the protein NMR experiments carried out in this study. 
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2.4.7 Protein crystallisation, data collection and processing 
2.4.7.1 Na-FAR-1 complex with oleic acid 
RP-HPLC purified protein was prepared in pure dH2O at 5 mg/ml or 10 mg/ml 
concentration. Oleic acid sodium salt was added in a 4-fold molar excess to the protein for 
co-crystallisation. Crystallisation was carried out using JCSG+ and PACT Premier screens 
(Molecular Dimensions) by sitting drop vapour diffusion method. For crystallisation, 0.5 µl 
protein was mixed with reservoir solution in 1:1 ratio by Cartesian Honeybee robot 
(Genomic Solutions) at room temperature. The plates were incubated at 16 °C. 
Cubic crystals were observed after 24 hours in JCSG+ condition C6 
(0.1 M phosphate-citrate pH 4.2, 40% PEG-300) and were grown further for 10 days. 
Largest crystal (approximate dimensions = 150 x 150 x 150 µm) was frozen without any 
further cryoprotection in liquid N2 and used for remote data collection at Diamond Light 
Source (Research Complex at Harwell, Oxfordshire, UK) beamline I03. Two data sets 
were merged and processed by xia2 (Winter, 2010) using the flag -3dii for XDS (Kabsch, 
2010) pipeline to produce the working data set.  
2.4.7.2 Na-FAR-1 complex with DOPA 
RP-HPLC purified protein was prepared in dH2O at 5 mg/ml or 10 mg/ml concentration. 
Dioleoyl PA (DOPA) sodium salt was added to the protein in 7-fold molar excess and the 
mixture was incubated at 35 °C for ~ 2 hours to allow ligand binding to the protein. The 
sample was centrifuged at 11000 x g table-top microcentrifuge to pellet the unbound 
DOPA. The supernatant was transferred to a clean Eppendorf tube and used for 
crystallisation screening. Crystallisation screening was carried out using JCSG+ and PACT 
Premier screens (Molecular Dimensions). The screens were prepared as described for Na-
FAR-1 complex with oleic acid.  
No protein crystals were obtained. 
2.4.7.3 The TF and MBP fusions of Nir2 LNS2 domain 
TF Nir2 LNS2 samples for crystallisation screening were prepared in 20 mM Tris-HCl 
pH 7.5, 0.5 mM TCEP at 4 mg/ml and 10 mg/ml concentrations. MBP RdgB LNS2 
samples were prepared in 10 mM Tris-HCl pH 7.5, 5 mM maltose. Crystallisation 
screening was carried out using JCSG+ and PACT Premier screens (Molecular 
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Dimensions). The crystallisation screening trays were prepared as described for Na-FAR-1 
complex with oleic acid.  
No protein crystals were obtained. 
2.4.8 CD spectroscopy 
CD spectroscopy was carried out on a Jasco J-810 spectrapolarimeter. Quartz cuvettes with 
0.02 cm path-length were used for measurements. TF Nir2 LNS2-S samples with or 
without LUVs (1 mM) were prepared in 20 mM Tris-HCl pH 7.5, 150 mM NaCl. The 
protein concentration was 0.71 mg/ml. Nir1 LNS2-S (0.12 mg/ml) was prepared in 50 mM 
Tris-HCl pH 7.5, 300 mM NaCl. Spectra recorded from the buffer-only or liposome-only 
samples were subtracted from the spectra recorded from the protein-containing samples to 
correct for background light scattering. Measured ellipticity values were converted into the 
molar ellipticity values by correcting for protein concentration in the sample. TF Nir2 
LNS2-S spectra were analysed using K2d algorithm developed by Andrade et al. (Andrade 
et al., 1993). The spectrum of Nir1 LNS2-S was analysed using the CDSSTR algorithm 
(Sreerama and Woody, 2000), a modification of VARSLC algorithm developed by 
Johnson (Compton and Johnson, 1986; Manavalan and Johnson, 1987), using reference 
data set 7. The analysis was carried out on DICHROWEB (Whitmore and Wallace, 2004). 
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3. Protein expression and purification 
Biochemical and structural characterisation of proteins and protein-ligand interactions 
typically requires milligram amounts of pure, homogenous protein. There are two ways of 
obtaining protein for characterisation: purification from natural source or recombinant 
expression. Protein purification from natural source is ridden with technical difficulties, 
costly, time-consuming and is often limited to proteins that are expressed at high levels in 
the organism of interest. Conversely, recombinant protein expression, which involves 
introduction of an artificial gene encoding the protein of interest into a heterologous host, 
is a cost-effective, scalable and often quick method of obtaining large amounts of pure 
protein. Hence, recombinant expression was used as the method-of-choice for producing 
Na-FAR-1 and the LNS2 domain-containing C-terminal fragments of the human Nirs and 
Drosophila RdgB proteins for their characterisation.  
In previous studies, Na-FAR-1 was successfully produced and purified for structure 
determination by X-ray crystallography and NMR spectroscopy. It was expressed to high 
levels from a pET-based expression vector and proved to be stable during manipulations 
required for structural investigations. Hence, existing protocols were employed for 
expression and purification of Na-FAR-1 with a few modifications allowing a higher yield 
of the 15N-labelled protein to be achieved for NMR spectroscopy. 
As opposed to Na-FAR-1, the C-terminal fragments of Nirs and RdgB have been 
previously produced only in small quantities for biochemical lipid binding assays (Chang 
and Liou, 2015; Kim et al., 2013). Because of the difficulty of producing recombinant 
Nir1-3 and RdgB fragments that was observed early in this project, a significant amount of 
work had to be carried out to identify the constructs and conditions that enabled sufficient 
yield of recombinant proteins to be obtained for characterisation. 
Below, the detailed process of designing, cloning, expressing and purifying of the LNS2 
domain-containing fragments of Nir1-3 and RdgB will be described. The process of Na-
FAR-1 expression and purification will be touched upon in less detail owing to the ease of 
Na-FAR1 production and the small number of optimisations that were carried out. 
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3.1. The LNS2 domain of Nir1-3 and RdgB 
3.1.1 Recombinant protein expression strategy 
Many recombinant expression systems have been developed over the years to suit different 
research needs. These can be divided into prokaryotic [e.g, Escherichia coli (Baneyx, 
1999; Makrides, 1996), Brevibacillus chosinensis (Mizukami and Miyauchi, 2010)] 
eukaryotic [e.g., insect cells (Jarvis, 2009), mammalian cells (Jäger et al., 2015), yeast 
(Mattanovich et al., 2012)] and cell-free systems (Carlson et al., 2012). Important 
considerations in choosing the suitable expression systems are the cost-effectiveness of the 
system, the source organism of the protein, ease of manipulation, the time required for 
protein expression and scalability of expression. 
The most commonly used expression system is E. coli, which has many advantageous 
properties for protein production. These include fast growth rates, high recombinant 
protein yields, ease of cell transformation, availability of a range of expression vectors, 
growth media and cell strains, and good understanding of E. coli genetics and protein 
expression machinery. In addition, the relative ease of isotope-labelled protein production 
in E. coli offers a specific advantage for structural investigations using biomolecular NMR 
spectroscopy, which relies heavily on the use of isotope-labelled proteins.  
Nevertheless, there are also a number of disadvantages associated with the use of E. coli 
for expression of eukaryotic proteins such as Nir2, our protein of interest. Eukaryotic 
proteins often fail to express and/or fold in the prokaryotic expression systems due to lack 
of the eukaryotic protein expression and folding machinery, the absence of the post-
translational modifications, inadequate formation of disulfide bridges or the high rate of 
translation in prokaryotic cells. However, many strategies exist to circumvent these 
problems, including protein secretion to the periplasm for disulfide-bond formation, co-
expression with molecular chaperones such as trigger factor (TF) (Nishihara et al., 2000) 
for enhanced protein folding or the use of solubility-enhancing fusion partners such as 
maltose-binding protein (MBP) (Kapust and Waugh, 1999) or thioredoxin (Trx) (LaVallie 
et al., 2000) for increased stability and solubility. 
In this study, E. coli was chosen as the primary expression system due to the advantages 
described above and the presence of the technical facilities suitable for E. coli cultivation. 
Additionally, LNS2 domain expression was also tested in Spodoptera frugiperda Sf9 cells 
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to determine whether expression in eukaryotic system is preferred for the protein of 
interest. 
3.1.2 Design of the LNS2 domain fragments for recombinant expression 
The LNS2 domain of Nir2 was chosen as the primary target for the investigation due to its 
regulatory function in PI(4,5)P2 signalling, as described in Chapter 1. However, expression 
of the LNS2 domains of three close Nir2 homologs (Nir1, Nir3 and RdgB) was also 
attempted. This was done to increase the probability of obtaining soluble protein, as even 
small variations in the amino acid sequence of homologous domain are known to influence 
protein yields in recombinant expression.  
It also is often the case that the yield and solubility of a recombinant protein domain 
depends on the choice of expression boundaries when designing the construct (Edavettal et 
al., 2012). Hence, two different fragments containing the LNS2 domain were designed for 
each of the four proteins, the ‘short’ fragment (LNS2-S) and the ‘long’ fragment 
(LNS2-L), which differed in the length of the sequence flanking the LNS2 domain. The 
LNS2-S fragments contained the LNS2 domain flanked by a few neighbouring residues, 
whereas LNS2-L comprised the LNS2 domain as well as the larger portion of the C-
terminal part of the protein. To give an example, the LNS-S and the LNS2-L fragments of 
Nir2 comprised amino acids 995-1221 and 911-1244, respectively (Fig 3-1). The full list of 
the fragments is given in Table 3-1.  
The boundaries of the LNS2 domain were determined by analyzing the C-terminal portions 
of Nir1-3 and RdgB using Simple Modular Architecture Research Tool (SMART, 
www.smart.embl-heidelberg.de) (Letunic et al., 2015; Schultz et al., 1998) and Protein 
BLAST (www.blast.ncbi.nlm.nih.gov/) (Altschul et al., 1997) to identify conserved 
sequence that might delineate the extent of the domain. Additionally, the C-terminal 
fragments of the proteins were subjected to analysis by the disorder predicting algorithm 
VL-XT (Li et al., 1999) using Predictor of Naturally Disordered Regions (PONDR, 
www.pondr.com) and the secondary structure predicting algorithm JNet (Drozdetskiy et 
al., 2015) using JPred 4 (http://www.compbio.dundee.ac.uk/jpred/) to identify the likely 
ordered and structured regions in the C-terminal parts of the protein containing the LNS2 
domain. Based on SMART, protein BLAST, JPred 4 and PONDR analyses, the expression 
fragments were chosen in such a way that they contained a complete LNS2 homology 
region and an additional stretch of residues at the both termini of LNS2-S and the 
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N-terminus of LNS2-L that are predicted to be ordered. The sequences were chosen such 
that they started and ended with hydrophilic, polar residues. This was assumed to increase 
the likelihood of production of a stable and soluble protein by ensuring the lack of exposed 
hydrophobic residues that may interact in an inter-molecular fashion and cause protein 
aggregation. The intention was also to improve the chance of crystallising each protein, as 
the presence of the disordered regions at the protein termini may lead to sample 
inhomogeneity and inhibit crystal formation. The LNS2-L fragment of Nir2 was chosen to 
be identical to the Nir2 fragment expressed in E. coli in two previous studies (Chang and 
Liou, 2015; Kim et al., 2013). 
Protein Fragment Residues* 
Nir1 LNS2-S 726-895 
Nir1 LNS2-L 726-971 
Nir2  LNS2-S 995-1171 
Nir2 LNS2-L 911-1244 
Nir3 LNS2-S 1057-1261 
Nir3 LNS2-L 1057-1341 
RdgB LNS2-S 1046-1198 
RdgB LNS2-L 1001-1250 
* Residue numbers in the full-length protein. 
 
 
 
 
 
3.1.3 Creation of the high-throughput expression construct library  
After selecting the C-terminal fragments of Nir proteins and RdgB to produce, a library of 
recombinant constructs for high-throughput expression screening of the protein fragments 
Figure 3-1. Schematic representation of the LNS2 domain-containing Nir2 fragments used 
for recombinant expression. Full-length Nir2 is shown for comparison. 
Table 3-1. Fragments of Nir1-3 and RdgB proteins used for recombinant protein 
expression. 
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was generated using the vectors of the pOPIN vector suite (Bird, 2011). The pOPIN suite 
allows rapid production of constructs for protein expression with a variety of solubility-
enhancing fusion partners and purification tags, and is suitable for expression screening in 
E. coli, insect and mammalian cells, which aids the identification of optimally expressed 
constructs in a relatively short timeframe. The library creation and screening was carried at 
the Oxford Protein Production Facility (OPPF-UK) located at the Research Complex at 
Harwell in Oxfordshire, UK under the guidance of Dr Louise Bird and with help from Mr 
Valtteri Järvinen.  
Due to the limited time available at the OPPF-UK for creation and testing of the expression 
constructs, only the fragments of Nir2, Nir3 and RdgB proteins were chosen for the high-
throughput screening. Of these three, the majority of the constructs were created with the 
LNS2 domains of Nir2 and RdgB owing to the relatively large evolutionary distance 
between Nir2 and RdgB compared to Nir2 and Nir3, and hence the higher possibility of 
observing differences in the expression yield and stability of the protein fragments. 
The cloning was carried out using In-Fusion® ligation independent cloning kit (Raman and 
Martin, 2014). For cloning, each Nir and RdgB fragment was amplified by PCR from a 
synthetic DNA template, which was codon-optimised for expression in E. coli (See 
Appendix A for the list of the PCR primers). The fragments were cloned into a set of 
pOPIN vectors pre-digested with HindIII and KpnI restriction endonucleases. The presence 
of the insert in the reconstituted vectors was confirmed by PCR and, in some instances, by 
Sanger sequencing. Subsequently, the constructs were transformed into E. coli or used for 
creation of recombinant baculovirus for insect cell expression.  
Additionally, a number of polyhistidine-tagged Nir and RdgB constructs were produced by 
ligation independent cloning in our home laboratory using a pNIC28-Bsa4 vector. The full 
list of the constructs created in this study for expression screening of Nir and RdgB LNS2 
domains is given in Tables 3-2A-B.  
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Protein Fragment Plasmid Tag 
Nir1 LNS2-S pNIC28-Bsa4 N-H6 
Nir1 LNS2-L pNIC28-Bsa4 N-H6 
Nir2 LNS2-S pOPINF N-H6 
Nir2 LNS2-L pOPINF N-H6 
Nir2 LNS2-S pOPINE-3C-HALO7 HALO7-H6-C 
Nir2 LNS2-L pOPINE-3C-HALO7 HALO7-H6-C 
Nir2 LNS2-S pOPINEneo H6-C 
Nir2 LNS2-L pOPINEneo H6-C 
Nir2 LNS2-S pOPINF N-H6 
Nir2 LNS2-L pOPINF N-H6 
Nir2 LNS2-S pOPINHALO7 N-H6-HALO7 
Nir2 LNS2-L pOPINHALO7 N-H6-HALO7 
Nir2 LNS2-S pOPINJ N-H6-GST 
Nir2 LNS2-L pOPINJ N-H6-GST 
Nir2 LNS2-S pOPINM N-H6-MBP 
Nir2 LNS2-L pOPINM N-H6-MBP 
Nir2 LNS2-S pOPINNUSA N-H6-NusA 
Nir2 LNS2-L pOPINNUSA N-H6-NusA 
Nir2 LNS2-S pOPINS3C N-H6-SUMO 
Nir2 LNS2-L pOPINS3C N-H6-SUMO 
Nir2 LNS2-S pOPINTF N-H6-TF 
Nir2 LNS2-L pOPINTF N-H6-TF 
Nir2 LNS2-S pOPINTRX N-H6-Trx 
Nir2 LNS2-L pOPINTRX N-H6-Trx 
Nir2 LNS2-S pNIC28-Bsa4 N-H6 
Nir2 LNS2-L pNIC28-Bsa4 N-H6 
Nir3 LNS2-S pOPINEneo H6-C 
Nir3 LNS2-S pOPINF N-H6 
Nir3 LNS2-S pOPINHALO7 N-H6-HALO7 
Nir3 LNS2-S pOPINJ N-H6-GST 
Nir3 LNS2-S pOPINM N-H6-MBP 
Nir3 LNS2-S pOPINS3C N-H6-SUMO 
Nir3 LNS2-S pOPINTRX N-H6-Trx 
Nir3 LNS2-S pOPINEneo H6-C 
Nir3 LNS2-S pNIC28-Bsa4 N-H6 
Nir3 LNS2-L pNIC28-Bsa4 N-H6 
 
Table 3-2A. Expression constructs of Nir1-3 designed in this study. The names and positions of 
the solubility and purification tags are given in the last column. N- or -C = N- or C-terminal tag, H6 
= hexahistidine tag, GST = glutathione transferase, MBP = maltose-binding protein, TF = trigger 
factor, Trx = thioredoxin. 
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Protein Fragment Plasmid Tag 
RdgB LNS2-S pOPINE-3C-HALO7 HALO7-H6-C 
RdgB LNS2-L pOPINE-3C-HALO7 HALO7-H6-C 
RdgB LNS2-S pOPINEneo H6-C 
RdgB LNS2-L pOPINEneo H6-C 
RdgB LNS2-S pOPINF N-H6 
RdgB LNS2-L pOPINF N-H6 
RdgB LNS2-S pOPINHALO7 N-H6-HALO7 
RdgB LNS2-L pOPINHALO7 N-H6-HALO7 
RdgB LNS2-S pOPINJ N-H6-GST 
RdgB LNS2-L pOPINJ N-H6-GST 
RdgB LNS2-S pOPINM N-H6-MBP 
RdgB LNS2-L pOPINM N-H6-MBP 
RdgB LNS2-S pOPINNUSA N-H6-NusA 
RdgB LNS2-L pOPINNUSA N-H6-NusA 
RdgB LNS2-S pOPINS3C N-H6-SUMO 
RdgB LNS2-L pOPINS3C N-H6-SUMO 
RdgB LNS2-S pOPINTF N-H6-TF 
RdgB LNS2-L pOPINTF N-H6-TF 
RdgB LNS2-S pOPINTRX N-H6-Trx 
RdgB LNS2-L pOPINTRX N-H6-Trx 
RdgB LNS2-S pNIC28-Bsa4 N-H6 
 
Table 3-2B. Expression constructs of RdgB designed in this study. The names and the locations 
of solubility and purification tags are given in the last column. N- or -C = N- or C-terminal tag, H6 
= hexahistidine tag, GST = glutathione transferase, MBP = maltose-binding protein, TF = trigger 
factor, Trx = thioredoxin. 
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3.1.4 High-throughput expression screening of Nir2, Nir3 and RdgB LNS2 
domain in E. coli and insect cells 
3.1.4.1 Expression in E. coli 
The high-throughput expression screening was carried out in Lemo21 (DE3) and Rosetta 
cells either in Overnight Express™ autoinduction medium or TB medium with IPTG 
induction. The recombinant proteins were purified from 2 ml of lysate by Ni2+-affinity 
chromatography, and protein elution fractions were analysed by SDS-PAGE to identify the 
expression constructs exhibiting the highest expression levels of Nir2-3 and RdgB LNS2 
domain fragments. 
The LNS2 domains from the different proteins displayed somewhat different protein 
yields. Namely, RdgB LNS2 fragments appeared to be expressed slightly better than Nir2 
and Nir3 fragments, with expression of 7 out of 20 constructs detected for RdgB, 5 out of 
20 for Nir2, and 2 out of 10 for Nir3 (Fig 3-2, 3-3). The best overall protein yield was 
observed in Lemo21 cells grown in Overnight Express™ medium, whereas protein yields 
obtained with IPTG induction were lower, as judged from the intensity of the recombinant 
bands. This result was not unexpected, as Overnight Express™ medium supports higher 
cell densities than the rich medium used with IPTG induction. 
Expression screening revealed that the LNS2 domain is a difficult protein to produce. It 
was observed that most LNS2 domain constructs containing short purification tags such as 
His6-tag, GST (Harper and Speicher, 2001) or SUMO (Malakhov et. al, 2004; Marblestone 
et al., 2006) either failed to express or showed very low protein yield, as the corresponding 
bands were not clearly visible on the polyacrylamide gels. An exception is the thioredoxin 
(Trx) fusion of RdgB LNS2-L, which notably was present in the cell lysate only after 
expression in the autoinduction medium, and not after expression in the rich medium with 
IPTG induction.  
Generally, only bands containing high molecular weight (MW) (> 65 kDa) fusions of the 
LNS2 domain, i.e. Trigger factor (TF), N-utilisation substance A (NusA) (Davis et al., 
1999) and maltose-binding protein (MBP) fusions, were detectable on the gels. Of these, 
the intensity of the bands corresponding to the MBP fusion of Nir2 LNS2-S and LNS2-L, 
the NusA fusion of Nir2 LNS2-S, the TF fusion of Nir2 LNS2-L, the SUMO fusion of 
Nir3 LNS2-S, the Trx fusion of Nir3 LNS2-S, the NusA fusion of RdgB LNS2-L and the 
Trx fusion of RdgB LNS2-L was weak and comparable to the intensity of the endogenous 
  
74 
E. coli protein bands observed in the gel. In contrast, the bands corresponding to the TF 
fusion of Nir2 LNS2-S, the MBP fusion of RdgB LNS2-L, and the TF fusion of RdgB 
LNS2-S and LNS2-L were intense and clearly stood out of the background, indicating that 
the expression yield of those constructs was relatively high. Here, the TF fusion of Nir2 
LNS-S fusion demonstrated the highest expression yield compared to other recombinant 
proteins, and hence appeared to be the most promising candidate for expression scale-up.  
It is unclear why the majority of LNS2 fusion proteins exhibited very low expression levels 
in E. coli, but the possible explanations include the lack machinery necessary for 
successful folding of mammalian proteins or post-translational modifications in bacterial 
cells, general poor solubility of LNS2 domain or the toxic effects it may have on the cells. 
Not entirely unexpected, TF and MBP appeared to be most successful at solubilising the 
fragments, which is consistent with the previous evidence demonstrating their 
effectiveness as solubility tags (Kapust and Waugh, 1999; Lebendiker and Danieli, 2014). 
 
 
 
Figure 3-2. SDS-PAGE analysis of Nir2 and Nir3 LNS2 high-throughput expression screening in 
E. coli. Ni2+-affinity purified lysates are shown. Coomassie® protein staining. A. Nir2 LNS2 
expression with IPTG induction in rich medium. B. Nir2 LNS2 expression with autoinduction in 
Overnight Express™ medium. C. Nir3 LNS2 expression with IPTG induction in rich medium. D. Nir3 
LNS2 expression with autoinduction in Overnight Express ™ medium. Recombinant protein bands are 
marked by white asterisks. The intense band in the N-H6-Halo7 L lanes corresponds to Halo7 
expressed without the recombinant LNS2 fragment or a degradation product of the fusion protein. The 
names of the LNS2 domain constructs tested are specified below the lanes (S = LNS2-S, L = LNS2-L). 
Types and positions of the recombinant expression tags are specified above the lanes. N = N-terminal 
tag, C = C-terminal tag. H6 = hexahistidine tag, GST = glutathione S-transferase, MBP = maltose 
binding protein, SUMO = small ubiquitin-like modifier, TF = trigger factor, Trx = thioredoxin. 
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3.1.4.2 Expression in insect cells 
In contrast to E. coli, insect cells (Sf9) appeared more efficient at producing recombinant 
LNS2. As judged by SDS-PAGE analysis (Fig 3-4), a variety of lower MW (< 65 kDa) 
LNS2 fusion proteins appeared to be expressed at markedly higher levels than in E. coli 
allowing their detection by Coomassie® staining. This included a 37 kDa C-terminally 
His-tagged Nir2 LNS2-L construct, which was thought to be suitable for analysis by 
protein NMR and X-ray crystallography due its small size and the absence of large fusion 
partners that have been reported to inhibit protein crystallisation. Interestingly, the 
analogous N-terminally His6-tagged LNS2-L construct was expressed to much lower yield, 
suggesting that the position of the tag can influence the efficiency of LNS2 domain 
expression in insect cells. 
In contrast to screening in E. coli, Nir2 constructs were generally better expressed than 
RdgB constructs in insect cells. Expression of eleven Nir2 constructs was detected, 
compared to only nine RdgB constructs. Interestingly, expression of His6-tagged RdgB 
fragments was not detected at all. The LNS2 domain of Nir3 has demonstrated the lowest 
protein yield compared to Nir2 and RdgB. The reason for the observed differences in 
expression is unknown, but has probably to do with the differences in the physiochemical 
properties of the constructs arising from the variations in the primary sequence. 
Furthermore, in insect cell, the longer LNS2-L fragments demonstrated higher expression 
levels that the shorter LNS-S fragments. This was also in contrast with screening in E. coli, 
where fusions with the short LNS2 fragment were expressed to higher yield. This might 
suggest that the extra protein sequence flanking the LNS2 domain in LNS2-L fragments 
aids its folding in eukaryotic cells.  
Based on the satisfactory results of expressing screening in insect cells, large-scale 
overexpression of C-terminally His6-tagged Nir2 LNS2-L construct was attempted, as 
described below. Expression of other constructs was not taken further due to time 
constraints and the fact that some of the large LNS2 domain fusions had already 
demonstrated reasonable expression levels in E. coli. 
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   Figure 3-3. SDS-PAGE analysis of RdgB LNS2 high-throughput expression screening in E. coli. Ni2+-affinity purified lysates are shown. Coomassie® protein staining. Recombinant 
protein bands are marked by white asterisks. Type and position of recombinant tags are specified 
above the lanes. The intense band in the N-H6-Halo7 S lanes corresponds to Halo7 expressed 
without the recombinant LNS2 fragment or a degradation product of the fusion protein. A. IPTG 
induction in rich medium. B. Autoinduction in Overnight Express™ medium. The names of the 
LNS2 domain constructs tested are specified below the lanes (S = LNS2-S, L = LNS2-L). Types 
and positions of the recombinant expression tags are specified above the lanes. N = N-terminal 
tag, C = C-terminal tag. H6 = hexahistidine tag, GST = glutathione S-transferase, MBP = maltose 
binding protein, SUMO = small ubiquitin-like modifier, Trx = thioredoxin. 
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3.1.5 Small-scale expression of His6-tagged Nir1 and Nir2 LNS2 domain 
fragments in E. coli 
As no soluble His6-only tagged LNS2 domain fragments of Nir2, Nir3 and RdgB were 
obtained in the high-throughput screen in E. coli from pOPIN vectors, expression of Nir1 
LNS2 domain was attempted from pNIC28-Bsa4 vector. For comparison, expression of 
His6-only tagged Nir2 LNS2 domain was also carried out using the same protocol.  
Small-scale (1 ml) expression test were performed using N-terminally His6-tagged Nir1 
LNS2-S (21 kDa) and Nir2 LNS2-S (22 kDa) fragments. In order to determine whether 
there is any recombinant protein accumulation in E. coli inclusion bodies, the lysate was 
separated by centrifugation into two fractions: a fraction containing soluble proteins and a 
Figure 3-4. SDS-PAGE analysis of the LNS2 domain high-throughput expression screening 
in insect cells. Ni2+-affinity purified lysates are shown. Coomassie® protein staining. 
Recombinant protein bands are marked by white asterisks. А. Nir2 fragments. B. RdgB 
fragments. C. Nir3 fragments. The names of the LNS2 domain constructs tested are specified 
below the lanes (S = LNS2-S, L = LNS2-L). Types and positions of the recombinant expression 
tags are specified above the lanes. N = N-terminal tag, C = C-terminal tag. H6 = hexahistidine 
tag, GST = glutathione S-transferase, MBP = maltose binding protein, SUMO = small ubiquitin-
like modifier, TF = trigger factor, Trx = thioredoxin. 
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fraction containing insoluble cell debris and inclusion bodies. For reference, the lysate 
from uninduced cells and unseparated post-induction lysate were also analysed. 
From the SDS-PAGE analysis (Fig 3-5), it became evident that the expression level of 
Nir1 LNS2 was higher than that of Nir2 LNS2. This is suggested by the fact that only the 
band corresponding to Nir1 LNS2 construct was observed, albeit rather weakly, in all 
post-induction fractions, at slightly below 25 kDa, whereas a band corresponding to Nir2 
LNS2 could not be clearly distinguished on the gel. 
Nevertheless, it should be noted that the expression levels of both proteins were likely very 
low, as the intensity of all recombinant protein bands is lower compared to the E. coli 
protein bands. Also, His6 Nir1 LNS2-S appeared to be mostly found in the insoluble 
fraction, which likely indicates problems with protein folding in the cell, and could explain 
why LNS2 domain fusions with large solubility tags were more successfully expressed in 
the screens. 
 
3.1.6 Large-scale expression of Nir2, Nir3 and RdgB LNS2 domain fragments 
in E. coli and insect cells 
Next, it was attempted to scale-up the expression of recombinant LNS2 domain fragments 
identified in the expression tests and screens. The scale-up of all constructs, except C-His6-
tagged Nir2 LNS2-L, was carried out in E. coli. Expression of C-His6-tagged Nir2 LNS2-L 
was carried out in insect cells. 
Figure 3-5. Small-scale expression of N-terminally 
His6-tagged Nir1 LNS2 and Nir2 LNS2. 
Coomassie® protein staining. Nir1 LNS2 bands are 
marked by white asterisks. Nir2 LNS2 bands are not 
distinguishable from the background. U = total lysate 
from uninduced cells, T = total lysate from induced 
cells, S = soluble fraction of induced cell lysate, I = 
insoluble fraction of induced cell lysate. 
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3.1.6.1 Expression in E. coli  
In E. coli, large-scale expression was carried out in LB medium or rich phosphate-buffered 
terrific broth (TB) medium using IPTG induction. Large TF Nir2 LNS2-S (70 kDa), 
TF RdgB LNS2-S (67 kDa), MBP RdgB LNS2-L (70 kDa) fusions were used for 
expression, as they displayed the highest expression levels in the screen. MBP RdgB 
LNS2-L was chosen instead of MBP RdgB LNS2-S due to its apparent higher yield under 
IPTG induction. Additionally, expression of the shorter Тrx RdgB LNS2-S fusion 
(30 kDa), SUMO RdgB LNS2-L (40 kDa), N-terminally His6-tagged Nir1 and LNS2-S 
(21 kDa and 22 kDa, respectively) was attempted in the hope of obtaining a protein 
construct directly suitable for structural analysis by NMR spectroscopy, which is 
challenging with high MW proteins. Large-scale expression of His6-tagged Nir1-2 LNS2-S 
constructs was carried out from pET-based pNIC28-Bsa4 plasmids. 
All three large fusion proteins were successfully expressed in shake-flask cultures and 
purified by Ni2+-affinity chromatography, as evident from the presence of protein bands in 
the chromatography elution fractions (Fig 3-6). TF Nir2 LNS2-S and TF RdgB LNS2-S 
were expressed in the same culture volume and purified using identical conditions, 
whereas MBP RdgB LNS2-L fusion was purified using a different protocol. Thus, the 
intensity the MBP-fusion band cannot be directly compared with TF-fusions to estimate 
protein yield. From the gel it can be concluded, however, that the protein yield was similar 
between the two TF-fusion. The total protein yield for each construct was estimated using 
UV/Vis spectroscopy and was found to be equal to ~ 14 mg/L of TB or ~ 2 mg/L of LB for 
both TF Nir2 LNS2-S and TF RdgB LNS2-S and to ~ 6 mg/L of TB for MBP RdgB 
LNS2-L, which was consistent with the relative expression levels observed in the 
expression screening.  
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As expected, large-scale production of shorter (~ 20-40 kDa) LNS2 constructs was much 
less successful (see Fig 3-7 for three examples). From SDS-PAGE analysis alone it was 
not entirely clear whether recombinant protein bands were present in Ni2+-affinity elution 
fractions, as they could not be readily distinguished from the co-purifying E. coli proteins. 
The presence of the His6 Nir2 LNS2-S and Trx RdgB LNS-S recombinant proteins was, 
however, confirmed by Western blotting using an anti-His-tag antibody (data not shown).  
The highest yield of soluble protein was observed with His6-tagged Nir1 LNS2-S (~ 
0.1 mg/L of LB), which however, was very low compared to the protein yields obtained 
with large LNS2 domain fusions. Similar or lower yields of soluble protein were observed 
for His6 Nir2 LNS2-S and Trx RdgB LNS-S. This is in contrast with the results of the 
high-throughput expression screen, where a relatively higher amount of soluble protein 
was obtained with the SUMO- and Trx-fusions of RdgB LNS2 domain fusion compared to 
the His6-tagged LNS2 domain fragments during E. coli expression. 
In an attempt to improve the yield of His6 Nir1 LNS2 domain, 10-20% glycerol and/or 
50 mM L-arginine and L-glutamine were added to the lysis and affinity chromatography 
buffers. Although this helped to obtain higher amount of purer soluble protein (Fig 3-7A), 
it was found that the LNS2 domain fragment was very prone to aggregation and could not 
be easily purified further by size-exclusion chromatography, exchanged into additive-free 
buffers by diafiltration or dialysis, or concentrated above ~ 0.5 mg/ml, making it unsuitable 
Figure 3-6. Large-scale expression of trigger factor (TF) and maltose-binding protein 
(MBP) fusions of Nir2 and RdgB LNS2 domains in E. coli. Coomassie® protein staining. 
A. TF Nir2 LNS2 (70 kDa). B. TF RdgB LNS2 (67 kDa). C. MBP RdgB LNS2-L (70 kDa). 
Two elution fractions from Ni2+-affinity chromatography are shown for each protein. 
Recombinant protein bands are highlighted by a red arrow. 
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for characterisation by many biochemical and biophysical methods. Nevertheless, the Nir1 
fragment was used for characterisation by CD spectroscopy, as described in Chapter 4. 
 
 
 
3.1.6.2 Expression in insect cells 
In insect cells, only scale-up of the C-terminally His6-tagged Nir2 LNS2-L (C-His6 Nir2 
LNS2-L) construct was attempted (Fig 3-8), as this was the fragment with the smallest 
MW detected in the high-throughput screen. It was found the protein was expressed in 
insect cells with an adequate yield of ~ 0.5 mg per 100 ml of adherent Sf9 cell culture, 
which was in contrast with the His6-tag-only LNS2 domain constructs expressed in E. coli. 
Although higher purity of the protein could be achieved already after the affinity 
chromatography, C-His6 Nir2 LNS2-L also proved to be very prone to aggregation during 
further manipulations both in the absence and the presence of 10-20% glycerol, and hence 
could not be successfully used for characterisation of the PA binding by major techniques. 
Insect cell expression was carried out with support from Dr Jan Petersen (University of 
Glasgow). 
Based on the outcomes of the large-scale expression, characterisation of the LNS2 domain 
binding properties was carried out mostly with the large fusions of the LNS2 domain, 
Figure 3-7. Large-scale expression of His6-tagged Nir1 LNS domain, and thioredoxin (Trx) 
and SUMO fusions of RdgB LNS2 in E. coli. Coomassie® protein staining. A. His6 Nir2 
LNS2-S (22 kDa). Left. Protein purified in the absence of 20% glycerol. Right. Protein purified 
in the presence of 20% glycerol. Position of the recombinant protein band is marked by a red 
arrow. B. Trx RdgB LNS2-S (30 kDa). C. SUMO RdgB LNS2-S (40 kDa). Two elution fractions 
from Ni2+-affinity chromatography are shown for each protein.  
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which could be successfully purified from E. coli in markedly higher amounts and did not 
require additives for stability and solubility. The foldedness and functionality of some 
His6-tagged LNS2 domain fragments nevertheless investigated, as described in Chapter 4. 
 
3.1.7 Purification and characterisation of the TF and MBP fusions of Nir2 
LNS2 domain by size-exclusion chromatography 
3.1.7.1 TF fusions of Nir2 and RdgB LNS2 domain 
After suitable LNS2 domain constructs were identified, further purification and 
characterisation of the fragments was a carried out by size-exclusion chromatography 
(SEC). SEC is a robust technique used for batch purification of proteins and analysis of 
protein samples to determine the oligomeric state of the protein and presence of aggregates 
in the sample. In SEC, proteins are separated based on their size or, more accurately, their 
Stokes radii, which generally correlate with the molecular weight of the proteins. 
Separation is achieved by filtration of the analytes through a porous matrix, where larger 
proteins are retained for a longer period of time than smaller proteins.  
Analysis of affinity-purified TF Nir2 LNS2-S fusion by SEC has demonstrated that the 
samples are polydisperse and the protein is found in a number of distinct states (Fig 3-9). A 
set of peaks corresponding to the fusion protein was observed in the A280 trace at the 
retention volumes of 7.9 ml, 10.2-11.0 ml, 11.8 ml and 13.4 ml. From a calibration curve 
constructed using a set of known protein standards with molecular weights up to 67 kDa, it 
Figure 3-8. Large-scale expression of His6-tagged Nir2 LNS 
domain in insect cells. Coomassie® protein staining. Flow-through 
(FT), wash (W) and elution (E) fractions from Ni2+-affinity 
chromatography are shown. Position of the recombinant protein band 
is marked by a red arrow. Theoretical MW of the protein is 37 kDa. 
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was estimated that the molecular weight of the species eluting at 13.4 ml is approximately 
68 kDa, which is close to the theoretical MW of the monomeric protein (70 kDa). The peak 
that eluted at 7.9 ml was assumed to correspond to a high MW aggregate present in the 
sample, as it eluted close to the void volume of the column (7.3 ml).  
To characterise the TF Nir2 LNS2-S species more accurately, the fusion protein solution 
was further analysed by multi-angle light scattering (MALS). In MALS, light scattering by 
a protein is measured at different angles, and the size and molecular weight of the protein 
are calculated based on the observed light scattering properties. When used in tandem with 
SEC, MALS allows determination of the molecular weights of individual proteins and 
distinct protein forms in a complex mixture.  
Analysis of TF Nir2 LNS2 by SEC-MALS has revealed four protein peaks eluting at 6.8, 
7.1 ml, 7.6 ml and 8.2 ml (Fig 3-10). Unlike in Fig 3-9, only a weak peak corresponding to 
high MW aggregates was observed at ~ 6.1 ml. The differences in retention volumes of the 
peaks in Fig 3-10 and Fig 3-9 are due to the use of different SEC columns in the 
experiments. The differences in the relative intensity of the peaks can be attributed to the 
variations between protein batches. 
MW calculations were carried out for each peak using MALS data. The peaks at 6.8 ml 
and 7.1 ml were poorly separated and were treated as one peak for the calculation. The 
average MWs of the eluting protein species were found to be ~ 309 kDa for the 6.8 – 7.1 
ml peak, ~ 170 kDa for the 7.6 ml peak ~ 93 kDa for the peak at 8.2 ml. The 93 kDa and 
170 kDa peaks were mostly monodisperse [polydispersity index (PDI) = 1.00, 1.01, 
respectively], whereas the 309 kDa peak was polydisperse (PDI = 1.06) with MWs ranging 
from ~ 359 kDa to ~ 221 kDa (Fig 3-10, red lines). Based on this data, the 93 kDa peak 
was assumed to contain the monomeric form of the protein, the 170 kDa peak the dimeric 
form of the protein, and the 309 kDa peak a mixture of protein microaggregates or 
trimers/quadromers. The difference between the calculated and the theoretical MWs of the 
protein monomer (93 kDa and 70 kDa, respectively) and dimer (170 kDa and 140 kDa) can 
be explained by the elongated shape of Trigger factor (Hoffmann et al., 2010) and the 
resulting problems in the MW calculations which are based on an assumption that the 
protein is an ideal sphere. From the peak areas, it was estimated that 42% of total protein 
was found in the putative microaggregate form, with respective proportions of dimeric and 
monomeric forms equal to 23% and 35%.  
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Figure 3-9. SEC trace of Ni2+-affinity purified TF fusion of Nir2 LNS2-S. Complex 
elution profile is observed. Assumed contents of the elution peaks are displayed above or 
near the peaks. Polyacrylamide gel containing 9-14 ml elution fractions is displayed in the 
upper right corner.  
Figure 3-10. Tandem SEC-multi-angle light scattering (MALS) analysis of Ni2+-affinity 
purified TF Nir2 LNS2-S fusion. Relative refractive index is plotted in conjunction with 
calculated molecular weight (MW). The peaks corresponding to the putative monomeric, dimeric 
and microaggregate forms of the protein are labelled. Average calculated MW and PDI 
(polydispersity index) of the peak are displayed. SEC-MALS allowed more accurate 
characterisation of the protein forms than SEC alone (see Fig 3-9). PDI = Mw/Mn. 
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3.1.7.2 MBP fusions of RdgB LNS2 domain 
A slightly different picture was observed with MBP RdgB LNS2-L (Fig 3-11). Although a 
number of distinct peaks were found in the SEC UV trace, from SDS-PAGE analysis it 
became clear the fusion protein eluted mostly in the peak at 10.2 ml. The peaks 7.3 ml and 
8.3 ml were assumed to correspond to protein aggregates due to their likely high MW and 
their proximity to the void volume (6.8 ml). The peaks eluting after 11 ml corresponded to 
the co-purifying E. coli proteins and fusion protein degradation products. The columns 
used for SEC purification of MBP RdgB LNS2-L and TF Nir2 LNS2-L were not identical, 
and hence a direct elution profile comparison cannot be made. 
In order to determine the molecular weight of the most abundant MBP RdgB LNS2-L 
species more accurately, the SEC fractions collected during the elution of the 10.2 ml peak 
were analysed by MALS. From MALS data (Fig 3-12), the MW of the LNS2 domain MBP 
fusion species was found to be ~ 402 kDa, which is close to the theoretical MW of the 
protein hexamer (420 kDa). Therefore, it was assumed that the MBP RdgB LNS2-L is 
mostly found in a hexameric form after affinity purification. As MBP is a monomeric 
protein, and does not produce oligomers in solution, it was assumed that the observed 
hexamer is formed due to the presence of the LNS2 domain in the fusion protein. It was, 
however, unclear whether the hexamer was a functional form of the fusion protein, a 
soluble microaggregate or a micelle-like structure formed by the fusion of the soluble MBP 
and relatively hydrophobic LNS2 domain. The column used for SEC-MALS anaylsis of 
the MBP fusion of Nir2 LNS2 was identical to that with the TF fusion of Nir2 LNS2. 
SEC-MALS was carried out by Mrs June Southall (University of Glasgow). 
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3.1.8 Removal of the solubility tag of TF Nir2 LNS2-S and RdgB LNS2-S 
fusion 
As the TF fusions of the LNS2 domain contained a human rhinovirus (HRV) 3C protease 
recognition site between the tag and the protein, an attempt was made to proteolytically 
cleave the tag in order to produce soluble, untagged LNS2 domain fragments. SEC 
fractions containing the putative TF fusion dimer peak were used for cleavage. About 
~50% of the protein was cleaved, as evident from the relative protein bands intensity on 
Figure 3-11. SEC trace of Ni2+-affinity purified MBP fusion of RdgB LNS2-L. Assumed 
contents of the elution peaks are displayed above or near the peaks. Polyacrylamide gel 
containing 8-11 ml elution fractions is displayed in the upper right corner. 
Figure 3-12. Multi-angle light 
scattering (MALS) analysis of 
SEC-purified MBP RdgB 
LNS2-L fusion. Relative 
refractive index is plotted in 
conjunction with calculated 
molecular weight (MW). The 
observed peak likely 
corresponds to a protein 
hexamer. Average calculated 
MW and PDI (polydispersity 
index) of the peak are 
displayed. PDI = Mw/Mn. 
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the SDS-PAGE (Fig 3-13). It is not clear why the cleavage has not proceeded to 
completion. However, it could be an indication of sample heterogeneity and could suggest 
that the protein is found in at least two states in the sample: a state or multiple states in 
which HRV 3C is accessible to the protease, and a state or multiple states in which it is 
inaccessible to the protease. The different states might arise due to the formation of higher 
order oligomers in the sample or due to potential presence of microaggregates. The 
incomplete cleavage of the fusion protein is unlikely to be caused by problems with 
protease’s activity, as HRV 3C proteases from two different sources was employed in the 
reactions. His6-tagged home-produced HRV 3C was used for TF Nir2 LNS2-S cleavage, 
and commercial GST-tagged HRV 3C PreScission protease (GE Healthcare) was used for 
TF RdgB LNS2-S cleavage. 
Further, although the cleaved LNS2 domain appeared at the correct MW in the SDS-PAGE 
analysis, it was not possible to separate the cleaved fragment from the fusion protein by 
SEC. The fusion protein and the cleaved fragments eluted together, which could suggest 
that the fragment either forms a tight complex with the fusion protein, or, more likely, is 
aggregated as a result of cleavage, as the LNS2 domain has proved to be unstable in 
solution in the previous experiments. It should be noted that the cleavage products of the 
two fusions were purified using different types of SEC column, and therefore the elution 
profiles are slightly different to each other. 
Due to the fact that it was impossible to separate the cleaved LNS2 domains from the 
fusion proteins, full-length fusions of LNS2 were employed in the experiments in Chapter 
4 for characterisation of the ligand binding properties of the LNS2 domain. 
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3.2 Na-FAR-1  
3.2.1 Expression and purification 
As mentioned above, previously established for expression and purification of Na-FAR-1 
were used. Protein was expressed in E. coli from a recombinant pET-11d plasmid 
produced by Florencia M. Rey-Burusco (Universidad Nacional de La Plata, Argentina). 
The plasmid encoded a His6-tagged Na-FAR-1 without its N-terminal 14 amino acid 
secretion signal peptide, as previously described (Rey-Burusco et al., 2015). Na-FAR-1 
expression was easily repeated here. Na-FAR-1 has demonstrated a high yield of soluble 
protein (~ 25 mg/L of LB) after Ni2+-affinity chromatography. The protein was sufficiently 
pure after the affinity chromatography and did not require additional purification by SEC, 
as evident from SDS-PAGE analysis (Fig 3-14A).  
3.2.2 Removal of co-purifying E. coli lipids from recombinant Na-FAR-1 
It has been previously demonstrated that recombinant Na-FAR-1 binds native E. coli lipid 
during expression, including a range of fatty acids and phospholipids (Rey-Burusco et al., 
2015).  Hence, further purification step was necessary to remove the co-purifying lipids 
from the protein. This was achieved by reverse-phase high pressure liquid chromatography 
(RP-HPLC) using acetonitrile gradient elution. In RP-HPLC, lipids bind the hydrophobic 
Figure 3-13. Proteolytic cleavage of TF fusions of Nir2 and RdgB LNS2-S by HRV 3C 
protease. Coomassie® protein staining. A. SDS-PAGE analysis of TF Nir2 LNS2-S cleavage. SEC 
fractions (5-7.5 ml) and the protein sample loaded onto the column (L) are shown. LNS2-S 
fragment elutes together with the fusion protein. B. SDS-PAGE analysis of TF RdgB LNS2-S 
cleavage. SEC fractions (6-8.5 ml) and the protein sample loaded onto the column (L) are shown. 
The LNS2-S fragment elutes together with the fusion protein. Different columns were used for 
purification of the two fusions, and hence the elution volumes are not directly comparable. 
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stationary phase more tightly than the protein, and thus elute at different points in the 
gradient, allowing the separation of the protein from the lipids.  
In order to determine whether removal of the lipids from the protein was successful, lipids 
were extracted from the 3 mg of HPLC-purified Na-FAR-1 and from 3 mg of Na-FAR-1 
that was not purified by HPLC. The lipid extracts were used for thin-layer chromatography 
(TLC), and the results were compared (Fig 3-14B). From TLC, it was apparent that most of 
the lipids were successfully removed from the protein by RP-HPLC. Intense lipid spots 
were observed in the lane containing the extract of Na-FAR-1 not subjected to RP-HPLC, 
whereas only weak spots were observed in the lane that contained lipids from 
HPLC-purified Na-FAR-1. From densitometry analysis, it was estimated that ~ 94% of 
bound lipids were removed from the protein. As the protein was eluted in a mixture of 
acetonitrile and water from the HPLC, it was lyophilised to remove the solvents. The lipid-
free protein was then redissolved in a suitable buffer and used for the experiments 
described in the chapters that follow. 
It should be noted, however, that RP-HPLC purification of the Na-FAR-1 batch used for 
crystallisation with oleic acid (see Chapter 5) was less successful, and only ~ 82% of lipids 
were removed from Na-FAR-1, as estimated by TLC and densitometry. This was assumed 
to be due to an issue with the HPLC instrument experienced during purification.  
 
3.3 Conclusions 
3.3.1 The LNS2 domain of Nir1-3 and RdgB 
Recombinant protein fragments containing the LNS2 domain of the Nir proteins and RdgB 
were produced in E. coli after identification of the optimal expression constructs in the 
Figure 3-14. Purification of Na-FAR-1. 
A. SDS-PAGE analysis of Ni2+-affinity 
purified Na-FAR-1. Recombinant protein 
band is marked by a red arrow. 
Coomassie® protein staining. B. TLC 
analysis of lipid extracts from RP-HPLC-
purified Na-FAR-1 (Post HPLC lane) and 
Na-FAR-1 before HPLC purification 
(Pre HPLC lane). Lipids appear as dark 
spots on the silica plate. Approximately 
~ 94% of lipids were removed by RP-
HPLC.  
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high-throughput expression screening. LNS2 domain constructs containing only a His6-tag 
exhibited very low yields of soluble protein, and were found to be predominantly targeted 
to inclusion bodies when expressed in E. coli. Furthermore, the short His6-tagged 
constructs purified by affinity chromatography were found to be unstable and prone to 
aggregation. In contrast, LNS2 domain fusions with > 40 kDa solubility tags have 
displayed better yields of soluble protein compared to the constructs without a large fusion 
partner. Of these, the TF fusion of Nir2 LNS2 and the MBP fusion of RdgB LNS2 
demonstrated the highest yields of soluble protein in large-scale E. coli expression. 
Characterisation by SEC has revealed that the TF and MBP fusions of LNS2 have complex 
elution profiles, indicating heterogeneity of the affinity-purified protein samples. TF Nir2 
LNS2-S appeared to be found in several oligomeric states, with ~ 60% of the protein found 
in putative monomeric and dimeric forms as indicated by SEC-MALS analysis. In contrast, 
MBP RdgB LNS2-L was mostly found in a putative hexameric state. It is unknown 
whether the LNS2 domain oligomerises in vitro or in vivo, and therefore it was not clear 
whether the observed oligomers are formed by the folded protein or whether they 
correspond to soluble protein microaggregates containing unfolded or partially unfolded 
protein. However, as discussed in Chapter 4, oligomers of TF and MBP LNS2 domain 
fusions demonstrated PA binding, which suggests that they retain at least partial 
functionality. 
3.3.2 Na-FAR-1 
Na-FAR-1 is a soluble and stable protein, which was expressed and purified from E. coli 
without the need for expression screening or optimisation of expression and purification 
conditions. The protein was stripped of the ligands that have co-purified from E. coli by 
reverse-phase HPLC and used for the ligand-binding and structural characterisation.  
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4. Characterisation of the recombinant LNS2 domain of 
Nir2 and the interaction between the LNS2 domain and 
phosphatidic acid 
4.1 Introduction 
To obtain a deeper knowledge of Nir2 function in cellular homeostasis and disease, it is 
desirable to elucidate the molecular mechanism of the interaction between the LNS2 
domain of Nir2 and phosphatidic acid (PA), which regulates Nir2 localisation in the cell. In 
this study, several biochemical and biophysical methods were employed for the in vitro 
characterisation of the LNS2-PA interaction. 
Most experiments were performed using the Trigger factor (TF) fusion of Nir2 LNS2, as it 
had demonstrated the highest yield of soluble protein out of the constructs tested, as 
discussed in Chapter 3. Various forms of PA were used in the investigation, depending on 
the method employed for characterisation of the LNS2-PA binding. Where possible, lipid 
vesicles containing long-chain PA species were used as model membranes. In some 
instances, free short-chain PA species were used instead of the membrane-embedded long-
chain PA species due to their high solubility in aqueous buffers. 
The study has yielded several important results. First, it was clearly demonstrated that the 
recombinant TF and MBP fusions of the Nir2 LNS2 produced in E. coli retain their PA 
binding functionality in vitro. Secondly, by employing the recombinant protein, it was 
possible to obtain important insights into the mechanism of PA binding by LNS2. Thirdly, 
two potential ways of medium-to-high throughput screening for inhibitors of the PA and 
LNS2 interaction were identified.  
Unfortunately, the characterisation of the three-dimensional structure of the LNS2 domain 
could not be performed, as the TF and MBP fusion of the LNS2 domain failed to 
crystallise and proved too large to be readily investigated by biomolecular NMR 
spectroscopy. However, the secondary structure of the LNS2 domain of Nir1 was 
characterised by circular dichroism spectroscopy. 
Below, the results of the characterisation of PA binding will be discussed in detail. A brief 
introduction to each technique used for analysis of the LNS2-PA binding will be given. At 
the end of the chapter, conclusions will be drawn from the experiments. A proposed 
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mechanism for LNS2 and PA interaction at the membrane will be discussed and two 
strategies for the screening of PA interaction inhibitors will be presented. Future 
experiments which could be performed to test the proposed hypotheses and investigate the 
mechanism of LNS2-PA binding in more detail will be also be discussed. 
4.2 TF and MBP fusions of Nir2 LNS2 domain bind phosphatidic 
acid 
4.2.1 Lipid binding assays  
Lipids and lipid binding proteins are increasingly coming to prominence as crucial players 
in many normal and pathological cellular processes, including cell signalling, growth, 
motility and differentiation. Consequently, a variety of biochemical assays have been 
developed or adapted for quick analysis of protein-lipid interactions (Zhao and 
Lappalainen, 2012). Two of the most-widely used assays are the lipid overlay assay and 
the liposome sedimentation assay. Due to their ease of use, these two assays were 
employed for analysis of the LNS2 and PA interaction in the first instance. 
The lipid overlay assay is a type of immunoblot assay that is, in principle, similar to more 
widely known enzyme-linked immunosorbent assay and Western blotting. In the lipid 
overlay assay, lipids of interest are immobilised onto a piece of nitrocellulose membrane, 
after which the membrane is blocked with a solution of fatty acid free bovine serum 
albumin or fat free milk and incubated with a lipid binding protein of interest. Next, the 
membrane is washed and incubated with an antibody specific for the protein. The antibody 
is typically conjugated to an enzyme, such as alkaline phosphatase or horseradish 
peroxidase, that allows detection of the signal via a reaction with a specific substrate that 
produces a coloured product or light. Membranes containing sets of immobilised 
membrane phospholipids are available commercially. Here, they were produced as 
required for each experiment. The principle of the assay is visually summarized in 
Fig 4-1A. 
In contrast to the lipid overlay assay, the lipid co-sedimentation assay (LSA) does not use 
immobilised lipid layers. Instead, LSA is based on detection of lipid binding to lipid 
vesicles (liposomes). Several types of liposomes can be used for characterisation of 
protein-lipid binding, which vary by size and the number of lipid bilayers they contain. 
Most commonly, large unilamellar vesicles (LUVs) or multilamellar vesicles (MLVs) are 
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used in LSA as their curvature resembles the curvature of natural membranes (Zhao and 
Lappalainen, 2012). 
In LSA, liposomes are mixed with the solution of a lipid binding protein, and the mixture 
is incubated to allow protein-liposome binding to occur. The mixture is then centrifuged to 
pellet the liposomes, and the pellet and supernatant fractions are analysed by SDS-PAGE. 
The presence of the protein in the pellet fraction is typically a sign of interaction between 
the protein and the liposomes, but the protein can also be pelleted with the liposomes due 
to a non-specific interaction with the vesicles or aggregation. Thus, an appropriate control 
should be carried out to determine whether the binding observed in the LSA is specific. In 
this study, liposomes containing only phosphatidylcholine (PC) were as a control for non-
specific protein binding, as PC does not interact with the LNS2 domain of Nir2 (Kim et al., 
2013). The experimental procedure of the assay is visually summarized in Fig 4-1B. 
 
 
4.2.2 Recombinant Nir2 and RdgB LNS2 domains interact with PA 
Due to the complex elution profile of the TF fusion of Nir2 LNS2 observed during 
characterisation by SEC-MALS, it was assumed that at least part of the recombinant 
protein may be in the aggregated or misfolded state. Therefore, in the first step in the 
characterisation of the PA interaction with the LNS2 domain it had to be confirmed that 
Figure 4-1. Lipid binding assays. A. Visual summary of the lipid overlay assay. Protein-lipid 
interaction is detected by immunostaining. B. Visual summary of the liposome co-sedimentation 
assay. Protein-lipid interaction is detected by analysis of the supernatant and pellet fractions. 
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the recombinant fusion of the LNS2 domain retains its PA binding function after 
purification.  
Analysis of lipid binding by both lipid overlay and liposome co-sedimentation assays has 
demonstrated that the recombinant LNS2 domain of Nir2 is able to bind both the natural 
PA derived from the egg yolk extract, as was reported previously (Chang and Liou, 2015; 
Kim et al., 2013), and synthetic PA species. Furthermore, binding between the MBP fusion 
of the RdgB LNS2 and natural PA was demonstrated. Synthetic PA species were not used 
in the RdgB LNS2 binding experiments. 
4.2.2.1 Analysis of PA binding by lipid overlay assay 
Lipid overlay assay was carried out with the TF fusion of Nir2 LNS2-S and the MBP 
fusion of Nir2 LNS2-L purified from E. coli, and the C-terminally His6-tagged 
Nir2 LNS2-L purified from insect cells (Fig 4-2). Prior to the assay, the TF and MBP 
fusions of the LNS2 domain were purified by SEC. Each of the TF Nir2 LNS2 fractions 
corresponding to putative oligomeric forms of the fusion protein was analysed separately. 
The MBP fusion of RdgB LNS2-L was used in the predominant putative hexameric form 
(see Chapter 3). The C-terminally His6-tagged Nir2 LNS2-L was used directly after 
Ni2+-affinity chromatography, without further purification. In addition, a negative control 
was carried out using recombinant His6-tagged TF purified from E. coli. This was done to 
ensure that any binding observed in the assay was not due to a non-specific interaction of 
TF with the lipids.  
The recombinant LNS2 domain bound to PA but not to PC in all assays. This was evident 
from the fact that the staining signal was observed only from the PA dot on the lipid blots 
(Fig 4-2). Interestingly, binding was also seen with the SEC fractions of the recombinant 
TF Nir2 LNS2 that were believed to contain the protein in the aggregated form (8.5 – 
9.0 ml and 9.5 – 10 ml fractions). This indicates that each of the TF Nir2 LNS2 SEC 
fractions used in the assay contained at least a portion of the recombinant protein that is 
able to specifically interact with PA. However, it is unlikely that all recombinant protein 
present in the SEC fractions possesses PA binding functionality. For instance, the observed 
binding of the putative microaggregates to PA might be explained by the presence of 
partially folded protein in the microaggregate species. Consistently, the MBP fusion of 
RdgB LNS2-L and the His6-tagged Nir2 LNS2-L fragment also demonstrated specific 
binding to PA. Reassuringly, no TF binding to the phospholipids was detected, suggesting 
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that the binding observed in the assays was occurring specifically due to presence of the 
LNS2 domain in the TF fusion proteins. MBP is not expected to bind to the phospholipids. 
4.2.2.2 Analysis of PA binding by liposome co-sedimentation assay 
The results of the LSA were in agreement with the results of the lipid overlay assay. MLVs 
were employed for the qualitative assay due to the ease of their preparation. MLVs 
contained either egg yolk PA and PC mixed in 1:2 mass ratio or only PC. Only binding of 
the TF fusion of Nir2 LNS2 domain to PA was assessed by using LSA. 
Protein was clearly found in the pellet in the presence of the PA-containing MLVs 
(Fig 4-3A). In the representative example shown in Fig 4-3A, no protein band was 
observed in the PC-only MLV pellet lane. However, the band in the PC-only pellet was 
occasionally present in the gels after SDS-PAGE. This suggests that either a small degree 
of protein precipitation was occurring in the sample in the presence of lipid vesicles, which 
is not uncommon in LSA, or that the protein was interacting with PC in the vesicles, which 
is unlikely, as it was not observed in the lipid overlay assays. Convincingly, as the intensity 
of protein band in the PA-containing liposome pellet was always greater than that of the 
band in the PC-only liposome pellet, it was concluded that the protein was preferentially 
binding to PA-containing MLVs, which is indicative of a specific protein-PA interaction.  
In addition, a semi-quantitative assessment of the apparent dissociation constant (Kapp) 
of Nir2 LNS2 binding to PA was carried out. As quantification of the molar lipid 
concentrations was required for Kapp determination, pure synthetic dioleoyl PA (DOPA or 
di-18:1 cis-9 PA) and dioleoyl PC (DOPC or di-18:1 cis-9 PC) species were used in the 
assay rather than the natural PA and PC extracted from egg yolk, as those comprised a 
mixture of PA and PC with varying acyl chain lengths and MWs. Also, LUVs were 
employed in the assay instead of MLVs, as LUVs contain a single membrane layer, 
allowing estimation of the PA concentration accessible to the protein to be achieved (see 
below). LUVs were prepared by extrusion through a semi-permeable membrane. The semi-
quantitative LSA was carried out using high-speed centrifugation (150,000 x g) to ensure 
that all potential protein-LUV complexes were pelleted in the experiment. For the assay, 
PA-containing LUVs were mixed with the TF Nir2 LNS2 fusion to obtain a range of 
protein-LUV mixtures with varying total lipid concentrations (2 mM, 1 mM, 0.5 mM, 
0.3 mM, 0.1 mM and 0.05 mM). Protein concentration was kept constant in the assay at 
2 µM. 
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After the LSA fractions were analysed by SDS-PAGE, it was observed that the intensity of 
the protein band in the pellet increased with the concentration of liposomes in the sample, 
as was expected. The intensities of protein bands in the supernatant and pellet fractions 
were analysed by densitometry using Fiji (Schindelin et al., 2012). The percentage of the 
bound protein was calculated by dividing the integrated intensity of the pellet protein band 
by the sum of the integrated intensities of the protein bands in the pellet and the 
supernatant fractions. The maximum percentage of the protein bound to liposomes was 
observed with 2 mM total lipid and was equal to 33%. In the presence of 1 mM, 0.5 mM, 
0.3 mM, 0.1 mM and 0.05 mM total lipid, 22%, 13%, 10% and 0% of protein was found in 
the pellet, respectively.  
In order to estimate the Kapp for PA binding, the concentration of DOPA accessible to the 
LNS2 domain in the sample was calculated assuming that DOPA is evenly split between 
the two layers of the LUV membrane and that the protein is only able to interact with the 
lipids in the outer membrane layer. The percentage of the protein bound was plotted as 
function of the concentration of accessible DOPA in the sample, and the binding data were 
fitted to Equation 4-1 describing one-site binding:  
!" = 	 [!"]'()× " (++,(-- + " (++  
where [PL] is the percentage of the protein bound, [PL]max is the maximum specific 
binding, [L]acc is the concentration of DOPA accessible to the protein and Kapp is the 
apparent dissociation constant. Protein-membrane binding affinities are often reported in 
terms of Kapp values instead of the real dissociation constant Kd values. This is because 
protein-membrane binding is complex and involves multiple types of interactions between 
the amino acids in the protein and the membrane lipids which are difficult to account for in 
the calculation of the real Kd (Zhao and Lappalainen, 2012). Based on the data obtained in 
the experiments, the Kapp was calculated to be equal to ~ 0.5 mM.  
It should be noted that the Kapp value reported here should only be treated as an estimate. 
This is because the LSA is in principle prone to underestimation of Kapp because of the 
possibility of protein aggregation occurring in the sample that could interfere with the 
binding analysis. Indeed, as mentioned above, protein precipitation was observed in the 
presence of PC-only vesicles, which was difficult to account for in the semi-quantitative 
experiment, and therefore it is likely that the Kapp value reported here is lower than the real 
value. Also, due to time constraints, replicates were carried out only with LUVs containing 
Equation 4-1. 
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150 µM accessible PA (1 mM total lipid), which makes the precision of the estimation 
difficult to assess. The bound protein percentages in the presence of 150 µM PA were, 
however, relatively consistent, with the mean value equal to 18 ± 4% (n = 4; ± s.e.m.). 
In order to obtain a more accurate Kapp value, a liposome co-flotation assay can be carried 
out, in which the protein bound to the liposomes is separated from the free protein by 
centrifugation in a density gradient. Soluble protein bound to the liposomes will also be 
separated from the aggregated protein, which will sediment to the bottom of the gradient 
due to its high density. This allows protein aggregation to be accounted for during Kapp 
estimation. Nevertheless, the components used for gradient preparation in the co-flotation 
assay can themselves cause protein aggregation, and hence it might not be suitable for use 
with Nir2 LNS2. 
To summarise, Kapp estimation by LSA allowed the affinity of DOPA binding by the LNS2 
domain to be placed into at least high micromolar range. Since the affinity of LNS2-PA 
binding was not characterised in the previous studies, this is the first glimpse into the in 
vitro affinity of PA binding by the LNS2 domain.  
 
 
 
Figure 4-2. Lipid overlay assay with the recombinant Nir2 and RdgB LNS2 domains. 
Representative assay results are shown. Detection was carried out by incubation with an 
anti-His6-tag antibody. A. Lipid overlay assays using four size-exclusion chromatography (SEC) 
fractions of the TF fusion of Nir2 LNS2 domain. The fraction elution volumes are given above 
each image. The fractions contained the following putative oligomeric species of the fusion 
protein: microaggregates/multimers (8.0 – 8.5 ml and 9.5 – 10 ml), dimer (11.5 – 12.0 ml) or 
monomer (13.5 – 14.0 ml). Binding to PA but not to PC was observed in all assays. The assay 
with TF was carried out as a negative control. TF did not bind to any phospholipids. B. Lipid 
overlay assays using the MBP fusion of RdgB LNS2-L fragment and C-terminally His6-tagged 
Nir2 LNS2-L. Both proteins demonstrated binding to PA but not to PC.  
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4.3 Analysis of Nir2 LNS2 domain binding to PA by 
ligand-observed NMR spectroscopy 
4.3.1 Ligand-observed NMR spectroscopy 
NMR spectroscopy (or simply NMR) is a powerful and versatile technique which can be 
applied to structural and functional characterisation of proteins and protein-ligand 
interactions. By using NMR, the signals of both the protein and the ligand can be detected 
in the protein-ligand complexes, and thus protein-ligand interactions can be investigated 
Figure 4-3. Liposome co-sedimentation assay (LSA) with the recombinant TF fusion of 
Nir2 LNS2 domain. A. LSA with MLVs prepared from natural PA and PC from egg yolk. 
Protein interaction is observed with the MLVs containing 33% PA but not to the MLVs 
containing 0% PA. S = supernatant, P = pellet. B. Semi-quantitative LSA with LUVs consisting 
of 30% DOPA (di-18:1 cis-9 PA) and 70% DOPC (di-18:1 cis-9 PC). Protein concentration was 
kept constant in the assay, while LUV concentration was varied. Concentration of accessible 
DOPA is displayed below the images. The amount of the protein bound to LUVs increased with 
increasing concentration of the vesicles. S = supernatant, P = pellet.  C. Binding isotherm for the 
semi-quantitative LSA. Data were fitted to a one-site binding equation by least squares method. 
Apparent dissociation constant (Kapp) was found to be equal to ~ 0.5 mM. n = 1 except for the 
point at [DOPA]accessible = 150 µM, for which n = 4 independent experiments (the data point 
represents the mean, error bars represent ± s.e.m.). 
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from two angles: by observing the resonance signals of the ligand (ligand-observed NMR) 
or by observing the resonance signals of the protein (protein-observed NMR).  
4.3.1.1 Limitations of protein-observed NMR spectroscopy in protein-ligand 
binding studies 
In protein-observed NMR, chemical shifts of protein atoms are usually monitored. From 
the chemical shifts, one can obtain a great wealth of information about the protein 
structure, conformation and folding state, as they report on the immediate chemical 
environment of the corresponding nuclei. Since proteins are the main targets of 
biomolecular NMR investigations, a wide variety of NMR experiments have been 
developed that allow accurate assignment of the resonances in the protein spectra to 
specific residues and atoms in the protein. One can then use these assignments to 
determine the structure of the protein in complex with the ligand, map ligand binding sites 
in the protein or follow conformational changes in the protein structure upon ligand 
binding.  
There are, however, important limitations associated with protein-observed NMR. As 
mentioned above, in order to obtain an interpretable spectrum, the protein sample needs to 
be concentrated (normally 0.1-2 mM) and homogenous. This can be challenging to achieve 
if the protein is poorly expressed in heterologous hosts or is prone to aggregation in 
solution. Further, due to the complexity of the protein NMR spectra, one needs to observe 
at least both 1H and 15N nuclei, or ideally 1H, 15N and 13C nuclei to carry out accurate 
assignments of the resonance signals to protein atoms. Since the natural abundance of 
magnetically active spin-1/2 13C and 15N nuclei is low (1.1% and 0.36%, respectively), the 
protein typically needs to be uniformly isotopically labelled, which is achieved by 
expression in a minimal medium supplemented with nutrients synthetically enriched in the 
relevant isotopes. As isotope-labelled nutrients are relatively expensive and protein yields 
in minimal media are generally lower that in normal rich media, this can make the 
production of protein sample prohibitively expensive, especially in the case of difficult-to-
express, unstable proteins.  
Another limitation of protein-observed NMR spectroscopy lies in protein size. Protein size 
limitations arise due to effects of signal broadening and crowding in the spectra of large 
proteins. Although modern methods allow investigation of very large monomeric and 
multimeric protein systems (100 kDa - 1.1 MDa) (Fiaux et al., 2002; Gelis et al., 2007; 
Mainz et al., 2013; Sprangers and Kay, 2007), this remains a challenging, non-trivial and 
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labour-intensive task. Typically, best results are obtained with proteins with molecular 
weight smaller or equal to 25-35 kDa. 
For a more detailed description of protein-observed NMR spectroscopy and the theory of 
NMR please see Chapter 6. 
4.3.1.2 Ligand-observed NMR spectroscopy 
In contrast to protein-observed NMR, in ligand-observed NMR protein signals are not the 
objects of investigation. Thus, ligand-observed NMR does not have any limitations 
associated with the protein size or spectral crowding, as long as the ligand is a small 
molecule. Indeed, the use of larger proteins is often beneficial in ligand-observed NMR, as 
it results in higher sensitivity in certain types of experiments. Importantly, in ligand-
observed NMR, proteins do not require isotopic labelling, and experiments can be 
successfully carried out even with low protein concentrations (~ 0.1-100 µM). 
Ligand-observed NMR spectroscopy detects the effects of protein-ligand interaction on 
ligand signals. Although ligand-observed NMR does not provide any information on 
protein structure in protein-ligand complexes, it can be used as a tool to qualitatively or 
quantitatively characterise ligand binding. Due to its low cost, minimal protein sample 
requirements and the short experimental time required to produce an interpretable 
spectrum, ligand-observed NMR is widely employed in pharmaceutical industry for drug 
discovery (Pellecchia et al., 2008; Renaud and Delsuc, 2009; Śledź et al., 2012; Unione et 
al., 2014; Zhang et al., 2015). In the fragment-based drug screening, the use of 
ligand-observed NMR is especially advantageous, as it can be used to detect a range of 
weak (~ 1 mM) to moderately strong (~ 0.1 µM) binding events. The advantages of 
ligand-observed NMR also apply to low-throughput analyses of protein-ligand binding, 
such as in the study described here. Several types of ligand-observed NMR experiments 
have been developed, which rely on observation of different NMR parameters of ligands, 
which include T1 and T2 relaxation rates, NOEs and saturation transfer parameters (Meyer 
and Peters, 2003).  
To record T2 relaxation-edited experiments, the Carr-Purcell-Meiboom-Gill (CPMG) pulse 
sequence (Carr and Purcell, 1954; Meiboom and Gill, 1958) is typically used. In a CPMG-
based experiment, signals arising from the protein or protein-bound ligand nuclei can be 
distinguished from the signals of the free ligand due to their short T2 relaxation times 
compared to the those of the free ligand signals. In the sample containing a ligand 
transiently bound to a protein, a reduction in the intensity of the ligand resonance signals 
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will be observed due to the averaging of the signals arising from the ligand molecules 
bound to the protein and the free ligand molecules. Thus, by comparing small molecule 
signal intensities in the spectra acquired in the absence and in the presence of the protein, 
one can determine whether a small molecule interacts with the protein in the experiment. 
Saturation transfer difference (STD) (Angulo and Nieto, 2011; Mayer and Meyer, 1999) is 
a technique which is also widely used in ligand-observed NMR. In STD, protein in the 
presence of a large excess of a small molecule is irradiated with a radiofrequency pulse 
selective for the protein methyl protons. If the small molecule interacts with the protein, 
magnetisation is transferred from the protein methyl protons to the small molecule protons 
via the Nuclear Overhauser effect (NOE). This results in increased intensity of the 
corresponding small molecule signals in the recorded 1H spectrum. By comparing the 
intensity of the small molecule signals in the presence and in the absence of the protein, 
protein-ligand binding in the sample can be detected and characterised. 
4.3.1.3 WaterLOGSY  
Water-Ligand Observed by Gradient SpectroscopY (waterLOGSY) (Dalvit et al., 2001) is 
another common ligand-observed NMR experiment. Like STD, it is also based on 
saturation transfer. However, in waterLOGSY, the bulk water nuclei are saturated with a 
selective pulse instead of the protein nuclei. From the bulk water, magnetisation is 
transferred to the protein and the small molecule in solution. When the magnetisation is 
transferred to the protein, it can spread through the protein via intramolecular NOE. If a 
small molecule binds to the protein, the magnetisation from the protein can be further 
transferred to the small molecule through intermolecular NOE. The direct magnetisation 
transfer from bulk water to the ligand occurs in the fast tumbling regime, whereas the 
magnetisation transfer from bulk water to the ligand via the protein occurs in the slow 
tumbling regime. As a consequence, the sign of protein-ligand NOE will be opposite to 
that of water-ligand NOE. For a ligand that is transiently binding to the protein, these two 
transfer processes occur simultaneously, however, the magnetisation transferred from the 
protein will dominate, as protein-ligand NOE build up is faster than water-ligand NOE 
build up. 
Like in STD, the differences in the waterLOGSY magnetisation transfer pathways can be 
exploited for characterisation of ligand binding. To determine whether a small molecule 
interacts with a protein, one can record 1H waterLOGSY spectra of the molecule in the 
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absence and the presence of the protein. If small molecule is a ligand, in the presence of a 
protein its resonance signals will either be of opposite sign or of reduced intensity 
compared to those in the absence of the protein. If there is no binding between the small 
molecule and the protein, the small molecule signal will be the same independent of the 
presence of the protein. WaterLOGSY experiments are usually set up in such a way so that 
the signals of the nuclei interacting with the protein appear as positive in the spectrum, and 
the signals of non-interacting nuclei as negative. 
In addition to qualitative analysis, waterLOGSY can be employed for quantitative analysis 
of ligand binding (Asencio-Hernández et al., 2016; Dalvit et al., 2001; Forget et al., 2015; 
Hopkinson et al., 2015). Since the waterLOGSY signal intensity depends on the 
concentration of protein-ligand complexes in the sample, this can be done by monitoring 
the changes in the intensity of the ligand signals upon ligand titration into a 
substoichiometric protein solution. 
Signal intensity (I) for a ligand proton i is given by the following equation (Dalvit et al., 
2001):  
/	 ∝ !" 12345678 + 	 129 + 	 12:45678: 	93 + ["] 123;<==3 + 	 12:;<==:  
where [PL] is the concentration of the ligand bound to the protein, [L] is the concentration 
of the free ligand, σ is the cross-relaxation rate constant, j is an index of ligand 
exchangeable protons, k is an index of protein protons next to the ligand and w is an index 
of water molecules near ligand. [L] is equal to [Ltot] – [PL], where [Ltot] is the total 
concentration of the ligand added to the sample.  
Due to the dependence of signal intensity on both [L] and [PL], in cases where the 
dissociation constant Kd is relatively large and the ligand in high excess, the contribution 
of the second term of the equation will outweigh the contribution of the first term, which 
will lead to a reduction in the signal intensity. Thus, for an accurate estimate of binding 
affinity, a correction must be made for the increasing ligand concentration during the 
titration. In order to do this, a spectrum of the ligand in the absence of the protein can be 
recorded, and the observed ligand intensity values can be subtracted from those recorded in 
the presence of the protein. The corrected signal intensities can then be plotted as a 
function of [L] to construct a binding isotherm for Kd determination. One caveat is that 
waterLOGSY has been reported to overestimate the Kd due to re-binding of ligands to 
proteins after saturation transfer (Fielding et al., 2005; Huang et al., 2017), but the 
Equation 4-2. 
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estimation was found to be adequate when a low protein concentration (~ < 20 µM) and a 
short mixing time (~ 0.5 s) was used in the experiments (Huang et al., 2017).  
4.3.2 Nir2 LNS2 interacts with short-chain PA and the fatty acyl chains of 
short-chain PC 
Due to the ease of data interpretation, simplicity and good experimental sensitivity 
(Antanasijevic et al., 2014) of waterLOGSY compared to other ligand-observed NMR 
techniques, it was chosen as a primary method of probing the interaction between the 
LNS2 domain of Nir2, PA and other ligands. Additionally, CPMG experiments were 
carried out to confirm the results of waterLOGSY. 
In order to carry out the binding characterisation, a suitable PA species had to be identified 
for use in the experiments. Since the use of lipid vesicles and micelles is not compatible 
with ligand-observed NMR, short acyl chain dihexanoyl phosphatidic acid (DHPA or di-
6:0 PA) and phosphatidylcholine (DHPC or di-6:0 PC) were employed due to their high 
solubility in the aqueous buffers and millimolar cmc (Marsh, 1990). DHPC was intended 
to be used as a negative control in these experiments, as the LNS2 domain of Nir2 has not 
been previously shown to bind to PC.  
The spectra of the waterLOGSY experiments are shown in Fig 4-3. Standard 1H spectra 
with water suppression are shown for reference. Changes in the sign and intensity of 
DHPA fatty acyl tail signals 1-4 and the glycerol backbone signals were observed after 
addition of TF Nir2 LNS2, which was indicative of DHPA interaction with the LNS2 
domain. The signals from the two most downfield shifted backbone proton signals were 
relatively weak likely because of their close proximity to the H2O signal (not shown). The 
hydroxyl resonance signal of the phosphate head group of DHPA was not visible due to 
fast exchange with the solvent. In the control experiment with TF, no positive ligand 
signals were observed in the presence of the protein, indicating that there was no 
interaction between DHPA and TF. The positive broad signals observed in the presence of 
the protein arise from the TF protons. The lack of DHPA interaction with TF suggests that 
the DHPA was specifically binding to the LNS2 domain in the experiments using the TF 
fusion of Nir2 LNS2. Importantly, the data showed that all NMR-observable DHPA 
protons were interacting with the protein. 
Interestingly, in the NMR experiments DHPC also displayed binding to the LNS2 domain, 
which was unexpected. Signals 1-4 corresponding to DHPC fatty acyl protons changed 
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their sign after addition of the LNS2 fusion protein, although the signal intensities did not 
increase as strongly as was observed in the DHPA binding experiments. For example, the 
increase in the intensity of the acyl chain methyl signal 1 after protein addition was 
approximately 2.5-fold smaller in the DHPC experiments than in the DHPA experiments. 
As the intensity of proton resonances in waterLOGSY spectra is related to the 
concentration of protein-ligand complexes in the sample, this observation suggests that the 
binding of LNS2 domain to DHPC is likely to be of weaker affinity than to DHPA. 
Significantly, no clear change in the sign and intensity of the DHPC glycerol backbone and 
head group signals (including the very strong phosphocholine methyl signal 5) was 
observed after protein addition, indicating that the DHPC head group is not interacting 
with the protein or that the interaction is too weak to be detected by waterLOGSY. 
Next, CPMG experiments were carried out using DHPA or DHPC with the LNS2 domain 
of Nir2 to confirm the findings of the waterLOGSY experiments. As described in Section 
4.3.1.2, CPMG uses a different principle of detecting protein-ligand interaction than 
waterLOGSY, and hence it can be used to distinguish any possible artefacts in the 
waterLOGSY spectra from the real binding events. Reassuringly, the findings in the 
CPMG experiments were in agreement with the waterLOGSY data. In the experiments 
using DHPA (Fig 4-5A), the intensity of all the DHPA proton resonance signals observed 
in the spectrum decreased after addition of the TF fusion of Nir2 LNS2, indicating that 
DHPA was interacting with the protein. In the CPMG experiments with DHPC (Fig 4-5B), 
the intensity of the DHPC fatty acyl chain resonances 1-4 also decreased, suggesting that 
an interaction was taking place between the acyl chain of DHPC and the protein, as was 
observed in waterLOGSY.  
The percent decrease in the intensity of DHPA and DHPC resonances after addition of the 
LNS2 domain in CPMG experiments is summarised in Fig 4-5C. In signal multiplets, the 
intensity of the most intense component was measured. From the chart, it can be seen that 
the decrease in the intensity of DHPA resonance signals (~ 40-60%) is greater than that of 
DHPC resonances (~ 15-35%). This suggests that DHPA spends on average more time 
bound to the protein than DHPC, and hence that DHPA interacts with the protein with 
higher affinity than DHPC. In both the DHPA and DHPC experiments, the strongest 
decrease is observed for acyl chain signals 4a and 4b, which arise from the methylene 
groups bonded to the oxygen atom in the two chains. Interestingly, only a slight decrease 
in intensity (~ 3%) was observed for the DHPC phosphocholine head group signal 5, which 
is a ~ 5- to 7.5-fold smaller decrease in intensity compared to the decrease observed for 
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other DHPC resonances. This might suggest that the chemical environment and/or mobility 
of the DHPC head group is different to the rest of the molecule in the presence of the 
protein, which could indicate that the head group is not participating in the interaction with 
the protein. The apparent small change in the intensity of signal 5 is also consistent with 
the waterLOGSY experiments, where the same signal did not appear to change its sign on 
protein addition in contrast to the fatty acyl resonances of DHPC. 
From this data, it can be inferred that the interaction of Nir2 LNS2 with DHPC occurs 
through the acyl chains of DHPC, whereas the phosphocholine head group of DHPC does 
not participate in the interaction. Also, the interaction between DHPC and the LNS2 
domain is likely of a weaker affinity than the one between DHPA and the LNS2 domain. 
This might suggest that although the LNS2 domain appears to have weak affinity for the 
fatty acyl tails of both DHPA and DHPC, the presence of negatively charged phosphate 
head group of DHPA is responsible for the higher affinity of the LNS2-DHPA interaction 
compared to the LNS2-DHPC interaction.  
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Figure 4-4. Analysis of DHPA (di-6:0 PA) and DHPC (di-6:0 PC) interaction with the Nir2 
LNS2 domain by NMR waterLOGSY. a. Reference 1D 1H spectrum, b. waterLOGSY spectrum in 
the absence of Nir2 LNS2, c. waterLOGSY spectrum in the presence of TF Nir2 LNS2, d. 
waterLOGSY spectrum in the presence of trigger factor (TF). Structures of DHPA and DHPC are 
displayed for reference. DHPA and DHPC protons with corresponding resonance signals are 
numbered. A. DHPA experiments. In waterLOGSY spectra, the sign of all DHPA proton resonances 
(1-4) is inverted upon protein addition, indicating that DHPA interacts with the protein. No 
interaction between TF and DHPA is observed. B. DHPC experiments. The sign of acyl proton 
signals 1-4 is inverted upon protein addition, whereas no clear change is observed in the head group 
methyl signal 5 as well as in the head group and glycerol backbone methylene signals. This indicates 
an interaction between the fatty acyl tails of the DHPC molecule and the protein, but not between the 
head group moiety and the protein.  
a.	
b.	
c.	
B 
a.	
b.	
c.	
d.	
A 
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Figure 4-5. Analysis of DHPA (di-6:0 PA) and DHPC (di-6:0 PC) interaction with the Nir2 
LNS2 domain by CPMG. a. CPMG 1H spectrum in the absence of Nir2 LNS2, b. CPMG spectrum 
in the presence of Nir2 LNS2. Structures of DHPA and DHPC are displayed for reference. DHPA 
and DHPC protons with corresponding resonance signals are numbered. Resonances below 
~ 3.2 ppm are not shown due to their poor signal-to-noise ratio. A. DHPA experiments. Intensity of 
the DHPA proton resonances 1-4 is reduced in the presence of the protein, which is indicative of the 
interaction between the molecule and the protein. B. DHPC experiments. Intensity of the DHPC 
acyl chain resonances 1-4 is reduced in the presence of the protein, but to a lower extent than 
observed for DHPA. Only slight reduction in intensity is observed for the head group methyl 
resonance 5 (whole peak is not shown). C. Comparison of the observed changes in the intensity 
(ICPMG) of the proton resonances of DHPA (black bars) and DHPC (grey bars) after addition of the 
Nir2 LNS2. In multiplets, the intensities of the highest peaks were compared. Resonance signals are 
numbered as in A and B. Larger intensity changes are observed in the DHPA acyl chain signals 
(~ 40-60%) than in the DHPC acyl chain signals (~ 15-35%). Very slight decrease in intensity is 
observed for the DHPC head group methyl signal 5 (~ 3%). Proton resonance equivalent to DHPC 
resonance 5 is not present in DHPA (absence is marked by *). Changes in the intensity of the 
DMSO signal reflect slight differences in the ligand concentration between the experiments. 
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4.3.3 Nir2 LNS2 does not interact with free hexanoic acid nor with free 
glycerol 3-phosphate  
As it was observed that the fatty acyl chains of DHPA and DHPC interact with the TF 
fusion of Nir2 LNS2 domain, next it was decided to determine if the protein is able to bind 
free short-chain fatty acids. This would help to reveal whether the protein is able to bind 
lipids non-specifically. In order to investigate short-chain fatty acid binding, a series of 
NMR waterLOGSY experiments was carried out with hexanoic acid, a C6 fatty acid 
fragment of DHPA and DHPC. The experiments were carried out under conditions 
identical to the ones used in the NMR experiments with DHPA and DHPC. 
Significantly, no interaction between hexanoic acid and the Nir2 LNS2 domain was 
observed in the experiments. None of the methyl or methylene proton signals have changed 
the sign after addition of the LNS2 in the waterLOGSY spectrum (Fig 4-6A), indicating 
that hexanoic acid is not interacting with the Nir2 LNS2 domain.  
In order to determine whether the LNS2 binds the glycerol backbone of phospholipids in 
the absence of the fatty acyl tails, waterLOGSY experiments were carried out using 
glycerol 3-phosphate (G3P), which forms the backbone moiety of glycerophospholipids. 
No evidence of interaction between G3P and the LNS2 domain was observed, as apparent 
from the absence of positive G3P proton signals after protein addition (Fig 4-6B). In the 
waterLOGSY spectra, negative G3P peaks are indistinguishable from the background due 
to the poor signal-to-noise ratio. 
Based on this data, it can be concluded that the presence of both the fatty acyl tails and the 
glycerol backbone is required for LNS2 binding, which indicates that the LNS2 domain of 
Nir2 interacts with DHPA and the fatty acyl chains of DHPC through a mechanism that 
allows specific recognition of glycerophospholipids. Furthermore, although Nir2 LNS2 
recognises DHPC and interacts with its acyl chains, Nir2 LNS2 does not appear to interact 
with the backbone and the head group of DHPC, which suggests that the identity of the 
head group is important for phospholipid binding by the LNS2 domain. Thus, it can also be 
concluded that the specificity of the interaction between the LNS2 domain and PA is 
brought about by the presence of unsubstituted, negatively charged phosphate group in the 
PA molecule. To summarise, it is apparent that both the hydrophobic interactions with the 
fatty acyl tails as well as polar interactions with the glycerol backbone and the head group 
of PA play a role in the LNS2-PA binding, and the polar interactions with the head group 
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of PA are required for the specificity of PA binding.  
 
 
 
 
 
 
Figure 4-6. Analysis of hexanoic acid and glycerol 3-phosphate interaction with the Nir2 
LNS2 domain. a) Reference 1D 1H spectrum, b) waterLOGSY spectrum in the absence of Nir2 
LNS2, c) waterLOGSY spectrum in the presence of Nir2 LNS2. Structures of hexanoic acid and 
glycerol 3-phoshpate bis(cyclohexylammonium) salt used in the experiments are displayed for 
reference. Acyl and glycerol proton resonance regions are labelled in the relevant spectra A. 
Hexanoic acid experiments. No change in the sign of proton resonances is observed upon protein 
addition in the waterLOGSY spectra, indicating that no interaction is occurring between hexanoic 
acid and the LNS2 domain. B. Glycerol 3-phoshate (G3P) experiments. No positive ligand signals 
are observed in the presence of the protein, indicating that no interaction is occurring between G3P 
and the LNS2 domain.  
a.	
b.	
c.	
A 
a.	
b.	
c.	
B 
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4.3.4 Nir2 LNS2 interacts with DHPA with millimolar affinity  
To obtain a more quantitative picture of DHPA binding, the affinity of the interaction 
between DHPA and Nir2 LNS2 was measured by waterLOGSY. For this, DHPA was 
added to the protein sample in a series of steps and a waterLOGSY spectrum was recorded 
after each addition. Mixing time in the experiments was set to 0.5 s and the protein 
concentration was kept relatively low (10 µM) to increase the likelihood of obtaining a 
more accurate Kd value, as described in the literature (Huang et al., 2017). The intensity of 
the highest peak in the triplet at 0.68 ppm that corresponds to the methyl protons of the 
fatty acyl chains of DHPA was measured, as it was the most intense peak in the 
waterLOGSY spectrum. To be sure that the ligand was not aggregating at higher 
concentrations, the measurements was first carried out using DHPA in the absence of the 
protein. The plot of the signal intensity against the ligand concentration was linear 
(Fig 4-7A), which suggests that no aggregation of the ligand was occurring. After DHPA 
was titrated into the protein solution, the intensity of the 0.68 ppm peak was plotted as a 
function of DHPA concentration for Kd determination (Fig 4-7B). Prior to the construction 
of the plot, the intensity values measured in the presence of the protein were corrected for 
the signal of the free ligand by subtracting the ligand intensities in the absence of the 
protein from the ligand intensities in the presence of the protein (see Section 4.3.1.3 for the 
theory).  
After correction, the data were fitted by the least square method to Equation 4-3 describing 
one-site binding:  
/ = 	 /'()	×	 " >5>,8 + " >5>  
where Imax is the maximum intensity, [L]tot is the total ligand concentration and Kd is the 
dissociation constant. This binding model assumes that [L]tot is approximately equal to the 
concentration of free ligand [L], which is true at high excess of ligand to the protein used 
in the measurements. Curve fitting using the data from three independent experiments has 
yielded Kd = 13.0 ± 0.4 mM. It should be noted that since the binding did not start to reach 
saturation in the titration experiments, it is possible that the Kd reported here is 
underestimated. Nevertheless, LNS2-DHPA binding can be defined as weak and placed 
into the millimolar range. 
Equation 4-3. 
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4.4 Analysis of Nir2 LNS2 domain binding to PA by fluorescence 
spectroscopy 
4.4.1 A brief overview of fluorescence spectroscopy 
4.4.1.1 Fluorescence   
Fluorescence spectroscopy is a mainstay of molecular bioscience that is continuing to find 
new applications with the development of novel fluorescent probes. Fluorescence 
spectroscopy is based on the fundamental physical phenomenon termed fluorescence, 
which is defined as the emission of light by a molecule (called a fluorophore) that has 
absorbed electromagnetic radiation. Fluorescence is observed when said molecule 
transitions from a high-energy excited state, which it enters on absorption of 
electromagnetic radiation, to a low-energy ground state. Since part of the energy of a 
molecule in an excited state is lost to the environment as a result of non-radiative decay, 
the energy of the light emitted during transition to the ground state is lower than that of the 
light absorbed by the fluorophore. Fluorophores remain in an excited state only for a short 
Figure 4-7. Kd calculation of the 
Nir2 LNS2-DHPA (di-6:0 PA) 
interaction using NMR 
waterLOGSY. The intensity of the 
highest peak in the triplet at 0.68 
ppm corresponding to the protons 
of the DHPA methyl group is 
shown as a function of DHPA 
concentration. A. DHPA titration in 
the absence of the protein. Intensity 
changes linearly with the increasing 
DHPA concentration, indicating 
that no aggregation of ligand is 
occurring. The data were fitted to a 
linear equation. B. DHPA titration 
in the presence of 10 µM TF fusion 
of Nir2 LNS2. The data were 
corrected for the free ligand 
concentration by subtracting the 
line in A. The corrected values 
were fitted to a hyperbolic one-site 
binding equation. The mean 
corrected values from triplicate 
experiments are shown. Error bars 
represent ± s.e.m. The calculated 
Kd value is shown.  
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period of time (10-7-10-9 s) before emitting light, which distinguishes fluorescence from 
phosphorescence, another type of radiative decay. 
Importantly, the photophysical properties of a fluorophore, such as the lifetime, 
wavelength and intensity of fluorescence, often depend on its local environment. For 
instance, if the fluorophore is in a solution, its properties can be influenced by the 
physicochemical properties of the solvent (e.g., polarity, pH and ionic strength) and may 
change if the fluorophore binds to a macromolecule or finds itself in a close proximity to 
another fluorophore. This environmental sensitivity of fluorophores is harnessed in 
biomolecular research to analyse the behaviour of biomolecules in vivo and in vitro.  
4.4.1.2 Fluorescence emission, excitation and anisotropy measurements 
By using fluorescence spectroscopy, one can measure several properties of the 
fluorophore. These include fluorescence excitation and emission maxima, fluorescence 
lifetime and fluorescence anisotropy. Furthermore, fluorescence measurements can be 
broadly divided into two types: time-resolved measurements and steady-state 
measurements. As the name implies, steady-state measurements report on the time-and-
ensemble average state of the system during the measurement, whereas with time-resolved 
measurements one is able to follow changes in the system as they occur, and hence obtain 
more detailed information about its behaviour.  
Fluorescence excitation and emission measurements are the most traditional types of 
fluorescence experiments. They are normally carried out in steady-state mode and require 
less sophisticated equipment than lifetime or anisotropy measurements. In emission and 
excitation measurements, light is shone onto the sample and the intensity of the outgoing 
fluorescence is recorded. During the measurement, monochromators can be used to 
transmit light with selected wavelength to and from the sample to acquire excitation or 
emission spectra. Fluorescence emission and excitation spectra can provide information 
about the environment of the fluorophore and can be used to observe fluorescence 
quenching (Mátyus et al., 2006) or fluorescence resonance energy transfer (Clegg, 2009; 
Lakowicz, 2006). Emission and excitation measurements are widely employed for a 
variety of investigations, including analysis of protein-ligand and protein-protein binding, 
formation of macromolecular complexes, characterisation of enzymatic reaction kinetics, 
determination of intermolecular distances in the cell, and others. 
As measurement of fluorescence emission and excitation spectra relies on the accurate 
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measurement of fluorescence intensity of the sample, there are certain limitations 
associated with these types of experiments. Fundamentally, fluorescence intensity is 
dependent on the fluorophore concentration, intensity of the excitation light and the 
pathlength of the light in the cell from which the measurement is made. This makes 
measurements of fluorescence spectra highly dependent on the instrumental settings, 
sample and cell specifications. Because of this, technical difficulties may arise during 
intensity measurements when the experimental conditions cannot be tightly controlled. 
Moreover, the emission and excitation spectra of a fluorophore in two different states or 
environments are often not sufficiently different from each other to allow discrimination 
between the different states of the fluorophores that may be present in the sample. Hence, 
an additional dimension may be required, which can be obtained by anisotropy or lifetime 
measurements. 
Fluorescence anisotropy measurements are based on the photoselection principle in 
fluorescence. That is, a fluorophore preferentially absorbs light whose electric vector is 
aligned in a specific way to the molecular axis (Lakowicz, 2006), leading to anisotropy of 
the emitted light. Anisotropy can be affected by several factors, including rotational 
diffusion. Crucially, fluorescence anisotropy reports on the mobility and shape of the 
fluorophore in solution. When a fluorophore associates with a larger molecule, rotational 
diffusion of the fluorophore will now be influenced by the associated partner, which will 
lead to changes in the observed fluorescence anisotropy. Fluorescence anisotropy 
measurements can be carried out in both steady-state and time-resolved modes. Unlike 
fluorescence intensity, fluorescence anisotropy does normally not depend on the 
concentration of the fluorophore. Although anisotropy measurements are a great tool in the 
study of biomolecular interactions, such as protein-protein or protein-ligand binding, their 
applications are more limited than those of fluorescence lifetime measurements. This is 
especially true when binding between the fluorophore and its interaction partner does not 
lead to sufficiently large changes in fluorescence anisotropy that can be detected 
experimentally. 
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4.4.1.3 Fluorescence lifetime measurements 
In contrast to fluorescence intensity, fluorescence lifetime is an intrinsic property of a 
fluorophore, and hence is independent of the excitation parameters, instrumentation or 
fluorophore concentration. Fluorescence lifetime is the average time required for the 
fluorophore in the excited state to return to the ground state via non-radiative decay and 
photon emission (Lakowicz, 2006). As mentioned previously, fluorescence lifetimes 
generally range from picoseconds to nanoseconds, and are sensitive of the fluorophore 
microenvironment.  
Fluorescence lifetimes are measured with time-resolved techniques. The use of lifetime 
measurements allows to discriminate between several populations of a fluorophore that 
might be present in the sample and find their respective proportions if they have different 
lifetimes. As fluorescence decays are very short, sophisticated instrumentation is required 
for the measurements. One of the most commonly used method of fluorescence lifetime 
measurement is time-correlated single photon counting (TCSPC) (O’Connor and Phillips, 
1984). In TCSPC, single photons emitted by the fluorophore are detected repetitively in a 
precisely timed manner, where the time of the excitation pulse serves as a reference for 
photon detection. As only a single photon is detected at a time, light pulses of low energy 
are used, which helps to prevent sample degradation and non-desirable optical effects. The 
data acquired from many cycles of single-photon measurements are processed digitally to 
produce a histogram of photon counts against arrival time of the photons after the pulse. 
The histogram is then used for lifetime determination. 
Fluorescence decay is an exponential process. To calculate the fluorescence lifetime from 
the histogram obtained in the experiment, the fluorescence decay trace formed by the 
photon counts is fitted with an exponential function by a non-linear least squares method. 
In its simplest form, fluorescence decay is expressed by a single exponential equation: / ? = 	 /@	AB>/D 
where I(t) is time-dependent fluorescence intensity, I0 is intensity at time zero and τ is 
fluorescence lifetime. The decay may also be fitted with a multi-exponential function, if 
several populations of the fluorophore are present in the sample.  
 
Equation 4-3. 
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Multi-exponential fluorescence decay is expressed by Equation 4-4: 
/ ? = 	 /@ E22 AB>/D 
where αi is the pre-exponential factor or amplitude of a lifetime component i.  
As can be seen from Equation 4-3, by fitting the data to a multi-exponential function one 
can determine the fractional contributions of the fluorophore in different states or 
environments to the time-dependent fluorescence intensity. This allows quantification of 
the different fluorophore populations and determination of their lifetimes in the sample. In 
this way, fluorescence lifetime measurements can provide a window into the intricate 
details of the molecular environment of the fluorophore in the sample, which are 
inaccessible by many other methods.  
Importantly, fluorescence measurements are becoming increasingly popular in the 
pharmaceutical industry and academic research for drug and tool compound screening in a 
high-throughput format. For this purpose, various fluorescence-based assays which involve 
fluorescence anisotropy and lifetime measurements have been developed (Boettcher et al., 
2014; Pritz et al., 2011; Zhang et al., 2015). High-throughput fluorescence experiments are 
carried out on fluorescence spectrometers equipped with microplate readers, which are 
available commercially. A common type of assay that can be used for the screening is a 
competition assay, in which a complex of a fluorescently-labelled ligand with a receptor 
protein is pre-formed, and competitor molecules from a compound library are added to the 
mixture to identify strong binders that displace the labelled ligand from the protein. The 
displacement can be monitored by measuring changes in the fluorescence anisotropy or 
fluorescence lifetime of the fluorophore.  
4.4.2 Time-domain fluorescence lifetime measurements confirm DHPA 
binding to Nir2 LNS2 
In this study, fluorescence lifetime measurements were used to further characterise the 
binding of LNS2 to DHPA and explore the potential for developing an assay for high-to-
medium throughput screening of the LNS2-PA interaction inhibitors. In order to determine 
the feasibility of carrying out such an assay and to further confirm the LNS2-DHPA 
Equation 4-4. 
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interaction, a DHPA molecule labelled with a fluorophore (nitrobenzoxadiazole or NBD) 
at one of the fatty acyl tails was used. With the fluorescently-labelled ligand, a series of 
fluorescence lifetime measurements were performed by using picosecond TCSPC. The 
measurements were carried out in a 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT 
buffer in a quartz cuvette. The probe was excited at 460 nm, and the fluorescence was 
measured at 534 nm. The photon counts recorded in the experiments were used to 
construct the fluorescence decay traces. The decay traces were fitted in FluoFit software 
(PicoQuant) using an exponential model with reconvolution described by Equation 4-5:  
/ ? = 	 /FG(?′) E2A>B>KDL 	M?′72>BN  
where IRF is the instrument response function, and the other parameters are as in Eq. 4-3 
and Eq. 4-4. Accordingly, n = 1 for single exponential decay, and n = 2 for biexponential 
decay. IRF was deconvoluted from the measured fluorescence response to allow 
determination of the amplitudes and lifetimes of the fluorophore populations in the sample. 
The lifetime measurements of DHPA-NBD fluorescence were performed either in the 
presence or the absence of TF Nir2 LNS2. When measured in the absence of the protein, 
the decay trace of the DHPA-NBD fluorescence resembled a straight line when photon 
counts were plotted on a log scale as a function of the time of photon arrival (Fig 4-8, 
green). The decay data were fitted to an exponential equation (χ2 = 1.06), and the average 
lifetime τav was determined to be equal to 1.27 ns. After addition of the protein, a drastic 
change in the fluorescence decay trace was observed (Fig 4-8, purple). In the presence of 
the protein, the decay trace was no longer linear, but resembled a curve. Hence, the decay 
was fitted to a biexponential equation (χ2 = 0.989), and two distinct amplitude-weighted 
lifetime values were calculated. The first lifetime τ1 was equal to 1.21 ns, which was 
similar to the lifetime of DHPA-NBD fluorescence observed in the absence of the protein. 
Interestingly, the second lifetime τ2 was found to be 7.78 ns, which was ~ 6.5-fold longer 
than τ1 or the DHPA-NBD lifetime in the absence of the protein. The fractional 
contributions of the two lifetimes were equal to 97.5% for τ1 and 2.50% for τ2, and τav was 
1.38 ns, suggesting that the fluorophore was mostly found in the state with the shorter 
lifetime τ1. 
The presence of τ2 was assumed to be due to the binding of DHPA-NBD to the LNS2 
domain and the resulting change in the fluorophore surroundings. This notion is supported 
Equation 4-5. 
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by evidence from literature, as NBD has been previously reported to be highly sensitive to 
environmental polarity (Chattopadhyay and London, 1988; Chattopadhyay and Mukherjee, 
1993), and possess a characteristic lifetime of ~ 7-8 ns when it is incorporated into lipid 
membranes (Chattopadhyay and Mukherjee, 1993; Mukherjee et al., 2004) and a much 
shorter ~1 ns (Lin and Struve, 1991) lifetime in pure water. Consistently, it can be 
proposed that the short lifetime τ1 (1.21 ns) is observed from the free fluorophore 
population, and the longer lifetime τ2 (7.78 ns) is observed from the fluorophore population 
bound to the protein. Therefore, if we consider the fractional contribution of τ2 to 
correspond to the fraction of the ligand bound to the protein, it is apparent that only 2.5% 
of the ligand in the sample was in a bound state at the 1:4 protein:ligand ratio used in the 
experiment. Such low proportion of bound ligand was likely observed due to the low 
binding affinity of DHPA-NBD to the LNS2 domain of Nir2, as the binding appears to be 
away from saturation at this ligand concentration.  
In addition, lifetime measurements using TF and DHPA-NBD were carried out to 
determine if the observed lifetime changes in the presence of the fusion were caused by 
ligand binding to the LNS2 domain in the fusion and not to TF. TF was added to the 
sample to reach the 1:4 protein:ligand ratio used in the measurements with the fusion 
protein. Unexpectedly, the addition of TF has also lead to a change in the decay trace 
(Fig 4-8, blue), which appeared to be curved in the presence of the protein. The decay trace 
was fitted to a biexponential equation, and lifetimes τ1 and τ2 were identified, which were 
equal to 1.22 ns and 5.31 ns, respectively. The fact that a second lifetime was observed in 
the presence of TF indicates that DHPA-NBD also binds to TF in the absence of the LNS2 
domain. However, this binding appears to be different from the binding observed between 
TF and the probe, as the τ2 values observed in the presence of the fusion protein and TF 
alone were different (7.78 ns and 5.31 ns, respectively). The fractional contributions of the 
decay components in the presence of TF were 1.0% for τ2 and 99% for τ1, and the τav was 
equal to 1.38 ns.  
From the τ2 fractional contribution we can assume that only 1% of the fluorophore 
molecules were interacting with TF in the sample, which is a lower proportion of the 
interacting molecules than the one observed with the fusion protein, suggesting that 
DHPA-NBD-TF binding is of even lower affinity. Importantly, as in the ligand-observed 
NMR experiments no binding was observed between DHPA and TF, it is likely that it is 
the NBD moiety that is interacting with TF rather than the DHPA moiety the DHPA-NBD 
conjugate. Alternatively, it may be that the DHPA moiety also interacts with TF, but the 
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interaction is too weak to be detected by the ligand-observed NMR experiments, which 
points towards its very transient nature. Since τ2 is shorter in the presence of TF than in the 
presence of the LNS2 fusion protein, it is also likely that the probe is in a less hydrophobic 
environment when bound to TF than when it is bound to TF Nir2 LNS2, and is partially 
exposed to the solvent when interacting with TF. The interaction may therefore be 
occurring with the exposed hydrophobic patches present of the surface of TF (Hoffmann et 
al., 2010), and hence is likely non-specific.  
To summarise, the data show that the recombinant TF fusion of the Nir2 LNS2 domain 
weakly interacts with DHPA-NBD, which confirms the findings in the ligand-observed 
NMR experiments (see above). DHPA-NBD also displayed interaction with TF in the 
absence of the LNS2 domain, but that interaction appears to occur via a different 
mechanism and is of weaker affinity than the interaction between DHPA-NBD and the 
LNS2 domain fusion proteins.  
The results of fluorescence lifetime measurements are summarised in Table 4-1. 
Protein/competitor τ1 (ns) τ2 (ns) τava (ns) τavb (ns) α1c α2 c χ2 
None 1.28 N/A 1.28 1.28 1.00 N/A 1.06 
TF-LNS2d 1.21 7.78 1.38 2.14 0.03 0.97 0.99 
TF-LNS2/5 µM DHPA 1.22 7.48 1.32 1.83 0.02 0.98 1.01 
TF-LNS2/10 µM DHPA 1.21 7.48 1.31 1.76 0.02 0.98 1.01 
TF-LNS2/20 µM DHPA 1.22 7.50 1.32 1.78 0.02 0.98 1.06 
TF 1.22 5.31 1.25 1.38 0.01 0.99 0.99 
a. Amplitude-weighted average lifetime. 
b. Intensity-weighted average lifetime. 
c. Normalised pre-exponential factors (amplitudes). 
d. The TF fusion of Nir2 LNS2. 
 
 
 
Table 4-1. Fluorescence decay parameters of DHPA-NBD (di-6:0 PA-NBD). The decay 
parameters are shown in the absence or the presence of proteins (TF Nir2 LNS2 or TF), with or 
without a competitor molecule (DHPA) at 5, 10 or 20 µM concentration. The parameters were 
obtained from fitting the decay data to single exponential or biexponential equations after 
correction for instrumental response, as described in the text. 
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Since an interaction between TF and the fluorescently-labelled DHPA-NBD was detected, 
it was instrumental to confirm experimentally that the binding between DHPA-NBD and 
the Nir2 LNS2 domain fusion protein is caused by the interaction between the DHPA 
moiety of DHPA-NBD and the LNS2 domain. For this purpose, displacement of the 
fluorescently-labelled DHPA-NBD from TF Nir2 LNS2 was attempted with the unlabeled 
DHPA. Displacement was expected if the interaction between the DHPA part of DHPA-
NBD and the LNS2 domain was present.   
For the displacement assay, DHPA was titrated into the sample to the final concentrations 
of approximately 5 µM, 10 µM and 20 µM, corresponding to the ligand:competitor ratios 
Figure 4-8. Fluorescence lifetime measurements of DHPA-NBD (di-6:0 PA-NBD). 
Fluorescence decay traces of DHPA-NBD alone in buffer (green lines), in the presence of TF 
Nir2 LNS2 (purple lines) and in the presence of TF (blue lines). In the absence of TF Nir2 LNS2, 
the decay signal can be fitted to a single exponential equation (τ = 1.27 ns), whereas in the 
presence of TF Nir2 LNS2 and TF, the decay can be fitted to a biexponential equation (τ1 = 1.21 
ns, τ2 = 7.47 ns for TF Nir2 LNS2). Fitted decay models are shown as black curves. Residuals of 
best fits are shown below the decay graph. 
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of 1:2.5, 1:5 and 1:10, respectively. The fluorescence of DHPA-NBD appeared to decay 
faster after addition of DHPA, as judged from the observed decay traces (Fig 4-9, grey, 
orange and red lines). Like the other decay traces of DHPA-NBD measured in the presence 
of TF Nir2 LNS2, they were fitted by a biexponential model. χ2 was 0.989 for the 5 µM 
DHPA, 1.01 for 10 µM DHPA and 1.06, representing a good fit. The τ2 values arising due 
to the interaction of DHPA-NBD with the protein were calculated to be equal to 7.48 ns in 
the presence of 5 µM and 10 µM DHPA, and 7.50 ns in the presence of 20 µM DHPA. The 
τ2 values were very close to the τ2 value (7.47 ns) measured in the absence of the 
competitor, as described above. Similarly, the shorter lifetime τ1 was equal to 1.21 or 
1.22 ns, consistent with the previous measurements. The fractional contribution of τ2 has 
decreased from 2.50% in the absence of the competitor to a minimum of 1.54% (38% 
decrease) after the addition of 10 µM unlabelled DHPA, indicating that DHPA is 
displacing DHPA-NBD from the protein. An apparent 0.02% increase in the τ2 fractional 
contribution was observed after addition of DHPA to 20 µM concentration. As the increase 
was very low, it was assumed to be an artifact of curve fitting. Consistently, the amplitude-
weighted τav values have decreased from 1.38 ns in the absence of the competitor to a 
minimum of 1.31 ns in the presence of DHPA in ~ 5 molar excess to DHPA-NBD.  
The fact that complete displacement was not observed in the experiment can be explained 
by the presence of non-specific binding between DHPA-NBD and TF and/or higher 
affinity of TF Nir2 LNS2 to DHPA-NBD than to DHPA. Nevertheless, it appears that the 
binding between DHPA-NBD and TF Nir2 LNS2 is in large part caused by the LNS2 
domain. In order to confirm this, fluorescence of NBD not linked to DHPA can be 
measured in the absence and the presence of the protein to determine whether NBD alone 
can also interact with the protein.  
Importantly, it was shown that DHPA-NBD can be at least partially displaced from the 
protein by addition of a competitor molecule. Hence, it can be proposed that a competition-
based assay using the fluorescence intensity measurements of DHPA-NBD or another 
fluorescently-labelled PA molecule can be employed for identification of inhibitors of 
LNS2-PA binding. The considerations for designing such an assay are discussed at the end 
of this chapter. 
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Figure 4-9. Fluorescence lifetime measurements of DHPA-NBD (di-6:0 PA-NBD) 
displacement from TF Nir2 LNS2 by DHPA. Fluorescence decay traces of DHPA-NBD are 
shown in the presence of TF fusion of Nir2 LNS2 (purple lines) and in the presence of both TF 
fusion of Nir2 LNS2 and a competitor DHPA molecule at either 5 µM, 10 µM or 20 µM 
concentrations (grey, orange and red lines, respectively). Fitted decay models are shown as 
black curves. Residuals of best fits are shown below the decay graph. 
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4.5 Analysis of the interaction between Nir2 LNS2 and 
PA-containing LUVs by CD spectroscopy 
4.5.1 CD spectroscopy 
Circular dichroism (CD) spectroscopy is a biophysical technique commonly used in 
protein research for characterisation of the secondary structure of proteins (Greenfield, 
2006; Kelly et al., 2005). Circular dichroism arises when the two circularly polarised 
components (left and right) of plane polarised light are absorbed differentially by the 
sample. In CD spectroscopy, the sample is illuminated with plane polarized light and the 
difference in absorbance of polarised light components is measured. Differential 
absorbance is reported in degrees of ellipticity of light transmitted through the sample. 
Ellipticity refers to the measure of elliptical polarisation of light, which occurs when 
circularly polarised components of incident light are absorbed unequally by the sample. 
The degree of ellipticity corresponds to the tangent of the ratio of the two components of 
plane polarised light.  
To obtain a CD spectrum of a protein, one can follow the absorbance of peptide bonds (far 
UV region, < 240 nm), aromatic amino acid side-chains (near UV region, 260-320 nm) or 
disulphide bridges (~ 260 nm). Proteins are CD active due to the intrinsic chirality of 
amino acids and the presence of chiral secondary and tertiary structure components such as 
α-helices and β-sheets. Conveniently, the common types of protein secondary structures 
can be distinguished by their CD spectra. A set of representative far UV CD spectra of 
secondary structure components is shown in Fig 4-10 [reproduced from (Greenfield, 
2006)]. Typically, α-helices display positive ellipticity in the region from 190 to 202 nm, 
with the peak value at 193 nm, and negative ellipticity in the region from 202 to 250 nm, 
with the lowest value at 222 nm (Greenfield and Fasman, 1969). Typical antiparallel 
β-sheets demonstrate positive ellipticity in the region from 190 nm to 205 nm, with the 
maximum at 195 nm, and negative ellipticity between 208 and 238 nm, with a dip in the 
spectrum at 217 nm. Like α-helices and β-sheets, disordered peptide chain also has a 
characteristic CD spectrum with negative ellipticity between 190 and 210 nm. Several 
other protein secondary structures, such as the collagen triple-helix, display other unique 
spectral shapes (Fig 4-10).  
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Information about the secondary structure of protein of interest is typically obtained by 
comparison of the measured CD spectrum to the reference CD spectra of proteins with 
known three-dimensional structures. Most commonly, the analysis of CD spectra is carried 
out online by using DICHROWEB (Whitmore and Wallace, 2004), an online server for 
protein secondary structure analysis. DICHROWEB provides access to most popular 
analytical algorithms including SELCON3 (Sreerama and Woody, 1993), CONTIN/LL 
(Provencher and Gloeckner, 1981), CDSSTR (Johnson, 1999; Sreerama et al., 2000) and 
K2d (Andrade et al., 1993), as well as seven reference CD datasets (Sreerama et al., 2000).  
In protein-ligand binding studies, CD spectroscopy can be used for monitoring the 
conformational change in the protein upon interaction with the ligand. This is done by 
recording the CD spectra of the protein in the presence and the absence of the ligand, and 
comparing the shapes of the spectra and the predicted secondary structure proportions. 
Changes in the CD spectra can be attributed to a structural change in the protein that occurs 
upon ligand binding, and could reveal structural details about the ligand binding 
mechanism. It should be noted, however, that ligand binding does not always result in the 
conformational change in the protein or, if a conformational change does occur, it might be 
not reflected in the CD spectrum.  
Figure 4-10. Characteristic CD spectra of 
peptide and protein secondary structures. 
Spectra 1-3 correspond to poly-L-tryptophan 
in α-helical, anti-parallel β-sheet and 
disordered forms, respectively. Spectra 4 and 
5 correspond to collagen in a triple-helical and 
denatured forms, respectively. 
Reprinted by permission from Springer 
Customer Service Centre GmbH: Springer 
Nature, Nature Protocols (Greenfield, N.J. 
Using circular dichroism spectra to estimate 
protein secondary structure. 2006. Nature 
Protocols 1, 2876–2890), copyright (2006).  
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4.5.2 No secondary structure change is observed in the TF fusion of Nir2 
LNS2 domain upon PA binding  
Here, CD spectroscopy was employed to determine whether there is any observable change 
in the secondary structure of the LNS2 domain of Nir2 upon PA binding. The putative 
dimeric form of the fusion protein was used in the experiments. 
Far UV CD spectra were recorded from samples containing either: 1) TF Nir2 LNS2 only, 
2) TF Nir2 LNS2 in the presence of PA-containing LUVs, or 3) TF Nir2 LNS2 in the 
presence of PC-only LUVs. PC-only LUVs were used as a control, as no specific binding 
was expected between the LNS2 domain of Nir2 and PC. Spectra recorded in the absence 
of the protein were used to correct for the background scattering by buffer components and 
the vesicles. The appearance of the spectra was very similar in the absence and the 
presence the vesicles (Fig 4-11). The difference between the spectra observed in the region 
from 190 to 196 nm can be attributed to non-specific effects of vesicle addition or light 
scattering by the vesicles that was not corrected by subtraction of vesicle-only spectra. 
Importantly, the CD spectra obtained from the samples containing 30% PA, 70% PC LUVs 
and PC-only LUVs in the presence of TF Nir2 LNS2 appeared nearly identical, signifying 
that the presence of PA does not specifically influence the secondary structure of the LNS2 
domain. The spectra were analysed by K2d neural network algorithm (Andrade et al., 
1993) to estimate the fractions of the secondary structure components in the protein (Table 
4-2). Consistently, in all three samples, the protein was found to comprise 37% α-helices, 
17-18% β-sheets and 45-46% turns and unordered regions, indicating that the secondary 
structure of the protein did not change on PA binding. 
It should be noted, however, that it was the TF fusion of the Nir2 LNS2 domain that was 
used for CD measurements and not the LNS2 domain alone. Since TF forms the largest 
portion of the fusion protein (69% by MW), it is a larger contributor to the CD spectrum 
than the recombinant LNS2 domain, which constitutes only 28% of the fusion. 
Nevertheless, it would be expected that at least small differences between the spectra 
obtained in the presence of PA-containing LUVs versus PC-only LUVs would be observed 
if there was a secondary structure change in the LNS2 domain upon binding to PA.  
The analysis of the secondary structure composition of the Nir2 LNS2 domain in the 
absence of TF could not be carried out due to the low protein expression yield and the 
tendency of the protein to aggregate in solution, as described in Chapter 3. A way of 
obtaining the structural contributions of Nir2 LNS2 from the CD spectrum of the fusion 
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protein would be to record a CD spectrum of TF under the same conditions as used for the 
fusion protein, subtract the spectrum of TF from that of the fusion and carry out the 
secondary structure analysis by one of the conventional algorithms. The fractional 
secondary structure contributions obtained in such way should approximately correspond 
to those of the Nir2 LNS2 domain, assuming that the secondary structure of TF in the 
fusion protein and in the free form is not majorly different. This work was not carried out 
in this study due to time constraints. 
Sample α-helix β-sheet Unordered Max. error 
TF-LNS2 alone 0.37 0.17 0.45 0.08 
TF-LNS2 + PA:PC  0.37 0.17 0.46 0.08 
TF-LNS2 + PC 0.37 0.18 0.45 0.08 
 
 
 
 
 
 
 
4.5.3 The LNS2 domain of Nir1 has β-sheet-rich fold in solution  
As it was not possible to carry out a direct analysis of the secondary structure of Nir2 
LNS2, N-terminally His6-tagged Nir1 LNS2-S fragment was employed for CD 
spectroscopy to obtain information about the secondary structure of the LNS2 domain from 
Figure 4-11. Far UV CD spectra of the TF fusion of Nir2 LNS2. The spectra were recorded in 
the absence (black curve) and the presence of LUVs either containing 30% PA and 70% PC (red 
curve) or only PC (blue dotted curve). All three spectra appear indistinguishable in the region above 
200 nm. 
Table 4-2. Secondary structure analysis of the TF fusion of Nir2 LNS2 domain. The CD spectra 
were recorded in the absence (TF-LNS2) and presence of LUVs containing either 30% PA and 70% 
PC (TF-LNS2 + PA:PC) or only PC (TF-LNS2 + PC) are shown. Fractional contributions of 
secondary structure components and maximum errors of the estimates are shown. Analysis was 
carried out by K2d unsupervised neural network algorithm (Andrade et al., 1993). Maximum error is 
the sum of root mean square deviations of α-helix and β-sheet predictions. The prediction is 
considered to be reliable if the maximum error is less than 0.227. 
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a human protein. The recombinant Nir1 LNS2 domain was expressed as described in 
Chapter 3. Purification was carried out by Ni2+-affinity chromatography in the presence of 
20% glycerol to improve the purity of the recombinant protein. CD spectroscopy in the far 
UV region revealed that recombinant Nir1 LNS2 has spectral characteristics of a folded 
protein (Fig 4-12). Structural analysis was successfully carried out by the CDSSTR 
algorithm (Johnson, 1999; Sreerama et al., 2000) despite the noise that was observed in the 
spectrum due to the low protein concentration in the sample (0.12 mg/ml; higher 
concentration was difficult to obtain because of protein instability). The 193-260 nm 
spectral region was used for analysis. Nir1 LNS2 was predicted to comprise 10% α-helices, 
48% β-sheets, 12% turns and 29% unordered regions, indicating that the LNS2 domain of 
Nir1 is rich in β-sheets. The normalised root mean square deviation value was equal to 
0.029, indicative of a reliable prediction (Whitmore and Wallace, 2004). Although it is yet 
to be shown experimentally that the secondary structure of the LNS2 domain is conserved 
between the human Nirs, this is likely to be the case because of the high sequence 
similarity between the LNS2 domain of Nir1, Nir2 and Nir3. Ideally, the protein 
purification procedure should be optimised further to obtain samples with sufficient 
concentrations of Nir2 and Nir3 LNS2 domains for CD analysis. Buffers containing 
solubility-enhancing additives (e.g., glycerol) should be considered for CD measurements.  
CD measurements and analysis of CD spectra were carried out by Dr Sharon Kelly 
(University of Glasgow). 
 
 Figure 4-12. Far UV CD spectrum of the Nir1 LNS2-S fragment. Noise is observed in the 
spectrum due to the low protein concentration in the sample (0.12 mg/ml). 
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4.6 Conclusions and discussion 
In the experiments described in this chapter several findings were made concerning the 
interaction of the LNS2 domain of Nir2 and PA. First, the ability of the recombinant 
fusions of Nir2 LNS2 to bind PA was confirmed by several methods, and the affinity of the 
Nir2 LNS2-PA interaction was estimated using PA-containing LUVs and short fatty acyl 
chain PA species. Secondly, it was discovered that the protein interacts with both the 
hydrophobic and polar regions of PA. Thirdly, it was observed that the protein does not 
appear to change its secondary structure upon PA binding. Fourthly, the secondary 
structure composition of Nir1 LNS2 was characterised, and the protein was found to 
consist mostly of β-sheets. Moreover, two competition-based assays were proposed that 
could be employed for medium-to-high throughput screening of the LNS2-PA interaction 
inhibitors. 
4.6.1 The mechanism of PA binding by the LNS2 domain of Nir2 
Taking into account the data obtained from the biophysical and biochemical experiments, 
several assumptions can be made about the mechanism of the LNS2-PA interaction. As 
mentioned above, the results of the ligand-observed NMR studies strongly suggest that the 
LNS2 domain of Nir2 interacts with both the fatty acyl chains and with the 
glycerophosphate backbone of PA. From these studies, it is also apparent that the protein 
recognises the presence of the anionic phosphate group in DHPA, as differences were 
observed between the LNS2-DHPA and LNS2-DHPC interactions where the LNS2 
domain of Nir2 bound to the polar region of DHPA but not DHPC. However, the 
interaction between the phosphate group of PA and the protein could not be demonstrated 
directly due to the fast chemical exchange of the phosphate hydroxyl proton with the bulk 
water. A potential way to confirm the interaction would be to carry out 31P NMR 
measurements of the chemical shift, T2 relaxation time or the lineshape of the DHPA 
phosphate signal in the presence and the absence of the protein. It is possible that either a 
change in the chemical shift, or shortening of the T2 relaxation time and broadening of the 
linewidth of the phosphate group signal would be observed upon addition of the protein to 
the phospholipid. Furthermore, as it was observed that Nir2 LNS2 did not interact with free 
hexanoic acid and glycerol 3-phosphate within the range of concentrations tested, it is clear 
that the protein specifically recognises the structural features of phospholipids and not of 
their isolated parts. 
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From comparing the estimated high micromolar (~ 0.5 mM) apparent dissociation constant 
for DOPA in LUVs estimated in the liposome co-sedimentation experiments to a ~ 13 mM 
dissociation constant for DHPA measured in the waterLOGSY experiments, it can be seen 
that the LNS2 domain appears to interact with PA with ~ 25-fold stronger affinity when 
PA is embedded in a lipid membrane. Both interactions are, however, weak on the absolute 
scale. Also, it is unclear whether the affinity of the LNS2-membrane interaction in vivo is 
comparable to the calculated value for the LNS2-LUV binding, or whether the low affinity 
is observed only in vitro with the recombinant TF fusion of Nir2 LNS2. For instance, one 
reason for the observed low in vitro LNS2-PA affinity could be that a significant part of 
the recombinant LNS2 domain used in the experiments was in a misfolded or partially 
misfolded state with reduced ability to interact with PA. A definitive conclusion on the 
folding state of the TF Nir2 LNS2 oligomeric species could not be made in this study. 
Interestingly, lower affinity to free lipids compared to membrane-embedded lipids was 
previously reported for PI(3)P-binding zinc finger FYVE domains and phorbol 
ester/DAG-binding C1 domains. FYVE domains bind at least 20 times more strongly to 
PI(3)P in the lipid bilayer than to the short-chain PI(3)P or the free IP2 head group of 
PI(3)P (Gaullier et al., 2000; Kutateladze et al., 1999), and C1 domains have a 104-fold 
higher affinity for phorbol esters embedded in the membrane than for free phorbol esters 
(Kazanietz et al., 1995). Crystal structures of FYVE (Misra and Hurley, 1999) and C1 
(Zhang et al., 1995) domains have revealed that the domains dock onto the membrane 
through insertion of specific hydrophobic residues into the lipid bilayer and formation of 
salt bridges between charged amino acids and the polar functional groups of phospholipids 
in the membrane. It is therefore possible that the LNS2 domain contains similar structural 
elements that aid its interaction with phospholipid membranes. This notion is supported by 
the apparent inability of Nir2 LNS2 to interact with free glycerol 3-phosphate, suggesting 
that the interaction between the polar region of the membrane and the protein may not be 
sufficient for protein-membrane binding. Indeed, the ability of the LNS2 domain to interact 
with the fatty acyl chains of phospholipids indicates that the interaction between the 
aliphatic region of the membrane and the protein is highly likely. Furthermore, the 
apparent low affinity of PA binding by the LNS2 domain suggests that it is unlikely that 
the PA molecule is enclosed in a deep binding pocket or a cavity when bound to the LNS2 
domain, as observed for the PITP domain or the nematode FARs (see Sections 1.3 and 
1.4). Instead, the PA-binding site of the LNS2 domain is likely located on the surface of 
the protein or in a shallow pocket. This is further supported by the fact that the protein does 
not appear to have lipid-solubilising properties, as evident from the fact that it remains 
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bound to the blot and the lipid vesicles after binding the ligand in the lipid overlay and 
liposome co-sedimentation assays, respectively. 
The potential membrane-interacting hydrophobic residues of Nir2 include W1055 and 
W1079 which are conserved between the LNS2 domains of Nir1-3 and RdgB (Fig 4-13). 
Tryptophan residues were singled out as they often play a key role in membrane binding 
by the membrane-interacting proteins (Das and Rahman, 2014; Feng et al., 2002; Glomset, 
1999; Lee et al., 2006) and possess the highest free energy of partitioning from bilayer 
interface into water (Wimley and White, 1996). However, other hydrophobic residues, 
which are abundant in the LNS2 domain, may also participate in the proposed membrane 
interaction. Of interest here is the hydrophobic linear peptide consisting of Y1060-LIVY-
V1065 that is conserved across the Nir1-3 and RdgB LNS2 domains as the 
Y(L/M)(I/L)XY(I/V) sequence motif where X is a non-aromatic apolar amino acid. It is, 
however, unknown whether any of these residues are found on the exterior of the protein, 
where they could contact they membrane. 
The LNS2 domain of Nir2 also contains a number of distributed charged residues that are 
conserved between the Nir1-3 and RdgB LNS2 domains, and which could participate in an 
electrostatic interaction with the phospholipid head groups in the membrane. The 
conserved basic residues in Nir2 LNS2 include four lysines (K1043, 1104, 1127 and 1151) 
and six arginines (R1045, 1053, 1068, 1075, 1147 and 1150). Furthermore, eight acidic 
residues are also highly conserved (D1028, 1041, 1050, 1057, 1070, 1094, 1099 and 1128). 
It can be proposed that at least some of the conserved basic residues could form salt 
bridges to the anionic head group of PA. Correspondingly, the function of the acidic 
residues might be to orient the protein relative to the membrane in such a way as to allow 
the PA binding to occur or to coordinate solvent molecules in the binding site that can in 
turn interact with the polar groups of PA. Since the LNS2 domain was unable to bind the 
head group of DHPC in the ligand-observed NMR experiments, it is unlikely that the 
acidic residues interact with cationic head groups of membrane lipids. 
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Previously, no common PA binding motif has been identified, and it is widely assumed 
that PA binding protein rely of the presence of appropriately spaced basic amino acids that 
bind the phosphate group of PA through electrostatic interactions (Lemmon, 2008; Stace 
and Ktistakis, 2006). However, at least two PA binding peptides including the PA binding 
region of Raf-1 (Kraft et al., 2008) and synthetic lysine polymers (Takahashi et al., 1991) 
are known to adopt β-sheet-like structure upon PA binding. It is therefore a possibility that 
the β-sheet-rich structure of the LNS2 domain of Nir1 and, possibly, other Nirs and RdgB 
somehow contributes to PA binding. Unfortunately, the three-dimensional structure of Nir1 
LNS2 could not be determined, as the protein was prone to aggregation in solution and 
displayed very low protein yield in recombinant expression (see Chapter 3). 
Disappointingly, crystallisation screening of the more stable TF and MBP fusions of Nir2 
LNS2 failed to identify conditions that produced protein crystals.  
To summarise, it can be suggested that the hypothetical PA binding site of Nir2 LNS2 is 
located in a shallow pocket and contains polar amino acids that interact with the head 
group and the glycerol region of PA via hydrogen bonding and electrostatic interactions, 
and apolar residues that interact with the aliphatic region of PA and, possibly, of other 
membrane lipids. It is also possible these or other apolar residues can insert into the 
hydrophobic interior of the membrane, contributing binding energy to the LNS2-
membrane interaction. Further experiments would be required to confirm these hypotheses. 
Figure 4-13. Multiple sequence alignment of the LNS2 domains of Nir1-3 and RdgB. 
Amino acid sequences of the LNS2 domains are shown, as defined by SMART (Schultz et al., 
1998). Conserved tryptophan residues (yellow), as well as basic and acidic residues (blue and 
red, respectively) are highlighted. Fully conserved residues are highlighted in dark colour, 
partially conserved residues are in light colour. The alignment was produced in Jalview 
(Waterhouse et al., 2009). 
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4.6.2 Proposed assays for identification of Nir2 LNS2-PA interaction 
inhibitors 
Development of inhibitors of the Nir2 LNS2-PA would provide an efficient way of 
determining the role of the interaction in phosphoinositide signalling. Based on the 
experimental findings reported here, at least two simple assays can be proposed for 
screening of Nir2 LNS2-PA interaction inhibitors, which can be adapted for use in a 
medium-to-high throughput format. Both assays are competition-based and use short-chain 
PA molecules due to their high solubility in water and ability to bind the LNS2 domain of 
Nir2. Short descriptions of the principles are given below. 
The first proposed assay employs ligand-observed NMR spectroscopy, which is a very 
common tool in drug discovery (Klages et al., 2007; Mashalidis et al., 2013; Pellecchia et 
al., 2008). The assay could be used for the fragment-based screening of the LNS2-PA 
inhibitors that bind to the LNS2 domain with medium-to-weak affinity. For the assay, short 
chain PA (e.g., DHPA) should be mixed with a fragment in the presence of a 
substoichiometric concentration of recombinant LNS2 domain. Additionally, a mixture of 
the DHPA and the protein should also be prepared in the absence of the fragment. The 
DHPA concentration should be kept constant in both mixtures. STD, CPMG and 
waterLOGSY (see Section 4.3) as well as a standard 1H spectrum of the ligand mixtures 
should then be recorded. By comparing the DHPA signals in the absence and in the 
presence of fragments, it can be determined whether displacement of the DHPA from the 
protein is occurring. The spectra should also be recorded in the absence of the protein to 
ensure that no aggregation of DHPA is occurring in the presence of the fragments, which 
could lead to a false negative result in the assay. After identification of displacers, their 
affinity to the LNS2 domain can be estimated using ligand-observed NMR as described in 
Section 4.3, or by an orthogonal technique such as surface plasmon resonance (SPR). In 
order to scale up the screening, automation can be employed for sample preparation and 
sample insertion into the magnet, as well as data acquisition. 
The second proposed assay employs fluorescence lifetime measurements, a robust 
technique that has recently found its way into drug discovery. The principles of 
fluorescence lifetime measurements were discussed in Section 4.4. A fluorescently-labeled 
short-chain PA, such as DHPA-NBD used in this study, can be employed in the assay. To 
carry out the assay, the ligand should be mixed with the LNS2 domain, a fragment added 
to the mixture and the lifetime of DHPA-NBD fluorescence measured. If the fragment is a 
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displacer of DHPA-NBD, the τ2 lifetime of NBD fluorescence will reduce from ~ 8 ns 
observed when the ligand is bound to the LNS2 domain closer to ~ 1 ns in the aqueous 
buffer (see Section 4.4). To avoid interference with the fluorescence of the ligand, 
fragments should be selected for the lack of intrinsic fluorescence. The assay can be 
adapted for medium-to-high throughput compound screening by the use of a fluorescence 
spectrometer fitted with a multi-well microplate reader. Alternatively, instead of the 
lifetime, anisotropy of a fluorescently-labelled ligand can be measured in the assay. 
Anisotropy measurements can be performed using polarisation function of, e.g., Analyst™ 
HT Plate Reader (Molecular Devices, USA). 
Other methods of inhibitor identification include structure-guided inhibitor design or in 
silico screening of inhibitors (Zoete et al., 2009). However, since structural details of the 
LNS2 domain are required for such strategies, and no structure of Nir2 LNS2 is available, 
these methods are not discussed here. 
4.6.3 Future directions 
A number of experiments can be carried out to obtain more details of the mechanism of the 
LNS2-PA binding.  
In order to determine whether the LNS2 domain inserts into the membrane on binding to 
liposomes, measurements of 1,6-diphenyl-1,3,5-hexatriene (DPH) fluorescence anisotropy 
can be performed. DPH is a fluorescent dye that incorporates into the lipid membranes and 
serves as a reporter of membrane fluidity. The reduction of membrane fluidity which can 
be caused by protein insertion leads to an increase in mobility of DPH, which results in a 
decrease in anisotropy that can be monitored (Jasniewski et al., 2008). Furthermore, 
steady-state intrinsic fluorescence intensity of the Nir2 LNS2 tryptophans could also be 
monitored in the absence and presence of lipid vesicles to determine if they participate in 
the interaction with the membrane.  
A quantitative characterisation of the affinity of the LNS2-liposome binding could be 
achieved by SPR. Sensor chips coated with aliphatic groups could be used for 
immobilisation of the liposomes, and the protein concentration can be varied to obtain the 
Kapp. Furthermore, as PA is a known pH sensor in the cell (Shin and Loewen, 2011), 
dependence of the LNS2-PA binding affinity on the pH of the buffer can be investigated 
by SPR or the methods used in this study. The effect of salt concentration on the binding 
affinity can also be assessed to determine the importance of electrostatic interactions in PA 
  
133 
binding. To investigate the role of individual LNS2 residues in the binding, site-directed 
mutagenesis can be carried out to mutate the residues of interest one-by-one, and assess the 
PA binding properties of the mutants. This would also require measurements of the CD 
spectra of the mutants and comparison of the spectra to that of the wild type protein to 
ensure that the mutations do not lead to significant conformational change in the protein, 
which could disrupt the binding in a non-specific way.  
Lastly, further optimisation of the crystallisation conditions can be carried out to obtain 
crystals of the LNS2 domain of human Nirs for structure determination by X-ray 
crystallography. A number of detergents or other additives may be added during 
purification and/or crystallisation of the protein, which could improve the stability of the 
protein and potentially promote crystal growth. Screening of detergents/additives can be 
carried out in the multi-well plate format, as described in the literature for membrane 
proteins (Parker and Newstead, 2016; Shimizu et al., 2008). Detergents with low 
aggregation number such as CHAPS (Hjelmeland, 1980) may also be used during sample 
preparation for the structural analysis of the LNS2 domain by protein-observed NMR to 
prevent or reduce protein aggregation and obtain higher protein concentrations.   
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5. Determination of the crystal structure of Na-FAR-1 
complex with oleic acid 
5.1 Introduction 
Necator americanus FAR-1 protein (Na-FAR-1) belongs to a family of fatty acid and 
retinol binding proteins (FARs), which are known to bind a broad spectrum of lipid ligands 
and have been proposed to play a role in parasitism (see Chapter 1). To understand the 
mechanisms behind the lipid specificity of FAR proteins that could reveal clues about the 
biological functions of FARs, structural information is required. To date, the structure of 
Na-FAR-1 is the most extensively characterised among FARs. Importantly, it has been 
determined both in the ligand-free form and in the ligand-bound form (Rey-Burusco et al., 
2015). However, although the structure of ligand-bound Na-FAR-1 was solved, the ligands 
with which the protein was co-crystallised comprised a mixture of endogenous E. coli 
lipids that were co-purified with the protein after recombinant expression. The 
heterogeneity of the mixture made identification of the ligands and mapping of the ligand 
binding sites difficult, and only one binding site was identified with certainty. Hence, it 
was highly desirable to obtain more structural details about the locations of ligands in the 
Na-FAR-1-ligand complex and map the protein-ligand interactions with higher accuracy. 
In this study, the structure of the Na-FAR-1 complex with one of its natural fatty acid 
ligands, oleic acid, was determined by X-ray spectroscopy at high resolution (1.29 Å). 
Oleic acid was chosen as a ligand in the structural investigation as its Na-FAR-1 binding 
stoichiometry was previously determined by NMR experiments, revealing that the protein 
is able to bind a maximum of four oleic acid molecules (Rey-Burusco et al., 2015). Ligand 
densities were identified inside the internal cavity of the Na-FAR-1 oleic acid complex, 
and the interactions between the ligands and Na-FAR-1 amino acids were mapped. As a 
result, significant clues were obtained about the fatty acid binding mechanism by 
Na-FAR-1.  
In this chapter, a brief overview of protein X-ray crystallography will be given and the 
structure of the oleic acid complex will be presented. The process of structure 
determination and identification of the oleic acid binding sites will be described in detail. 
At the end of the chapter, the fatty acid binding mechanism of Na-FAR-1 will be 
discussed, and experiments to validate the findings of this study will be suggested. 
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5.2 A brief overview of protein X-ray crystallography 
5.2.1 The history of protein X-ray crystallography in a flash 
It is difficult to find a technique that has played a more significant role in the development 
of modern biomolecular science than X-ray crystallography. Since the discovery of X-ray 
diffraction by Max von Laue in 1912 and invention of the X-ray spectrometer by William 
Henry Bragg in 1913, X-ray crystallography has been an invaluable tool in molecular 
structure investigations, finding applications in mineralogy, chemistry and other 
disciplines. Biology and X-ray crystallography first came together when X-ray diffraction 
was observed from pepsin crystals in 1934 by John Desmond Bernal and his student, 
Dorothy Hodgkin (Bernal and Crowfoot, 1934), who made many significant contributions 
to the field of macromolecular X-ray crystallography in the following years (Jaskolski et 
al., 2014). The first protein structure solved by X-ray crystallography was that of 
myoglobin (1958) (Kendrew et al., 1958), shortly followed by the structure of 
haemoglobin in 1960 (Perutz et al., 1960). In last 25 years, technological advances such as 
emergence of ultra-fast pixel array detectors, tunable synchrotron X-ray radiation sources, 
cryocrystallography, as well as improvements in the computational power available to 
researchers allowed protein X-ray crystallography to flourish and become a routine 
technique in biology. Landmark protein structures determined in this period include high-
resolution crystal structures of F1-ATP synthase (Abrahams et al., 1994), RNA polymerase 
II (Cramer et al., 2001; Gnatt et al., 2001) and the ribosomal 50S and 30S subunits (Ban et 
al., 2000; Harms et al., 2001; Wimberly et al., 2000). These structures helped to elucidate 
molecular mechanisms crucial for the life of the cell and lead to several Nobel prizes. In 
total, more than 130,000 protein and peptide structures determined by X-ray 
crystallography are deposited on the Protein Data Bank (PDB) today. 
5.2.2 A brief introduction to the theory of protein X-ray crystallography  
5.2.2.1 Diffraction and crystals 
X-ray crystallography is based on the fundamental wave-like behaviour of light and the 
resultant ability of light to diffract when meeting an obstacle, such as a diffraction grating. 
Crucially, the pattern of the diffracted light and the nature of the obstacle are reciprocally 
related, and hence the diffraction pattern can be used to obtain information about the 
obstacle. Like a diffraction grating, molecules are also able to diffract light. Since the 
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distances between the atoms in a molecule are very short (~ 1-3 Å), X-rays with the 
wavelength comparable to the interatomic distance are used to observe diffraction. 
In molecules, X-rays are scattered primarily by electrons in the atomic electron shells. 
Scattering occurs when an X-ray beam incident on an electron is absorbed by the electron 
and then re-emitted as scattered light. Importantly, electrons can scatter X-rays elastically 
(i.e., the frequency of the incident radiation and the scattered radiation is identical). Due to 
the small size of molecules, X-ray diffraction from a single molecule is nearly impossible 
to detect with the current crystallography systems due to the very poor signal-to-noise 
ratio. Therefore, to obtain information about the structure of a molecule, a crystal is used, 
where the molecules are arranged in a periodic pattern called the crystal lattice. Since all 
the molecules in a crystal are identically oriented, the diffraction pattern of a molecule is 
amplified many times through constructive interference when obtained from a crystal, 
which makes its detection possible.  
The repeated component of the crystal lattice from which the whole crystal can be build is 
called the unit cell, which is defined by three axial lengths (a, b, c) and three interaxial 
angles (α, β, γ). The reciprocals of a, b and c define the dimensions of the reciprocal unit 
cell, a basic unit of the reciprocal lattice. The reciprocal lattice is a purely imaginary 
crystallographic concept which, however, is extremely useful for understanding diffraction 
patterns. The reciprocal lattice can be divided into crystallographic planes specified by the 
Miller indices (h, k, l) that describe the intercepts of the planes with the crystallographic 
axes. The diffraction spots (reflections) observed in a crystallography experiment 
correspond to the points on the (hkl) planes in the reciprocal lattice, and hence their relative 
positions and intensities can be related back to the real crystal lattice to obtain the 
information about the unit cell and its contents, respectively. 
5.2.2.2 Bragg’s law 
There are rules that specify the conditions for observing diffraction from atoms in the 
crystal lattice, which are to do with the interference effects observed due to the wave-like 
properties of X-rays. These rules are conveniently formulated by Bragg’s law, which can 
be written in the form of the following equation:  
2MPQRS = 	RT Equation 5-1. 
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where d is the distance between two lattice planes in a crystal, θ is the angle between the 
incident X-rays and the planes, λ is the wavelength of the incident X-rays and n is an 
integer. To illustrate Bragg’s law, in Fig 5-1, a diagram is shown depicting X-ray 
scattering from atoms lying on two adjacent lattice planes in a crystal. As can be seen from 
the diagram, the X-ray beam incident on the bottom plane travels an extra distance before 
it is scattered, compared to the beam incident on the top plane. The extra distance that the 
beam travels depends on the separation between the planes in the crystal and the angle of 
incidence, and is equal to 2dsinθ. The X-ray waves scattered from the planes will be out of 
phase unless 2dsinθ is equal is an integer multiple of the wavelength of the incident X-
rays. If the X-rays scatter out of phase, destructive interference will occur, which will lead 
to cancellation or partial cancellation of the scattered waves. If the 2dsinθ = nλ condition is 
satisfied, the scattered X-rays will be in phase, and constructive interference will lead to 
magnification of the amplitude of the scattered X-ray waves. As a result, intense reflection 
spots will be detected. It should be noted that the reflection spots do not only carry 
information about the atoms lying on the planes diffraction from which satisfies the 
Bragg’s law, but about all the atoms in the crystal that interact with the incident radiation. 
 
 
 
 
Figure 5-1. Schematic depiction of X-ray scattering from atoms lying on two lattice planes 
in a crystal. The X-ray beam that is incident on the plane shown on the bottom travels more 
distance than the X-ray beam incident on the plane shown on the top. The difference in the 
distance travelled by the two waves is highlighted in red and is equal to 2dsinθ, where d is the 
interplanar separation and θ is the angle of incidence. Intense diffraction spots are observed when 
2dsinθ is equal to an integer of the wavelength of the incident X-rays, so that the X-rays scattered 
from the different lattice planes remain in phase. 
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5.2.2.3 Structure factors and the phase problem 
Intensities of the diffraction spots tell us about the distribution of the electron density 
inside the unit cell, which is crucial for determination of the structure of its contents. In 
order to extract the information about the electron density from the intensities, structure 
factors are used. Structures factors are functions that correlate the amplitude and phase of 
the waves diffracted from crystal lattice planes with the electron density distribution in the 
unit cell. Structure factor for an (hkl) reflection can be expressed by the following 
equation, where the structure factor is a Fourier transform of the electron density 
distribution in the unit cell: 
G(ℎVW) = X Y Z[\ A]^2 _)`	9a`	bc MZM[M\dce@
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Here, F(hkl) is the structure factor, V is the volume of the unit cell, x, y, z are the fractional 
coordinates in the unit cell and ρ(xyz) is the electron density at position (xyz). This equation 
can be transformed to produce the equation describing the electron density distribution in 
the unit cell as a function of all structure factors F(hkl): 
Y Z[\ = 	 1X G ℎVW A B]^2 _)`9a`bc `2g _9bb9_  
where |F(hkl)| is the amplitude of the structure factor and α(hkl) is its phase angle. From 
Eq. 5-3, it can be seen that in order to calculate the electron density distribution, we need to 
know both the amplitude of the structure factor, which can be obtained from the intensities 
of the diffraction spots, and the phase angle. As the information about the phases is lost 
during detection, the origin of the famous phase problem in crystallography becomes clear.  
5.2.2.4 Ways to solve the phase problem 
Several methods have been developed to solve the phase problem. The most popular ones 
are molecular replacement (MR), multiple isomorphous replacement (MIR), multiple 
wavelength anomalous diffraction (MAD) and single wavelength anomalous diffraction 
(SAD). Of these techniques, MR is by far the easiest and the quickest, but requires access 
to a structure of a protein with a similar fold. In contrast to MR, each of MIR, MAD and 
SAD can be used for structure determination de novo.  
Equation 5-3. 
Equation 5-2. 
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Multiple isomorphous replacement (MIR) is the oldest of the methods, and was famously 
used to solve the structures of myoglobin and haemoglobin. MIR relies on the attachment 
of strongly-scattering heavy atoms, such as mercury or lead, to a limited number of sites in 
the protein. Crucially, the structural arrangement of the crystal and dimensions of the unit 
cell should not change after attachment of the heavy atoms. The perturbation of the 
diffraction pattern by the heavy atoms is then used to determine the positions of the heavy 
atoms in the crystal, which are in turn used to estimate the experimental phases. MAD and 
SAD also rely on the introduction of heterogeneous atoms into the protein crystal, but 
instead of strong scatterers, atoms that scatter X-rays anomalously are used, such as 
selenium or sulphur. Selenium is most commonly introduced into the protein via 
selenomethionine labelling by recombinant expression in a minimal medium supplemented 
with selenomethionine using an E. coli strain that is a methionine auxotroph. The presence 
of anomalously scattering atoms in the unit cell leads to the differences in the intensity of 
observed (hkl) reflections versus (-h-k-l) reflections, from which the location of the 
anomalous scatters in the unit cell can be deduced. This information is used to predict the 
phases for structure determination, in a way similar to MIR. Typically, the SHELX 
software family (Sheldrick, 2008) is used for obtaining experimental phases from MIR, 
MAD and SAD data.  
Unlike MIR, MAD and SAD, MR does not require any additional experimentation beyond 
collecting the complete set of reflections from a protein crystal. As mentioned above, MR 
relies on the use of a previously-solved structure of a protein that is structurally related to 
the protein of interest. In brief, the known structure is fitted into the unit cell of the crystal 
via a series of rotations and translations, and the theoretical diffraction pattern predicted for 
the known structure in the unit cell is compared to the diffraction pattern observed 
experimentally. If the known structure is positioned correctly, the patterns will match, and 
the theoretical phases calculated from this model can then be used together with the 
experimentally determined amplitudes of the structure factors to calculate the electron 
density distribution in the unit cell and solve the structure of the protein of interest. A 
number of programs have been developed for performing MR. The most popular ones 
include MrBUMP (Keegan and Winn, 2008) and Phaser (McCoy et al., 2007), which are 
available in the CCP4 crystallographic software package. 
Detailed descriptions of MR, MIR, MAD and SAD are beyond the scope of this thesis, and 
have been presented elsewhere (Drenth, 2007; Evans and McCoy, 2008; Rossmann, 2001; 
Rossmann and Blow, 1962; Taylor, 2010). 
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5.2.2.5 Refinement and validation of the model 
After the electron density distribution has been calculated, the model of the protein 
structure can be created by fitting the protein atoms into the determined electron density. 
The agreement of the model with the experimental data is assessed by comparing the sum 
of the structure factor amplitudes calculated from the model (|Fcalc| or |Fc|) to the sum of 
the structure factor amplitudes determined from experimental data (|F(hkl)| or |Fobs| or 
|Fo|).  
The agreement is typically quantified by calculating the reliability factor (R-factor) using 
the following equation:  
F = 	 G5 −	 G+G5  
where R is the R-factor. Consequently, if the R-factor is equal to 0, the model and the 
experimental data are in perfect agreement, and if the R-factor is equal to 1, there is no 
agreement between the model and the data. R-factor is rarely equal to 0 for protein 
structures because of their complexity. R-factor also tends to vary with the resolution that 
can be collected, with high-resolution structures (~ < 1.5 Å) typically demonstrating lower 
R-factors than medium- or low-resolution structures. Refinement of the model is carried 
out to increase its agreement with the experimental data. Normally, a small set of 
reflections is excluded from refinement and used to calculate the so-called free R-factor 
(Rfree) after the refinement. If no over-fitting of the data has occurred, Rfree and the R-factor 
of the refined model (Rwork) should be consistent with each other. 
Refinement is performed by changing the coordinates of the protein atoms, temperature 
factors (B-factors), which describe the degree of displacement of each protein atom due to 
various molecular effects, and other parameters of the atoms in the model. Refinement can 
be performed automatically using programs such as REFMAC (Murshudov et al., 1999, 
1997) and semi-automatically using real-space refinement (Diamond, 1971) in the program 
Coot (Emsley et al., 2010). Typically, both types of refinement strategies are used.  
To aid refinement of the model, several programs have been developed to validate the 
accuracy of the models from the physicochemical perspective. Validation can be carried 
out by analysing the geometry of the atomic bonds, energetic favourability of the 
combinations of protein dihedral angles and the presence of interatomic clashes in the 
model. The most popular tools for structure validation are MolProbity (Chen et al., 2010) 
Equation 5-4. 
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and PROCHECK (Laskowski et al., 1993); several validation tools are also available in 
Coot.  
Electron density maps are used to visually represent the electron density distribution during 
refinement. Two most common types of the electron density maps are the Fo-Fc map and 
the 2Fo-Fc map. The Fo-Fc map is often called the difference map, as it simply shows the 
differences in the electron density distribution calculated from the model and the 
experimental data. The 2Fo-Fc map is a composite map which contains the information 
about the density distribution calculated from the experimental data in addition to the 
information about the differences between the model and the data. As it represents the 
protein electron density more accurately, it is commonly used for fitting of the protein 
atoms during model refinement in Coot. 
5.3 High-resolution crystal structure of Na-FAR-1 in complex with 
oleic acid 
5.3.1 Data collection and structure determination 
For structure determination by X-ray crystallography, Na-FAR-1 was co-crystallised with 
four molar equivalents of oleic acid sodium salt. The details of crystallisation conditions 
and data collection are given in Chapter 2. High quality data was collected from the largest 
crystal (approximate dimension ~ 150 µm x 150 µm x 150 µm), with the resolution 
reaching 1.29 Å. The unit cell was found to have cubic symmetry, and was in the same 
space group (P 432) as in the previously solved structure of Na-FAR-1 complex with E. 
coli lipids (PDB ID 4XCP) (Rey-Burusco et al., 2015). The diffraction pattern recorded 
from the crystal is shown in Fig 5-2.  
The three-dimensional crystal structure of the Na-FAR-1 oleic acid complex was 
determined by MR using 4XCP as a search model in Phaser. Ligands were excluded from 
the search model by setting the ligand atom occupancies to zero. The model was refined 
using iterative cycles of anisotropic refinement in REFMAC, as well as real-space 
refinement and model building in Coot. The data collection and refinement statistics are 
summarised in Table 5-1. The final Rwork and Rfree values were equal to 0.137 and 0.162, 
respectively, suggesting good agreement between the model and the experimental data. 
Remote data collection at the synchrotron was carried out by Dr Aleksander Roszak 
(University of Glasgow).  
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 Na-FAR-1 oleic acid complex 
Data collection  
Space group P 432 
Cell dimensions  
 a, b, c (Å) 121.38, 121.38, 121.38 
 α, β, γ (°) 90.0, 90.0, 90.0 
Resolution (Å) 42.91-1.29 (1.32-1.29) * 
I/σI 25.9 (1.5) 
Rpim 0.016 (0.697) 
Completeness 100.0 (100.0) 
Multiplicity 21.3 (8.3) 
  
Refinement  
Resolution (Å) 42.91-1.29  
No. reflections 73075 
Rwork/Rfree 0.137/0.162 
Number of atoms  
    Protein 1284 
    Ligand 80 
    Water 313 
B-factors  
    Protein 23.2 
    Ligand 46.0 
    Water 53.9 
RMS deviations  
    Bond lengths (Å) 0.015 
    Bond angles (°) 1.800 
* Highest resolution shell is shown in parentheses. 
Figure 5-2. Diffraction pattern recorded from the crystal of Na-FAR-1-oleic acid complex. 
Well-resolved reflections can be observed. 
Table 5-1. Data collection and refinement statistics for the Na-FAR-1 complex with oleic acid.  
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5.3.2 Structural features of the Na-FAR-1-oleic acid complex 
It was observed that the overall conformation of Na-FAR-1 in complex with oleic acid was 
very similar to that of 4XCP (Fig 5-3, RMSD for all heavy atoms = 0.52 Å). Like in the 
4XCP structure, the protein contained eleven α-helices (α1-11, numbered from the N-
terminal to the C-terminal). The helices formed the internal cavity of Na-FAR-1, which 
serves as the binding site for ligands. The positions of α-helices were nearly identical in the 
two complexes. The most noticeable difference was in a flexible loop formed by T101, 
G102 and R103, located between α7 and α8, which had a different conformation in the 
oleic acid complex, compared to 4XCP. When viewed in the surface representation, the 
structure of the oleic acid complex appeared slightly more expanded than that of 4XCP. 
Several entrances to the cavity present in 4XCP either had reduced area or were absent in 
the oleic acid complex (an example is given in Fig 5-3C).  
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Consistent with these observations, analysis by the protein surface topology tool CASTp 
(Binkowski et al., 2003) revealed that the internal cavity volume of Na-FAR-1 oleic acid 
complex was slightly larger than that of 4XCP when measured both with a 1.4 Å probe 
equivalent to a water molecule (2983 Å3 vs 2570 Å3, respectively) and with a 1.925 Å 
probe equivalent to a CH2 group (2437 Å3 vs 2170 Å3). 
Figure 5-3. The structure of the Na-FAR-1 oleic acid complex and its comparison with the 
structure of the Na-FAR-1 complex with E. coli lipids (PDB ID 4XCP). A. The structure of the 
oleic acid complex is shown in cartoon representation, coloured from blue to red (N-terminus to 
C-terminus) with the α-helices numbered. B. Superimposed cartoons of Na-FAR-1 in complex 
with oleic acid (grey) and with E. coli lipids (green) [PDB ID 4XCP, (Rey-Burusco et al., 2015)]. 
The location of the internal cavity of Na-FAR-1 is marked in the structures of the left. In the 
structures on the right, α7-α8 loop that has different conformations in the two complexes is 
marked. C. A representative small conformational difference on the surface of the two complexes. 
One of the entrances to the internal cavity is partially closed in the oleic acid complex. The 
location of the entrance is highlighted in red. The colour-coding is identical to B. 
A 
C 
B 
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Previously, it was demonstrated that Na-FAR-1 expands on ligand binding (Rey-Burusco 
et al., 2015). From the data presented here, it can be suggested that the degree of 
Na-FAR-1 expansion depends on the nature of the ligands bound to the protein or the 
stoichiometry of the protein-ligand complex. In 4XCP, Na-FAR-1 was believed to contain 
a 16-carbon palmitic acid molecule inside its cavity, along with other unidentified lipids 
(Rey-Burusco et al., 2015). In contrast to 4XCP, the structure reported here contained 
18-carbon oleic acid molecules, as the majority of the E. coli lipids were removed by the 
reverse-phase HPLC (see Chapter 3), and any remaining lipids were expected to have been 
displaced by the excess of oleic acid. It appears that in the oleic acid complex, the internal 
cavity of Na-FAR-1 has expanded further to accommodate either the larger ligands, the 
higher loading, or both. The apparent ability of Na-FAR-1 to adjust the volume of its 
internal cavity to accommodate different types of molecules might be one of the reasons 
behind the observed diversity ligands that NaFAR1 can bind. 
5.3.3 Location of the oleic acid binding sites in the Na-FAR-1 internal cavity  
5.3.3.1 Ligand fitting 
Volumes of electron density were observed inside the internal cavity of Na-FAR-1-oleic 
acid complex in the 2Fo-Fc map, into which the ligands were fitted. Prior to fitting of the 
ligands, water molecules were introduced into the model in Coot. As the electron density 
of the ligands appeared less well defined than the electron density of the protein atoms, 
fitting of some of the ligands proved to be a challenging task. Ligand modelling was 
carried out by first locating the electron density patches that could be fitted with the 
carboxylic head groups of oleic acid. The preference was given to the patches located near 
the polar groups of the protein residues, as it was postulated that it would be energetically 
favourable for the oleic acid head groups to make polar contacts to the protein. 
Subsequently, the oleic acid aliphatic chains were extended into the electron density 
protruding from the identified head group densities. If negative or positive density peaks 
surrounding the ligand atoms were observed in the in the Fo-Fc map after refinement, the 
positions of the ligands or the occupancies of the ligand atoms were adjusted manually, 
and the automatic refinement was repeated until the difference peaks either disappeared or 
at least reduced were in size in the Fo-Fc map. The change in the R-factor was also 
monitored after each refinement step, and the models that displayed the lowest Rwork and 
Rfree values that were in agreement with each other were selected. In the end, four oleic 
acid molecules were fitted into the cavity (OLA1-4, Fig 5-4A).  
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It should be noted that inconsistencies between the model and the experimental data were 
still expected to be present in the final model. For instance, after the final model was 
refined, many fragments of positive electron density were still found inside the cavity in 
the Fo-Fc map, especially near OLA2, 3 and 4 (Fig 5-4B). This density could originate 
from different conformations of the oleic acid aliphatic tails, which are expected to be 
highly flexible. However, since it was difficult to find unambiguous solution to model the 
alternative conformations, these remaining positive Fo-Fc density regions near the modelled 
ligands were left unfilled. 
In the cavity, all four oleic acid molecules were oriented in a similar way. Their carboxylic 
acid head groups were contacting either the solvent or the polar groups at the surface of the 
cavity, whereas their aliphatic tails were hidden in the interior of the cavity. The aliphatic 
tails of the ligands formed an apparent hydrophobic core inside the cavity, the presence of 
which may prevent collapse of the cavity structure observed in the ligand-free form of 
Na-FAR-1 (Rey-Burusco et al., 2015). The positions of each of the ligand molecules are 
presented below. 
 
 
 
 
Figure 5-4. Ligand molecules inside the Na-FAR-1 complex with oleic acid. A. Cartoon 
representation of the Na-FAR-1-oleic acid complex structure. The surface of the Na-FAR-1 internal 
cavity is shown within the backbone cartoon, coloured according to its electrostatic potential (blue 
and red represent positive and negative potential, respectively). The oleic acid molecules inside the 
cavity (OLA1-4) are depicted as sticks. B. Electron density of OLA1-4. Top. The 2Fo-Fc map (blue 
mesh). Bottom. The 2Fo-Fc map (blue mesh) superimposed with the Fo-Fc difference map (green 
and red mesh for positive and negative peaks, respectively). Ligands are depicted as sticks. 2Fo-Fc 
map is contoured at 1σ and carved at 1.6 Å around the ligands. The Fo-Fc map is contoured at 3σ 
and carved at 2.0 Å around the ligands.  
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5.3.3.2 Ligand binding sites 
OLA1 was fitted into the most well-defined electron density inside the internal cavity of 
Na-FAR-1 in the 2Fo-Fc map (Fig 5-4B). The ligand was located close to an opening in the 
protein surface between helices α3, α6 and α10. The OLA1 head group was in a position to 
make hydrogen bonds to the backbone amide groups of F138 (2.9 Å) and L139 (3.0 Å), 
and a polar contact with a solvent molecule (Fig 5-5A). The fatty acyl tail of OLA1 
contacted the apolar groups in the side-chains of P15, M69, V70, S88, I89, F136, F138 and 
L139. It should be noted that the protonation state of the carboxyl acid group of oleic acid 
molecules in the protein-ligand complex was unclear, as the pH of the mother liquor 
(~ 4.5) was too close to the theoretical pKa of oleic acid in water (5.0) predicted by 
ChemAxon model (www.chemaxon.com). However, the ligands were predicted to be 
deprotonated by the Protoss software (Bietz et al., 2014) based on the structural features of 
the complex, and hence were drawn accordingly in Fig 5-5.  
In contrast to OLA1, the electron density of OLA2 was less defined. For instance, in the 
final model, no electron density was observed around ligand carbons 2, 3 and 10 in the 
2Fo-Fc map contoured at 1σ, which may be explained by a higher conformational flexibility 
of the ligand regions containing these atoms compared to the rest of the molecule. A small 
negative density peak was observed close to carbon 2 in the Fo-Fc map contoured at 3.0σ, 
which was not completely removed by refinement. This peak might have arisen due to the 
problems in the model caused by the incomplete modelling of alternative conformations of 
oleic acid tails, as mentioned above. Unlike OLA1, the head group of OLA2 was not 
located near a cavity entrance, but was hidden inside the cavity, contacting a cavity wall 
formed by α7 and α8. The carboxylic acid group of OLA2 made hydrogen bonds to the 
hydroxyl groups of Y10 (2.7 Å) and S113 (2.6 Å) (Fig 5-5B). The aliphatic tail of the 
molecule was curved at carbon 4, after which point it extended away from the wall into the 
central cavity. The ligand had hydrophobic contacts to the side-chains of I6, L13, M14, 
A92, I95, Y99, V114 and V117, as well as to the aliphatic tail of OLA4. 
The carboxylic acid group of OLA3 was fitted into a region of electron density near the 
side-chain of K96 in conformation A (K96a). OLA3 was located near a large region of 
positive electrostatic potential in the cavity next to the largest cavity opening between α4, 
α5 and α7. In this position, the carboxylic acid group of OLA3 appeared to make hydrogen 
bonds to the side-chain amine group of K96a (2.8 Å) and the hydroxyl group of Y100 
(2.7 Å) (Fig 5-5C), as well as contacted a solvent molecule. In addition, the ligand made 
hydrophobic contacts to the side-chains of L33, V36, F37, T45, S48, I49, V63, H67 and 
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the fatty acyl tail of OLA4. The aliphatic tail of OLA3 was curved in way similar to the 
OLA2 tail, making a turn after carbon 3 and extending into the cavity.  
Finally, OLA4 was placed into the electron density close to OLA2 and OLA3. The head 
group of OLA4 was located close to the cavity opening found between α4, α7 and the 
N-terminus of the protein. Its carboxylic oxygen atoms made hydrogen bonds with the 
backbone amide of F1 (3.1 and 3.2 Å) (Fig 5-5D) and a polar contact with a solvent 
molecule. The ligand also contacted the hydrophobic side-chains of F1, F21, L22, K30, 
L33, K34 and Y100, as well as the fatty acyl tails of OLA2 and OLA3. It should be noted 
that the electron density of OLA4’s head group was rather poorly defined in the 2Fo-Fc 
map compared to the other ligands. This might suggest that at least the head group region 
of OLA4 is relatively mobile and might occupy an alternative, unknown binding site in the 
cavity. It should also be noted that F1 is the N-terminal residue in the secreted form of 
Na-FAR-1, as the residues preceding F1 in the structure reported here belong to the 
recombinant tag. However, as in the native form of the protein the amino group of F1 is 
expected to carry a positive charge and thus would be able to form a salt bridge with the 
negatively charged group of oleic acid, it is likely that the interaction between F1 and 
OLA4 will also be observed in the native protein. 
To summarise, four oleic acid binding sites in the cavity were mapped. The head groups of 
all the ligand molecules appeared to be hydrogen bonded to either backbone amide groups 
or the polar side-chain groups of the protein residues. The head groups of three oleic acid 
molecules (OLA1, OLA3 and OLA4) were located close to the cavity openings, whereas 
the head group of one ligand (OLA2) was hidden inside the cavity. The head groups of 
OLA1, OLA2 and OLA4 contacted structured waters in their binding sites. The aliphatic 
tails of all ligands made a large number of contacts with the hydrophobic amino acid side-
chains in the internal cavity of the protein. Hence, fatty acid binding by Na-FAR-1 is 
expected to be predominantly hydrophobic in nature, although polar interactions also 
appear to play a role in positioning the ligands. 
The proposed mechanism of Na-FAR-1-fatty acid binding is discussed below. 
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  Figure 5-5. Oleic acid binding sites in the Na-FAR-1-oleic acid complex. A. OLA1 binding site. B. 
OLA2 binding site. C. OLA3 binding site. D. OLA4 binding site. Left column: OLA1-4 molecules and 
Na-FAR-1 residues contacting OLA1-4 are shown as sticks (yellow and teal, respectively). Predominant 
conformations of Na-FAR-1 residue side-chains are shown. In cases when the side-chain conformations 
were modelled in two conformations, the conformation closest to the ligand is shown. Water molecules 
that make polar contacts to OLA1-4 are shown as spheres (magenta). Polar contacts between the 
carboxylic groups of OLA1-4 and either protein residues or water molecules are depicted as yellow dashed 
lines. Right column: LigPlot depictions (Wallace et al., 1995) of the interactions between OLA1-4 and the 
protein. Residues making polar contacts to the ligands are shown as balls-and-sticks. Hydrogen bonds 
between the protein residues and OLA1-4 are shown as green dashed lines (bond length is in Å). 
Hydrophobic contacts are represented as red arcs with spikes oriented towards the contacting atom.  
A 
B 
C 
D 
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5.4 Conclusions and discussion 
5.4.1 Comparison of the Na-FAR-1 ligand complexes and implications for the 
mechanism of fatty acid binding by Na-FAR-1 
The structure of the Na-FAR-1 oleic acid complex was determined at a high resolution 
(1.29 Å), which allowed fitting of protein residues with high accuracy. As reported above, 
the conformation of Na-FAR-1 in the oleic acid complex was found to be largely similar to 
that of Na-FAR-1 in complex with E. coli lipids (PDB ID 4XCP). An important difference, 
however, was in the volume of the internal cavity, which was larger in the oleic acid 
complex than in 4XCP. As noted above, it is likely that the ability to change the volume of 
its cavity might help Na-FAR-1 to accommodate lipids of varying sizes and shapes or form 
lipid complexes with different protein-ligand stoichiometries. It is, however, unclear what 
the maximum volume that the internal cavity of Na-FAR-1 can expand to is. 
The increase in the cavity volume was accompanied by reduction in the sizes of the cavity 
openings in the oleic acid complex, which was a consequence of the conformational 
changes in the side-chains of Na-FAR-1 residues. However, cavity openings were still 
present in the structure, and the head groups of three oleic acid molecules were located 
close to the openings, likely due to the local environmental polarity. Furthermore, three 
oleic acid molecules appeared to contact structured water molecules, one of which was 
located in the interior of the cavity. Hence, it can be suggested that water plays a specific 
role in the oleic acid binding by Na-FAR-1 by making polar contacts to the oleic acid head 
groups, and thereby aiding the positioning of the ligands inside the cavity in a 
thermodynamically favourable manner.  
The aliphatic tails of different oleic acid molecules contacted one another in the internal 
cavity of Na-FAR-1. If we assume that oleic acid molecules bind Na-FAR-1 in a sequential 
manner, which is apparent from the ability of Na-FAR-1 to form a number of distinct 
complexes with different protein-ligand stoichiometries (Rey-Burusco et al., 2015), it is 
possible that binding of at least some of the ligands might occur via a cooperative 
mechanism. Here, binding of one ligand might lead to an increase in affinity for binding of 
the next ligand due to the increase in the hydrophobicity of the cavity interior as a result of 
ligand binding. The same is likely to hold true for other fatty acids with chain lengths 
similar to that of oleic acid. 
  
151 
As mentioned above, differences in the conformations of many amino acid side-chains in 
the cavity were observed between 4XCP and the oleic acid complex. The most interesting 
example here is K96, which was located in the region of the cavity with a large positive 
electrostatic potential and was involved in ligand binding. The side-chain of K96 was 
found to have two conformations in the oleic acid complex (K96a and K96b) and only one 
in 4XCP (Fig 5-6). In the oleic acid complex, K96a was the predominant conformer (70% 
occupancy), which made a hydrogen bond with the carboxylic head group of OLA3. In 
4XCP, the side-chain of K96 also appeared to contact the ligand, but the amino acid was in 
a conformation that was equivalent to K96b in the oleic acid complex and not to K96a. As 
the ligand in 4XCP was believed to be palmitic acid rather than oleic acid, the change in 
the position of the side-chain could have been caused by the structural differences between 
the ligands in the two structures. Hence, it can be proposed that the side-chain of K96 may 
help the protein to accommodate fatty acids with different aliphatic tail lengths by flipping 
between at least two conformations, and changing the spatial arrangement and the local 
charge distribution of the cavity in this way. Additionally, K96 appears to regulate the size 
of the largest cavity entrance, which is partially obstructed by K96’s side-chain in the oleic 
acid complex. 
 
 
 
 
 
Figure 5-6. Conformation of Na-FAR-1 K96 side-chain in the oleic acid complex and in 
the E. coli lipid complex containing palmitic acid (PDB ID 4XCP). In the oleic acid 
complex (grey cartoon), K96 is found in two conformations (K96a and K96b). K96a is the 
predominant conformation (70% occupancy), in which the residue makes a hydrogen bond 
with an oleic acid molecule (OLA3, grey sticks). In 4XCP (green cartoon) (Rey-Burusco et 
al., 2015), K96 is only found in a conformation equivalent to K96b, in which the residue 
makes a hydrogen bond with a palmitic acid molecule (green sticks). The change in the K96 
side-chain conformation might be required to accommodate different types of ligands. 
Hydrogen bonds between the ligands and K96 are represented as yellow dashes. 
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To summarise, from the structures of Na-FAR-1 complexes with oleic acid and E. coli 
lipids, a number of propositions can be made regarding the Na-FAR-1 mechanism of fatty 
acid binding. First, the internal cavity of Na-FAR-1 can expand to varying degrees to 
accommodate different types of ligands or allow formation of complexes with varying 
protein-ligand stoichiometries. Second, fatty acid binding by Na-FAR-1 involves both 
polar and apolar interactions. Apolar interactions are, likely, the major contributors to the 
binding energy of Na-FAR-1, whereas polar interactions might be responsible for fixing 
the ligands in an energetically favourable conformation inside the cavity. Third, the 
conformation of certain protein residues, such as K96, may regulate the ligand binding 
properties of Na-FAR-1, and may change the local arrangement of the cavity to 
accommodate fatty acids of different chain length. Fourth, the binding of fatty acids by Na-
FAR-1 is likely to be cooperative due to the hydrophobic effect associated with the 
aliphatic tails of the fatty acids. 
Apparent differences between the mechanisms of fatty acid and phospholipid binding by 
Na-FAR-1 will be discussed in Chapter 6.  
5.4.2 Future directions 
The results presented here suggest several experimental avenues that could be explored to 
test the hypotheses put forward. 
The role of specific Na-FAR-1 residues in oleic acid binding could be tested by 
site-directed mutagenesis. For that purpose, the residues whose side-chains appear to make 
polar to the ligands head groups in the crystal structure can be mutated to, e.g., alanine 
residues that lack polar side-chains. The influence of the mutations on binding affinity 
could then be assessed, for example, by a fluorescence-based assay which was used 
previously for analysis of lipid binding by FARs and other lipid binding proteins 
(Basavaraju et al., 2003; Mei et al., 1997), and the principle of which is described in 
Chapter 6. To complement the functional analysis, structures of Na-FAR-1 mutants in 
complex with oleic acid can be determined by X-ray crystallography to characterise the 
effects of mutations on the positioning of ligands in the complex. It should be noted that 
three Na-FAR-1 residues (F1, F138 and L139) appeared to make hydrogen bonds to oleic 
acid via their backbone amides. Therefore, it would be difficult to use site-directed 
mutagenesis to confirm the role of these residue in oleic acid binding, as mutation of the 
residues to prolines would be required to disrupt the hydrogen bonds between the 
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backbone amides of the residues and the oleic acid head groups, which could have a 
significant impact on the protein backbone conformation. 
As the fitting of some of the ligands proved to be challenging, oleic acid labelled with 
strongly-scattering bromine atoms at specific aliphatic tail carbons could be used to 
confirm the location of the ligands in the internal cavity of Na-FAR-1 and potentially 
simplify the fitting procedure. Previously, brominated lipids were successfully used to 
identify lipid binding sites in the photosynthetic reaction center of Rhodobacter 
sphaeroides (Roszak et al., 2007). However, it should be noted that the presence of the 
large bromine atoms in the aliphatic tail of the ligands might affect the positioning of the 
lipids inside the Na-FAR-1 cavity, and hence the structure of the Na-FAR-1 complex with 
brominated oleic acid might not appear in agreement with the structure reported in this 
study. 
Furthermore, the mechanism of the interaction between Na-FAR-1 and fatty acids of 
different chain lengths could be investigated by X-ray crystallography. However, due to 
the structural similarities between the long-chain fatty acids that Na-FAR-1 shows a 
preference for, their mechanism of binding is not expected to be radically different from 
the one observed with oleic acid, and, hence, is unlikely to provide new information. 
However, determination of the crystal structure with, for example, 14-carbon myristic acid 
would help to confirm or refute the proposed role of K96 side-chain conformation in ligand 
binding by Na-FAR-1. 
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6. Analysis of phospholipid binding by Na-FAR-1 
6.1 Introduction 
The structure of Necator americanus FAR-1 protein (Na-FAR-1) in complex with one of 
its natural fatty acid ligand, oleic acid, was solved in this study. As a result, clues about the 
fatty acid binding mechanism of Na-FAR-1 were obtained, which were discussed in 
Chapter 5.  
Recently, it has also been demonstrated that Na-FAR-1 is also able bind 
phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) (Rey-Burusco et al., 2015). 
PG and PE belong to a class of molecules termed phospholipids, which are structurally 
distinct from fatty acids and other known ligands of Na-FAR-1, such as retinol and retinoic 
acid. Although the biological importance of phospholipid binding by Na-FAR-1 is 
unknown, lipid binding by secreted nematode lipid binding proteins has been previously 
proposed to play a role in parasitism by facilitating nutrient acquisition from the host 
and/or by host immunomodulation through sequestration of signalling lipids (Basavaraju et 
al., 2003; Kennedy, 2000). Therefore, it can be proposed that phospholipid binding by Na-
FAR-1 might play a similar role in the parasite infections, especially since soluble 
phospholipids, such as lysophosphatidic acid (LPA) (Yun and Kumar, 2015; Zhao et al., 
2015; Zhao and Natarajan, 2013), are known mediators of inflammatory responses. 
In order to obtain insights into the mechanism that Na-FAR-1 employs for phospholipid 
binding, structural and functional characterisation of a Na-FAR-1-phospholipid complex 
was carried out. Protein nuclear magnetic resonance (NMR) spectroscopy and a 
fluorescence-based lipid binding assay were employed to characterise Na-FAR-1-
phospholipid binding. Phosphatidic acid (PA) was chosen as the model phospholipid for 
the binding analysis. In addition, Na-FAR-1 binding to LPA was demonstrated. 
In the beginning of the chapter, the results of the fluorescence-based assay used to 
demonstrate binding of PA and LPA to Na-FAR-1 will be presented, and the principle of 
the assay will be described. Next, an overview of protein NMR spectroscopy will be given, 
and the results of the NMR experiments will be presented. The chapter will end with the 
discussion of the results and proposals for future study of phospholipid binding by Na-
FAR-1. 
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6.2 Na-FAR-1 binds phosphatidic acid and lysophosphatidic acid  
In order to characterise phospholipid binding by Na-FAR-1, a fluorescence-based 
competition assay was carried out that was previously used for characterisation of the Na-
FAR-1-oleic acid interaction. The assay employs 11-(Dansylamino)undecanoic acid 
(DAUDA), an environment-sensitive fluorescent dye that is weakly fluorescent in polar 
solvents and strongly fluorescent in a hydrophobic environment. When transferred from 
apolar into a polar environment, a red shift of DAUDA emission maximum is observed.  
The principle of the assay is based on the fluorescence properties of DAUDA. For the 
assay, protein-DAUDA complexes are premade in an aqueous buffer, and the fluorescence 
emission spectrum of DAUDA is measured. When bound to a protein, DAUDA is in a 
hydrophobic environment, and hence will fluoresce with high intensity. Subsequently, a 
ligand of interest is added to the premade protein-DAUDA complexes, and the 
fluorescence emission spectrum is recorded again. If the binding site of the ligand and 
DAUDA overlap, the ligand will at least partially displace DAUDA from the protein. As a 
certain population of DAUDA molecules will now be found in a polar environment, the 
total measured fluorescence intensity will reduce, and the fluorescence emission maximum 
of DAUDA will undergo a red shift. In this way, protein-ligand binding can be 
characterised by following the intensity and wavelength of DAUDA fluorescence emission 
during ligand titration. 
Dioleoyl PA (DOPA or di-18:1 cis-9 PA) was chosen as a model phospholipid for analysis 
of Na-FAR-1 phospholipid binding, as PA forms the basic unit of all glycerophospholipids 
in the cell. DOPA was titrated into the mixture of Na-FAR-1 and DAUDA, and 
displacement of DAUDA by DOPA was monitored by measuring the emission spectrum of 
DAUDA. It was observed that DOPA displaced DAUDA from Na-FAR-1, as was evident 
from a decrease in DAUDA fluorescence emission intensity and the shift in the 
fluorescence emission maximum from 470 nm to 530 nm after sequential additions of 
DOPA (Fig 6-1). After the concentration of DOPA was brought to 8 µM, the intensity of 
the DAUDA emission maximum was found to be equal to 11% of its intensity in the 
absence of DOPA, and did not decrease in the further titration steps. 
Next, it was decided to investigate whether Na-FAR-1 binds oleoyl lysophosphatidic acid 
(OLPA or 18:1 cis-9 LPA), a soluble phospholipid involved in inflammatory signalling 
that shares structural similarity with DOPA and that Na-FAR-1 is likely to encounter in its 
natural environment after secretion by the worm. It was observed that OLPA was also able 
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to displace DAUDA from Na-FAR-1, as was evident from the decrease in DAUDA 
fluorescence observed on OLPA addition. The ability of OLPA to displace DAUDA 
suggests that OLPA also binds to Na-FAR-1 and shares a binding site with DAUDA. 
Once it was determined that Na-FAR-1 is able to bind DOPA and OLPA, characterisation 
of DOPA binding by Na-FAR-1 was carried out by using protein NMR spectroscopy. 
 
 
 
 
6.3 Analysis of phosphatidic acid binding by Na-FAR-1 using 
protein-observed NMR spectroscopy 
6.3.1 A brief overview of protein NMR spectroscopy 
6.3.1.1 Introduction 
Compared to X-ray crystallography described in Chapter 5, NMR spectroscopy is a 
relative newcomer to biology. Although the phenomenon of NMR in bulk materials was 
first observed separately by Bloch (Bloch et al., 1946) and Purcell (Purcell et al., 1946) in 
1946, it took decades of technological and scientific advances for NMR spectroscopy to 
become an established technique in biomolecular science and structural biology. Today, 
however, it is widely used for various type of biochemical and biophysical investigations, 
including analyses of protein structure, dynamics and protein-ligand interactions. Although 
Figure 6-1. DAUDA displacement assay using di-oleoyl phosphatidic acid (DOPA, di-18:1 cis-9 
PA) and oleoyl lysophosphatidic acid (OLPA, 18:1 cis-9 LPA). Fluorescence emission spectrum 
of DAUDA is shown (λex = 345 nm). A. DAUDA is displaced from Na-FAR-1 by sequential 
additions of DOPA to 2, 4, 8 and 10 µM total DOPA concentration. B. DAUDA is displaced from 
Na-FAR-1 by sequential additions of OLPA to 0.5, 1, 4 and 16 µM total OLPA concentration. A 
Raman scattering peak is observed at 390 nm in both spectra. Structures of DOPA and OLPA are 
shown for reference. 
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structure determination by NMR spectroscopy is fundamentally difficult for biomolecules 
with MW larger than ~ 25-35 kDa (see Section 4.3.1.1 for a brief discussion of protein 
NMR spectroscopy limitations), numerous structures of protein and protein domains have 
been solved by NMR spectroscopy. To date, Protein Data Bank (PDB) includes more than 
10,000 solution structures of protein and peptides determined using NMR spectroscopy. 
6.3.1.2 From nuclear spin to NMR spectrum 
NMR spectroscopy uses magnetic properties of atomic nuclei to obtain information about 
molecular structure and dynamics. To understand how this is achieved, the concept of spin 
has to be introduced. Since there is no macroscopic equivalent to spin, it is difficult to 
understand the concept of spin intuitively. In basic terms, spin can be defined as quantum 
mechanical property of elementary particles that can be understood as a form of angular 
momentum. It should be noted, however, that in contrast to classical angular momentum, 
spin angular momentum does not arise due to the rotation of a particle, but is its intrinsic 
property. As nuclei consist of elementary particles, they also carry spin angular 
momentum. Spin angular momentum of particles and nuclei is characterised by spin 
quantum number. The nuclear spin quantum number depends on the spin quantum 
numbers of the elementary particles that form the nucleus. If the nuclear spin quantum 
number is non-zero, then the nucleus possesses a spin magnetic moment and can be 
investigated by NMR spectroscopy. Typically, nuclei with spin quantum number equal to 
1/2 (further, spin 1/2 nuclei) are used in NMR spectroscopy, as they have convenient 
magnetic properties for investigation by NMR spectroscopy. The ratio of the magnetic 
moment of a nucleus to its spin angular momentum is called the gyromagnetic (or 
magnetogyric) ratio, the value of which is unique to each isotope. 
When a nucleus with non-zero spin is placed into a magnetic field, its spin magnetic 
moment will precess around the magnetic field. The precession occurs at a frequency 
termed the Larmor frequency (ω), which is defined by the following equation:  
i	 = 	−jk	 
where γ is the gyromagnetic ratio and B is the magnetic field strength at the position of the 
nucleus. The energy of the interaction between spin magnetic moment of a nucleus and the 
magnetic field depends on the orientation of the magnetic moment in relation to the 
direction of the magnetic field. The energy of the interaction will be lowest when the spin 
Equation 6-1. 
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magnetic moment is oriented in parallel to the magnetic field, and the highest when the 
orientations of the magnetic moment and the magnetic field are opposite.  
Next, let us consider a bulk sample containing numerous identical nuclei. In the absence of 
the external magnetic field, spin magnetic moments of individual nuclei will be oriented 
randomly due to the thermal motion of the nuclei. If we place the sample into an external 
magnetic field, slight anisotropy of the spin magnetic moment orientations will be 
observed, as the magnetic moments of the nuclei will tend to align in parallel to the 
magnetic field. This will lead to build up of a net nuclear magnetic moment, which will be 
oriented in the direction of the magnetic field. In NMR spectroscopy, this net magnetic 
moment is commonly referred to as longitudinal magnetisation. However, due to the small 
energy difference between the highest energy and the lowest energy arrangements of the 
nuclear magnetic moments in the sample, the net magnetic moment is relatively small 
compared to the diamagnetism of the sample caused by the interaction of atomic electrons 
with the magnetic field. Hence, longitudinal magnetisation is essentially immeasurable 
directly. 
In order to detect nuclear magnetisation, the sample can be irradiated with a 
radiofrequency pulse of a specific length and energy that will rotate the net nuclear 
magnetisation vector into the plane perpendicular to the external magnetic field. As a 
result, the sample will acquire transverse magnetisation. As the nuclei will continue to 
experience the external magnetic field, the net transverse magnetic moment will precess at 
the Larmor frequency of the nuclei, generating a small magnetic field. If a coil is wound 
around the sample, this precession will induce an oscillating electric current in the coil, 
which can be amplified and measured. The oscillation will decay over time as the 
transverse magnetisation of the sample decays away due to transverse (or T2) relaxation. 
The oscillating current is called the free-induction decay (FID) and corresponds to the 
NMR signal in the time domain. In order to convert the signal into the frequency domain to 
produce an NMR spectrum, a Fourier transform is performed on the FID. Phasing of the 
signal is then carried out to obtain a traditional Lorentzian absorption peak. The position of 
the peak in the spectrum will depend on the Larmor frequency of the corresponding nuclei, 
whereas the intensity of the peak will depend on the number of the nuclei with the identical 
Larmor frequency in the sample. 
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6.3.1.3 Chemical shift, J-couplings and nuclear Overhauser effect (NOE) 
When NMR measurements are made of a solution of molecules, nuclei of the same isotope 
in a molecule do not necessarily experience identical magnetic field and therefore may not 
have identical Larmor frequencies. This is because the strength of the external magnetic 
field that the nuclei experience is affected by the local magnetic effects in the molecule. 
These local magnetic effects are caused by the magnetism of the atomic electrons, or of the 
neighbouring nuclei, which interferes with the external magnetic field. The information 
provided by the local magnetic field inhomogeneities in a molecule is thus of immense 
importance, as it reports on the chemical structure of the molecule. Reduction in the 
Larmor frequency of a nucleus as a result of the local magnetic effects is commonly 
referred to as shielding (from the external magnetic field), whereas an increase in the 
Larmor frequency of a nucleus is called deshielding. 
From Eq. 6-1 it can be seen that nuclear Larmor frequency depends on the strength of the 
magnetic field that a nucleus experiences. Therefore, the same nucleus will display NMR 
signals at different frequencies when placed into NMR spectrometers that produce 
magnetic fields of different strengths. To standardise NMR measurements, the positions of 
NMR signals in the spectrum are usually not presented in Larmor frequencies, but in field-
independent chemical shifts. To determine a chemical shift of a nucleus, its Larmor 
frequency is measured in a magnetic field of a particular strength and is then compared to a 
Larmor frequency of an isotopic nucleus in a reference compound that was measured in a 
magnetic field of the same strength. The chemical shift (δ) of a nucleus is expressed by the 
following equation:  
l = 	i −	imim  
where ω is the Larmor frequency of the nucleus of interest and ωR is the Larmor frequency 
of the nucleus in a reference compound. Most commonly, trimethylsilane is used as a 
reference compound in 1H and 13C NMR spectroscopy. 
Nuclear spins in a molecule can interact primarily by two mechanisms: scalar coupling 
(J-coupling) and dipole-dipole coupling (DD-coupling). As J-coupling involves 
interactions between nuclei in atoms connected by covalent bonds and the bonding 
electrons, it is sometimes also called indirect DD-coupling. Importantly, J-coupling 
provides information about through-bond connectivities between nuclei in a molecule, 
which is extremely useful for determination of molecular structure. J-coupling also leads to 
Equation 6-2. 
  
160 
spin-spin splitting effects, which are used by organic chemists to determine what 
functional groups are present in a molecule. Due to the complexity of the spectra of 
biomolecules, spin-spin splitting is typically undesirable in biomolecular NMR 
spectroscopy, and decoupling radiofrequency pulses are used during signal acquisition to 
eliminate the splitting effect.  
In contrast to J-coupling, DD-coupling occurs directly between the nuclei and acts through 
space. Although DD-coupling is approximately three orders of magnitude larger than 
J-coupling, it is not observable in isotropic liquids due to its orientation dependence and 
the averaging effects of molecular tumbling. Nevertheless, DD-coupling is very important 
in NMR spectroscopy, as it constitutes a major source of relaxation. DD-coupling between 
two nuclei can lead to observation of the nuclear Overhauser effect (NOE). The NOE is 
defined as a change in the intensity of a resonance when spin transitions of another 
resonance are perturbed. As the NOE occurs due to through-space interaction between 
nuclear spins, it can be employed for the determination of inter- and intramolecular 
distances. The NOE plays a crucial role in protein structure determination by NMR 
spectroscopy, where NMR experiments based on the NOE are used to obtain distance 
restraints between nuclei to guide protein structure calculation. The NOE reduces quickly 
with distance, and is observable only between nuclei separated by a distance shorter than 
approximately 5-6 Å.  
More detailed description of the theory of NMR spectroscopy is beyond the scope of this 
thesis, and has been given in a number of highly respectable textbooks (Cavanagh et al., 
2007; Keeler, 2010; Levitt, 2008). The NMR experiments used in this study to obtain 
functional and structural information about PA binding by Na-FAR-1 will be described in 
brief below. 
6.3.1.4 Multidimensional experiments in protein NMR spectroscopy 
Proteins are large molecules containing thousands of atomic nuclei, each of which is 
theoretically able to contribute to an NMR spectrum. Even a small 20 kDa protein that can 
be conveniently investigated by NMR spectroscopy (further, simply NMR) will consist of 
approximately 200 amino acid residues and 4000 atoms. Furthermore, as the chemical 
structure of natural amino acids is largely similar, the chemical shift distributions of the 
amino acid nuclei are rather narrow. If we also consider that a single amino acid type is 
often found multiple times in the polypeptide chain of a protein, it will be clear that a 
significant overlap between the NMR signals of distinct atomic nuclei will be observed in 
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protein NMR spectra. Hence, one-dimensional 1H and 13C NMR experiments popular in 
organic chemistry will reveal little to no information about protein structure.  
In order to resolve the signals of protein nuclei, multidimensional NMR experiments are 
employed. Multidimensional NMR experiments can either be homonuclear or 
heteronuclear. In homonuclear experiments, chemical shifts of the nuclei of the same 
isotope are recorded, whereas in heteronuclear experiments, chemical shifts of the nuclei 
of, typically, two or three isotopes are measured. Multidimensional experiments report on 
the interactions between nuclei via either through-bond (J-coupling) or through-space 
(NOE) mechanisms. The chemical shifts of the interacting nuclei are plotted on several 
frequency axes (e.g., F1 and F2 in a two-dimensional experiment), giving rise to a cross-
peak. Homonuclear experiments, such as 2D 1H, 1H COrrelation SpectroscopY (COSY), 
TOtal Correlation SpectroscopY (TOCSY) or NOE SpectroscopY (NOESY), are of limited 
use in NMR of proteins over ~ 10 kDa, as they do not provide sufficient signal resolution. 
Therefore, heteronuclear experiments are typically used to observe protein NMR signals. 
Since all amino acids contain hydrogen, carbon and nitrogen atoms, the typical isotopes 
used in heteronuclear protein NMR experiments are 1H, 13C and 15N. As the natural 
abundances of 13C and 15N are very low (1.1% and 0.37%, respectively), uniform isotope 
labelling of proteins is normally required for 13C and 15N experiments (see Section 4.3.1.1).  
Experiments that report on through-bond correlations of protein nuclei are used for the 
assignment of protein NMR signals to particular atomic nuclei in the protein residues. 
Usually, a combination of 2D, 3D or even 4D heteronuclear double- and triple-resonance 
experiments (i.e., experiments involving magnetisation transfer between two and three 
different isotopes, respectively) are used for this purpose. 
A typical 2D double-resonance experiment used for determination of the chemical shifts of 
15N and 1HN nuclei of the protein amide and amine groups is the 1H, 15N heteronuclear 
single quantum coherence (HSQC) experiment. Typically, 1H, 15N HSQC provides 
sufficient resolution to distinguish between the most directly bonded 15N-1H pairs in the 
protein. The chemical shifts of the backbone amide 15N-1HN pairs are then used as a 
starting point for assigning the nuclei to particular residues in the protein with the help of 
more complex 3D experiments. Examples of such 3D triple-resonance experiments include 
1H, 13C, 15N HNCO (Grzesiek and Bax, 1992a; Kay et al., 1990; Muhandiram and Kay, 
1994), HNCA (Farmer et al., 1992; Grzesiek and Bax, 1992a; Kay et al., 1990), HNcaCO 
(Clubb et al., 1992), HNcoCA (Bax and Ikura, 1991), CBCANH (Grzesiek and Bax, 
1992b), CBCAcoNH (Grzesiek and Bax, 1992c), HBHANH (Wang et al., 1994) and 
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HBHAcoNH (Grzesiek and Bax, 1993). These experiments can be used for establishing the 
sequential links between groups of nuclei assigned to particular types of residues in order 
to deduce the positions of the residues in the protein primary sequence. A 3D double-
resonance experiment very useful for determination of through-bond connectivities of 
protein nuclei is HCCH-TOCSY (Bax et al., 1990; Kay et al., 1993), which can be used to 
establish correlations between all aliphatic 13C and 1H nuclei in a residue, and hence is 
useful for assigning the NMR signals of the residue side-chain nuclei.  
Although experiments based on through-space nuclear interactions can also be used during 
assignment of the protein resonance signals, their major role in protein NMR spectroscopy 
is to reveal the distances between the protein atoms for protein structure determination. 
Typical 3D experiments that reveal through-space connectivities in the protein are the 1H, 
1H, 15N NOESY-HSQC and 1H, 1H, 13C NOESY-HSQC (Marion et al., 1989a, 1989b; 
Zuiderweg and Fesik, 1989). In these experiments, the NOE is first used to obtain through-
space correlations between neighbouring 1H nuclei. Subsequently, one-bond correlations of 
1H nuclei to either 15N or 13C are obtained via J-couplings. As a result, the distances 
between the neighbouring 1H nuclei in the protein can be estimated and used to guide 
structure determination. 
The heteronuclear 2D and 3D experiments employed in this study as well as the principle 
of protein structure determination from NMR data are described in more detail in the 
following sections of this chapter. 
6.3.1.5 2D HSQC and HMQC 
The HSQC is one of the most commonly used 2D experiments in protein NMR 
spectroscopy. It is employed to correlate chemical shifts of a 1H nucleus and a 
heteronucleus (13C or 15N) that are linked by a covalent bond. HSQC uses an Insensitive 
Nuclei Enhanced by Polarization Transfer (INEPT) pulse sequence element to create 
transverse magnetisation on 1H and transfer the magnetisation from 1H to the heteronucleus 
through J-coupling. The magnetisation is then evolved on the heteronucleus, and the 
reverse-INEPT sequence is used to transfer the magnetisation back to 1H for detection. 
Signal detection at 1H rather than at the heteronucleus enhances the sensitivity of the 
experiment, as 1H is more magnetically susceptible than 13C and 15N due to its higher 
gyromagnetic ratio. Heteronuclear multiple quantum coherence (HMQC) experiment is 
very similar to HSQC, and is used to obtain the same information as HSQC. The difference 
between the two is in the coherence pathways involved during the magnetisation evolution. 
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In protein NMR spectroscopy, 1H, 15N HSQC is used to obtain a chemical shift correlation 
map of the protein amide and amine groups (of amine groups, typically, only tryptophan 
and arginine side-chain amines can be observed). The 1H, 15N HSQC spectrum of a protein 
can be considered one of its “fingerprints”, as the spectra obtained for different proteins are 
usually fairly distinguishable. The chemical shifts of the protein NH groups measured in 
HSQC are used during protein resonance assignment. 1H, 15N HSQC/HMQC spectra are 
also commonly used for investigation of protein-ligand binding. As chemical shifts are 
influenced by their chemical environment, conformational change or ligand binding by a 
protein typically leads to the change in the position of at least some of the cross-peaks in 
the 1H, 15N HSQC spectrum. By following the cross-peak movements in the spectrum 
during ligand titration, information about the binding affinity and stoichiometry can be 
obtained.  
6.3.1.6 3D triple-resonance experiments for backbone assignment 
In protein NMR spectroscopy, 3D 1H, 13C, 15N triple-resonance experiments, such as 
HNCO, HNCA, HNcaCO, CBCANH, CBCAcoNH, HBHANH and HBHAcoNH, are used 
to obtain chemical shifts correlations of the backbone 15N and 1HN nuclei to the backbone 
13Cα, 13CO, 1Hα as well as the side-chain 13Cβ and 1Hβ nuclei. In all these experiments 
one-bond or two-bond J-couplings are used to transfer the magnetisation between the 
nuclei. The magnetisation starts on 1HN or on 1Hα and 1Hβ and the signal is typically 
detected on 1HN. As in the HSQC, INEPT sequences are employed during initial and the 
final steps of the magnetisation transfer. The names of the triple-resonance experiments 
typically reference the nuclei involved in the magnetisation transfer pathway, where N 
refers to the backbone 15N, H to the backbone 1HN, CA to the backbone 13Cα, CB to the 
side-chain 13Cβ, HA to 1Hα and HB to 1Hβ. The nuclei whose chemical shifts are measured 
in the experiment (i.e., on which the chemical shift is evolved) are written in upper-case, 
whereas the nuclei that are involved in the magnetisation transfer but on which the 
chemical shift is not evolved are written in lower-case or in parentheses [e.g, 13Cα in 
HNcaCO, which can also be written as HN(CA)CO]. 
Importantly, by the use of different combinations of the triple-resonance experiments, 
protein intra- and interresidue correlations can be identified. For instance, the 
HNCO/HNcaCO pair of experiments allows the intra- and interresidue 1HN, 15N, 13CO 
correlations to be distinguished. This is achieved because magnetisation transfer in an 
HNcaCO occurs through one-bond and two-bond 15N-13Cα J-couplings (JNCα), which 
allows correlations between the amide group of a residue i and both the 13CO of the same 
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residue and the preceding residue i-1 to be obtained. Since the HNCO does not use JNCα, in 
HNCO the correlations are obtained only for 1HN, 15N and 13CO of the residue i-1. By 
comparing the HNCO and HNcaCO spectra, the cross-peaks can be assigned to either 
residue i or i-1. In a similar way, other pairs of complimentary triple-resonance 
experiments can be used to obtain intra- and interresidue correlations of other backbone 
nuclei. These pairs include HNCA/HNcoCA, HNCACB/CBCAcoNH and 
HBHANH/HBHAcoNH, which are used to obtain 1HN, 15N correlations to 13Cα, 13Cα and 
13Cβ, and 1Hα and 1Hβ, respectively. After links between short stretches of residues are 
established, they can be connected into a longer polypeptide sequence until assignment of 
the whole backbone chain is obtained. In many cases, however, complete assignment is not 
possible, as some of the backbone nuclei signals may not be observable due to relaxation 
as a result of chemical exchange or conformation flexibility of certain regions of the 
protein. Once assignment of the majority of the protein backbone nuclei is established, 
assignment of the side-chain nuclei can be carried out. The magnetisation transfer 
pathways of several common 3D triple-resonance NMR experiments are summarised in 
Figure 6-2. 
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  Figure 6-2. Magnetisation transfer pathways in common 3D protein NMR spectroscopy 
experiments. Nuclei whose chemical shifts are recorded are shown in circles. The magnetisation 
transfer direction is shown with red arrows. 
  
166 
6.3.1.7 3D TOCSY 
Typically, TOCSY experiments are used for assignment of the side-chain nuclei in the 
protein. All TOCSY experiments employ isotropic mixing to transfer the magnetisation 
between nuclei via strong J-coupling Hamiltonian. In protein NMR this is typically 
achieved by using broad band mixing pulses such as the Decoupling In the Presence of 
Scalar Interactions (DIPSI) pulse sequence. The initial and last steps of magnetisation 
transfer are typically performed by using INEPT and reverse-INEPT sequences, 
respectively. Two of the most popular TOCSY experiments for the residue side-chain 
assignment are the double-resonance HCCH-TOCSY (Bax et al., 1990; Kay et al., 1993) 
and the triple-resonance HCCcoNH-TOCSY (Montelione et al., 1992). 
The conventional HCCH-TOCSY developed by Bax et al. allows correlations between all 
aliphatic 13C nuclei in a residue to all aliphatic 1H nuclei in the same residue to be 
observed. As a result, complex spectra are obtained that in the absence of relaxation will 
contain cross-peaks between any aliphatic 1H-13C pair in a residue. Three 3D variants of 
the HCCH-TOCSY exist (hCCH-, HcCH- and HCcH-TOCSY), which are distinguished by 
the positions of the delays during which the chemical shift evolution takes place in the 
experiment. The use of both the hCCH and HcCH/HCcH variants of HCCH-TOCSY 
during side-chain resonance assignment can help to distinguish between the nuclei with 
overlapping chemical shifts in the protein. Recently, H(CaliCaro)H-TOCSY has been 
developed (Kovacs and Gossert, 2014), which allows correlations between the aromatic 
and the aliphatic 1H-13C pairs in the residue to be obtained. 
In contrast to the double-resonance HCCH-TOCSY, the HCCcoNH-TOCSY is a triple-
resonance experiment that correlates the 1HN and 15N amide pair of a residue i to aliphatic 
backbone and side-chain 1H and 13C nuclei of the residue i-1. Typically, 3D forms of 
HCCcoNH-TOCSY (hCCcoNH- and HcccoNH-TOCSY) are employed to reveal 
correlations of the backbone amide nuclei to the aliphatic 13Ci-1 and 1Hi-1 nuclei, 
respectively. HCCcoNH-TOCSY is typically of lower sensitivity than HCCH-TOCSY. 
The magnetisation transfer pathways of HCCH-TOCSY and HCCcoNH-TOCSY are 
schematically presented in Fig 6-2. 
6.3.1.8 2D experiments for assignment of aromatic side-chains 
Assignment of aromatic side-chains nuclei is typically more complicated than that of 
aliphatic side-chain nuclei, as conventional HCCH-TOCSY does not reveal the 
correlations between the aliphatic and the aromatic nuclei in the residue. As an alternative 
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or a complement to H(CaliCaro)H-TOCSY, 2D double-resonance hbCBcgcdHD and 
hbCBcgcdceHE (Yamazaki et al., 1993) are often used, which reveal the aliphatic-
aromatic 13Cβ-1Hδ and 13Cβ-1Hε correlations, respectively. After the aliphatic 13C-aromatic 
1H correlations have been obtained in the 2D experiments, one can use the chemical shifts 
of the aromatic 1H nuclei to identify the chemical shifts of the correlated aromatic 13C 
nuclei from 1H, 13C-HSQC, 1H, 13C aromatic Transervse Relaxation Optimised 
SpectroscopY (aroTROSY) (Pervushin et al., 1997) and 3D NOESY-HSQC spectra (see 
below) to complete the assignment. As aromatic groups have relatively high chemical shift 
anisotropy compared to aliphatic groups, aroTROSY is a more sensitive experiment for 
detection of the aromatic 1H-13C correlations and produces better resolved peaks than 
HSQC. 
6.3.1.9 3D NOESY-HSQC 
After the protein backbone and side-chain assignments have been carried out with the help 
of double- and triple-resonance experiments, distances between the protein nuclei need to 
be determined to obtain distance restraints for protein structure calculation. Distances 
between the protein 1H nuclei are typically obtained from 3D NOESY-HSQC experiments. 
3D NOESY-HSQC pulse sequence combines the homonuclear 2D NOESY sequence with 
an HSQC sequence. The heteronucleus employed in the HSQC part of the NOESY-HSQC 
experiment can either be 13C or 15N. By using 13C NOESY-HSQC and 15N NOESY-HSQC 
experiments, one can obtain through-space correlations between 1H nuclei in 1H-13C pairs 
and their neighbouring 1H nuclei, and between 1H nuclei of 1H and 15N pairs and their 
neighbouring 1H nuclei, respectively. The 3D NOESY-HSQC experiments typically 
provide a good resolution of the protein NOE signals and allow a sufficient number of 1H-
1H distance restraints to be obtained for the calculation of a protein’s 3D structure. 
As NOESY-HSQC spectra reveal through-space correlation of the neighbouring 1H nuclei, 
they can also be used to guide the assignment of protein resonances or to confirm the 
validity of the assignments. For instance, 1HN-1HN and 1HN-1Hα correlations that can be 
obtained from 15N NOESY-HSQC can provide information about the sequential links 
between the residues that help assignment of the protein backbone. Similarly, 13C NOESY-
HSQC can be used to obtain intraresidue correlations between the aromatic 1H and 13C 
nuclei for the aromatic side-chain assignment, as mentioned above. 
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6.3.1.10 Structure calculation 
Information about three-dimensional protein structure cannot be directly obtained from the 
chemical shifts of the protein nuclei. Instead, sets of restraints, the main ones being the 1H-
1H distance restraints obtained from NOESY experiments, are used to produce a model of 
the protein structure. The process of model generation from the sets of restraints is called 
structure calculation. As well as 1H-1H distance restraints, peptide dihedral angles, residual 
dipolar couplings, hydrogen bond restraints and other types of restrains can be used to 
constraint the structure calculation, together with empirical “forcefield” terms about bond 
length and angles. Usually, the restraints do not carry enough information to 
unambiguously define a single structural model. Therefore, as a result of structure 
calculation from NMR data, an ensemble of models is generated, where each model 
satisfies the restraints used during the calculation. Typically, a small set of final models 
with the lowest energies is presented after structure determination by protein NMR. 
Several algorithms have been developed for automatic assignment of NOESY spectra, 
generation of 1H-1H distance restraints and structure calculation. One of the most popular 
programs is ARIA (Ambiguous Restraints for Iterative Assignment) (Linge et al., 2003a, 
2001), which employs an algorithm based on the use of ambiguous distance restraints for 
assignment of NOE signals (Nilges, 1995; Nilges et al., 1997) and CNS software for 
performing the structure calculation (Brünger et al., 1998). In ARIA, calibration of 
NOESY spectra, generation of distance restraints, structure calculation and analysis of 
violated restraints are carried out in an iterative manner. In the first round of structure 
calculation by ARIA, unambiguous restrains obtained from the manually assigned NOEs 
and ambiguous restraints generated by the program are used to calculate a set of 
preliminary structures. The structures are then utilised to guide assignment and selection of 
restraints by analysis of restraint violations. This process is repeated until the structures 
obtained in the calculations converge. After the final iteration, the structures are refined in 
explicit solvent (water or DMSO) (Linge et al., 2003b) to yield a set of final models. The 
program outputs an ensemble of the refined structures (typically, 5 or 10), the list of 
violated restraints in the final structures, and the results of the stereochemical structure 
analysis by PROCHECK (Laskowski et al., 1993) and similar programs, if required. The 
list of violations can then be examined manually to correct any obvious misassignments of 
the NOE signals in the NOESY spectra. Typically, at least several rounds of structure 
calculations by ARIA and manual analysis of NOESY spectra are required to obtain a 
satisfactory model. 
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CYANA is another popular program used for structure calculation from NMR data 
(Güntert et al., 1997; Herrmann et al., 2002), which uses a torsion angle dynamics 
algorithm for structure calculation and an algorithm similar to ARIA for assignment of 
NOEs. Since CYANA was not employed in this study, it will not be discussed further. 
6.3.2 Chemical shift perturbation analysis of Na-FAR-1-PA binding  
6.3.2.1 Na-FAR-1 forms at least three distinct complexes with PA  
In order to investigate the mechanism of PA binding by Na-FAR-1, either 1H, 15N HSQC 
or HMQC spectra, which provide identical information, were recorded during DOPA 
titration into the solution of apo Na-FAR-1. Gradual changes in the chemical shift of the 
majority of backbone amide cross-peaks were observed during DOPA addition (Fig 6-3), 
which was assumed to be due to the conformational change in the protein occurring on 
ligand binding. After addition of two molar equivalents of DOPA to the protein, four 
distinct cross-peaks were observed for many of the backbone amides, indicating that the 
protein was in slow exchange between four different states. One of the cross-peaks was 
present at the chemical shift identical to the one observed in the apo protein spectrum, 
which was assumed to correspond to the ligand-free state of the protein. The other three 
cross-peaks were shifted compared to the cross-peak coming from the ligand-free protein. 
These were assumed to arise from three different ligand-bound forms of the protein, likely 
corresponding to the protein bound to one, two and three or more molecules of DOPA. The 
cross-peaks originating from the Na-FAR-1 complex with two and three or more DOPA 
molecule were overlapping with each other and were more intense than the rest of the 
peaks, suggesting that the Na-FAR-1-DOPA complex mostly contained two molecules of 
DOPA when DOPA was present in a two-fold molar excess to the protein. 
In the subsequent titration step, peaks corresponding to the ligand-free protein and to the 
Na-FAR-1 complex with a single DOPA were no longer visible, suggesting that the protein 
was now in the fast exchange regime between the states containing two and three or more 
DOPA molecules. Once a four-fold excess of ligand was added to Na-FAR-1, the protein 
appeared to enter a fast exchange regime where separate ligand-bound forms of Na-FAR-1 
could no longer be distinguished and only one cross-peak was observed for most residues. 
The chemical shifts of the amide cross-peaks observed at this ligand concentration were 
identical to those of the cross-peaks originating from Na-FAR-1 complex with three or 
more DOPA recorded when the ligand was in two-fold excess. The binding appeared to be 
saturated at this point, and little change in chemical shifts was observed after further 
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additions of DOPA. From this data, it can be concluded that Na-FAR-1 is able to form at 
least three distinct complexes with PA that have different protein:ligand stoichiometries. 
Although it could not be determined what is the maximum number of PAs that Na-FAR-1 
can bind, the data indicate that Na-FAR-1 can accommodate at least three DOPA 
molecules. 
 
 Figure 6-3. Chemical shift perturbation analysis of the Na-FAR-1 interaction with PA. Superimposed 1H, 15N-HSQC spectra of the ligand-free Na-FAR-1 (blue cross-peaks), Na-FAR-1 in 
the presence of 2, 3 and 4 molar equivalents of PA (purple, orange and green cross-peaks, 
respectively), and an 1H, 15N-HMQC spectrum of Na-FAR-1 in the presence of 0.5 molar equivalent 
of PA (teal cross-peaks) are shown. Changes in the chemical shifts of amide cross-peaks are 
observed with increasing PA concentration. Several examples of cross-peak movements are 
highlighted. An expansion of the region containing the G78 cross-peaks is shown above. The cross-
peaks are proposed to originate from the ligand-free Na-FAR-1 (0 PA) and distinct Na-FAR-1 
complexes containing 1, 2 and 3 or more PA molecules. 
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6.3.2.2 Mapping of the chemical shift changes in Na-FAR-1 induced by DOPA 
binding  
For the next step in the analysis of Na-FAR-1-DOPA binding, Na-FAR-1 complex with 
DOPA was prepared by mixing Na-FAR-1 with seven-molar excess of dry DOPA. 1H, 15N 
HSQC spectrum of the DOPA complex was recorded and compared to the 1H, 15N HSQC 
spectrum of apo Na-FAR-1 to map the differences between the chemical shifts of the 
backbone amide nuclei in the presence and the absence of the ligand (Fig 6-4). Since the 
chemical shift of the nuclei depends on their chemical environment, changes in the 
chemical shift of the backbone amide nuclei report on the conformation change in the 
regions where the nuclei are located and/or on binding of the ligand in proximity of the 
nuclei. The resonances of the Na-FAR-1 complex with PA were assigned with the help of 
3D triple- and double-resonance experiments, as described in the section below (see Fig 6-
8 for the spectrum). The spectrum of the apo Na-FAR-1 protein produced in this study was 
assigned with the help of the apo Na-FAR-1 spectrum previously assigned by Dr Florencia 
M. Rey-Burusco (Instituto Nacional de Tecnologia Agropecuaria, Buenos Aires, 
Argentina) (Rey-Burusco et al., 2014).  
The geometric distances between the cross-peaks in the spectra of apo Na-FAR-1 and 
Na-FAR-1-PA complex were calculated by using the following equation: 
Ml = [∆ldo] + (0.15	×	∆ldst)]] 
where dδ is the chemical shift distance between two cross-peaks in the 1H, 15N HSQC 
spectra, ∆δ1H is the chemical shift difference in 1H dimension, ∆δ15N is the chemical shift 
difference in 15N dimension, and 0.15 is the scaling factor for 15N. Chemical shift distance 
could be calculated for ~ 75% of residues in the protein (116 out of 155, not counting the 
residues in the recombinant tag). For the remaining ~ 25% of the protein residues, 
chemical shift distances could not be calculated due to the absence of the corresponding 
cross-peaks either in the apo Na-FAR-1 spectrum, the DOPA complex spectrum or both. 
The majority of such residues were located in the loop regions between the helices and in 
the helix α10, which could indicate the high conformational flexibility of these regions or 
the rapid hydrogen exchange rates between the relevant backbone amide groups and the 
solvent. The residues whose backbone chemical shifts changed in the presence of PA are 
highlighted on the previously determined structure of apo Na-FAR-1 (PDB ID 4UET) 
(Fig 6-4B). Large changes in the cross-peak positions were observed for most residues, 
Equation 6-3. 
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with 20 residues demonstrating dδ larger than 0.5 ppm, 51 residues demonstrating dδ larger 
than 0.3 ppm and 76 residues demonstrating dδ larger than 0.2 ppm. Since from this and 
the previous studies (Rey-Burusco et al., 2014) it was known that the protein expands on 
ligand binding and that many protein residues contact ligand atoms in the central cavity of 
Na-FAR-1, extensive changes in the positions of the cross-peaks in the HSQC spectrum of 
Na-FAR-1 were expected after ligand addition.  
The largest dδ (0.93 ppm) was observed for T101, which is located in a flexible loop 
between α7 and α8, and the smallest dδ (0.01 ppm) was observed for the C-terminal 
residue N155. From Fig 6-4B it can be observed that most of the residues that displayed 
the largest dδ were located in the regions of the helices that form the largest portions of the 
cavity walls in the ligand-bound forms of Na-FAR-1 (see Chapter 5), such as the central 
regions of α6 and α7, and the region of α4 proximal to the C-terminus. In contrast, small dδ 
were observed for the backbone amides of the residues located in α9, which forms only a 
small portion of the central cavity in the ligand-bound Na-FAR-1.  
The residues with the largest dδ that were located in the cavity-forming regions of the 
helices in the ligand-bound forms of Na-FAR-1 included V70 (0.70 ppm, α6), F37 (0.62 
ppm, α4), E35 (0.62 ppm, α4), A85 (0.60 ppm, α7), R98 (0.58 ppm, α7), A68 (0.58 ppm, 
α6), R93 (0.52 ppm, α7), K71 (0.51 ppm, α6) and I95 (0.48 ppm, α7). It possible that the 
large chemical shift perturbations observed for these residues in the presence of PA are 
caused by the binding of PA molecules close to the residues. As it was observed that the 
structure of Na-FAR-1 is very similar in both the oleic acid complex and the E. coli lipid 
complex, it is expected that the structure of Na-FAR-1-PA complex will not be radically 
different from the previously determined ligand-bound structures. Interestingly, from these 
residues, the side-chains of I95, R93, A85, V70 and F37 line the cavity of the ligand-bound 
forms of Na-FAR-1, and the side-chains of I95, V70, F37 made apolar contacts to the 
ligands in the Na-FAR-1-oleic acid complex. If the same structural arrangement of the 
cavity is present in the Na-FAR-1-PA complex, it can be proposed that the side-chains of 
I95, R93, A85, V70 and F37 could be making contacts to the PA molecules in the PA 
complex. It should be noted that the residues with smaller dδ than the residues listed above 
could also interacting with PA in the complex. This is because the involvement of residues 
in ligand binding cannot be predicted directly from the magnitude of dδ, as the chemical 
shift of the protein nuclei can be affected by many factors apart from direct interaction 
with the ligand. 
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To summarise, the chemical shift perturbation analysis of Na-FAR-1-PA binding has 
revealed that Na-FAR-1 is able to form at least three DOPA complexes with distinct 
stoichiometries. Furthermore, from comparison of the backbone amide cross-peak 
positions in the 1H, 15N HSQC spectra of Na-FAR-1 in the presence and the absence of PA, 
clues about the location of PA binding sites were obtained. Many of the largest backbone 
amide chemical shift changes were observed for the residues located in the central regions 
of α6 and α7 and the region of α4 proximal to the C-terminus, indicating that these regions 
might be involved in PA binding.  
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Figure 6-4. Backbone amide chemical shift perturbations between the 1H, 15N HSQC spectra 
of apo Na-FAR-1 and Na-FAR-1 in complex with PA. A. The 1H, 15N HSQC spectra of apo 
Na-FAR-1 (blue) and Na-FAR-1 in the presence of 7 molar equivalent of PA (red; aliased cross-
peaks are shown in green). Assignments are not shown. B. А histogram displaying the 1H, 15N 
chemical shift distances (dδ = u[∆ldo] + (0.15	×	∆ldst)]]) between the cross-peaks in the 
spectra in A. In cases when dδ is equal to zero, either no chemical shift change was observed or 
the chemical shift change was not calculated due to the absence of the assigned cross-peaks in one 
or both spectra. A schematic chart of the secondary structure elements in apo Na-FAR-1 is shown 
below the graph for reference. C. A cartoon representation of apo Na-FAR-1 [PDB ID 4UET 
(Rey-Burusco et al., 2015)] highlighting the residues which displayed the chemical shift distances 
presented in B. The residues are coloured according to their dδ from blue (lowest dδ) to red 
(highest dδ) through magenta (medium dδ). The residues for which dδ could not be determined are 
shown in light grey. The residues which showed the largest dδ are predominantly located in the 
cavity-forming helices. 
B
C
C 
A 
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6.3.3 Resonance assignment of the Na-FAR-1 complex with PA 
Clues about the mechanism of PA binding by Na-FAR-1 were obtained from the chemical 
shift perturbation analysis. To obtain molecular details about the PA binding mechanism 
and the residues involved in PA binding, it was decided to determine the structure of the 
Na-FAR-1 complex. An attempt to co-crystallise Na-FAR-1 with PA for X-ray 
crystallography was made. However, crystallisation screening failed to identify conditions 
suitable for crystallisation of the Na-FAR-1-PA complex, and hence, crystals could not be 
obtained for structural analysis. Since the complex produced good quality HSQC spectra, 
protein NMR spectroscopy was chosen as a means of structure determination. The Na-
FAR-1-PA complex was prepared by mixing Na-FAR-1 with seven molar equivalent of 
dry DOPA. As a first step in the structure determination process, assignment of the Na-
FAR-1 backbone and side-chain resonances in the PA complex was carried out.  
6.3.3.1 Backbone resonance assignment 
Backbone resonance assignment was carried out with the help of 1H, 15N HSQC, HNCA, 
CBCANH/CBCAcoNH, HNCO/HNcaCO, HBHANH/HBHAcoNH and 15N NOESY-
HSQC (see Section 6.3.1 for the overview of protein NMR experiments) in the CcpNmr 
Analysis software (Vranken et al., 2005). Acquisition parameters of the experiments used 
in this study for structure determination of the Na-FAR-1-PA complex are summarised in 
Table 2-1. 
In the first step of the assignment, 1H, 15N HSQC spectrum of the Na-FAR-1-PA complex 
was peak picked and each cross-peak was assigned to a separate spin system. The concept 
of spin system is central to CcpNmr Analyis, where it is understood as a collection of 
nuclei that are J-coupled with one another. In the assignment of protein resonances, one 
typically uses a spin system to represent a particular residue in the protein. 1H, 15N HSQC 
cross-peaks arising from the side-chain NH2 groups of glutamines and asparagines were 
identified based on their characteristic chemical shifts and their appearance as pairs of 
cross-peaks with the same 15N chemical shift, and grouped accordingly. The reference 
chemical shifts were obtained from RefDB (Zhang et al., 2003), a database of uniformly 
referenced chemical shifts derived from Biological Magnetic Resonance Bank (BMRB) 
(Ulrich et al., 2008). After exclusion of the side-chain cross-peaks, the rest of the peaks 
were assumed to arise from the backbone amide groups of the protein residues, and were 
assigned accordingly. 
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In the next step of backbone assignment, the chemical shifts of the amide resonance pairs 
were used to navigate into the corresponding regions of the HNCA, CBCANH, 
CBCAcoNH, HNCO, HNcaCO, HBHANH and HBHAcoNH spectra. The cross-peaks 
present at the frequencies of the amide resonance pairs were peak picked and assigned to 
13Cα/13Cβ or 13CO in the HNCA/CBCANH/CBCAcoNH and HNCO/HNcaCO spectra, 
respectively, and to 1Hα/1Hβ in the HBHANH/HBHAcoNH spectra, depending on the type 
of the spectrum in which the cross-peak was present and its chemical shifts. Furthermore, 
the cross-peaks in the triple-resonance spectra were assigned either to the same spin system 
as the correlated amide resonances (corresponding to residue i) or to a new spin system 
(corresponding to residue i-1). This was done by comparing the complimentary pairs of the 
triple-resonance spectra, such as the CBCANH and CBCAcoNH. For example, since it was 
known that the CBCANH reveals both the inter- and intra-residue correlations of 1HN-15N 
with 13Cα and 13Cβ, whereas the CBCAcoNH reveals only the inter-residue correlations of 
the same nuclei, the cross-peaks that appeared only in the CBCAcoNH spectrum were 
assigned to 13Cαi-1 and 13Cβi-1, and the cross-peaks that appeared only in the CBCANH 
spectrum were assigned to 13Cαi and 13Cβi. The HNCA experiment, which is more sensitive 
than the CBCANH, was used to confirm the assignments of 13Cαi. In a similar way, the 
chemical shifts of 13COi and 13COi-1 were distinguished by using HNCO and HNcaCO 
spectra, and the chemical shifts of 1Hαi, 1Hαi-1, 1Hβi and 1Hβi-1 were distinguished by using 
the HBHANH and HBHAcoNH. 
After the atom type assignments were established, the spin systems were semi-
automatically linked into short sequences by using the Protein Sequence Assignment tool 
in CcpNmr Analysis. Protein Sequence Assignment matches all 13Ci and 13Ci-1 resonances 
in the complimentary triple-resonance spectra, i.e., the 13Cαi and 13Cβi resonances of one 
spin system in the CBCANH spectrum with the 13Cαi-1 and 13Cβi-1 resonances of another 
spin system in the CBCAcoNH spectrum. If the resonances match, then it is likely that the 
spin systems are linked sequentially. Since unambiguous resonance matching is 
complicated by the fact that the chemical shifts of the same type of nuclei can often be 
similar in different residues, 13COi and 13COi-1 resonances were also used in the matching 
process to increase the likelihood of finding the correct link between the spin systems. 
Optimal matches were chosen manually in each case. An example of a short sequence of 
residues (F82, G83 and K84) connected by using the 13Cα, 13Cβ and 13CO resonances in 
the triple-resonance spectra is shown in Fig 6-5. 
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After the short linked sequences were established, assignment of several spin systems to 
particular types of residues was carried out. This was possible because some types of 
amino acids have characteristic 13Cα and 13Cβ chemical shifts distinct from other amino 
acids. Typical examples include serine and threonine, which have unusually large 13Cβ 
shifts, glycine which only has 13Cα and alanine which has a relatively small 13Cβ shift. The 
patterns of residue types appearing in the spin system sequences were used to link the short 
sequences into the longer spin system stretches by using the primary Na-FAR-1 sequence 
to guide the process. Based on the match between the residue pattern in the spin system 
stretch and the primary protein sequence, the spin systems were assigned to particular 
residues in the protein. If the spin system sequences could not be linked together in an 
unambiguous way, the sequential links between the spin systems were re-analysed by 
using the Protein Sequence Assignment tool and corrected, if needed. This process was 
repeated many times until assignments of as many spin systems as possible were obtained. 
Finally, 15N NOESY-HSQC was used to confirm the links between the residues and 
identify several missing links primarily by analysis of the 1HN-1HN through-space 
correlations. 
Since prolines lack a backbone NH group when they are a part of a polypeptide, no 
correlations to the proline backbone amide group can be obtained. Hence, proline 13Cα, 
13Cβ and 13CO chemical shifts were primarily obtained from the CBCAcoNH and HNCO 
spectra of the next residue in the primary sequence. Proline assignment was further 
complicated by the fact that 13% of the Na-FAR-1 residues, including several that follow 
prolines in the primary sequence, did not produce observable backbone amide resonance 
signals. Hence, although several proline resonance assignments were obtained from the 13C 
NOESY-HSQC spectrum, only 4 out of 8 proline residues were assigned in the Na-FAR-1 
sequence.  
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Figure 6-5. Backbone resonance assignment using triple-resonance NMR experiments. Strips 
showing F82, G83 and K84 cross-peaks in the overlaid HNCA (dark blue), CBCANH (light blue for 
positive peaks, orange for negative peaks), CBCAcoNH (red), HNCO (purple) and HNcaCO (green) 
spectra. The chemical shifts of the cross-peaks in the 15N dimension are shown in the bottom left 
corner of each strip. Cross-peaks marked i arise due to intraresidue correlations, cross-peaks marked 
i-1 arise due to interresdidue correlations. By identifying the matching i and i-1 cross-peaks across 
the spectrum, sequential connections between the residues can be made (marked by solid horizontal 
lines between the strips). 
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6.3.3.2 Side-chain resonance assignment 
Once the majority of the backbone resonance assignments were established, assignment of 
the residue side-chains was carried out. In this study, primarily HcCH-TOCSY, 
hCCH-TOCSY and hCCcoNH were used for the assignment of the aliphatic side-chains, 
and hbCBcgcdHD, hbCBcgcdceHE, 1H, 13C TROSY and 13C NOESY-HSQC for 
assignment of the aromatic side-chains.  
Aliphatic side-chain assignment from the HCcH-TOCSY and hCCH-TOCSY spectra was 
carried out as follows. The chemical shifts of the 1Hα/13Cα and 1Hβ/13Cβ pairs determined 
from the triple-resonance experiments were used to navigate into relevant the parts of the 
TOCSY spectra, and strips of the spectrum were created that were centered at the chemical 
shifts of each 1Hα/13Cα and 1Hβ/13Cβ pair. As HCCH-TOCSY-type experiments reveal 
correlations between all aliphatic 1H-13C pairs in the residue, in each 1Hα/13Cα and 
1Hβ/13Cβ strip, correlations to all intraresidue aliphatic 1H-13C pairs were observed. In 
HCcH-TOCSY, the cross-peaks that appeared at each 1H-13C strip revealed the chemical 
shifts of the 1H nuclei in the correlated aliphatic pairs, whereas in hCCH-TOCSY, the 
cross-peaks revealed the 13C chemical shifts of the correlated pairs. In order to identify the 
13C chemical shifts of all correlated aliphatic pairs in HCcH-TOCSY, the spectrum was 
inspected for repetition of the cross-peak pattern observed for the 1Hα/13Cα or 1Hβ/13Cβ 
pair used for initial analysis of the spectrum. The 13C chemical shift at which the identical 
cross-peak pattern appeared corresponded to the 13C chemical shift of the correlated pair. 
Similarly, 1H correlations were obtained from the hCCH-TOCSY spectra. The correlated 
1H and 13C resonances were assigned to particular types of nuclei by using the reference 
chemical shifts in RefDB and by inspection of the correlations between the nuclei. The use 
of both HCcH-TOCSY and hCCH-TOCSY allowed better resolution of many overlapped 
signals in the spectra, especially in the case of the lysine and glutamate side-chains. See 
Figure 6-6 for an example of the HCcH spectrum of V70, and the intraresidue correlations 
observed. 
As the hCCcoNH-TOCSY provides correlations between the amide nuclei of residue i and 
the aliphatic 13C nuclei of residue i-1, the spectrum was analysed in the manner similar to 
the triple-resonance experiments described in the backbone assignments section of the 
chapter. The hCCcoNH-TOCSY was used in parallel with HCCH-TOCSY to obtain the 
13C aliphatic shifts for the analysis of the HCCH-TOCSY spectra and to confirm the side-
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chain assignments obtained from HCCH-TOCSY. In addition, the use of hCCcoNH-
TOCSY allowed the accuracy of the sequential links between the residues to be verified. 
As neither the HCCH-TOCSY nor hCCcoNH-TOCSY reveal correlations between the 
aliphatic and aromatic CH groups in the protein, a different strategy was adopted for 
assignment of the aromatic side-chain resonances, and hbCBcgcdHD, hbCBcgcdceHE and 
1H, 13C TROSY aromatic spectra were recorded. Since 13Cβ chemical shifts of aromatic 
residues were obtained from the HCCH-TOCSY and hCCcoNH-TOCSY spectra, it was 
possible to find the chemical shifts of the aromatic 1Hδ and 1Hε nuclei by identified the 
intraresidue cross-peaks at the 13Cβ shifts in hbCBcgcdHD and hbCBcgcdceHE, 
respectively. After the aromatic 1Hδ and 1Hε shifts were identified, the correlated 13Cδ and 
13Cε shifts could be identified from the cross-peaks in the 1H, 13C TROSY spectrum. 
However, unambiguous assignment was difficult to achieve due to the overlap between the 
chemical shifts of the aromatic side-chain nuclei in the protein. Hence, the aromatic side-
chain assignments were also supported by analysis of the intra- and interresidue through-
space correlations in the 13C NOESY-HSQC spectrum. Similarly, the 13C NOESY-HSQC 
was also used to confirm the aliphatic side-chain resonance assignments.  
 
 
 
 
 
Figure 6-6. Side-chain resonance assignment from HCcH-TOCSY. Strips showing intraresidue 
V70 cross-peaks in the HCcH-TOCSY spectrum. The chemical shifts of the cross-peaks in the 13C 
dimension are shown in the top left corner of each strip. Cross-peaks arise due to correlations 
between the 1H-13C pairs in the residue. In a strip centred at the 1H and 13C chemical shits of a single 
1H-13C pair, cross-peaks to all side-chain 1H nuclei in the residue are visible. The chemical shifts of 
the correlated 13C nuclei can be identified by locating the matching patterns of cross-peaks across 
the 13C dimension. The identical chemical shift information can be obtained from the hCCH-
TOCSY spectrum. 
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6.3.3.3 Assignment of DOPA resonances 
For assignment of the ligand signals, a model DOPA molecule was introduced into the 
CcpNmr Analysis project of the Na-FAR-1 PA complex. The model DOPA molecule was 
created by Dr Brian Smith (University of Glasgow) in CCPN ChemBuild software. For the 
assignment of ligand resonances, a 2D NOESY experiment 13C-filtered in F2 was used, 
which is a NOESY variant that only reveals through-space correlations between the ligand 
1H nuclei or the ligand and the protein 1H nuclei, but not between the protein 1H nuclei. 
Several ligand-ligand NOEs were observed in the spectrum (Fig 6-7). The cross-peaks 
were assigned to several types of aliphatic 1H nuclei in the ligand based on their chemical 
shifts. For instance, the most upfield cross-peaks in the aliphatic region of the spectrum 
were assigned to the methyl protons of the ligand, the most downfield aliphatic cross-peaks 
were assigned to the COCH2 protons, and the cross-peaks at ~ 5.2 ppm were assigned to 
the methine protons. Since only four distinct DOPA CH2 proton chemical shifts could be 
determined, the chemical shifts of the majority of CH2 protons were assumed to be 
degenerate. The ligand chemical shifts were used to identify potential contacts between the 
ligand and the protein in the NOESY-HSQC spectra, as described in Section 6.3.4.  
  
Figure 6-7. A fragment of the 13C-filtered 
2D NOESY spectrum showing ligand-
ligand NOEs. NOE signals (NOEs) 
between the ligand protons were used for 
determination of the ligand proton chemical 
shifts. NOEs were observed between the 
ligand fatty acyl tail methyl (CH3), 
methylene (CH2) and methine (=CH-) group 
protons. Dashed lines are shown at the 
chemical shift of the distinct ligand protons. 
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6.3.3.4 Protein resonance assignment summary 
Final resonance assignment statistics of the Na-FAR-1-PA complex are presented in Table 
6-2 and the assigned 1H, 15N HSQC spectrum is shown in Figure 6-8. In total, 155 Na-
FAR-1 residues were available for assignment, excluding the residues in the recombinant 
tag. No assignments were obtained for P7, P15, D27, P47, P105, F138, E144 and G146. 
Furthermore, as mentioned above, backbone amide resonances of 13% of residues were not 
assigned as the residues lacked identifiable cross-peaks in the spectra of the experiments 
that reveal NH correlations. Nevertheless, assignment of 86% hydrogen atoms was 
achieved in this study, providing a good basis for generation of 1H-1H distance restraints 
for structure determination. 
Category Available Assigned % Assigned 
Residues 155 147 95 
C atoms 744 613 82 
H atoms 937 802 86 
N atoms 200 133 67 
Backbone amides 465 404 87 
Side-chain H atoms 624 522 84 
Side-chain non-H atoms 479 341 71 
 
 
 
  
Table 6-1. Assignment statistics of the Na-FAR-1 residues in the Na-FAR-1-PA complex. 
The residues in the recombinant tag are not included. 
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Figure 6-8. Assigned 1H, 15N HSQC spectrum of Na-FAR-1 in complex with PA. Top: Full view of 
the spectrum. Side-chain amide cross-peaks are connected by dashed lines. Assignment of the central 
region is not shown due to crowding. Aliased cross-peaks are shown in green. Bottom: Close-up view 
of the central region of the spectrum. Full assignment is shown. 
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6.3.4 Structural analysis of the Na-FAR-1-PA complex 
6.3.4.1 Structure calculation in ARIA 
After as many protein resonances as possible were assigned, structure determination of the 
Na-FAR-1 complex with PA was attempted. Structure calculation was carried out in ARIA 
software (see Section 6.3.1.10 for description of the software). 
In order to obtain 1H-1H distance restraints for the structure calculation, the cross-peaks in 
the 15N and 13C NOESY-HSQC spectra were picked in CcpNmr Analysis. Care was taken 
to avoid picking artefact peaks, especially near the water frequency. Typically, the cross-
peaks were left unassigned in the indirect dimension, to avoid introducing incorrect 
assignments into the structure calculation process. In cases when neither of the dimensions 
could be assigned unambiguously, peaks were left completely unassigned. After the peak-
picking was completed, lists of ambiguous and unambiguous restraints were generated in 
CcpNmr Analysis and merged together according to the type of the spectrum from which 
they were obtained. The NOESY cross-peaks whose chemical shifts in the indirect 1H 
dimension were within 0.3 ppm of the ligand 1H chemical shifts were not used for restraint 
generation. This was done to avoid misguiding the structure calculation, as the Na-FAR-1 
structure calculation was carried out without the ligand.  
In addition to distance restraints, a set of dihedral angle restraints was generated by 
DANGLE software in CcpNmr Analysis. DANGLE uses Bayesian inference to predict φ 
and ψ angles and the secondary structure of the protein of interest by comparing the 
chemical shifts and the primary sequence of the protein to a database of proteins with 
known dihedral angles and chemical shifts (Cheung et al., 2010). Consistent with the 
previously determined structure of Na-FAR-1, DANGLE predicted the structure of Na-
FAR-1 in the PA complex to be predominantly α-helical.  
Next, the sets of restraints were imported into ARIA and the structure calculation was 
carried out. Nine iterations of structure calculation were carried out in each separate run. 
The structure calculations were performed in the torsion angle mode. For the most part, the 
standard ARIA protocol was used for structure calculation. Changes were made to the 
molecular dynamics parameters, where the number of steps at 1000 K and 50 K were 
increased to 8000 and 10000, respectively, and to the iteration protocols, which are 
summarised in Table 6-3. Since dihedral restraints were obtained from parameters that are 
not directly correlated with the real values of φ and ψ, but from the values predicted by 
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DANGLE, the restraints were not used in the final stage of each iteration of the structure 
calculation to avoid introducing bias into the final set of models.  
Although a set of model structures was obtained from ARIA, visual inspection of the 
models has revealed that they did not fully resemble the previously determined structures 
of Na-FAR-1. Furthermore, it was observed that a significant number of restraints were 
violated during the structure calculation. This suggested that the accurate models of the 
Na-FAR-1 could not be obtained due to the presence of a significant number of 
missassigned or artefact cross-peaks in the NOESY spectra used for restraint generation, so 
that too many restraints were rejected during the structure calculation and the number of 
the remaining restraints was not sufficient to guide the calculation. Also, it is a possibility a 
significant number of long-range NOEs were simply absent from the spectrum, and 
therefore could not be used for restraint generation. The second notion is supported by the 
fact that although the number of restraint violations decreased after three rounds of manual 
violation analysis and a degree of convergence between the models was observed, a 
satisfactory final model of globular Na-FAR-1 could not be obtained. Due to the time 
constraints, the structure determination of Na-FAR-1-PA complex was not taken further in 
this study. The strategies for obtaining the structure of the complex will be discussed in 
Section 6.3.6. 
Iteration No. structures Viol. tolerance (Å) pa 
0 20 1000 1.0 
1 20 5.0 0.99 
2 20 3.0 0.99 
3 20 1.0 0.99 
4 20 1.0 0.98 
5 20 1.0 0.96 
6 20 0.3 0.95 
7 40 0.3 0.95 
8 40 0.3 0.95 
a. Partial assignment cut-off. 
 Table 6-2. Iteration parameters of the structure calculation in ARIA. 
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6.3.4.2 Analysis of protein-ligand contacts from NOEs 
Although the structure of the Na-FAR-1-PA complex was not determined in this study, 
further clues were obtained about the positions of the ligand in the complex by analysis of 
through-space correlations between the ligand and the protein nuclei.  
13C-filtered 2D NOESY, 13C NOESY-HSQC and 15N NOESY-HSQC were employed to 
determine the protein-ligand correlations. Since the 13C-filtered 2D NOESY was carried 
out in D2O, ligand 1H correlations were primarily observed to the aromatic side-chain 1H 
nuclei in the protein (Fig 6-9) due to the chemical exchange of the protein amides and 
D2O. However, three cross-peaks could also be distinguished in the chemical shift range 
corresponding to the backbone amide protons. Two sets of cross-peaks were assigned to 
A92 and V117, as these residues had observable amide cross-peaks in the 1H, 15N HSQC 
spectrum in D2O whose chemical shifts closely matched the chemical shifts of the 13C-
filtered NOESY cross-peaks. The third set of cross-peaks could not be unambiguously 
assigned to any residue, as several backbone amides had similar 1H chemical shifts in the 
D2O 15N HSQC spectrum. Similarly, the cross-peaks arising from the correlations of the 
aliphatic ligand protons and the aromatic side-chain protons could not be assigned due to 
their broadness and the high degree of overlap between the chemical shifts of the aromatic 
side-chain protons. 
It was expected that the through-space correlations between the ligand and the protein 
would also be observed in the 13C NOESY-HSQC and 15N NOESY-HSQC spectra. In the 
NOESY spectra, the cross-peaks potentially arising due to the protein-ligand correlations 
were selected based on the match between the chemical shift of the cross-peaks in the 
indirect 1H dimension and the ligand 1H chemical shifts. Before assigning the cross-peaks 
to the ligand nuclei, assignments to protein resonances were considered. If no neighbouring 
protein atom with a closely matching chemical shift (Δδ < 0.03 ppm) was available for 
assignment, the cross-peak was assigned to the ligand atoms. The judgement about the 
potential distance between the protein atoms was made based on their relative position in 
the primary protein sequence and their separation in the previously reported structures of 
Na-FAR-1. Based on the NOESY data, ligand correlations to L22, L33, T45, V70, S88, 
I89, A92, R93, I95, L110 can be proposed. These are partially consistent with the 13C-
filtered NOESY data, where correlations between the ligand and A92 were observed. More 
putative protein-ligand NOEs were observed in the 15N HSQC-NOESY than in the 13C-
filtered NOESY, as the former experiment was carried out in H2O instead of D2O. 
However, it should be noted that since full assignment of the Na-FAR-1-PA complex was 
  
187 
not obtained, at least some of the correlations observed might be to the unassigned protein 
1H nuclei, and not the ligand nuclei. 
 
 
 
 
6.4 Conclusions and discussion 
In this study, phospholipid binding by Na-FAR-1 was characterised using a fluorescence-
based assay and protein NMR spectroscopy. It was determined that Na-FAR-1 binds PA, 
which is in agreement with the previous experiments that demonstrated PE and PC binding 
by Na-FAR-1 (Rey-Burusco et al., 2015). Importantly, this study is the first to demonstrate 
lysophosphatidic acid (LPA) binding by Na-FAR-1. The interaction between LPA and Na-
FAR-1 is especially interesting due to the known role of LPA in cell signalling and the fact 
that LPA is present in the extracellular environment where Na-FAR-1 can encounter it 
after being secreted by the parasite. The biological implications of the Na-FAR-1 
phospholipid binding will be discussed in more detail in Chapter 7.  
From the chemical shift perturbation analysis of the Na-FAR-1-PA interaction, it was 
apparent that PA binding induces a conformational change in the protein. By monitoring 
the exchange regimes during the DOPA titration, it was also apparent that the protein is 
able to form three distinct complexes with the ligand, which likely contain one, two and 
three or more DOPA molecules. Backbone amide chemical shift changes were observed 
with the majority of the protein residues, but were mostly concentrated in the central 
Figure 6-9. A region of the 13C-filtered 2D NOESY spectrum showing Na-FAR-1-PA NOEs. 
NOEs between the Na-FAR-1 aromatic protons and the ligand (aromatic-aliphatic NOEs), as well 
as between the Na-FAR-1 amide protons and the ligand (amide-aliphatic NOEs) are observed. 
Two of the amide-aliphatic cross-peak sets were assigned to the backbone amides of A92 and 
V117 in the indirect dimension. Unambiguous assignment of other cross-peaks could not be 
carried out.  
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regions of the cavity-forming helices α4, α6 and α7. Although the structure of the Na-FAR-
1-PA could not be determined, 86% hydrogen atoms and 84% carbon atoms in Na-FAR-1 
were assigned from the NMR spectra of the Na-FAR-1-PA complex, and several chemical 
shifts of the ligand 1H nuclei were obtained from the 13C-filtered 2D NOESY spectrum. 
Based on the assignments, putative contacts between the ligands and L22, L33, T45, V70, 
S88, I89, A92, R93, I95, L110 and V117 were established from the 13C and 15N NOESY-
HSQC experiments. Of these residues, L22 is located in α3, L33 in α4, V70 in α6, S88, 
I89, A92, R93 and I95 in α7, L100 and V117 in α8. The fact that most putative ligand 
correlations were observed to the residues in α7 is consistent with the chemical shift 
changes observed in α7 in the chemical shift perturbation analysis. Interestingly, some of 
the largest chemical shift changes in Na-FAR-1 induced by DOPA addition were observed 
for V70, R93 and I95, which provides more support for their hypothetical role in DOPA 
binding.  
Since strict criteria were used for identification of the protein-ligand correlations from 
NOEs, it is a possibility that at least a number of cross-peaks arising from to the Na-FAR-
1-PA contacts were selected against during the analysis of the NOESY-HSQC spectra. In 
order to map the protein-ligand contacts with greater accuracy, determination of the 
structure of Na-FAR-1 complex with PA will be required. From the Na-FAR-1 structure in 
complex with PA, the distances between the protein atoms can be estimated more 
accurately and the conformation of the residue side-chains will be apparent, which will 
help to analyse the through-space correlations in the NOESY spectra and identify the real 
protein-ligand correlations. Furthermore, structure determination of the complex can be 
attempted by including the ligand model into the structure calculation. 
6.4.1 Comparison of the Na-FAR-1 oleic acid and PA binding mechanisms 
Based on the Na-FAR-1 lipid binding data obtained in this study, comparison between the 
Na-FAR-1 interaction mechanisms with oleic acid and PA can be made. From the previous 
chemical shift perturbation studies of Na-FAR-1-oleic acid binding, it was clear that Na-
FAR-1 can make four distinct complexes with oleic acid that likely contain one, two, three 
and four or more oleic acid molecules (Rey-Burusco et al., 2015). A similar picture was 
observed in Na-FAR-1-PA binding, where Na-FAR-1 appeared to make distinct complexes 
with one, two and three or more DOPA molecules. The differences in the number of 
distinct ligand complexes that Na-FAR-1 can form with oleic acid and DOPA likely stems 
from the structural differences between the ligands. It should be noted that since the 
volume of DOPA is more than two times larger than the volume of oleic acid, it is likely 
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that the volume of the Na-FAR-1 central cavity saturated with PA is larger than the cavity 
volume in the structure of Na-FAR-1 in complex with oleic acid.  
Further conclusions about the mechanism of ligand binding by Na-FAR-1 can be made 
from the exchange regimes observed during oleic acid and PA titration. During the oleic 
acid titration, it was observed that Na-FAR-1 is in a slow exchange regime in the presence 
of 1, 2 and 3 molar equivalents of oleic acid, and in fast exchange regime in the presence 
of 4 oleic acid equivalents, suggesting that the protein binds three oleic acid molecules 
with high affinity, and the fourth oleic acid molecule with lower affinity (Rey-Burusco et 
al., 2015). In contrast, during DOPA titration, slow exchange was only observed when the 
ligand was added in up to two-molar equivalents to the protein, indicating that the protein 
binds two DOPA molecules with high affinity, and a third DOPA molecule with lower 
affinity. The proposed differences in the affinities of DOPA and oleic acid binding by Na-
FAR-1 can also be explained by the structural differences between the ligands. Since 
DOPA is bulkier than oleic acid, it is likely that the high affinity lipid binding sites in Na-
FAR-1 are saturated by a smaller number of DOPA molecules than oleic acid molecules.  
As many of the backbone amide chemical shifts of Na-FAR-1 are different in the oleic acid 
and PA complexes, it is likely that the conformation of Na-FAR-1 is dissimilar in the two 
complexes. A hint as to the conformational dissimilarity can also be obtained from the 
different crystallisation properties of the Na-FAR-1 complexes with oleic acid and DOPA. 
Na-FAR-1 in complex with oleic acid crystallised readily in this study (see Chapter 2 for 
conditions), whereas no crystals of the Na-FAR-1 DOPA complex were obtained in the 
identical or any other conditions tested in this study. This could suggest that the Na-FAR-1 
complex with DOPA has a different conformation and/or higher conformational 
heterogeneity compared to the oleic acid complex, which can affect crystal packing. 
Since the structure of the Na-FAR-1-DOPA complex was not solved, direct comparison of 
the Na-FAR-1 structure in the two complexes cannot be made. However, from the analysis 
of the protein-ligand NOEs in the Na-FAR-1-DOPA complex it can be concluded that at 
least several Na-FAR-1 residues are involved in the binding of both DOPA and oleic acid. 
These likely include L22, L33, S88, I89, A92, I95 and V117, apparent ligand contacts to 
which were observed in both complexes. Furthermore, S88, I89, A92, R93, I95, which 
displayed putative contacts to the ligand in the DOPA complex, are found in proximity to 
K96, which made hydrogen bonds to oleic acid head group in the Na-FAR-1-oleic acid 
complex. Since K96 is found in a region of the cavity surface with a positive electrostatic 
potential and carries a positive charge itself, it is likely that K96 can also interact with the 
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negatively charged head group of DOPA. If the DOPA head group is indeed bound to K96, 
DOPA fatty acyl tails might extend along the cavity wall where they could contact S88, 
I89, A92, R93 and I95, giving rise to the correlations observed in the NOESY spectra.  
6.4.2 Future directions 
In order to complete the structure determination of Na-FAR-1-DOPA complex, further 
manual analysis of the restraint violation lists produced by ARIA can be carried out to 
eliminate any remaining misassignments in the NOESY spectra. This will result in a higher 
number of restraints available for structure calculation which might then lead to generation 
of a more accurate model of the Na-FAR-1 structure. Furthermore, paramagnetic 
relaxation enhancement (PRE) (Nadaud et al., 2007) can be used to obtain additional long-
range distance restraints, and residual dipolar coupling (RDC) (Chen and Tjandra, 2012) 
can be used to obtain directional information about the dipole-dipole interactions between 
the protein nuclei. These two types of restraints are often very useful in constraining the 
structure calculation when the restraints obtained from NOEs are not sufficient to guide the 
calculation. With the use of PRE and/or RDC restraints, and an increased number of NOE 
restraints, it is highly likely that the solution structure of the Na-FAR-1-PA complex can 
be solved in the future. 
To determine whether Na-FAR-1 shows preference for certain classes of phospholipids, 
the affinity of the interaction between various phospholipids and Na-FAR-1 can be 
assessed by, e.g., the DAUDA displacement assay used in this study. It would be 
especially interesting to compare the affinity of Na-FAR-1 to lysophospholipids and 
diacylphospholipids, as well as to phospholipids with different net charges. The 
comparison of Na-FAR-1 affinity to different types of phospholipids could reveal which 
phospholipids Na-FAR-1 is more likely to interact with and hence what the biological 
function of the phospholipid binding of Na-FAR-1 may be. Further, Na-FAR-1 binding to 
other classes of bioactive lipids could be characterised, including prostaglandins, 
thromboxanes and specialised pro-resolving lipid mediators. Of special interest here are the 
pro-inflammatory lipid messengers such as 2-arachidonoglycerol, arachidonic acid, 
prostaglandin E2 and prostaglandin D2, by binding to which Na-FAR-1 could modulate 
immune response in the host upon parasite infection. 
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7. Final summary 
7.1 The LNS2 domain of Nir2 
This study has provided first insights into the mechanism of phosphatidic acid (PA) 
binding by the LNS2 domain of Nir2, which has been previously proposed to regulate the 
plasma membrane association and lipid transport activity of Nir2 (Chang and Liou, 2015; 
Kim et al., 2013, 2015). For the biochemical and structural characterisation, the LNS2 
domain was expressed in E. coli as a recombinant Trigger factor fusion protein. This 
allowed the yield, stability and solubility of the recombinant LNS2 domain to be enhanced, 
as the LNS2 domain was found to be highly prone to aggregation when expressed without 
a large fusion partner.  
By employing a number of biochemical and biophysical techniques, the PA binding 
activity of the recombinant LNS2 domain was demonstrated in vitro. Further ligand-
observed NMR spectroscopy experiments using short-chain phospholipids and 
phospholipid fragments showed that the LNS2 domain of Nir2 interacts with both the fatty 
acyl and the glycerol backbone regions of the PA molecule, and that the presence of both 
these regions in a molecule was required for the interaction to occur. Moreover, the LNS2 
domain was found to interact with the polar region of PA and not with the polar region of 
PC, which contains a positively charged head group. Although the interaction between the 
fatty acyl tails of PC and the LNS2 domain was also observed, it appeared to be weaker 
than that with the fatty acyl tails of PA, indicating that the negatively charged head group 
of PA is involved in binding. Furthermore, as it was previously demonstrated that the Nir2 
LNS2 domain binds only to lipid vesicles containing PA but not to lipid vesicles 
containing PS (Kim et al., 2013) which, like PA, is negatively charged, it is highly likely 
that the LNS2 domain is a specific PA binder. The structural mechanism behind the PA 
specificity of LNS2 remains unclear, but the binding could occur via the hydrogen 
bond/electrostatic switch mechanism previously proposed for other PA binding proteins 
(Kooijman et al., 2007). 
The fact that Nir2 LNS2 binds to both the fatty acyl chains and the polar region of PA and 
does not bind to free glycerol-3-phosphate, which constitutes the polar region of PA, 
indicates that the plasma membrane association mechanism of Nir2 LNS2 might involve 
both an interaction with the hydrophobic region of the lipid bilayer and hydrogen bonding 
or electrostatic interactions with polar region of PA. Interestingly, the mechanism of the 
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LNS2 domain phospholipid binding appears to be different to that of the PH domain, 
which has been shown to interact with the isolated PI(4,5)P2 head group with higher 
affinity than with the intact phospholipid. In contrast, the ligand binding properties of the 
LNS2 domain appear to be similar to those of the PI(3)P-binding FYVE domain and DAG 
and phorbol ester-binding C1 domain, which bind the membrane-embedded ligands with 
higher affinity than the free ligands (Gaullier et al., 2000; Kazanietz et al., 1995; 
Kutateladze et al., 1999). A distinguishing feature of the membrane association by the 
FYVE and C1 domains is the insertion of specific hydrophobic residues into the membrane 
upon ligand binding, which does not normally occur during membrane association by the 
PH domain. Hence, due to the inability of the LNS2 domain to bind the isolated polar 
region of PA, it can be proposed that membrane insertion plays a role in membrane binding 
by the LNS2 domain. Consistent with this notion, the LNS2 domain was estimated to have 
a higher affinity for the membrane-embedded PA than for the free PA. However, since the 
measurement of the LNS2 affinity to membrane-embedded PA was carried out only in a 
semi-quantitative manner, further experiments would be required to confirm the findings. 
A strategy to test the LNS2 membrane insertion hypothesis was proposed in Section 4.6.3, 
along with several strategies for further analysis of the LNS2-PA interaction. 
Due to the large size of the Trigger factor fusion of the LNS2 domain that impeded its 
analysis by protein NMR spectroscopy, the failure of the fusion protein to crystallise, and 
the difficulty of obtaining high amounts of pure and homogenous Nir2 LNS2 domain 
without the fusion partner, the three-dimensional structure of the LNS2 domain could not 
be determined in this study. However, analysis of the Nir1 LNS2 domain by CD 
spectroscopy was carried out, which revealed that the LNS2 domain has a β-sheet-rich 
structure.  
Since atomic details of the LNS2-PA binding could not be obtained, a tool compound 
targeting the interaction could not be designed rationally. However, based on the results of 
the fluorescence lifetime measurements and ligand-observed NMR experiments, two 
assays were proposed for the screening of a small library of compounds or fragments for 
identification of the LNS2-PA interaction inhibitors (see Section 4.5.2 for the description 
of the assays). 
7.2 Na-FAR-1 
The high-resolution structure of Na-FAR-1 in complex with oleic acid was determined in 
this study. Four ligand molecules were identified in the complex, and the contacts between 
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the ligands and the protein residues were mapped. It was observed that the central cavity of 
Na-FAR-1 was more expanded when the protein was complexed with oleic acid than when 
it was complexed with a mixture of E. coli lipids (Rey-Burusco et al., 2015), suggesting 
that the volume of the Na-FAR-1 cavity might change to allow accommodation of different 
ligand types or formation of ligand complexes with varying stoichiometries.  
Furthermore, it was demonstrated that Na-FAR-1 interacts with PA and lysophosphatidic 
acid (LPA), which provides the first evidence of Na-FAR-1 interaction with 
lysophospholipids. If Na-FAR-1 also binds LPA in vivo, this interaction might have wide-
reaching biological implications. This is because LPA is a well-known mediator of 
inflammatory signalling (Yung et al., 2014) that also facilitates wound healing in the gut 
(Khurana et al., 2008). Hence, by binding to and, possibly, sequestering LPA, Na-FAR-1 
could affect the inflammatory responses in the host, thereby allowing the hookworm to 
modulate the host’s immune system to its benefit. Potential LPA sequestration by Na-
FAR-1 might also inhibit the healing of the feeding wounds produced by the worm in the 
gut epithelium, which could enhance hookworm survival in the host. However, it is clear 
that LPA is only one molecule from the wide repertoire of lipids that Na-FAR-1 is known 
to interact with. Therefore, if the Na-FAR-1-LPA interaction does have a biological role, it 
is expected that the probable Na-FAR-1 function in parasitism is not restricted to LPA 
binding. 
Analysis of the Na-FAR-1-PA binding mechanism was carried out by NMR spectroscopy. 
From the chemical shift perturbation experiments it was observed that Na-FAR-1 formed 
three distinct complexes with PA, which were assumed to contain one, two and at least 
three PA molecules. The appearance of the slow chemical exchange regime upon addition 
of two molar equivalents of PA to Na-FAR-1 and the later transition into the fast exchange 
regime upon further additions of PA indicated that Na-FAR-1 binds two molecules of PA 
with higher affinity than the third and any subsequent ones. Similar findings were 
previously reported for oleic acid binding by Na-FAR-1 (Rey-Burusco et al., 2015), 
suggesting that Na-FAR-1 employs similar mechanisms for binding of different lipids 
classes. To map the contacts between the ligand and the protein, structure determination of 
the Na-FAR-1-PA complex was attempted by NMR spectroscopy. Although assignment of 
82% of carbon atoms and 85% of hydrogen atoms of Na-FAR-1 was achieved, structure 
determination could not be completed due to the time constraints. Nevertheless, it is very 
likely that the structure of the complex can be obtained in the future, providing further 
insights into the lipid binding functionality of Na-FAR-1. 
  
194 
References 
Abrahams, J.P., Leslie, A.G.W., Lutter, R., Walker, J.E., 1994. Structure at 2.8 A 
resolution of F1-ATPase from bovine heart mitochondria. Nature 370, 621–628. 
Ahearn, I.M., Haigis, K., Bar-Sagi, D., Philips, M.R., 2012. Regulating the regulator: post-
translational modification of RAS. Nat. Rev. Mol. Cell. Biol. 13, 39–51. 
Altomare, D.A., Testa, J.R., 2005. Perturbations of the AKT signaling pathway in human 
cancer. Oncogene 24, 7455–7464. 
Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W., Lipman, 
D.J., 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database 
search programs. Nucleic Acids Res. 25, 3389–3402. 
Altucci, L., Leibowitz, M.D., Ogilvie, K.M., de Lera, A.R., Gronemeyer, H., 2007. RAR 
and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug. Discov. 6, 
793–810. 
Amarilio, R., Ramachandran, S., Sabanay, H., Lev, S., 2005. Differential Regulation of 
Endoplasmic Reticulum Structure through VAP-Nir Protein Interaction. J. Biol. 
Chem.  280, 5934–5944.  
Andrade, M., Chacón, P., Merelo, J., Morán, F., 1993. Evaluation of secondary structure of 
proteins from UV circular dichroism spectra using an unsupervised learning neural 
network. Protein Eng. 6, 383–390. 
Angulo, J., Nieto, P.M., 2011. STD-NMR: application to transient interactions between 
biomolecules—a quantitative approach. Eur. Biophys. J. 40, 1357–1369.  
Antanasijevic, A., Ramirez, B., Caffrey, M., 2014. Comparison of the Sensitivities of 
WaterLOGSY and Saturation Transfer Difference NMR Experiments. J. Biomol. 
NMR 60, 37–44. 
Asencio-Hernández, J., Kieffer, B., Delsuc, M.-A., 2016. NMR WaterLOGSY Reveals 
Weak Binding of Bisphenol A with Amyloid Fibers of a Conserved 11 Residue 
Peptide from Androgen Receptor. PLoS One 11, e0161948. 
Baier, L.J., Sacchettini, J.C., Knowler, W.C., Eads, J., Paolisso, G., Tataranni, P.A., 
Mochizuki, H., Bennett, P.H., Bogardus, C., Prochazka, M., 1995. An amino acid 
substitution in the human intestinal fatty acid binding protein is associated with 
  
195 
increased fatty acid binding, increased fat oxidation, and insulin resistance. J. Clin. 
Invest. 95, 1281–1287. 
Balla, T., 2013. Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation. 
Physiol. Rev. 93, 1019–1137. 
Ban, N., Nissen, P., Hansen, J., Moore, P.B., Steitz, T.A., 2000. The Complete Atomic 
Structure of the Large Ribosomal Subunit at 2.4 Å Resolution. Science 289, 905–920. 
Baneyx, F., 1999. Recombinant protein expression in Escherichia coli. Curr. Opin. 
Biotechnol. 10, 411–421.  
Basavaraju, S., Zhan, B., Kennedy, M.W., Liu, Y., Hawdon, J., Hotez, P.J., 2003. Ac-
FAR-1, a 20 kDa fatty acid- and retinol-binding protein secreted by adult 
Ancylostoma caninum hookworms: gene transcription pattern, ligand binding 
properties and structural characterisation. Mol. Biochem. Parasitol. 126, 63–71.  
Bax, A., Clore, G.M., Gronenborn, A.M., 1990. 1H 1H correlation via isotropic mixing 
of 13C magnetization, a new three-dimensional approach for assigning 1H and 13C 
spectra of 13C-enriched proteins. J. Magn. Reson. 88, 425–431.  
Bax, A., Ikura, M., 1991. An efficient 3D NMR technique for correlating the proton 
and15N backbone amide resonances with the α-carbon of the preceding residue in 
uniformly15N/13C enriched proteins. J. Biomol. NMR 1, 99–104.  
Bernal, J., Crowfoot, D., 1934. X-Ray Photographs of Crystalline Pepsin. Nature 133, 
794–795. 
Berridge, M.J., 1983. Rapid accumulation of inositol trisphosphate reveals that agonists 
hydrolyse polyphosphoinositides instead of phosphatidylinositol. Biochem. J. 212, 
849–858. 
Bian, D., Su, S., Mahanivong, C., Cheng, R.K., Han, Q., Pan, Z.K., Sun, P., Huang, S., 
2004. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-
MEK Kinase 1 Pathway. Cancer Res. 64, 4209–4217. 
Bietz, S., Urbaczek, S., Schulz, B., Rarey, M., 2014. Protoss: a holistic approach to predict 
tautomers and protonation states in protein-ligand complexes. J. Cheminform. 6, 12.  
Binkowski, T.A., Naghibzadeh, S., Liang, J., 2003. CASTp: Computed Atlas of Surface 
Topography of proteins. Nucleic Acids Res. 31, 3352–3355. 
  
196 
Bird, L.E., 2016. OPPF-UK Standard Protocols: Cloning and Expression Screening 
[WWW Document]. 
Bird, L.E., 2011. High throughput construction and small scale expression screening of 
multi-tag vectors in Escherichia coli. Methods 55, 29–37.  
Bloch, F., Hansen, W.W., Packard, M., 1946. Nuclear Induction. Phys. Rev. 69, 127. 
Boettcher, A., Gradoux, N., Lorthiois, E., Brandl, T., Orain, D., Schiering, N., Cumin, F., 
Woelcke, J., Hassiepen, U., 2014. Fluorescence Lifetime–Based Competitive Binding 
Assays for Measuring the Binding Potency of Protease Inhibitors In Vitro. J. Biomol. 
Screen. 19, 870–877.  
Bravo, J., Karathanassis, D., Pacold, C.M., Pacold, M.E., Ellson, C.D., Anderson, K.E., 
Butler, P.J.G., Lavenir, I., Perisic, O., Hawkins, P.T., Stephens, L., Williams, R.L., 
2001. The Crystal Structure of the PX Domain from p40phox Bound to 
Phosphatidylinositol 3-Phosphate. Mol. Cell 8, 829–839.  
Brünger, A., Adams, P., Clore, G., DeLano, W., Gros, P., Grosse-Kunstleve, R., Jiang, J., 
Kuszewski, J., Nilges, M., Pannu, N., Read, R., Rice, L., Simonson, T., Warren, G., 
1998. Crystallography & NMR system: A new software suite for macromolecular 
structure determination. Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905–21. 
Bullen, H.E., Jia, Y., Yamaryo-Botté, Y., Bisio, H., Zhang, O., Jemelin, N.K., Marq, J.-B., 
Carruthers, V., Botté, C.Y., Soldati-Favre, D., 2016. Phosphatidic Acid-Mediated 
Signaling Regulates Microneme Secretion in Toxoplasma. Cell Host Microbe 19, 
349–360. 
Bunney, T.D., Katan, M., 2010. Phosphoinositide signalling in cancer: beyond PI3K and 
PTEN. Nat. Rev. Cancer 10, 342–352. 
Burger, K.N., Demel, R.A., Schmid, S.L., de Kruijff, B., 2000. Dynamin is membrane-
active: lipid insertion is induced by phosphoinositides and phosphatidic acid. 
Biochemistry 39, 12485–12493. 
Cantorna, M.T., Nashold, F.E., Hayes, C.E., 1994. In vitamin A deficiency multiple 
mechanisms establish a regulatory T helper cell imbalance with excess Th1 and 
insufficient Th2 function. J. Immunol. 152, 1515–1522. 
Carlson, E.D., Gan, R., Hodgman, C.E., Jewett, M.C., 2012. Cell-Free Protein Synthesis: 
Applications Come of Age. Biotechnol. Adv. 30, 1185–1194.  
  
197 
Carman, J., Pond, L., Nashold, F., Wassom, D., Hayes, C., 1992. Immunity to Trichinella 
spiralis infection in vitamin A-deficient mice. J. Exp. Med. 175, 111–120. 
Carr, H.Y., Purcell, E.M., 1954. Effects of Diffusion on Free Precession in Nuclear 
Magnetic Resonance Experiments. Phys. Rev. 94, 630–638. 
Cavanagh, J., Skelton, N., Fairbrother, W., Rance, M., Palmer, A.I., 2007. Protein NMR 
Spectroscopy, 2nd Edition. Principles and Practice. Academic Press. 
Chang, C.-L., Hsieh, T.-S., Yang, T.T., Rothberg, K.G., Azizoglu, D.B., Volk, E., Liao, J.-
C., Liou, J., 2013. Feedback Regulation of Receptor-Induced Ca2+ Signaling 
Mediated by E-Syt1 and Nir2 at Endoplasmic Reticulum-Plasma Membrane 
Junctions. Cell Rep. 5, 813–825. 
Chang, C.-L., Liou, J., 2015. Phosphatidylinositol 4,5-Bisphosphate Homeostasis 
Regulated by Nir2 and Nir3 Proteins at Endoplasmic Reticulum-Plasma Membrane 
Junctions. J. Biol. Chem.  290, 14289–14301. 
Chattopadhyay, A., London, E., 1988. Spectroscopic and ionization properties of N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)-labeled lipids in model membranes. Biochim. 
Biophys. Acta - Biomembr. 938, 24–34.  
Chattopadhyay, A., Mukherjee, S., 1993. Fluorophore environments in membrane-bound 
probes: A red edge excitation shift study. Biochemistry 32, 3804–3811.  
Cheever, M.L., Sato, T.K., de Beer, T., Kutateladze, T.G., Emr, S.D., Overduin, M., 2001. 
Phox domain interaction with PtdIns(3)P targets the Vam7 t-SNARE to vacuole 
membranes. Nat. Cell. Biol. 3, 613-618. 
Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., 
Yao, H., Su, F., Anderson, K.S., Liu, Q., Ewen, M.E., Yao, X., Song, E., 2011. 
CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via 
PITPNM3. Cancer Cell 19, 541–555. 
Chen, K., Tjandra, N., 2012. The Use of Residual Dipolar Coupling in Studying Proteins 
by NMR. Top. Curr. Chem. 326, 47–67.  
Chen, V.B., Arendall, W.B., Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., 
Murray, L.W., Richardson, J.S., Richardson, D.C., 2010.  MolProbity: all-atom 
structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D 
Biol. Crystallogr. 66, 12–21.  
  
198 
Cheung, M.-S., Maguire, M.L., Stevens, T.J., Broadhurst, R.W., 2010. DANGLE: A 
Bayesian inferential method for predicting protein backbone dihedral angles and 
secondary structure. J. Magn. Reson. 202, 223–233.  
Chmurzyńska, A., 2006. The multigene family of fatty acid-binding proteins (FABPs): 
Function, structure and polymorphism. J. Appl. Genet. 47, 39–48.  
Choi, J.W., Herr, D.R., Noguchi, K., Yung, Y.C., Lee, C.-W., Mutoh, T., Lin, M.-E., Teo, 
S.T., Park, K.E., Mosley, A.N., Chun, J., 2010. LPA Receptors: Subtypes and 
Biological Actions. Annu. Rev. Pharmacol. Toxicol. 50, 157–186.  
Clapham, D.E., 2007. Calcium Signaling. Cell 131, 1047–1058.  
Clegg, R.M., 2009. Chapter 1 Förster resonance energy transfer—FRET what is it, why do 
it, and how it’s done. Lab. Tech. Biochem. Mol. Biol. 33, 1–57.  
Clubb, R.T., Thanabal, V., Wagner, G., 1992. A constant-time three-dimensional triple-
resonance pulse scheme to correlate intraresidue 1HN, 15N, and 13C′ chemical shifts 
in 15N13C-labelled proteins. J. Magn. Reson. 97, 213–217.  
Cockcroft, S., 1999. Mammalian phosphatidylinositol transfer proteins: emerging roles in 
signal transduction and vesicular traffic. Chem. Phys. Lipids 98, 23–33.  
Cockcroft, S., Carvou, N., 2007. Biochemical and biological functions of class I 
phosphatidylinositol transfer proteins. Biochim. Biophys. Acta - Mol. Cell Biol. 
Lipids 1771, 677–691.  
Cockcroft, S., Garner, K., 2013. Potential role for phosphatidylinositol transfer protein 
(PITP) family in lipid transfer during phospholipase C signalling. Adv. Biol. Regul. 
53, 280–291.  
Cockcroft, S., Garner, K., 2011. Function of the phosphatidylinositol transfer protein gene 
family: is phosphatidylinositol transfer the mechanism of action? Crit. Rev. Biochem. 
Mol. Biol. 46, 89–117. 
Cockcroft, S., Garner, K., Yadav, S., Gomez-Espinoza, E., Raghu, P., 2016. RdgBα 
reciprocally transfers PA and PI at ER–PM contact sites to maintain PI(4,5) P2 
homoeostasis during phospholipase C signalling in Drosophila photoreceptors. 
Biochem. Soc. Trans. 44, 286–292. 
Cockcroft, S., Raghu, P., 2016. Topological organisation of the phosphatidylinositol 4,5-
  
199 
bisphosphate–phospholipase C resynthesis cycle: PITPs bridge the ER–PM gap. 
Biochem. J. 473, 4289–4310. 
Compton, L.A., Johnson, W.C., 1986. Analysis of protein circular dichroism spectra for 
secondary structure using a simple matrix multiplication. Anal. Biochem. 155, 155–
167. 
Cosker, K.E., Shadan, S., van Diepen, M., Morgan, C., Li, M., Allen-Baume, V., Hobbs, 
C., Doherty, P., Cockcroft, S., Eickholt, B.J., 2008. Regulation of PI3K signalling by 
the phosphatidylinositol transfer protein PITPα during axonal extension in 
hippocampal neurons. J. Cell Sci. 121, 796–803. 
Cramer, P., Bushnell, D.A., Kornberg, R.D., 2001. Structural Basis of Transcription: RNA 
Polymerase II at 2.8 Ångstrom Resolution. Science 292, 1863–1876. 
Creba, J.A., Downes, C.P., Hawkins, P.T., Brewster, G., Michell, R.H., Kirk, C.J., 1983. 
Rapid breakdown of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-
bisphosphate in rat hepatocytes stimulated by vasopressin and other Ca2+-mobilizing 
hormones. Biochem. J. 212, 733–747. 
Cullen, P.J., Cozier, G.E., Banting, G., Mellor, H., 2001. Modular phosphoinositide-
binding domains; their role in signalling and membrane trafficking. Curr. Biol. 11, 
R882–R893.  
Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M., Stockman, B., 2001. WaterLOGSY as 
a method for primary NMR screening: Practical aspects and range of applicability. J. 
Biomol. NMR 21, 349–359. 
Das, J., Rahman, G.M., 2014. C1 Domains: Structure and Ligand-Binding Properties. 
Chem. Rev. 114, 12108–12131. 
Davis, G.D., Elisee, C., Newham, D.M. & Harrison, R.G., 1999. New fusion protein 
systems designed to give soluble expression in Escherichia coli. Biotechnol. Bioeng. 
65, 382–388. 
Dawson, H., Solano-Aguilar, G., Beal, M., Beshah, E., Vangimalla, V., Jones, E., Botero, 
S., Urban, J.F., 2009. Localized Th1-, Th2-, T Regulatory Cell-, and Inflammation-
Associated Hepatic and Pulmonary Immune Responses in Ascaris suum-Infected 
Swine Are Increased by Retinoic Acid. Infect. Immun. 77, 2576–2587.  
de Silva, N.R., Brooker, S., Hotez, P.J., Montresor, A., Engels, D., Savioli, L., 2003. Soil-
  
200 
transmitted helminth infections: updating the global picture. Trends Parasitol. 19, 
547–551.  
Dennis, E.A., Norris, P.C., 2015. Eicosanoid Storm in Infection and Inflammation. Nat. 
Rev. Immunol. 15, 511–523.  
Diamond, R., 1971. A real-space refinement procedure for proteins. Acta Crystallogr. Sect. 
A 27, 436–452.  
Di Paolo, G., De Camilli, P., 2006. Phosphoinositides in cell regulation and membrane 
dynamics. Nature 443, 651–657. 
Donkor, J., Sariahmetoglu, M., Dewald, J., Brindley, D.N., Reue, K., 2007. Three 
Mammalian Lipins Act as Phosphatidate Phosphatases with Distinct Tissue 
Expression Patterns. J. Biol. Chem.  282, 3450–3457. 
Drenth, J., 2007. Principles of Protein X-Ray Crystallography, 3rd ed., Springer-Verlag 
New York. 
Drozdetskiy, A., Cole, C., Procter, J., Barton, G.J., 2015. JPred4: a protein secondary 
structure prediction server. Nucleic Acids Res. 43, W389–W394. 
Edavettal, S.C., Hunter, M.J., Swanson, R. V, 2012. Genetic Construct Design and 
Recombinant Protein Expression for Structural Biology. In: Structure-Based Drug 
Discovery. Methods in Molecular Biology (Methods and Protocols). Humana Press, 
pp. 29-47.  
Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., 2010. Features and development of 
Coot. Acta Crystallogr. Sect. D 66, 486–501. 
Evans, P., McCoy, A., 2008. An introduction to molecular replacement. Acta Crystallogr. 
Sect. D Biol. Crystallogr. 64, 1–10.  
Fahy, E., Cotter, D., Sud, M., Subramaniam, S., 2011. Lipid classification, structures and 
tools. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1811, 637–647.  
Fahy, E., Subramaniam, S., Brown, H.A., Glass, C.K., Merrill, A.H., Murphy, R.C., Raetz, 
C.R.H., Russell, D.W., Seyama, Y., Shaw, W., Shimizu, T., Spener, F., van Meer, G., 
VanNieuwenhze, M.S., White, S.H., Witztum, J.L., Dennis, E.A., 2005. A 
comprehensive classification system for lipids. J. Lipid Res. 46, 839–862.  
Fahy, E., Subramaniam, S., Murphy, R.C., Nishijima, M., Raetz, C.R.H., Shimizu, T., 
  
201 
Spener, F., van Meer, G., Wakelam, M.J.O., Dennis, E.A., 2009. Update of the LIPID 
MAPS comprehensive classification system for lipids. J. Lipid Res. 50, S9–S14.  
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., Chen, J., 2001. Phosphatidic acid-
mediated mitogenic activation of mTOR signaling. Science 294, 1942-1945. 
Farmer, B.T., Venters, R.A., Spicer, L.D., Wittekind, M.G., Müller, L., 1992. A refocused 
and optimized HNCA: Increased sensitivity and resolution in large macromolecules. 
J. Biomol. NMR 2, 195–202. 
Feng, J., Wehbi, H., Roberts, M.F., 2002. Role of Tryptophan Residues in Interfacial 
Binding of Phosphatidylinositol-specific Phospholipase C. J. Biol. Chem.  277, 
19867–19875. 
Ferguson, K.M., Lemmon, M.A., Schlessinger, J., Sigler, P.B., 1995. Structure of the high 
affinity complex of inositol trisphosphate with a phospholipase C pleckstrin 
homology domain. Cell 83, 1037–1046. 
Fernandis, A.Z., Wenk, M.R., 2007. Membrane lipids as signaling molecules. Curr. Opin. 
Lipidol. 18, 121-128. 
Fessler, M.B., Rudel, L.L., Brown, M., 2009. Toll-like receptor signaling links dietary fatty 
acids to the metabolic syndrome. Curr. Opin. Lipidol. 20, 379–385.  
Fiaux, J., Bertelsen, E.B., Horwich, A.L., Wuthrich, K., 2002. NMR analysis of a 900K 
GroEL-GroES complex. Nature 418, 207–211. 
Fielding, L., Rutherford, S., Fletcher, D., 2005. Determination of protein–ligand binding 
affinity by NMR: observations from serum albumin model systems. Magn. Reson. 
Chem. 43, 463–470. 
Fishman, D.A., Liu, Y., Ellerbroek, S.M., Stack, M.S., 2001. Lysophosphatidic Acid 
Promotes Matrix Metalloproteinase (MMP) Activation and MMP-dependent Invasion 
in Ovarian Cancer Cells. Cancer Res. 61, 3194–3199. 
Flesch, F.M., Yu, J.W., Lemmon, M.A., Burger, K.N.J., 2005. Membrane activity of the 
phospholipase C-δ(1) pleckstrin homology (PH) domain. Biochem. J. 389, 435–441.  
Forget, S.M., Jee, A., Smithen, D.A., Jagdhane, R., Anjum, S., Beaton, S.A., Palmer, 
D.R.J., Syvitski, R.T., Jakeman, D.L., 2015. Kinetic evaluation of glucose 1-
phosphate analogues with a thymidylyltransferase using a continuous coupled enzyme 
  
202 
assay. Org. Biomol. Chem. 13, 866–875.  
Franchini, G.R., Pórfido, J.L., Ibáñez Shimabukuro, M., Rey Burusco, M.F., Bélgamo, 
J.A., Smith, B.O., Kennedy, M.W., Córsico, B., 2015. The unusual lipid binding 
proteins of parasitic helminths and their potential roles in parasitism and as 
therapeutic targets. Prostaglandins, Leukot. Essent. Fat. Acids 93, 31–36.  
Gabrielsen, M., Rey-Burusco, M.F., Griffiths, K., Roe, A.J., Cooper, A., Smith, B.O., 
Kennedy, M.W., Corsico, B., 2012. Two crystal forms of a helix-rich fatty acid- and 
retinol-binding protein, Na-FAR-1, from the parasitic nematode Necator americanus . 
Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 68, 835–838.  
Garofalo, A., Kläger, S.L., Rowlinson, M.-C., Nirmalan, N., Klion, A., Allen, J.E., 
Kennedy, M.W., Bradley, J.E., 2002. The FAR proteins of filarial nematodes: 
secretion, glycosylation and lipid binding characteristics. Mol. Biochem. Parasitol. 
122, 161–170. 
Garofalo, A., Rowlinson, M.-C., Amambua, N.A., Hughes, J.M., Kelly, S.M., Price, N.C., 
Cooper, A., Watson, D.G., Kennedy, M.W., Bradley, J.E., 2003. The FAR Protein 
Family of the Nematode Caenorhabditis elegans: Differential Lipid Binding 
Properties, Structural Characteristics, and Developmental Regulation. J. Biol. Chem.  
278, 8065–8074.  
Gaullier, J.-M., Rønning, E., Gillooly, D.J., Stenmark, H., 2000. Interaction of the EEA1 
FYVE Finger with Phosphatidylinositol 3-Phosphate and Early Endosomes: Role of 
Conserved Residues. J. Biol. Chem. 275, 24595–24600. 
Gaullier, J.-M., Simonsen, A., D’Arrigo, A., Bremnes, B., Stenmark, H., Aasland, R., 
1998. FYVE fingers bind PtdIns(3)P. Nature 394, 432–433. 
Gelis, I., Bonvin, A.M.J.J., Keramisanou, D., Koukaki, M., Gouridis, G., Karamanou, S., 
Economou, A., Kalodimos, C.G., 2007. Structural Basis for Signal-Sequence 
Recognition by the Translocase Motor SecA as Determined by NMR. Cell 131, 756–
769. 
Ghosh, S., Strum, J.C., Sciorra, V.A., Daniel, L., Bell, R.M., 1996. Raf-1 kinase possesses 
distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic 
acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-
stimulated Madin-Darby canine kidney cells. J. Biol. Chem. 271, 8472-8480. 
  
203 
Giansanti, M.G., Bonaccorsi, S., Kurek, R., Farkas, R.M., Dimitri, P., Fuller, M.T., Gatti, 
M., 2006. The Class I PITP Giotto Is Required for Drosophila Cytokinesis. Curr. Biol. 
16, 195–201. 
Glomset, J.A., 1999. Lipids protein-lipid interactions on the surfaces of cell membranes. 
Curr. Opin. Struct. Biol. 9, 425–427.  
Gnatt, A.L., Cramer, P., Fu, J., Bushnell, D.A., Kornberg, R.D., 2001. Structural Basis of 
Transcription: An RNA Polymerase II Elongation Complex at 3.3 Å Resolution. 
Science 292, 1876–1882. 
Gobeil, F., Bernier, S.G., Vazquez-Tello, A., Brault, S., Beauchamp, M.H., Quiniou, C., 
Marrache, A.M., Checchin, D., Sennlaub, F., Hou, X., Nader, M., Bkaily, G., Ribeiro-
da-Silva, A., Goetzl, E.J., Chemtob, S., 2003. Modulation of Pro-inflammatory Gene 
Expression by Nuclear Lysophosphatidic Acid Receptor Type-1. J. Biol. Chem.  278, 
38875–38883. 
Greenfield, N.J., 2006. Using circular dichroism spectra to estimate protein secondary 
structure. Nat. Protoc. 1, 2876–2890. 
Greenfield, N.J., Fasman, G.D., 1969. Computed circular dichroism spectra for the 
evaluation of protein conformation. Biochemistry 8, 4108–4116.  
Grzesiek, S., Bax, A., 1993. Amino acid type determination in the sequential assignment 
procedure of uniformly 13C/15N-enriched proteins. J. Biomol. NMR 3, 185–204.  
Grzesiek, S., Bax, A., 1992a. Improved 3D triple-resonance NMR techniques applied to a 
31 kDa protein. J. Magn. Reson. 96, 432–440. 
Grzesiek, S., Bax, A., 1992b. An efficient experiment for sequential backbone assignment 
of medium-sized isotopically enriched proteins. J. Magn. Reson. 99, 201–207.  
Grzesiek, S., Bax, A., 1992c. Correlating backbone amide and side chain resonances in 
larger proteins by multiple relayed triple resonance NMR. J. Am. Chem. Soc. 114, 
6291–6293.  
Gulli, M.-P., Peter, M., 2001. Temporal and spatial regulation of Rho-type guanine-
nucleotide exchange factors: the yeast perspective. Genes Dev. 15, 365–379.  
Güntert, P., Mumenthaler, C., Wüthrich, K., 1997. Torsion angle dynamics for NMR 
structure calculation with the new program DYANA. E. J. Mol. Biol. 273, 283–298. 
  
204 
Guo, J., Friedman, S.L., 2010. Toll-like receptor 4 signaling in liver injury and hepatic 
fibrogenesis. Fibrogenesis Tissue Repair 3, 21. 
Han, G.-S., Wu, W.-I., Carman, G.M., 2006. The Saccharomyces cerevisiae Lipin 
Homolog Is a Mg2+-dependent Phosphatidate Phosphatase Enzyme. J. Biol. Chem.  
281, 9210–9218. 
Hancock, J.F., 2006. Lipid rafts: contentious only from simplistic standpoints. Nat. Rev. 
Mol. Cell Biol. 7, 456–462. 
Harms, J., Schluenzen, F., Zarivach, R., Bashan, A., Gat, S., Agmon, I., Bartels, H., 
Franceschi, F., Yonath, A., 2001. High Resolution Structure of the Large Ribosomal 
Subunit from a Mesophilic Eubacterium. Cell 107, 679–688.  
Harper, S., Speicher, D.W., 2001. Expression and Purification of GST Fusion Proteins. In: 
Current Protocols in Protein Science. John Wiley & Sons.  
Harris, W.A., Stark, W.S., 1977. Hereditary retinal degeneration in Drosophila 
melanogaster. A mutant defect associated with the phototransduction process. J. Gen. 
Physiol. 69, 261–291. 
Haugland, R.P., Spence, M.T.Z., 1996. Handbook of fluorescent probes and research 
chemicals. Molecular Probes. 
Herrmann, T., Güntert, P., Wüthrich, K., 2002. Protein NMR Structure Determination with 
Automated NOE Assignment Using the New Software CANDID and the Torsion 
Angle Dynamics Algorithm DYANA. J. Mol. Biol. 319, 209–227.  
Hjelmeland, L.M., 1980. A nondenaturing zwitterionic detergent for membrane 
biochemistry: design and synthesis. Proc. Natl. Acad. Sci.  77, 6368–6370. 
Hoffmann, A., Bukau, B., Kramer, G., 2010. Structure and function of the molecular 
chaperone Trigger Factor. Biochim. Biophys. Acta - Mol. Cell Res. 1803, 650–661.  
Hopkinson, R.J., Leung, I.K.H., Smart, T.J., Rose, N.R., Henry, L., Claridge, T.D.W., 
Schofield, C.J., 2015. Studies on the Glutathione-Dependent Formaldehyde-
Activating Enzyme from Paracoccus denitrificans. PLoS One 10, e0145085. 
Huang, R., Bonnichon, A., Claridge, T.D.W., Leung, I.K.H., 2017. Protein-ligand binding 
affinity determination by the waterLOGSY method: An optimised approach 
considering ligand rebinding. Sci. Rep. 7, 43727.  
  
205 
Huang, S., Rutkowsky, J.M., Snodgrass, R.G., Ono-Moore, K.D., Schneider, D.A., 
Newman, J.W., Adams, S.H., Hwang, D.H., 2012. Saturated fatty acids activate TLR-
mediated proinflammatory signaling pathways. J. Lipid Res. 53, 2002–2013.  
Huang, W.-C., Nagahashi, M., Terracina, K.P., Takabe, K., 2013. Emerging Role of 
Sphingosine-1-phosphate in Inflammation, Cancer, and Lymphangiogenesis. 
Biomolecules 3, 408–434.  
Hurley, J.H., Tsujishita, Y., Pearson, M.A., 2000. Floundering about at cell membranes: a 
structural view of phospholipid signaling. Curr. Opin. Struct. Biol. 10, 737–743.  
Hurst, R.J.M., Else, K.J., 2012. Retinoic acid signalling in gastrointestinal parasite 
infections: lessons from mouse models. Parasite Immunol. 34, 351–359.  
Iberkleid, I., Sela, N., Brown Miyara, S., 2015. Meloidogyne javanica fatty acid- and 
retinol-binding protein (Mj-FAR-1) regulates expression of lipid-, cell wall-, stress- 
and phenylpropanoid-related genes during nematode infection of tomato. BMC 
Genomics 16, 272.  
Iberkleid, I., Vieira, P., de Almeida Engler, J., Firester, K., Spiegel, Y., Horowitz, S.B., 
2013. Fatty Acid-and Retinol-Binding Protein, Mj-FAR-1 Induces Tomato Host 
Susceptibility to Root-Knot Nematodes. PLoS One 8, e64586. 
International Union of Biochemistry and Molecular Biology, 1992. Biochemical 
Nomenclature and Related Documents. Portland Press. 
Irvine, R.F., 2003. 20 years of Ins(1,4,5)P3, and 40 years before. Nat. Rev. Mol. Cell Biol. 
4, 580–585. 
Itoh, F., Divecha, N., Brocks, L., Oomen, L., Janssen, H., Calafat, J., Itoh, S., Dijke, P. ten, 
2002. The FYVE domain in Smad anchor for receptor activation (SARA) is sufficient 
for localization of SARA in early endosomes and regulates TGF-β/Smad signalling. 
Genes to Cells 7, 321–331.  
Jäger, V., Büssow, K., Schirrmann, T., 2015. Transient Recombinant Protein Expression in 
Mammalian Cells. In: Animal Cell Culture. Springer International Publishing, pp. 27-
64  
Jarvis, D.L., 2009. Chapter 14 Baculovirus–Insect Cell Expression Systems. Methods 
Enzymol. 463, 191–222. 
  
206 
Jaskolski, M., Dauter, Z., Wlodawer, A., 2014. A brief history of macromolecular 
crystallography, illustrated by a family tree and its Nobel fruits. FEBS J. 281, 3985–
4009. 
Jasniewski, J., Cailliez-Grimal, C., Younsi, M., Millière, J.-B., Revol-Junelles, A.-M., 
2008. Fluorescence anisotropy analysis of the mechanism of action of mesenterocin 
52A: speculations on antimicrobial mechanism. Appl. Microbiol. Biotechnol. 81, 
339–347. 
Johnson, W.C., 1999. Analyzing protein circular dichroism spectra for accurate secondary 
structures. Proteins Struct. Funct. Bioinforma. 35, 307–312. 
Jones, J.T., Kumar, A., Pylypenko, L.A., Thirugnanasambandan, A., Castelli, L., 
Chapman, S., Cock, P.J.A., Greiner, E., Lilley, C.J., Phillips, M.S., Blok, V.C., 2009. 
Identification and functional characterization of effectors in expressed sequence tags 
from various life cycle stages of the potato cyst nematode Globodera pallida. Mol. 
Plant Pathol. 10, 815–828.  
Jones, S.M., Alb, J.G., Phillips, S.E., Bankaitis, V.A., Howell, K.E., 1998. A 
Phosphatidylinositol 3-Kinase and Phosphatidylinositol Transfer Protein Act 
Synergistically in Formation of Constitutive Transport Vesicles from the Trans-Golgi 
Network. J. Biol. Chem. 273, 10349–10354.  
Jordanova, R., Groves, M.R., Kostova, E., Woltersdorf, C., Liebau, E., Tucker, P.A., 2009. 
Fatty Acid- and Retinoid-binding Proteins Have Distinct Binding Pockets for the Two 
Types of Cargo. J. Biol. Chem. 284, 35818–35826.  
Jose Lopez-Andreo, M., Gomez-Fernandez, J.C., Corbalan-Garcia, S., 2003. The 
Simultaneous Production of Phosphatidic Acid and Diacylglycerol Is Essential for the 
Translocation of Protein Kinase Cε to the Plasma Membrane in RBL-2H3 Cells. Mol. 
Biol. Cell 14, 4885–4895. 
Kabsch, W., 2010. XDS. Acta Crystallogr. Sect. D 66, 125–132.  
Kapust, R.B., Waugh, D.S., 1999. Escherichia coli maltose-binding protein is uncommonly 
effective at promoting the solubility of polypeptides to which it is fused. Protein Sci. 
8, 1668–1674. 
Karathanassis, D., Stahelin, R. V, Bravo, J., Perisic, O., Pacold, C.M., Cho, W., Williams, 
R.L., 2002. Binding of the PX domain of p47(phox) to phosphatidylinositol 3,4-
  
207 
bisphosphate and phosphatidic acid is masked by an intramolecular interaction. 
EMBO J. 21, 5057–5068.  
Katan, M., 2005. New insights into the families of PLC enzymes: looking back and going 
forward. Biochem. J. 391, e7.  
Kay, L.E., Ikura, M., Tschudin, R., Bax, A., 1990. Three-dimensional triple-resonance 
NMR spectroscopy of isotopically enriched proteins. J. Magn. Reson. 89, 496–514.  
Kay, L.E., Xu, G.Y., Singer, A.U., Muhandiram, D.R., Formankay, J.D., 1993. A 
Gradient-Enhanced HCCH-TOCSY Experiment for Recording Side-Chain 1H and 
13C Correlations in H2O Samples of Proteins. J. Magn. Reson. Ser. B 101, 333–337.  
Kazanietz, M.G., Barchi, J.J., Omichinski, J.G., Blumberg, P.M., 1995. Low Affinity 
Binding of Phorbol Esters to Protein Kinase C and Its Recombinant Cysteine-rich 
Region in the Absence of Phospholipids. J. Biol. Chem.  270, 14679–14684.  
Keegan, R.M., Winn, M.D., 2008.  MrBUMP: an automated pipeline for molecular 
replacement. Acta Crystallogr. Sect. D Biol. Crystallogr. 64, 119–124.  
Keeler, J., 2010. Understanding NMR Spectroscopy, 2nd Edition. Wiley-Blackwell. 
Keinan, O., Kedan, A., Gavert, N., Selitrennik, M., Kim, S., Karn, T., Becker, S., Lev, S., 
2014. The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and 
facilitates breast cancer metastasis. J. Cell Sci. 127, 4740–4749. 
Kelly, S.M., Jess, T.J., Price, N.C., 2005. How to study proteins by circular dichroism. 
Biochim. Biophys. Acta - Proteins Proteomics 1751, 119–139.  
Kendrew, J.C., Bodo, G., Dintzis, H.M., Parrish, R.G., Wyckoff, H., Phillips, D.C., 1958. 
A Three-Dimensional Model of the Myoglobin Molecule Obtained by X-Ray 
Analysis. Nature 181, 662–666. 
Kennedy, M.W., 2011. The polyprotein allergens of nematodes (NPAs) – Structure at last, 
but still mysterious. Exp. Parasitol. 129, 81–84.  
Kennedy, M.W., 2000. The polyprotein lipid binding proteins of nematodes. Biochim. 
Biophys. Acta - Protein Struct. Mol. Enzymol. 1476, 149–164.  
  
  
208 
Kennedy, M.W., Brass, A., McCruden, A.B., Price, N.C., Kelly, S.M., Cooper, A., 1995. 
The ABA-1 Allergen of the Parasitic Nematode Ascaris suum: Fatty Acid and 
Retinoid Binding Function and Structural Characterization. Biochemistry 34, 6700–
6710.  
Kersten, S., Desvergne, B., Wahli, W., 2000. Roles of PPARs in health and disease. Nature 
405, 421–424. 
Khurana, S., Tomar, A., George, S.P., Wang, Y., Siddiqui, M.R., Guo, H., Tigyi, G., 
Mathew, S., 2008. Autotaxin and lysophosphatidic acid stimulate intestinal cell 
motility by redistribution of the actin modifying protein villin to the developing 
lamellipodia. Exp. Cell Res. 314, 530–542.  
Kim, S., Kedan, A., Marom, M., Gavert, N., Keinan, O., Selitrennik, M., Laufman, O., 
Lev, S., 2013. The phosphatidylinositol-transfer protein Nir2 binds phosphatidic acid 
and positively regulates phosphoinositide signalling. EMBO Rep. 14, 891–899. 
Kim, Y.J., Guzman-Hernandez, M.-L., Wisniewski, E., Balla, T., 2015. 
Phosphatidylinositol-Phosphatidic Acid Exchange by Nir2 at ER-PM Contact Sites 
Maintains Phosphoinositide Signaling Competence. Dev. Cell 33, 549–561. 
Klages, J., Coles, M., Kessler, H., 2007. NMR-based screening: a powerful tool in 
fragment-based drug discovery. Analyst 132, 692–705.  
Klinkenberg, D., Long, K.R., Shome, K., Watkins, S.C., Aridor, M., 2014. A cascade of 
ER exit site assembly that is regulated by p125A and lipid signals. J. Cell Sci. 127, 
1765–1778. 
Kohn, L., Kadzhaev, K., Burstedt, M.S.I., Haraldsson, S., Hallberg, B., Sandgren, O., 
Golovleva, I., 2007. Mutation in the PYK2-binding domain of PITPNM3 causes 
autosomal dominant cone dystrophy (CORD5) in two Swedish families. Eur. J. Hum. 
Genet. 15, 664–671. 
Kooijman, E.E., Carter, K.M., van Laar, E.G., Chupin, V., Burger, K.N., de Kruijff, B., 
2005a. What makes the bioactive lipids phosphatidic acid and lysophosphatidic acid 
so special? Biochemistry 44, 17007–17015. 
Kooijman, E.E., Chupin, V., de Kruijff, B., Burger, K.N., 2003. Modulation of membrane 
curvature by phosphatidic acid and lysophosphatidic acid. Traffic 4, 162–174. 
Kooijman, E.E., Chupin, V., Fuller, N.L., Kozlov, M.M., de Kruijff, B., Burger, K.N.J., 
  
209 
Rand, P.R., 2005b. Spontaneous Curvature of Phosphatidic Acid and 
Lysophosphatidic Acid. Biochemistry 44, 2097–2102. 
Kooijman, E.E., Tieleman, D.P., Testerink, C., Munnik, T., Rijkers, D.T., Burger, K.N., de 
Kruijff, B., 2007. An electrostatic/hydrogen bond switch as the basis for the specific 
interaction of phosphatidic acid with proteins. J. Biol. Chem. 282, 11356–11364. 
Kovacs, H., Gossert, A., 2014. Improved NMR experiments with 13C-isotropic mixing for 
assignment of aromatic and aliphatic side chains in labeled proteins. J. Biomol. NMR 
58, 101–112.  
Kraft, C.A., Garrido, J.L., Fluharty, E., Leiva-Vega, L., Romero, G., 2008. Role of 
Phosphatidic Acid in the Coupling of the ERK Cascade. J. Biol. Chem. 283, 36636–
36645.  
Krohn, S., Garin, A., Gabay, C., Proudfoot, A., 2013. The Activity of CCL18 is Principally 
Mediated through Interaction with Glycosaminoglycans. Front. Immunol. 4, 193.  
Kruijff, B. de, 1997. Lipid polymorphism and biomembrane function. Curr. Opin. Chem. 
Biol. 1, 564–569.  
Kurooka, T., Yamamoto, Y., Takai, Y., Sakisaka, T., 2011. Dual Regulation of RA-
RhoGAP Activity by Phosphatidic Acid and Rap1 during Neurite Outgrowth. J. Biol. 
Chem. 286, 6832–6843. 
Kutateladze, T., Overduin, M., 2001. Structural Mechanism of Endosome Docking by the 
FYVE Domain. Science 291, 1793–1796. 
Kutateladze, T.G., 2007. Mechanistic similarities in docking of the FYVE and PX domains 
to phosphatidylinositol 3-phosphate containing membranes. Prog. Lipid Res. 46, 315–
327. 
Kutateladze, T.G., Ogburn, K.D., Watson, W.T., de Beer, T., Emr, S.D., Burd, C.G., 
Overduin, M., 1999. Phosphatidylinositol 3-Phosphate Recognition by the FYVE 
Domain. Mol. Cell 3, 805–811. 
Ladokhin, A.S., Isas, J.M., Haigler, H.T., White, S.H., 2002. Determining the Membrane 
Topology of Proteins:  Insertion Pathway of a Transmembrane Helix of Annexin 12. 
Biochemistry 41, 13617–13626. 
Lakowicz, J.R., 2006. Principles of Fluorescence Spectroscopy, 3rd ed. Springer US.  
  
210 
Lal, P.G., James, E.R., 1996. Onchocerca retinol- and ivermectin-binding protein activity. 
Parasitology 112, 221–225.  
Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., 1993. PROCHECK: a 
program to check the stereochemical quality of protein structures. J. Appl. 
Crystallogr. 26, 283–291. 
LaVallie, E.R., Lu, Z., Diblasio-Smith, E.A., Collins-Racie, L.A., McCoy, J.M., 2000. 
Thioredoxin as a fusion partner for production of soluble recombinant proteins in 
Escherichia coli. Methods Enzymol. 326, 322–340.  
Lebendiker, M., Danieli, T., 2014. Production of prone-to-aggregate proteins. FEBS Lett. 
588, 236–246.  
Lee, S.A., Kovacs, J., Stahelin, R. V, Cheever, M.L., Overduin, M., Setty, T.G., Burd, 
C.G., Cho, W., Kutateladze, T.G., 2006. Molecular Mechanism of Membrane 
Docking by the Vam7p PX Domain. J. Biol. Chem.  281, 37091–37101. 
Lemmon, M.A., 2008. Membrane recognition by phospholipid-binding domains. Nat. Rev. 
Mol. Cell Biol. 9, 99–111. 
Lemmon, M.A., 2004. Pleckstrin homology domains: not just for phosphoinositides. 
Biochem. Soc. Trans. 32, 707–711. 
Lemmon, M.A., 2003. Phosphoinositide Recognition Domains. Traffic 4, 201–213.  
Lemmon, M.A., Ferguson, K.M., 2000. Signal-dependent membrane targeting by 
pleckstrin homology (PH) domains. Biochem. J. 350, 1–18. 
Lemmon, M.A., Ferguson, K.M., O’Brien, R., Sigler, P.B., Schlessinger, J., 1995. Specific 
and high-affinity binding of inositol phosphates to an isolated pleckstrin homology 
domain. Proc. Natl. Acad. Sci. U. S. A. 92, 10472–10476. 
Letunic, I., Doerks, T., Bork, P., 2015. SMART: recent updates, new developments and 
status in 2015. Nucleic Acids Res. 43, D257–D260. 
Lev, S., 2004. The role of the Nir/rdgB protein family in membrane trafficking and 
cytoskeleton remodeling. Exp. Cell Res. 297, 1–10. 
Lev, S., Hernandez, J., Martinez, R., Chen, A., Plowman, G., Schlessinger, J., 1999. 
Identification of a Novel Family of Targets of PYK2 Related to Drosophila Retinal 
Degeneration B (rdgB) Protein. Mol. Cell. Biol. 19, 2278–2288. 
  
211 
Levitt, M., 2008. Spin Dynamics: Basics of Nuclear Magnetic Resonance, 2nd Edition. 
Wiley-Blackwell. 
Li, X., Romero, P., Rani, M., Dunker, A., Obradzovic, Z., 1999. Predicting protein 
disorder for N-, C-, and internal regions. Genome Informatics 10, 30–40. 
Lin, S., Struve, W.S., 1991. Time-resolved fluorescence of nitrobenzoxadiazole-
aminohexanoic acid: effect of intermolecular hydrogen-bonding on non-radiative 
decay. Photochem. Photobiol. 54, 361–365. 
Linge, J.P., Habeck, M., Rieping, W., Nilges, M., 2003a. ARIA: automated NOE 
assignment and NMR structure calculation. Bioinformatics 19, 315–316. 
Linge, J.P., O’Donoghue, S.I., Nilges, M., 2001. Automated Assignment of Ambiguous 
Nuclear Overhauser Effects with ARIA. Methods Enzymol. 339, 71–90.  
Linge, J.P., Williams, M.A., Spronk, C.A.E.M., Bonvin, A.M.J.J., Nilges, M., 2003b. 
Refinement of protein structures in explicit solvent. Proteins Struct. Funct. 
Bioinforma. 50, 496–506.  
Lingwood, D., Simons, K., 2009. Lipid Rafts As a Membrane-Organizing Principle. 
Science 327, 46–50. 
Litvak, V., Argov, R., Dahan, N., Ramachandran, S., Amarilio, R., Shainskaya, A., Lev, S., 
2004. Mitotic Phosphorylation of the Peripheral Golgi Protein Nir2 by Cdk1 Provides 
a Docking Mechanism for Plk1 and Affects Cytokinesis Completion. Mol. Cell 14, 
319–330. 
Litvak, V., Dahan, N., Ramachandran, S., Sabanay, H., Lev, S., 2005. Maintenance of the 
diacylglycerol level in the Golgi apparatus by the Nir2 protein is critical for Golgi 
secretory function. Nat. Cell Biol. 7, 225–234. 
Litvak, V., Tian, D., Carmon, S., Lev, S., 2002. Nir2, a Human Homolog of Drosophila 
melanogaster Retinal Degeneration B Protein, Is Essential for Cytokinesis. Mol. Cell. 
Biol.  22, 5064–5075. 
Liu, L.X., Serhan, C.N., Weller, P.F., 1990. Intravascular filarial parasites elaborate 
cyclooxygenase-derived eicosanoids. J. Exp. Med. 172, 993–996. 
Loewen, C.J., Roy, A., Levine, T.P., 2003. A conserved ER targeting motif in three 
families of lipid binding proteins and in Opi1p binds VAP. EMBO J. 22, 2025-2035. 
  
212 
Loewen, C.J.R., Levine, T.P., 2005. A Highly Conserved Binding Site in Vesicle-
associated Membrane Protein-associated Protein (VAP) for the FFAT Motif of Lipid-
binding Proteins. J. Biol. Chem.  280, 14097–14104. 
Mainz, A., Religa, T.L., Sprangers, R., Linser, R., Kay, L.E., Reif, B., 2013. NMR 
Spectroscopy of Soluble Protein Complexes at One Mega-Dalton and Beyond. 
Angew. Chemie Int. Ed. 52, 8746–8751. 
Majerus, P.W., York, J.D., 2009. Phosphoinositide phosphatases and disease. J. Lipid Res. 
50, S249–S254.  
Makrides, S.C., 1996. Strategies for achieving high-level expression of genes in 
Escherichia coli. Microbiol. Rev. 60, 512–538. 
Malakhov, M.P., Mattern, M.R., Malakhova, O.A., Drinker, M., Weeks, S.D., Butt, T.R., 
2004. SUMO fusions and SUMO-specific protease for efficient expression and 
purification of proteins. J. Struct. Funct. Genom. 5, 75-86. 
Manavalan, P., Johnson, W.C., 1987. Variable selection method improves the prediction of 
protein secondary structure from circular dichroism spectra. Anal. Biochem. 167, 76–
85.  
Marblestone, J.G., Edavettal, S.C., Lim, Y., Lim, P., Zuo, X., Butt, T.R., 2006. 
Comparison of SUMO fusion technology with traditional gene fusion systems: 
Enhanced expression and solubility with SUMO. Protein Sci. 15, 182–189.  
Marion, D., Driscoll, P.C., Kay, L.E., Wingfield, P.T., Bax, A., Gronenborn, A.M., Clore, 
G.M., 1989a. Overcoming the overlap problem in the assignment of proton NMR 
spectra of larger proteins by use of three-dimensional heteronuclear proton-nitrogen-
15 Hartmann-Hahn-multiple quantum coherence and nuclear Overhauser-multiple 
quantum coherence spectroscopy: Biochemistry 28, 6150–6156.  
Marion, D., Kay, L.E., Sparks, S.W., Torchia, D.A., Bax, A., 1989b. Three-dimensional 
heteronuclear NMR of nitrogen-15 labeled proteins. J. Am. Chem. Soc. 111, 1515–
1517. 
Marsh, D., 1990. CRC handbook of lipid bilayers. CRC Press. 
Martin, G.S., 2003. Cell signaling and cancer. Cancer Cell 4, 167–174.  
Mashalidis, E.H., Śledź, P., Lang, S., Abell, C., 2013. A three-stage biophysical screening 
  
213 
cascade for fragment-based drug discovery. Nat. Protoc. 8, 2309–2324. 
Mattanovich, D., Branduardi, P., Dato, L., Gasser, B., Sauer, M., Porro, D., 2012. 
Recombinant Protein Production in Yeast. In: Recombinant Gene Expression. 
Humana Press, pp. 329-358. 
Mátyus, L., Szöllősi, J., Jenei, A., 2006. Steady-state fluorescence quenching applications 
for studying protein structure and dynamics. J. Photochem. Photobiol. B Biol. 83, 
223–236.  
Mayer, M., Meyer, B., 1999. Characterization of Ligand Binding by Saturation Transfer 
Difference NMR Spectroscopy. Angew. Chemie Int. Ed. 38, 1784–1788. 
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, 
R.J., 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674.  
McLaughlin, S., Murray, D., 2005. Plasma membrane phosphoinositide organization by 
protein electrostatics. Nature 438, 605–611. 
Meenan, N.A.G., Ball, G., Bromek, K., Uhrín, D., Cooper, A., Kennedy, M.W., Smith, 
B.O., 2011. Solution Structure of a Repeated Unit of the ABA-1 Nematode 
Polyprotein Allergen of Ascaris Reveals a Novel Fold and Two Discrete Lipid-
Binding Sites. PLoS Negl. Trop. Dis. 5, e1040. 
Mei, B., Kennedy, M.W., Beauchamp, J., Komuniecki, P.R., Komuniecki, R., 1997. 
Secretion of a Novel, Developmentally Regulated Fatty Acid-binding Protein into the 
Perivitelline Fluid of the Parasitic Nematode, Ascaris suum. J. Biol. Chem.  272, 
9933–9941. 
Meiboom, S., Gill, D., 1958. Modified Spin-Echo Method for Measuring Nuclear 
Relaxation Times. Rev. Sci. Instrum. 29, 688–691. 
Meyer, B., Peters, T., 2003. NMR Spectroscopy Techniques for Screening and Identifying 
Ligand Binding to Protein Receptors . Angew. Chemie Int. Ed. 42, 864–890.  
Michalski, M.L., Monsey, J.D., Cistola, D.P., Weil, G.J., 2002. An embryo-associated fatty 
acid-binding protein in the filarial nematode Brugia malayi. Mol. Biochem. Parasitol. 
124, 1–10. 
Mietkiewska, E., Siloto, R.M.P., Dewald, J., Shah, S., Brindley, D.N., Weselake, R.J., 
2011. Lipins from plants are phosphatidate phosphatases that restore lipid synthesis in 
  
214 
a pah1Δ mutant strain of Saccharomyces cerevisiae. FEBS J. 278, 764–775.  
Misra, S., Hurley, J.H., 1999. Crystal Structure of a Phosphatidylinositol 3-Phosphate-
Specific Membrane-Targeting Motif, the FYVE Domain of Vps27p. Cell 97, 657–
666.  
Mizukami, M., Miyauchi, H.H. and A., 2010. Brevibacillus Expression System: Host-
Vector System for Efficient Production of Secretory Proteins. Curr. Pharm. 
Biotechnol. 11, 251-258. 
Montelione, G.T., Lyons, B.A., Emerson, S.D., Tashiro, M., 1992. An efficient triple 
resonance experiment using carbon-13 isotropic mixing for determining sequence-
specific resonance assignments of isotopically-enriched proteins. J. Am. Chem. Soc. 
114, 10974–10975. 
Mora, A., Komander, D., van Aalten, D.M.F., Alessi, D.R., 2004. PDK1, the master 
regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161–170.  
Mora, J.R., Iwata, M., von Andrian, U.H., 2008. Vitamin effects on the immune system: 
vitamins A and D take centre stage. Nat. Rev. Immunol. 8, 685–698. 
doi:10.1038/nri2378 
Muhandiram, D.R., Kay, L.E., 1994. Gradient-Enhanced Triple-Resonance Three-
Dimensional NMR Experiments with Improved Sensitivity. J. Magn. Reson. Ser. B 
103, 203–216. 
Mukherjee, S., Raghuraman, H., Dasgupta, S., Chattopadhyay, A., 2004. Organization and 
dynamics of N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-labeled lipids: a fluorescence 
approach. Chem. Phys. Lipids 127, 91–101.  
Murshudov, G.N., Vagin, A.A., Dodson, E.J., 1997. Refinement of Macromolecular 
Structures by the Maximum-Likelihood Method. Acta Crystallogr. Sect. D 53, 240–
255. 
Murshudov, G.N., Vagin, A.A., Lebedev, A., Wilson, K.S., Dodson, E.J., 1999. Efficient 
anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr. 
Sect. D 55, 247–255. 
Nadaud, P.S., Helmus, J.J., Höfer, N., Jaroniec, C.P., 2007. Long-Range Structural 
Restraints in Spin-Labeled Proteins Probed by Solid-State Nuclear Magnetic 
Resonance Spectroscopy. J. Am. Chem. Soc. 129, 7502–7503.  
  
215 
Nakanishi, H., de los Santos, P., Neiman, A.M., 2004. Positive and negative regulation of a 
SNARE protein by control of intracellular localization. Mol. Biol. Cell 15, 1802-1815 
Nettleship, J.E., 2016. OPPF-UK Standard Protocols: Insect Expression [WWW 
Document]. 
Nilges, M., 1995. Calculation of Protein Structures with Ambiguous Distance Restraints. 
Automated Assignment of Ambiguous NOE Crosspeaks and Disulphide 
Connectivities. J. Mol. Biol. 245, 645–660.  
Nilges, M., Macias, M.J., O’Donoghue, S.I., Oschkinat, H., 1997. Automated NOESY 
interpretation with ambiguous distance restraints: the refined NMR solution structure 
of the pleckstrin homology domain from β-spectrin. J. Mol. Biol. 269, 408–422.  
Nishihara, K., Kanemori, M., Yanagi, H., Yura, T., 2000. Overexpression of Trigger 
Factor Prevents Aggregation of Recombinant Proteins in Escherichia coli. Appl. 
Environ. Microbiol. 66, 884–889 
O’Connor, D. V, Phillips, D., 1984. Time-Correlated Single Photon Counting. Academic 
Press. 
Obal, G., Ramos, A.L., Silva, V., Lima, A., Batthyany, C., Bessio, M.I., Ferreira, F., 
Salinas, G., Ferreira, A.M., 2012. Characterisation of the Native Lipid Moiety of 
Echinococcus granulosus Antigen B. PLoS Negl. Trop. Dis. 6, e1642.  
Ooms, L.M., Horan, K.A., Rahman, P., Seaton, G., Gurung, R., Kethesparan, D.S., 
Mitchell, C.A., 2009. The role of the inositol polyphosphate 5-phosphatases in 
cellular function and human disease. Biochem. J. 419, 29–49. 
Osanai, M., Nishikiori, N., Murata, M., Chiba, H., Kojima, T., Sawada, N., 2006. Cellular 
Retinoic Acid Bioavailability Determines Epithelial Integrity: Role of Retinoic Acid 
Receptor α Agonists in Colitis. Mol. Pharmacol. 71, 250–258. 
Palmetshofer, A., Robson, S.C., Nehls, V., 1999. Lysophosphatidic Acid Activates Nuclear 
Factor Kappa B and Induces Proinflammatory Gene Expression in Endothelial Cells. 
Thromb. Haemost. 82, 1532–1537. 
Papackova, Z., Cahova, M., 2015. Fatty Acid Signaling: The New Function of Intracellular 
Lipases. Int. J. Mol. Sci. 16, 3831–3855. 
Park, J.B., Lee, C.S., Jang, J.-H., Ghim, J., Kim, Y.-J., You, S., Hwang, D., Suh, P.-G., 
  
216 
Ryu, S.H., 2012. Phospholipase signalling networks in cancer. Nat. Rev. Cancer 12, 
782–792. 
Parker, J.L., Newstead, S., 2016. Membrane protein crystallization: Current trends and 
future perspectives. Adv. Exp. Med. Biol. 922, 61–72.  
Patki, V., Lawe, D.C., Corvera, S., Virbasius, J. V, Chawla, A., 1998. A functional 
PtdIns(3)P-binding motif. Nature 394, 433–434. 
Paulick, M.G., Bertozzi, C.R., 2008. The Glycosylphosphatidylinositol Anchor: A 
Complex Membrane-Anchoring Structure for Proteins. Biochemistry 47, 6991–7000.  
Pellecchia, M., Bertini, I., Cowburn, D., Dalvit, C., Giralt, E., Jahnke, W., James, T.L., 
Homans, S.W., Kessler, H., Luchinat, C., Meyer, B., Oschkinat, H., Peng, J., 
Schwalbe, H., Siegal, G., 2008. Perspectives on NMR in drug discovery: a technique 
comes of age. Nat. Rev. Drug Discov. 7, 738–745. 
Pendaries, C., Tronchère, H., Plantavid, M., Payrastre, B., 2003. Phosphoinositide 
signaling disorders in human diseases. FEBS Lett. 546, 25–31.  
Perutz, M.F., Rossmann, M.G., Cullis, A.N.N.F., Muirhead, H., Will, G., North, A.C.T., 
1960. Structure of Haemoglobin: A Three-Dimensional Fourier Synthesis at 5.5-Å. 
Resolution, Obtained by X-Ray Analysis. Nature 185, 416–422. 
Pervushin, K., Riek, R., Wider, G., Wüthrich, K., 1997. Attenuated T2 relaxation by 
mutual cancellation of dipole–dipole coupling and chemical shift anisotropy indicates 
an avenue to NMR structures of very large biological macromolecules in solution. 
Proc. Natl. Acad. Sci.  94, 12366–12371. 
Ponting, C.P., 1996. Novel domains in NADPH oxidase subunits, sorting nexins, and 
PtdIns 3-kinases: binding partners of SH3 domains? Protein Sci. 5, 2353–2357. 
Popeijus, M., Blok, V.C., Cardle, L., Bakker, E., Phillips, M.S., Helder, J., Smant, G., 
Jones, J.T., 2000. Analysis of genes expressed in second stage juveniles of the potato 
cyst nematodes Globodera rostochiensis and G. pallida using the expressed sequence 
tag approach. Nematology 2, 567–574. 
Pritz, S., Doering, K., Woelcke, J., Hassiepen, U., 2011. Fluorescence lifetime assays: 
current advances and applications in drug discovery. Expert Opin. Drug Discov. 6, 
663–670.  
  
217 
Provencher, S.W., Gloeckner, J., 1981. Estimation of globular protein secondary structure 
from circular dichroism. Biochemistry 20, 33–37.  
Pullan, R.L., Smith, J.L., Jasrasaria, R., Brooker, S.J., 2014. Global numbers of infection 
and disease burden of soil transmitted helminth infections in 2010. Parasit. Vectors 7, 
37. 
Purcell, E.M., Torrey, H.C., Pound, R. V, 1946. Resonance Absorption by Nuclear 
Magnetic Moments in a Solid. Phys. Rev. 69, 37–38. 
Pyne, N.J., McNaughton, M., Boomkamp, S., MacRitchie, N., Evangelisti, C., Martelli, 
A.M., Jiang, H.-R., Ubhi, S., Pyne, S., 2016. Role of sphingosine 1-phosphate 
receptors, sphingosine kinases and sphingosine in cancer and inflammation. Adv. 
Biol. Regul. 60, 151–159.  
Raiborg, C., Schink, K.O., Stenmark, H., 2013. Class III phosphatidylinositol 3–kinase and 
its catalytic product PtdIns3P in regulation of endocytic membrane traffic. FEBS J. 
280, 2730–2742. 
Raman, M., Martin, K., 2014. One solution for cloning and mutagenesis: In-Fusion[reg] 
HD Cloning Plus. Nat. Meth. 11. 
Ranjit, N., Jones, M.K., Stenzel, D.J., Gasser, R.B., Loukas, A., 2006. A survey of the 
intestinal transcriptomes of the hookworms, Necator americanus and Ancylostoma 
caninum, using tissues isolated by laser microdissection microscopy. Int. J. Parasitol. 
36, 701–710.  
Rebecchi, M.J., Pentyala, S.N., 2000. Structure, Function, and Control of 
Phosphoinositide-Specific Phospholipase C. Physiol. Rev. 80, 1291–1335. 
Renaud, J.-P., Delsuc, M.-A., 2009. Biophysical techniques for ligand screening and drug 
design. Curr. Opin. Pharmacol. 9, 622–628.  
Resh, M.D., 2013. Covalent lipid modifications of proteins. Curr. Biol. 23, R431–R435.  
Reue, K., Dwyer, J.R., 2009. Lipin proteins and metabolic homeostasis. J. Lipid Res. 50, 
S109–S114.  
Rey-Burusco, M.F., Ibañez-Shimabukuro, M., Cooper, A., Kennedy, M.W., Córsico, B., 
Smith, B.O., 2014. (1)H, (13)C and (15)N chemical shift assignments of Na-FAR-1, a 
helix-rich fatty acid and retinol binding protein of the parasitic nematode Necator 
  
218 
americanus. Biomol. NMR Assign. 8, 19–21.  
Rey-Burusco, M.F., Ibáñez-Shimabukuro, M., Gabrielsen, M., Franchini, G.R., Roe, A.J., 
Griffiths, K., Zhan, B., Cooper, A., Kennedy, M.W., Córsico, B., Smith, B.O., 2015. 
Diversity in the structures and ligand-binding sites of nematode fatty acid and retinol-
binding proteins revealed by Na-FAR-1 from Necator americanus. Biochem. J. 471, 
403–414. 
Ricciotti, E., FitzGerald, G.A., 2011. Prostaglandins and Inflammation. Arterioscler. 
Thromb. Vasc. Biol. 31, 986–1000.  
Rivera, R., Chun, J., 2008. Biological effects of lysophospholipids. In: Reviews of 
Physiology Biochemistry and Pharmacology. Springer Berlin Heidelberg, pp. 25-46.  
Rizzo, M.A., Shome, K., Watkins, S.C., Romero, G., 2000. The recruitment of Raf-1 to 
membranes is mediated by direct interaction with phosphatidic acid and is 
independent of association with Ras. J. Biol. Chem. 275, 23911–23918. 
Rojas, J.M., Oliva, J.L., Santos, E., 2011. Mammalian Son of Sevenless Guanine 
Nucleotide Exchange Factors: Old Concepts and New Perspectives. Genes Cancer 2, 
298–305. 
Rossmann, M.G., 2001. Molecular replacement historical background. Acta Crystallogr. 
Sect. D 57, 1360–1366. 
Rossmann, M.G., Blow, D.M., 1962. The detection of sub-units within the crystallographic 
asymmetric unit. Acta Crystallogr. 15, 24–31. 
Roszak, A.W., Gardiner, A.T., Isaacs, N.W., Cogdell, R.J., 2007. Brominated Lipids 
Identify Lipid Binding Sites on the Surface of the Reaction Center from Rhodobacter 
sphaeroides. Biochemistry 46, 2909–2916.  
Rother, E., Brandl, R., Baker, D.L., Goyal, P., Gebhard, H., Tigyi, G., Siess, W., 2003. 
Subtype-Selective Antagonists of Lysophosphatidic Acid Receptors Inhibit Platelet 
Activation Triggered by the Lipid Core of Atherosclerotic Plaques. Circulation 108, 
741–747. 
Rubenfeld, J., Guo, J., Sookrung, N., Chen, R., Chaicumpa, W., Casolaro, V., Zhao, Y., 
Natarajan, V., Georas, S., 2005. Lysophosphatidic acid enhances interleukin-13 gene 
expression and promoter activity in T cells. Am. J. Physiol. - Lung Cell. Mol. Physiol. 
290, L66–L74. 
  
219 
Sacchettini, J.C., Gordon, J.I., Banaszak, L.J., 1989. Crystal structure of rat intestinal fatty-
acid-binding protein. J. Mol. Biol. 208, 327–339.  
Saio, T., Guan, X., Rossi, P., Economou, A., Kalodimos, C.G., 2014. Structural Basis for 
Protein Antiaggregation Activity of the Trigger Factor Chaperone. Science 344, 
1250494. 
Sani, B.P., Vaid, A., 1988. Specific interaction of ivermectin with retinol-binding protein 
from filarial parasites. Biochem. J. 249, 929–932. 
Sasaki, T., Takasuga, S., Sasaki, J., Kofuji, S., Eguchi, S., Yamazaki, M., Suzuki, A., 2009. 
Mammalian phosphoinositide kinases and phosphatases. Prog. Lipid Res. 48, 307–
343. 
Schanda, P., Brutscher, B., 2005. Very Fast Two-Dimensional NMR Spectroscopy for 
Real-Time Investigation of Dynamic Events in Proteins on the Time Scale of 
Seconds. J. Am. Chem. Soc. 127, 8014–8015.  
Scheffzek, K., Welti, S., 2012. Pleckstrin homology (PH) like domains – versatile modules 
in protein–protein interaction platforms. FEBS Lett. 586, 2662–2673.  
Schenning, M., Goedhart, J., Gadella Jr., T.W.J., Avram, D., Wirtz, K.W.A., Snoek, G.T., 
2008. The anti-apoptotic activity associated with phosphatidylinositol transfer protein 
α activates the MAPK and Akt/PKB pathway. Biochim. Biophys. Acta - Mol. Cell 
Res. 1783, 1700–1706.  
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., 
Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.-Y., White, D.J., 
Hartenstein, V., Eliceiri, K., Tomancak, P., Cardona, A., 2012. Fiji: an open-source 
platform for biological-image analysis. Nat. Meth. 9, 676–682. 
Schouten, A., Agianian, B., Westerman, J., Kroon, J., Wirtz, K.W.A., Gros, P., 2002. 
Structure of apo-phosphatidylinositol transfer protein α provides insight into 
membrane association. EMBO J. 21, 2117–2121. 
Schultz, J., Milpetz, F., Bork, P., Ponting, C.P., 1998. SMART, a simple modular 
architecture research tool: Identification of signaling domains. Proc. Natl. Acad. Sci.  
95, 5857–5864. 
Sever, R., Brugge, J.S., 2015. Signal Transduction in Cancer. Cold Spring Harb. Perspect. 
Med. 5, a006098. 
  
220 
Sheldrick, G.M., 2008. A short history of SHELX. Acta Crystallogr. Sect. A 64, 112–122.  
Shimizu, H., Nihei, C., Inaoka, D.K., Mogi, T., Kita, K., Harada, S., 2008. Screening of 
detergents for solubilization, purification and crystallization of membrane proteins: a 
case study on succinate:ubiquinone oxidoreductase from Escherichia coli. Acta 
Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 64, 858–862.  
Shin, J.J.H., Loewen, C.J.R., 2011. Putting the pH into phosphatidic acid signaling. BMC 
Biol. 9, 85. 
Siess, W., 2002. Athero- and thrombogenic actions of lysophosphatidic acid and 
sphingosine-1-phosphate. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1582, 204–
215. 
Simon, J.-P., Morimoto, T., Bankaitis, V.A., Gottlieb, T.A., Ivanov, I.E., Adesnik, M., 
Sabatini, D.D., 1998. An essential role for the phosphatidylinositol transfer protein in 
the scission of coatomer-coated vesicles from the trans-Golgi network. Proc. Natl. 
Acad. Sci. U. S. A. 95, 11181–11186. 
Simons, K., Sampaio, J.L., 2011. Membrane Organization and Lipid Rafts. Cold Spring 
Harb. Perspect. Biol. 3, a004697.  
Śledź, P., Abell, C., Ciulli, A., 2012. Ligand-Observed NMR in Fragment-Based 
Approaches. In: NMR of Biomolecules. Wiley-VCH Verlag GmbH & Co. KGaA, pp. 
264-280. 
Smathers, R.L., Petersen, D.R., 2011. The human fatty acid-binding protein family: 
Evolutionary divergences and functions. Hum. Genomics 5, 170–191. 
Smyth, J.D., Wakelin, D., 1994. Introduction to animal parasitology. Cambridge 
University Press. 
Snoek, G., 2004. Phosphatidylinositol Transfer Proteins: Emerging Roles in Cell 
Proliferation, Cell Death and Survival. IUBMB Life 56, 467–475.  
Sorof, S., 1994. Modulation of mitogenesis by liver fatty acid binding protein. Cancer 
Metastasis Rev. 13, 317–336.  
Spiegel, S., Milstien, S., 2011. The outs and the ins of sphingosine-1-phosphate in 
immunity. Nat. Rev. Immunol. 11, 403–415. 
Spiegel, S., Milstien, S., 2003. Sphingosine-1-phosphate: an enigmatic signalling lipid. 
  
221 
Nat. Rev. Mol. Cell Biol. 4, 397–407. 
Sprangers, R., Kay, L.E., 2007. Quantitative dynamics and binding studies of the 20S 
proteasome by NMR. Nature 445, 618–622. 
Sreerama, N., Venyaminov, S.Y., Woody, R.W., 2000. Estimation of Protein Secondary 
Structure from Circular Dichroism Spectra: Inclusion of Denatured Proteins with 
Native Proteins in the Analysis. Anal. Biochem. 287, 243–251.  
Sreerama, N., Woody, R.W., 2000. Estimation of Protein Secondary Structure from 
Circular Dichroism Spectra: Comparison of CONTIN, SELCON, and CDSSTR 
Methods with an Expanded Reference Set. Anal. Biochem. 287, 252–260.  
Sreerama, N., Woody, R.W., 1993. A Self-Consistent Method for the Analysis of Protein 
Secondary Structure from Circular Dichroism. Anal. Biochem. 209, 32–44.  
Stace, C.L., Ktistakis, N.T., 2006. Phosphatidic acid- and phosphatidylserine-binding 
proteins. Biochim. Biophys. Acta 1761, 913–826. 
Stephenson, L.S., Latham, M.C., Ottensen, E.A., 2000. Malnutrition and parasitic helminth 
infections. Parasitology 121, S23–S38.  
Stracke, M.L., Krutzsch, H.C., Unsworth, E.J., Arestad, A., Cioce, V., Schiffmann, E., 
Liotta, L.A., 1992. Identification, purification, and partial sequence analysis of 
autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524–2529. 
Sud, M., Fahy, E., Cotter, D., Brown, A., Dennis, E.A., Glass, C.K., Merrill, A.H., 
Murphy, R.C., Raetz, C.R.H., Russell, D.W., Subramaniam, S., 2007. LMSD: LIPID 
MAPS structure database. Nucleic Acids Res. 35, D527–D532.  
Sugiki, T., Takeuchi, K., Yamaji, T., Takano, T., Tokunaga, Y., Kumagai, K., Hanada, K., 
Takahashi, H., Shimada, I., 2012. Structural Basis for the Golgi Association by the 
Pleckstrin Homology Domain of the Ceramide Trafficking Protein (CERT). J. Biol. 
Chem. 287, 33706–33718.  
Takahashi, H., Matuoka, S., Kato, S., Ohki, K., Hatta, I., 1991. Electrostatic interaction of 
poly(l-lysine) with dipalmitoylphosphatidic acid studied by X-ray diffraction. 
Biochim. Biophys. Acta - Biomembr. 1069, 229–234.  
Tanford, C., 1980. The Hydrophobic effect : formation of micelles and biological 
membranes. John Wiley & Sons. 
  
222 
Tang, Y.T., Gao, X., Rosa, B.A., Abubucker, S., Hallsworth-Pepin, K., Martin, J., Tyagi, 
R., Heizer, E., Zhang, X., Bhonagiri-Palsikar, V., Minx, P., Warren, W.C., Wang, Q., 
Zhan, B., Hotez, P.J., Sternberg, P.W., Dougall, A., Gaze, S.T., Mulvenna, J., Sotillo, 
J., Ranganathan, S., Rabelo, E.M., Wilson, R.K., Felgner, P.L., Bethony, J., Hawdon, 
J.M., Gasser, R.B., Loukas, A., Mitreva, M., 2014. Genome of the human hookworm 
Necator americanus. Nat. Genet. 46, 261–269. 
Taylor, G.L., 2010. Introduction to phasing. Acta Crystallogr. Sect. D Biol. Crystallogr. 
66, 325–338.  
Thompson, J., Winter, N., Terwey, D., Bratt, J., Banaszak, L., 1997. The Crystal Structure 
of the Liver Fatty Acid-binding Protein: A complex with two bound oleates. J. Biol. 
Chem. 272, 7140–7150.  
Tian, D., Litvak, V., Toledo-Rodriguez, M., Carmon, S., Lev, S., 2002. Nir2, a Novel 
Regulator of Cell Morphogenesis. Mol. Cell. Biol.  22, 2650–2662.  
Tigyi, G., Hong, L., Yakubu, M., Parfenova, H., Shibata, M., Leffler, C.W., 1995. 
Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am. J. Physiol. - 
Hear. Circ. Physiol. 268, H2048-H2055. 
Tilley, S.J., Skippen, A., Murray-Rust, J., Swigart, P.M., Stewart, A., Morgan, C.P., 
Cockcroft, S., McDonald, N.Q., 2007. Structure-Function Analysis of 
Phosphatidylinositol Transfer Protein Alpha Bound to Human Phosphatidylinositol. 
Structure 12, 317–326.  
Tomlinson, L.A., Christie, J.F., Fraser, E.M., McLaughlin, D., McIntosh, A.E., Kennedy, 
M.W., 1989. MHC restriction of the antibody repertoire to secretory antigens, and a 
major allergen, of the nematode parasite Ascaris. J. Immunol. 143, 2349–2356. 
Trivedi, D., Padinjat, R., 2007. RdgB proteins: Functions in lipid homeostasis and signal 
transduction. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1771, 692–699.  
Ulrich, E.L., Akutsu, H., Doreleijers, J.F., Harano, Y., Ioannidis, Y.E., Lin, J., Livny, M., 
Mading, S., Maziuk, D., Miller, Z., Nakatani, E., Schulte, C.F., Tolmie, D.E., Kent 
Wenger, R., Yao, H., Markley, J.L., 2008. BioMagResBank. Nucleic Acids Res. 36, 
D402–D408.  
Unione, L., Galante, S., Diaz, D., Canada, F.J., Jimenez-Barbero, J., 2014. NMR and 
molecular recognition. The application of ligand-based NMR methods to monitor 
  
223 
molecular interactions. Medchemcomm 5, 1280–1289. 
Vance, J.E., 2015. Phospholipid Synthesis and Transport in Mammalian Cells. Traffic 16, 
1–18.  
Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., Foukas, L.C., 2005. Signalling by 
PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194–204.  
Várnai, P., Rother, K.I., Balla, T., 1999. Phosphatidylinositol 3-Kinase-dependent 
Membrane Association of the Bruton’s Tyrosine Kinase Pleckstrin Homology 
Domain Visualized in Single Living Cells. J. Biol. Chem. 274, 10983–10989.  
Veerkamp, J.H., Zimmerman, A.W., 2001. Fatty acid-binding proteins of nervous tissue. J. 
Mol. Neurosci. 16, 133–142.  
Vihtelic, T.S., Goebl, M., Milligan, S., O, Tousa, J.E., Hyde, D.R., 1993. Localization of 
Drosophila retinal degeneration B, a membrane-associated phosphatidylinositol 
transfer protein. J. Cell Biol. 122, 1013–1022. 
Vordtriede, P.B., Doan, C.N., Tremblay, J.M., Helmkamp  George M., Yoder, M.D., 2005. 
Structure of PITPβ in Complex with Phosphatidylcholine: Comparison of Structure 
and Lipid Transfer to Other PITP Isoforms. Biochemistry 44, 14760–14771.  
Vranken, W.F., Boucher, W., Stevens, T.J., Fogh, R.H., Pajon, A., Llinas, M., Ulrich, E.L., 
Markley, J.L., Ionides, J., Laue, E.D., 2005. The CCPN data model for NMR 
spectroscopy: Development of a software pipeline. Proteins Struct. Funct. 
Bioinforma. 59, 687–696.  
Wallace, A.C., Laskowski, R.A., Thornton, J.M., 1995. LIGPLOT: A program to generate 
schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127–134. 
Wang, A.C., Lodi, P.J., Qin, J., Vuister, G.W., Gronenborn, A.M., Clore, G.M., 1994. An 
Efficient Triple-Resonance Experiment for Proton-Directed Sequential Backbone 
Assignment of Medium-Sized Proteins. J. Magn. Reson. Ser. B 105, 196–198.  
Wang, X., Devaiah, S.P., Zhang, W., Welti, R., 2006. Signaling functions of phosphatidic 
acid. Prog. Lipid Res. 45, 250–278. 
Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., 2009. Jalview Version 2 - A 
multiple sequence alignment editor and analysis workbench. Bioinformatics 25.  
Watton, S.J., Downward, J., 1999. Akt/PKB localisation and phosphoinositide generation 
  
224 
at sites of epithelial cell-matrix and cell-cell interaction. Curr. Biol. 9, 433–436.  
Whitmore, L., Wallace, B.A., 2004. DICHROWEB, an online server for protein secondary 
structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 32, 
W668–W673.  
Williams, R.L., 1999. Mammalian phosphoinositide-specific phospholipase C. Biochim. 
Biophys. Acta - Mol. Cell Biol. Lipids 1441, 255–267.  
Wimberly, B.T., Brodersen, D.E., Clemons, W.M., Morgan-Warren, R.J., Carter, A.P., 
Vonrhein, C., Hartsch, T., Ramakrishnan, V., 2000. Structure of the 30S ribosomal 
subunit. Nature 407, 327–339. 
Wimley, W.C., White, S.H., 1996. Experimentally determined hydrophobicity scale for 
proteins at membrane interfaces. Nat. Struct. Mol. Biol. 3, 842–848. 
Winter, G., 2010. xia2: an expert system for macromolecular crystallography data 
reduction. J. Appl. Crystallogr. 43, 186–190. 
Wolfrum, C., Borrmann, C.M., Börchers, T., Spener, F., 2001. Fatty acids and 
hypolipidemic drugs regulate peroxisome proliferator-activated receptors α- and γ-
mediated gene expression via liver fatty acid binding protein: A signaling path to the 
nucleus. Proc. Natl. Acad. Sci.  98, 2323–2328.  
Wymann, M.P., Pirola, L., 1998. Structure and function of phosphoinositide 3-kinases. 
Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1436, 127–150.  
Wymann, M.P., Schneiter, R., 2008. Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 
9, 162–176. 
Xie, Y., Ding, Y.-Q., Hong, Y., Feng, Z., Navarre, S., Xi, C.-X., Zhu, X.-J., Wang, C.-L., 
Ackerman, S.L., Kozlowski, D., Mei, L., Xiong, W.-C., 2005. Phosphatidylinositol 
transfer protein-α in netrin-1-induced PLC signalling and neurite outgrowth. Nat. Cell 
Biol. 7, 1124–1132. 
Yadav, S., Garner, K., Georgiev, P., Li, M., Gomez-Espinosa, E., Panda, A., Mathre, S., 
Okkenhaug, H., Cockcroft, S., Raghu, P., 2015. RDGBα, a PtdIns-PtdOH transfer 
protein, regulates G-protein-coupled PtdIns(4,5)P(2) signalling during Drosophila 
phototransduction. J. Cell Sci. 128, 3330–3344.  
  
  
225 
Yamazaki, T., Forman-Kay, J.D., Kay, L.E., 1993. Two-dimensional NMR experiments 
for correlating carbon-13.beta. and proton.delta./.epsilon. chemical shifts of aromatic 
residues in 13C-labeled proteins via scalar couplings. J. Am. Chem. Soc. 115, 11054–
11055.  
Yoder, M.D., Thomas, L.M., Tremblay, J.M., Oliver, R.L., Yarbrough, L.R., Helmkamp, 
G.M., 2001. Structure of a Multifunctional Protein: Mammalian Phosphatidylinositol 
Transfer Protein Complexed With Phosphatidylcholine. J. Biol. Chem. 276, 9246–
9252.  
Yoon, H.S., Hajduk, P.J., Petros, A.M., Olejniczak, E.T., Meadows, R.P., Fesik, S.W., 
1994. Solution structure of a pleckstrin-homology domain. Nature 369, 672–675. 
Young, B.P., Shin, J.J., Orij, R., Chao, J.T., Li, S.C., Guan, X.L., Khong, A., Jan, E., 
Wenk, M.R., Prinz, W.A., Smits, G.J., Loewen, C.J., 2010. Phosphatidic acid is a pH 
biosensor that links membrane biogenesis to metabolism. Science 329, 1085–1088. 
Yun, C.C., Kumar, A., 2015. Diverse roles of LPA signaling in the intestinal epithelium. 
Exp. Cell Res. 333, 201–207.  
Yung, Y.C., Stoddard, N.C., Chun, J., 2014. LPA receptor signaling: pharmacology, 
physiology, and pathophysiology. J. Lipid Res.  55, 1192–1214.  
Zhang, B., Yin, C., Li, H., Shi, L., Liu, N., Sun, Y., Lu, S., Liu, Y., Sun, L., Li, X., Chen, 
W., Qi, Y., 2013. Nir1 promotes invasion of breast cancer cells by binding to 
chemokine (C–C motif) ligand 18 through the PI3K/Akt/GSK3β/Snail signalling 
pathway. Eur. J. Cancer 49, 3900–3913.  
Zhang, G., Kazanietz, M.G., Blumberg, P.M., Hurley, J.H., 1995. Crystal structure of the 
Cys2 activator-binding domain of protein kinase Cδ in complex with phorbol ester. 
Cell 81, 917–924.  
Zhang, H., Neal, S., Wishart, D.S., 2003. RefDB: A database of uniformly referenced 
protein chemical shifts. J. Biomol. NMR 25, 173–195.  
Zhang, H., Wu, Q., Berezin, M.Y., 2015. Fluorescence anisotropy (polarization): from 
drug screening to precision medicine. Expert Opin. Drug Discov. 10, 1145–1161.  
Zhao, C., Du, G., Skowronek, K., Frohman, M.A., Bar-Sagi, D., 2007. Phospholipase D2-
generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat. 
Cell. Biol. 9, 706–712. 
  
226 
Zhao, H., Lappalainen, P., 2012. A simple guide to biochemical approaches for analyzing 
protein–lipid interactions. Mol. Biol. Cell 23, 2823–2830.  
Zhao, J., Wei, J., Weathington, N., Jacko, A.M., Huang, H., Tsung, A., Zhao, Y., 2015. 
Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic 
inflammation in a mouse model of peritoneal sepsis. Transl. Res. 166, 80–88.  
Zhao, Y., Natarajan, V., 2013. Lysophosphatidic acid (LPA) and its receptors: Role in 
airway inflammation and remodeling. Biochim. Biophys. Acta - Mol. Cell Biol. 
Lipids 1831, 86–92.  
Zhao, Y., Tong, J., He, D., Pendyala, S., Evgeny, B., Chun, J., Sperling, A.I., Natarajan, 
V., 2009. Role of lysophosphatidic acid receptor LPA2 in the development of allergic 
airway inflammation in a murine model of asthma. Respir. Res. 10, 114.  
Zheng, J., Chen, R.-H., Corblan-Garcia, S., Cahill, S.M., Bar-Sagi, D., Cowburn, D., 1997. 
The Solution Structure of the Pleckstrin Homology Domain of Human Sos1: A 
Possible Structural Role for the Sequential Association of Diffuse B Cell Lymphoma 
and Pleckstrin Homology Domains. J. Biol. Chem. 272, 30340–30344.  
Zheng, Y., Voice, J.K., Kong, Y., Goetzl, E.J., 2000. Altered expression and functional 
profile of lysophosphatidic acid receptors in mitogen-activated human blood T 
lymphocytes. FASEB J. 14, 2387–2389. 
Zimmerman, A.W., Veerkamp, J.H., 2002. New insights into the structure and function of 
fatty acid-binding proteins. Cell. Mol. Life Sci. C. 59, 1096–1116.  
Zoete, V., Grosdidier, A., Michielin, O., 2009. Docking, virtual high throughput screening 
and in silico fragment-based drug design. J. Cell. Mol. Med. 13, 238–248.  
Zuiderweg, E.R.P., Fesik, S.W., 1989. Heteronuclear three-dimensional NMR 
spectroscopy of the inflammatory protein C5a. Biochemistry 28, 2387–2391. 
 
  
  
227 
Appendix A: Primers used in the expression screening of 
the LNS2 domains of Nir2, Nir3 and RdgB 
Nir2 
Name Plasmid Sequence (5’-3’) 
LNS2-S F pOPINE-3C-HALO7 AGGAGATATACCATGGTCTATCCGGTG 
CGTATGGTCGTGC 
LNS2-S R pOPINE-3C-HALO7 CAGAACTTCCAGTTTTTCCAGCTGACCC 
AGGTGTGCCAC 
LNS2-L F pOPINE-3C-HALO7 AGGAGATATACCATGGTTAAAATCCGT 
AACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINE-3C-HALO7 CAGAACTTCCAGTTTTTCTTCGCTGTCC 
AGTTTCAGAGAAATGCTGC 
LNS2-S F pOPINEneo AGGAGATATACCATGGTCTATCCGGTG 
CGTATGGTCGTGC 
LNS2-S R pOPINEneo GTGATGGTGATGTTTTTCCAGCTGACCC 
AGGTGTGCCAC 
LNS2-L F pOPINEneo AGGAGATATACCATGGTTAAAATCCGTA 
ACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINEneo GTGATGGTGATGTTTTTCTTCGCTGTCCA 
GTTTCAGAGAAATGCTGC 
LNS2-S F pOPINF AAGTTCTGTTTCAGGGCCCGGTCTATCCG 
GTGCGTATGGTCGTGC 
LNS2-S R pOPINF ATGGTCTAGAAAGCTTTATTCCAGCTGAC 
CCAGGTGTGCCAC 
LNS2-L F pOPINF AAGTTCTGTTTCAGGGCCCGGTTAAAATC 
CGTAACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINF ATGGTCTAGAAAGCTTTATTCTTCGCTGTC 
CAGTTTCAGAGAAATGCTGC 
LNS2-S F pOPINHALO7 AAGTTCTGTTTCAGGGCCCGGTCTATCCGG 
TGCGTATGGTCGTGC 
LNS2-S R pOPINHALO7 ATGGTCTAGAAAGCTTTATTCCAGCTGACC 
CAGGTGTGCCAC 
LNS2-L F pOPINHALO7 AAGTTCTGTTTCAGGGCCCGGTCTATCCGG 
TGCGTATGGTCGTGC 
LNS2-L R pOPINHALO7 ATGGTCTAGAAAGCTTTATTCCAGCTGACC 
CAGGTGTGCCAC 
LNS2-S F pOPINJ AAGTTCTGTTTCAGGGCCCGGTCTATCCGG 
TGCGTATGGTCGTGC 
LNS2-S R pOPINJ ATGGTCTAGAAAGCTTTATTCCAGCTGACC 
CAGGTGTGCCAC 
LNS2-L F pOPINJ AAGTTCTGTTTCAGGGCCCGGTTAAAATCC 
GTAACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINJ ATGGTCTAGAAAGCTTTATTCTTCGCTGTC 
CAGTTTCAGAGAAATGCTGC 
LNS2-S F pOPINM AAGTTCTGTTTCAGGGCCCGGTCTATCCGG 
TGCGTATGGTCGTGC 
LNS2-S R pOPINM ATGGTCTAGAAAGCTTTATTCCAGCTGACC 
CAGGTGTGCCAC 
LNS2-L F pOPINM AAGTTCTGTTTCAGGGCCCGGTTAAAATCC 
GTAACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINM ATGGTCTAGAAAGCTTTATTCTTCGCTGTCC 
AGTTTCAGAGAAATGCTGC 
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LNS2-S F pOPINNUSA AAGTTCTGTTTCAGGGCCCGGTCTATCCGG 
TGCGTATGGTCGTGC 
LNS2-S R pOPINNUSA ATGGTCTAGAAAGCTTTATTCCAGCTGACC 
CAGGTGTGCCAC 
LNS2-L F pOPINNUSA AAGTTCTGTTTCAGGGCCCGGTTAAAATCC 
GTAACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINNUSA ATGGTCTAGAAAGCTTTATTCTTCGCTGTCC 
AGTTTCAGAGAAATGCTGC 
LNS2-S F pOPINS3C AAGTTCTGTTTCAGGGCCCGGTCTATCCGGT 
GCGTATGGTCGTGC 
LNS2-S R pOPINS3C ATGGTCTAGAAAGCTTTATTCCAGCTGACCC 
AGGTGTGCCAC 
LNS2-L F pOPINS3C AAGTTCTGTTTCAGGGCCCGGTTAAAATCCG 
TAACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINS3C ATGGTCTAGAAAGCTTTATTCTTCGCTGTCCA 
GTTTCAGAGAAATGCTGC 
LNS2-S F pOPINTF AAGTTCTGTTTCAGGGCCCGGTCTATCCGGTG 
CGTATGGTCGTGC 
LNS2-S R pOPINTF ATGGTCTAGAAAGCTTTATTCCAGCTGACCCA 
GGTGTGCCAC 
LNS2-L F pOPINTF AAGTTCTGTTTCAGGGCCCGGTTAAAATCCGT 
AACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINTF ATGGTCTAGAAAGCTTTATTCTTCGCTGTCCA 
GTTTCAGAGAAATGCTGC 
LNS2-S F pOPINTRX AAGTTCTGTTTCAGGGCCCGGTCTATCCGGTG 
CGTATGGTCGTGC 
LNS2-S R pOPINTRX ATGGTCTAGAAAGCTTTATTCCAGCTGACCCA 
GGTGTGCCAC 
LNS2-L F pOPINTRX AAGTTCTGTTTCAGGGCCCGGTTAAAATCCGT 
AACGTCACCAGCAATCATCGCG 
LNS2-L R pOPINTRX ATGGTCTAGAAAGCTTTATTCTTCGCTGTCCA 
GTTTCAGAGAAATGCTGC 
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Nir3 
Name Plasmid Sequence 
LNS2-S F pOPINEneo AGGAGATATACCATGACCCTGGTCACGAAC 
AATAGCGGC 
LNS2-S R pOPINEneo GTGATGGTGATGTTTCGCACGGTGACTGTAT 
TTCAGCTGC 
LNS2-S F pOPINF AAGTTCTGTTTCAGGGCCCGACCCTGGTCAC 
GAACAATAGCGGC 
LNS2-S R pOPINF ATGGTCTAGAAAGCTTTACGCACGGTGACTG 
TATTTCAGCTGC 
LNS2-S F pOPINHALO7 AGGAGATATACCATGGTCTATCCGGTG 
CGTATGGTCGTGC 
LNS2-S R pOPINHALO7 GTGATGGTGATGTTTTTCCAGCTGACCC 
AGGTGTGCCAC 
LNS2-S F pOPINJ AAGTTCTGTTTCAGGGCCCGACCCTGGT 
CACGAACAATAGCGGC 
LNS2-F R pOPINJ ATGGTCTAGAAAGCTTTACGCACGGTGA 
CTGTATTTCAGCTGC 
LNS2-S F pOPINM AAGTTCTGTTTCAGGGCCCGACCCTGGTCAC 
GAACAATAGCGGC 
LNS2-S R pOPINM ATGGTCTAGAAAGCTTTACGCACGGTGACTG 
TATTTCAGCTGC 
LNS2-L F pOPINS3C AAGTTCTGTTTCAGGGCCCGACCCTGGTCAC 
GAACAATAGCGGC 
LNS2-L R pOPINS3C ATGGTCTAGAAAGCTTTACGCACGGTGACTG 
TATTTCAGCTGC 
LNS2-S F pOPINTRX AAGTTCTGTTTCAGGGCCCGACCCTGGTCAC 
GAACAATAGCGGC 
LNS2-S R pOPINTRX ATGGTCTAGAAAGCTTTACGCACGGTGACTG 
TATTTCAGCTGC 
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RdgB 
Name Plasmid Sequence 
LNS2-S F pOPINE-3C-HALO7 AGGAGATATACCATGGACTGCTACATG 
GCCGTTGTCCCGC 
LNS2-L F pOPINE-3C-HALO7 AGGAGATATACCATGGGTCAATGGACG 
TTCCTGAGTACCG 
LNS2-L R pOPINE-3C-HALO7 CAGAACTTCCAGTTTATTTTCGTTCGTG 
GCCTGTTCGTGC 
LNS2-S F pOPINEneo AGGAGATATACCATGGACTGCTACATG 
GCCGTTGTCCCGC 
LNS2-S R pOPINEneo GTGATGGTGATGTTTACCATCGCTCAG 
CACCGTCGC 
LNS2-L F pOPINEneo AGGAGATATACCATGGGTCAATGGAC 
GTTCCTGAGTACCG 
LNS2-L R pOPINEneo GTGATGGTGATGTTTATTTTCGTTCGT 
GGCCTGTTCGTGC 
LNS2-S F pOPINF AAGTTCTGTTTCAGGGCCCGGACTGC 
TACATGGCCGTTGTCCCGC 
LNS2-S R pOPINF ATGGTCTAGAAAGCTTTAACCATCGC 
TCAGCACCGTCGC 
LNS2-L F pOPINF AAGTTCTGTTTCAGGGCCCGGGTCAA 
TGGACGTTCCTGAGTACCG 
LNS2-L R pOPINF ATGGTCTAGAAAGCTTTAATTTTCGTT 
CGTGGCCTGTTCGTGC 
LNS2-S F pOPINHALO7 AAGTTCTGTTTCAGGGCCCGGACTGCT 
ACATGGCCGTTGTCCCGC 
LNS2-S R pOPINHALO7 ATGGTCTAGAAAGCTTTAACCATCGCT 
CAGCACCGTCGC 
LNS2-L F pOPINHALO7 AAGTTCTGTTTCAGGGCCCGGGTCAAT 
GGACGTTCCTGAGTACCG 
LNS2-L R pOPINHALO7 ATGGTCTAGAAAGCTTTAATTTTCGTTC 
GTGGCCTGTTCGTGC 
LNS2-S F pOPINJ AAGTTCTGTTTCAGGGCCCGGGTCAATG 
GACGTTCCTGAGTACCG 
LNS2-S R pOPINJ ATGGTCTAGAAAGCTTTAATTTTCGTTCG 
TGGCCTGTTCGTGC 
LNS2-L F pOPINJ AAGTTCTGTTTCAGGGCCCGGGTCAATGG 
ACGTTCCTGAGTACCG 
LNS2-L R pOPINJ ATGGTCTAGAAAGCTTTAATTTTCGTTCGT 
GGCCTGTTCGTGC 
LNS2-S F pOPINM AAGTTCTGTTTCAGGGCCCGGACTGCTACA 
TGGCCGTTGTCCCGC 
LNS2-S R pOPINM ATGGTCTAGAAAGCTTTAACCATCGCTCAG 
CACCGTCGC 
LNS2-L F pOPINM AAGTTCTGTTTCAGGGCCCGGGTCAATGGA 
CGTTCCTGAGTACCG 
LNS2-L R pOPINM ATGGTCTAGAAAGCTTTAATTTTCGTTCGTG 
GCCTGTTCGTGC 
LNS2-S F pOPINNUSA AAGTTCTGTTTCAGGGCCCGGACTGCTACA 
TGGCCGTTGTCCCGC 
LNS2-S R pOPINNUSA ATGGTCTAGAAAGCTTTAACCATCGCTCAG 
CACCGTCGC 
LNS2-L F pOPINNUSA AAGTTCTGTTTCAGGGCCCGGGTCAATGGA 
CGTTCCTGAGTACCG 
LNS2-L R pOPINNUSA ATGGTCTAGAAAGCTTTAATTTTCGTTCGTG 
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GCCTGTTCGTGC 
LNS2-S F pOPINS3C AAGTTCTGTTTCAGGGCCCGGACTGCTACAT 
GGCCGTTGTCCCGC 
LNS2-S R pOPINS3C ATGGTCTAGAAAGCTTTAACCATCGCTCAGC 
ACCGTCGC 
LNS2-L F pOPINS3C AAGTTCTGTTTCAGGGCCCGGGTCAATGGAC 
GTTCCTGAGTACCG 
LNS2-L R pOPINS3C ATGGTCTAGAAAGCTTTAATTTTCGTTCGTGG 
CCTGTTCGTGC 
LNS2-S F pOPINTF AAGTTCTGTTTCAGGGCCCGGACTGCTACATG 
GCCGTTGTCCCGC 
LNS2-S R pOPINTF ATGGTCTAGAAAGCTTTAACCATCGCTCAGCA 
CCGTCGC 
LNS2-L F pOPINTF AAGTTCTGTTTCAGGGCCCGGGTCAATGGAC 
GTTCCTGAGTACCG 
LNS2-L R pOPINTF ATGGTCTAGAAAGCTTTAATTTTCGTTCGTGG 
CCTGTTCGTGC 
LNS2-S F pOPINTRX AAGTTCTGTTTCAGGGCCCGGACTGCTACATG 
GCCGTTGTCCCGC 
LNS2-S R pOPINTRX ATGGTCTAGAAAGCTTTAACCATCGCTCAGCA 
CCGTCGC 
LNS2-L F pOPINTRX AAGTTCTGTTTCAGGGCCCGGGTCAATGGACG 
TTCCTGAGTACCG 
LNS2-L R pOPINTRX ATGGTCTAGAAAGCTTTAATTTTCGTTCGTGGC 
CTGTTCGTGC 
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Appendix B: Na-FAR-1-PA complex chemical shift table
 
-13 G
-12 S
-11 S
-10 H
-9 H
-8 H
-7 H
-6 H
-5 H
-4 S
-2 G
-1 H
0 M
1 F 4.54 2.93
2.94
7.11 57.81 40.79 131.98 H e * 7.10,
C e * 131.38
2 K 4.46 1.64
1.84
1.30
1.33
1.63
1.63
176.19 54.46 34.90 24.32 28.92 H e a 2.90,
H e b 2.91,
C e  41.78
3 Y 8.86 123.81 3.86 2.90
2.82
6.85 176.31 61.72 38.74 133.52 H e * 6.60,
C e * 118.99
4 E 9.01 113.67 3.67 1.86
2.09
2.36
2.20
175.98 58.82 28.57 37.55
5 D 7.76 118.19 4.39 2.64
2.73
177.38 55.58 41.24
6 I 7.61 121.73 3.97 1.66 0.91
1.86
0.95
0.82 177.35 59.85 38.25 28.21
17.64
13.76
7 P
8 A 3.74 1.44 178.14 56.21 18.73
9 D 8.86 112.76 4.29 2.55
2.38
177.84 56.05 39.12
10 Y 7.55 116.27 4.13 6.85 177.97 60.20 38.63 132.88 H e * 6.60,
C e * 118.29
11 R 7.99 119.30 3.80 1.81
2.02
1.59
1.60
3.34
3.15
178.65 60.55 30.62 28.07 43.76
12 D 8.10 115.93 4.44 2.63
2.56
176.74 56.37 40.65
13 L 7.31 116.62 4.31 2.03
1.55
1.80 0.82
0.81
177.69 54.92 43.70 26.50 22.83
14 M 7.36 117.57 3.88 2.01
1.73
15 P
16 P 4.01 2.33
1.94
2.02
2.18
3.84
3.79
178.17 65.82 31.88 27.72 50.77
17 E 10.20 116.77 4.05 1.85 180.12 60.39 29.41 37.25
18 A 7.41 119.58 4.16 1.36 177.75 54.27 19.24
19 R 7.66 118.51 3.80 1.82
1.82
1.47
1.22
3.18
3.23
177.61 60.56 30.46 28.50 43.63
20 D 8.35 116.66 4.09 2.63
2.49
177.94 57.29 41.60
21 F 7.13 116.78 4.14 3.33
3.04
6.99 176.68 60.19 39.78 132.29 H e * 7.01,
C e * 131.11
22 L 7.90 115.39 3.69 1.25
1.71
0.85
0.86
178.67 57.11 43.11 25.83 25.80
23 Q 8.36 117.09 3.41 1.93
1.93
176.60 58.50 28.76 34.07 N e 2 112.40,
H e 2a  6.88,
H e 2b  7.47
24 N 4.68 2.58
2.81
7.65
6.87
174.32 53.15 39.81 N d 2 116.09
25 L 6.61 121.65 4.23 1.43
1.52
1.58 0.49
0.49
176.59 55.56 42.39 25.22 25.29
25.29
26 S 9.35 124.98 4.70 3.99
4.34
175.42 56.70 66.66
27 D
28 G 3.84
3.84
176.43 47.09
29 D 7.95 123.45 4.33 2.44
3.03
178.30 57.22 41.84
30 K 7.94 118.39 3.78 2.03
1.85
1.66 178.30 60.92 32.35 25.60 29.76 H e a 2.68,
H e b 2.80,
C e  41.35
31 T 7.95 115.93 3.87 4.39 1.25 176.14 67.20 68.72 21.98
32 V 7.85 122.49 3.71 2.21 1.08
0.87
177.81 66.89 31.43 22.32
23.27
33 L 8.20 118.97 3.82 1.29
2.07
2.05 0.89
0.89
178.51 58.86 41.76 26.34 24.13
34 K 7.98 117.90 3.91 1.97
1.97
1.30
1.30
1.75
1.75
178.30 60.64 32.68 25.96 29.70 H e a 2.88,
H e b 2.95,
C e  41.96
35 E 8.43 119.05 3.94 2.04
2.25
2.53
2.53
180.49 59.74 29.69 36.72
36 V 8.64 119.52 3.72 2.16 0.84
1.02
180.16 66.72 31.58 23.98
37 F 8.68 122.48 4.31 3.22
3.29
7.06 179.20 62.85 39.29 132.02 H e * 7.15,
C e * 132.51
38 K 8.80 119.87 4.05 1.81
2.00
1.70
1.61
1.44
1.42
176.26 59.03 32.35 25.67 29.03 H e a 2.77,
H e b 2.99,
C e  41.91
39 A 7.27 119.94 4.08 1.50 176.87 51.94 18.73
40 G 7.15 104.20 3.83
3.83
43.80
41 P
42 Y
42 Y 4.61 3.16
2.59
7.09 56.80 40.70 133.23 H e * 6.65,
C e * 117.41
43 K 3.89 1.77
1.65
1.41 1.52 176.37 59.04 33.66 25.19 29.33 H e a 2.94,
H e b 3.01,
C e  41.94
44 N 7.32 108.45 4.69 3.21
3.29
7.05
6.69
175.94 51.61 39.56 N d 2 110.84
45 T 3.89 3.81 0.83 65.94 68.23 22.69
45 T
46 E 3.65 2.06
1.88
2.21
2.38
179.29 61.53 28.28 37.71
47 E 8.48 120.90 4.06 2.23
2.09
2.35
2.50
179.05 59.53 30.17 37.47
48 S 7.54 117.76 3.94 3.50
3.41
61.31 62.73
49 I 7.78 123.25 3.38 1.72 0.43
0.59
0.76
0.43 177.57 65.43 37.44 17.48
30.11
13.78
50 A 7.95 123.50 3.91 1.41 180.56 55.31 17.68
51 A 7.62 121.19 3.99 1.30 180.70 55.03 18.04
52 L 7.81 120.13 3.96 1.49
2.05
1.44 0.92
0.92
177.69 57.95 41.90 27.01 24.36
24.35
53 K 8.60 117.79 3.76 1.75
1.85
1.25
1.56
1.54
1.54
177.62 59.74 32.82 27.26 30.04 H e a 2.62,
H e b 2.69,
C e  41.87
54 K 7.28 115.39 3.96 1.85 1.56
1.42
1.66
1.75
1.66
1.68
178.02 58.62 32.66 25.38 29.43 H e 2 2.95,
H e 3 2.95,
C e  42.18
55 K 7.08 116.88 4.24 1.75
1.74
1.45
1.45
1.64
1.64
177.40 57.28 33.94 25.35 28.91 H e 2 2.94,
H e 3 2.94,
C e  42.06
56 S 8.52 111.31 4.83 3.68
3.76
177.41 54.68 62.86
57 P 4.34 2.40
1.97
2.15
2.15
3.96
3.49
179.82 66.19 32.29 27.24 50.25
58 E 8.77 118.17 4.08 1.95
2.03
2.28
2.28
179.12 59.96 29.37 36.84
59 L 7.70 121.75 4.19 1.71
1.71
1.62 0.93
0.97
179.78 57.74 41.89 27.26 25.88
23.67
60 G 8.94 104.15 3.36
3.55
174.30 47.65
61 A 8.02 122.86 4.22 1.53 180.58 55.14 18.32
62 K 7.57 117.89 4.06 2.20
1.89
1.38
1.65
179.76 60.02 33.51 26.22 30.63 H e 2 2.93,
H e 3 2.93,
C e  42.06
63 V 8.14 118.97 3.28 1.99 0.75
0.87
177.11 66.87 31.23 24.16
22.06
64 E 8.59 121.45 3.94 2.23
2.09
2.24
2.24
178.63 60.32 30.16 36.59
65 K 7.58 118.59 4.13 1.92
1.93
1.47
1.61
1.70
1.70
179.58 59.40 32.34 25.35 29.19 H e 2 2.95,
H e 3 2.95,
C e  42.19
66 L 7.61 120.45 4.01 1.75
1.28
1.63 0.33
0.59
178.11 58.09 41.97 26.74 23.25
25.01
67 H 8.73 119.93 4.05 2.92
3.26
176.58 60.63 31.38
68 A 8.23 120.45 3.81 1.50 180.70 55.25 17.85
69 M 7.89 119.07 4.06 2.00
2.00
2.77
2.25
178.73 58.88 32.36 31.24 H e * 1.86
70 V 8.13 119.84 3.33 1.91 0.40
0.58
67.36 31.06 21.96
23.08
71 K 8.37 119.18
72 S 8.06 115.61 4.16 3.93
3.93
176.63 61.74 62.86
73 K 7.63 123.95 3.89 1.06
1.71
1.66
1.74
178.39 60.01 34.94 25.18 29.42 H e a 2.90,
H e b 3.08,
C e  41.56
74 I 8.13 117.12 3.80 1.91 2.24
1.06
0.98
0.87 178.36 65.36 38.14 17.38
30.10
14.20
75 A 7.69 118.27 4.06 1.45 178.20 54.21 18.31
76 A 7.16 118.41 4.30 1.39 178.15 52.10 19.18
77 L 7.44 120.27 4.37 2.15
1.74
1.22 1.06 177.96 55.32 43.25 26.85 23.52
25.49
78 G 10.53 112.53 3.86
4.32
178.02 44.35
79 P 4.15 2.36
1.96
2.17
2.04
3.71
3.71
179.84 66.35 32.14 27.64 48.94
80 E 8.31 120.30 4.06 2.02 2.13
2.23
179.33 59.75 29.68 35.98
81 A 9.68 124.26 4.61 1.94 179.55 55.19 19.68
82 K 9.33 120.51 3.97 1.93
1.73
1.54
1.43
178.70 60.33 32.52 25.56 29.74 H e a 2.99,
H e b 3.06,
C e  42.09
83 G 8.02 106.28 3.95
3.64
176.52 47.12
84 F 7.60 123.52 4.37 3.28
3.43
6.83 177.62 60.36 39.78 131.89 H e * 6.83
85 A 8.66 125.17 3.34 1.44 179.10 55.48 17.78
86 E 8.87 116.14 3.87 2.19
2.01
2.56
2.56
180.30 60.07 29.48 36.89
87 K 8.21 120.77 4.05 1.84
1.91
1.50
1.42
1.70
1.70
179.73 59.22 32.52 25.38 28.99 H e 2 2.92,
H e 3 2.92,
C e  41.89
88 S 7.98 117.63 3.93 175.89 63.65 62.53
89 I 8.39 122.88 3.51 1.92 0.89
0.89
1.79
0.78 177.65 65.64 37.76 17.47
30.52
13.52
90 E 7.84 120.79 4.04 2.02
2.18
2.35
2.35
179.99 59.70 29.25 35.74
91 I 7.79 122.06 3.73 2.04 0.90
1.66
1.66
0.80 179.49 65.45 37.77 17.55
30.22
13.98
92 A 8.00 123.16 3.95 1.48 179.02 55.59 18.45
93 R 9.07 118.52 3.80 179.50 60.62 30.40 25.64 41.29
94 G 8.05 107.30 3.97
3.97
176.41 47.08
95 I 7.53 122.70 3.83 2.20 1.39
1.65
0.95
0.80 177.76 63.57 36.84 27.86
18.16
11.56
96 K 8.17 120.28 3.76 1.86 1.47
1.47
1.67
1.73
177.41 60.56 32.58 25.87 29.74 H e 2 2.68,
H e 3 2.68,
C e  41.81
97 A 8.11 118.05 4.27 181.28 55.20 18.14
98 R 7.71 116.95 4.07 1.70
1.70
3.23
3.05
178.97 59.11 29.94 27.84 43.78
99 Y 7.94 118.52 3.98 3.02
2.89
6.79 177.73 62.75 38.03 132.27 H e * 6.81,
C e * 118.66
100 Y 7.73 116.41 3.24
2.86
7.14 176.77 60.02 38.14 133.28 H e * 6.54,
C e * 117.59
101 T 7.59 108.97 4.52 4.48 1.31 174.94 61.95 70.66 21.65
102 G 7.93 108.47
102 G 3.84
4.13
173.53 45.62
103 N 7.85 120.33 4.91 2.47
2.64
6.82
7.40
173.88 51.71 38.92 38.69 N d 2 112.47
104 E 8.43 122.49 3.83 1.87
1.87
2.22
2.22
174.04 55.74 28.74 36.48
105 P
106 T 8.88 113.00 60.11
106 T 4.54 4.66 1.30 176.06 59.99 72.18 21.82
107 K 9.03 120.60 3.93 1.90 1.40
1.33
1.72
1.68
178.49 60.50 31.99 25.48 29.56 H e 2 2.95,
H e 3 2.95,
C e  41.81
108 D 7.95 117.36 4.35 2.46
2.60
179.06 57.76 40.41
109 D 7.80 122.23 4.42 2.56
3.05
179.54 57.58 40.93
110 L 8.10 121.05 3.79 1.53
1.76
1.75 0.87
0.72
179.16 58.04 41.09 26.94 25.60
23.59
111 K 26.00
112 A 7.97 120.28 181.10 55.41 18.05
113 S 7.93 116.21 4.33 3.73
3.98
181.12 63.19 63.18
114 V 8.11 121.74 3.49 2.31 0.91
1.07
177.50 67.26 31.32 23.88
115 K 8.43 119.64 3.77 2.00 1.52
1.54
1.59
1.62
178.58 60.83 32.29 25.91 29.74 H e 2 2.79,
H e 3 2.79,
H e a 2.73,
H e b 2.80,
C e  41.78
116 E 7.69 118.47 4.04 2.20
2.24
2.37
2.22
178.99 59.60 29.41 35.74
117 V 7.74 120.05 3.58 2.18 1.08
0.88
177.88 67.27 31.85 23.33
118 L 8.53 119.26 4.06 1.51 1.83 0.73
0.73
179.15 58.17 41.55 26.95 22.67
22.67
119 K 8.44 119.53 3.77 1.86
2.00
1.20
1.20
178.27 60.93 32.48 26.96 30.29 H e a 2.72,
H e b 2.80,
C e  42.01
120 L 3.97 1.62
2.33
1.95 0.87
0.87
179.07 57.61 42.07 26.51 22.76
22.76
121 Y 8.26 120.88 2.77 2.58
2.30
6.06 177.35 61.48 37.32 133.36 H e * 6.47,
C e * 116.70
122 K 8.22 115.92 3.42 1.82
1.82
1.82
1.99
1.65
1.51
1.51
1.52
1.66
1.66
177.66 58.96 32.36 25.74 29.44 H e 2 2.94,
H e 3 2.94,
C e  41.95
123 A 7.18 117.92 4.08 1.38 178.12 52.41 19.07
124 M 7.08 117.75 4.15 2.03
1.71
2.45
2.45
176.91 57.71 37.48 32.06
125 S 9.61 117.87 4.26 174.93 58.53 64.74
126 D 8.86 121.35 4.19 2.63
2.63
179.16 58.04 39.60
127 A 8.25 122.82 4.17 1.44 180.99 55.24 18.27
128 G 8.11 111.69 4.03
3.64
176.08 47.29
129 K 8.30 121.31 3.76 1.77 1.68
1.17
1.62
1.71
180.26 60.95 33.06 27.02 29.59 H e 2 2.69,
H e 3 2.69,
C e  42.44
130 A 8.25 123.17 4.14 1.48 180.09 54.92 17.94
131 D 7.98 120.01 4.41 2.91
3.04
177.86 57.48 42.70
132 F 8.58 117.17 4.23 3.16
3.28
7.37 177.72 62.76 39.97 131.74 H e * 6.93,
C e * 131.02
133 G 8.51 104.18 3.60
3.78
174.41 46.51
134 K 7.55 119.59 4.06 2.01 1.43
1.43
1.73
1.67
178.54 58.67 32.51 25.30 29.08 H e 2 2.96,
H e 3 2.96,
C e  41.87
135 Q 6.74 113.07 4.17 1.57
1.65
2.42
2.43
174.67 55.25 29.83 32.45 N e 2 112.75,
H e 2a  6.66,
H e 2b  7.57
136 F 8.20 115.59 4.61 2.68
2.57
171.41 55.14 39.26 H e * 6.93,
C e * 132.50
137 P 4.34 2.33
1.86
1.95
1.95
3.62
2.86
65.63 31.68 27.43 50.15
138 F
139 L 3.38 1.97
0.97
1.97 0.73
0.73
178.60 57.70 41.54 26.97 22.74
22.74
140 A 8.93 119.02 3.86 1.60 178.94 56.15 19.09
141 K 7.32 117.23 3.89 1.73
1.68
1.73
1.79
1.38
1.38
1.66
1.66
180.17 58.96 33.57 24.80 28.95 H e 2 2.95,
H e 3 2.95,
C e  41.82
142 V 3.60 2.23 1.16
1.11
67.44 31.66 22.38
23.74
143 F 4.21 2.80
3.44
7.22 61.74 37.27 133.20 H e * 7.21,
C e * 131.39
144 E
145 S 4.36 4.09
3.99
59.86 64.27
146 G
147 K 4.02 1.81
1.68
1.62
1.43
1.68
1.68
178.79 59.13 32.45 25.27 29.06 H e 2 2.96,
H e 3 2.96,
C e  41.88
148 A 7.73 120.87 3.96 1.38 178.28 55.37 18.45
149 A 7.63 119.73 3.91 1.45 180.10 55.02 18.02
150 K 7.92 118.29 4.06 1.71
1.87
1.46
1.41
1.65
1.65
179.31 58.72 32.30 25.07 29.14 H e 2 2.94,
H e 3 2.94,
C e  42.12
151 F 7.86 120.03 4.25 3.07
3.20
7.14 176.24 60.47 39.54 131.44
152 A 7.96 117.76 3.94 1.41 177.34 53.20 19.31
153 G 7.58 104.45 3.85
3.96
174.26 45.31
154 E 8.00 120.34 4.29 1.79
2.03
2.15
2.23
175.37 56.28 30.80 36.30
155 N 7.97 124.78 4.38 2.68
2.57
6.72
7.40
179.42 54.87 40.53 N d 2 112.61
H N aH bH gH dH C aC bC gC dC
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-13 G
-12 S
-11 S
-10 H
-9 H
-8 H
-7 H
-6 H
-5 H
-4 S
-2 G
-1 H
0 M
1 F 4.54 2.93
2.94
7.11 57.81 40.79 131.98 H e * 7.10,
C e * 131.38
2 K 4.46 1.64
1.84
1.30
1.33
1.63
1.63
176.19 54.46 34.90 24.32 28.92 H e a 2.90,
H e b 2.91,
C e  41.78
3 Y 8.86 123.81 3.86 2.90
2.82
6.85 176.31 61.72 38.74 133.52 H e * 6.60,
C e * 118.99
4 E 9.01 113.67 3.67 1.86
2.09
2.36
2.20
175.98 58.82 28.57 37.55
5 D 7.76 118.19 4.39 2.64
2.73
177.38 55.58 41.24
6 I 7.61 121.73 3.97 1.66 0.91
1.86
0.95
0.82 177.35 59.85 38.25 28.21
17.64
13.76
7 P
8 A 3.74 1.44 178.14 56.21 18.73
9 D 8.86 112.76 4.29 2.55
2.38
177.84 56.05 39.12
10 Y 7.55 116.27 4.13 6.85 177.97 60.20 38.63 132.88 H e * 6.60,
C e * 118.29
11 R 7.99 119.30 3.80 1.81
2.02
1.59
1.60
3.34
3.15
178.65 60.55 30.62 28.07 43.76
12 D 8.10 115.93 4.44 2.63
2.56
176.74 56.37 40.65
13 L 7.31 116.62 4.31 2.03
1.55
1.80 0.82
0.81
177.69 54.92 43.70 26.50 22.83
14 M 7.36 117.57 3.88 2.01
1.73
15 P
16 P 4.01 2.33
1.94
2.02
2.18
3.84
3.79
178.17 65.82 31.88 27.72 50.77
17 E 10.20 116.77 4.05 1.85 180.12 60.39 29.41 37.25
18 A 7.41 119.58 4.16 1.36 177.75 54.27 19.24
19 R 7.66 118.51 3.80 1.82
1.82
1.47
1.22
3.18
3.23
177.61 60.56 30.46 28.50 43.63
20 D 8.35 116.66 4.09 2.63
2.49
177.94 57.29 41.60
21 F 7.13 116.78 4.14 3.33
3.04
6.99 176.68 60.19 39.78 132.29 H e * 7.01,
C e * 131.11
22 L 7.90 115.39 3.69 1.25
1.71
0.85
0.86
178.67 57.11 43.11 25.83 25.80
23 Q 8.36 117.09 3.41 1.93
1.93
176.60 58.50 28.76 34.07 N e 2 112.40,
H e 2a  6.88,
H e 2b  7.47
24 N 4.68 2.58
2.81
7.65
6.87
174.32 53.15 39.81 N d 2 116.09
25 L 6.61 121.65 4.23 1.43
1.52
1.58 0.49
0.49
176.59 55.56 42.39 25.22 25.29
25.29
26 S 9.35 124.98 4.70 3.99
4.34
175.42 56.70 66.66
27 D
28 G 3.84
3.84
176.43 47.09
29 D 7.95 123.45 4.33 2.44
3.03
178.30 57.22 41.84
30 K 7.94 118.39 3.78 2.03
1.85
1.66 178.30 60.92 32.35 25.60 29.76 H e a 2.68,
H e b 2.80,
C e  41.35
31 T 7.95 115.93 3.87 4.39 1.25 176.14 67.20 68.72 21.98
32 V 7.85 122.49 3.71 2.21 1.08
0.87
177.81 66.89 31.43 22.32
23.27
33 L 8.20 118.97 3.82 1.29
2.07
2.05 0.89
0.89
178.51 58.86 41.76 26.34 24.13
34 K 7.98 117.90 3.91 1.97
1.97
1.30
1.30
1.75
1.75
178.30 60.64 32.68 25.96 29.70 H e a 2.88,
H e b 2.95,
C e  41.96
35 E 8.43 119.05 3.94 2.04
2.25
2.53
2.53
180.49 59.74 29.69 36.72
36 V 8.64 119.52 3.72 2.16 0.84
1.02
180.16 66.72 31.58 23.98
37 F 8.68 122.48 4.31 3.22
3.29
7.06 179.20 62.85 39.29 132.02 H e * 7.15,
C e * 132.51
38 K 8.80 119.87 4.05 1.81
2.00
1.70
1.61
1.44
1.42
176.26 59.03 32.35 25.67 29.03 H e a 2.77,
H e b 2.99,
C e  41.91
39 A 7.27 119.94 4.08 1.50 176.87 51.94 18.73
40 G 7.15 104.20 3.83
3.83
43.80
41 P
42 Y
42 Y 4.61 3.16
2.59
7.09 56.80 40.70 133.23 H e * 6.65,
C e * 117.41
43 K 3.89 1.77
1.65
1.41 1.52 176.37 59.04 33.66 25.19 29.33 H e a 2.94,
H e b 3.01,
C e  41.94
44 N 7.32 108.45 4.69 3.21
3.29
7.05
6.69
175.94 51.61 39.56 N d 2 110.84
45 T 3.89 3.81 0.83 65.94 68.23 22.69
45 T
46 E 3.65 2.06
1.88
2.21
2.38
179.29 61.53 28.28 37.71
47 E 8.48 120.90 4.06 2.23
2.09
2.35
2.50
179.05 59.53 30.17 37.47
48 S 7.54 117.76 3.94 3.50
3.41
61.31 62.73
49 I 7.78 123.25 3.38 1.72 0.43
0.59
0.76
0.43 177.57 65.43 37.44 17.48
30.11
13.78
50 A 7.95 123.50 3.91 1.41 180.56 55.31 17.68
51 A 7.62 121.19 3.99 1.30 180.70 55.03 18.04
52 L 7.81 120.13 3.96 1.49
2.05
1.44 0.92
0.92
177.69 57.95 41.90 27.01 24.36
24.35
53 K 8.60 117.79 3.76 1.75
1.85
1.25
1.56
1.54
1.54
177.62 59.74 32.82 27.26 30.04 H e a 2.62,
H e b 2.69,
C e  41.87
54 K 7.28 115.39 3.96 1.85 1.56
1.42
1.66
1.75
1.66
1.68
178.02 58.62 32.66 25.38 29.43 H e 2 2.95,
H e 3 2.95,
C e  42.18
55 K 7.08 116.88 4.24 1.75
1.74
1.45
1.45
1.64
1.64
177.40 57.28 33.94 25.35 28.91 H e 2 2.94,
H e 3 2.94,
C e  42.06
56 S 8.52 111.31 4.83 3.68
3.76
177.41 54.68 62.86
57 P 4.34 2.40
1.97
2.15
2.15
3.96
3.49
179.82 66.19 32.29 27.24 50.25
58 E 8.77 118.17 4.08 1.95
2.03
2.28
2.28
179.12 59.96 29.37 36.84
59 L 7.70 121.75 4.19 1.71
1.71
1.62 0.93
0.97
179.78 57.74 41.89 27.26 25.88
23.67
60 G 8.94 104.15 3.36
3.55
174.30 47.65
61 A 8.02 122.86 4.22 1.53 180.58 55.14 18.32
62 K 7.57 117.89 4.06 2.20
1.89
1.38
1.65
179.76 60.02 33.51 26.22 30.63 H e 2 2.93,
H e 3 2.93,
C e  42.06
63 V 8.14 118.97 3.28 1.99 0.75
0.87
177.11 66.87 31.23 24.16
22.06
64 E 8.59 121.45 3.94 2.23
2.09
2.24
2.24
178.63 60.32 30.16 36.59
65 K 7.58 118.59 4.13 1.92
1.93
1.47
1.61
1.70
1.70
179.58 59.40 32.34 25.35 29.19 H e 2 2.95,
H e 3 2.95,
C e  42.19
66 L 7.61 120.45 4.01 1.75
1.28
1.63 0.33
0.59
178.11 58.09 41.97 26.74 23.25
25.01
67 H 8.73 119.93 4.05 2.92
3.26
176.58 60.63 31.38
68 A 8.23 120.45 3.81 1.50 180.70 55.25 17.85
69 M 7.89 119.07 4.06 2.00
2.00
2.77
2.25
178.73 58.88 32.36 31.24 H e * 1.86
70 V 8.13 119.84 3.33 1.91 0.40
0.58
67.36 31.06 21.96
23.08
71 K 8.37 119.18
72 S 8.06 115.61 4.16 3.93
3.93
176.63 61.74 62.86
73 K 7.63 123.95 3.89 1.06
1.71
1.66
1.74
178.39 60.01 34.94 25.18 29.42 H e a 2.90,
H e b 3.08,
C e  41.56
74 I 8.13 117.12 3.80 1.91 2.24
1.06
0.98
0.87 178.36 65.36 38.14 17.38
30.10
14.20
75 A 7.69 118.27 4.06 1.45 178.20 54.21 18.31
76 A 7.16 118.41 4.30 1.39 178.15 52.10 19.18
77 L 7.44 120.27 4.37 2.15
1.74
1.22 1.06 177.96 55.32 43.25 26.85 23.52
25.49
78 G 10.53 112.53 3.86
4.32
178.02 44.35
79 P 4.15 2.36
1.96
2.17
2.04
3.71
3.71
179.84 66.35 32.14 27.64 48.94
80 E 8.31 120.30 4.06 2.02 2.13
2.23
179.33 59.75 29.68 35.98
81 A 9.68 124.26 4.61 1.94 179.55 55.19 19.68
82 K 9.33 120.51 3.97 1.93
1.73
1.54
1.43
178.70 60.33 32.52 25.56 29.74 H e a 2.99,
H e b 3.06,
C e  42.09
83 G 8.02 106.28 3.95
3.64
176.52 47.12
84 F 7.60 123.52 4.37 3.28
3.43
6.83 177.62 60.36 39.78 131.89 H e * 6.83
85 A 8.66 125.17 3.34 1.44 179.10 55.48 17.78
86 E 8.87 116.14 3.87 2.19
2.01
2.56
2.56
180.30 60.07 29.48 36.89
87 K 8.21 120.77 4.05 1.84
1.91
1.50
1.42
1.70
1.70
179.73 59.22 32.52 25.38 28.99 H e 2 2.92,
H e 3 2.92,
C e  41.89
88 S 7.98 117.63 3.93 175.89 63.65 62.53
89 I 8.39 122.88 3.51 1.92 0.89
0.89
1.79
0.78 177.65 65.64 37.76 17.47
30.52
13.52
90 E 7.84 120.79 4.04 2.02
2.18
2.35
2.35
179.99 59.70 29.25 35.74
91 I 7.79 122.06 3.73 2.04 0.90
1.66
1.66
0.80 179.49 65.45 37.77 17.55
30.22
13.98
92 A 8.00 123.16 3.95 1.48 179.02 55.59 18.45
93 R 9.07 118.52 3.80 179.50 60.62 30.40 25.64 41.29
94 G 8.05 107.30 3.97
3.97
176.41 47.08
95 I 7.53 122.70 3.83 2.20 1.39
1.65
0.95
0.80 177.76 63.57 36.84 27.86
18.16
11.56
96 K 8.17 120.28 3.76 1.86 1.47
1.47
1.67
1.73
177.41 60.56 32.58 25.87 29.74 H e 2 2.68,
H e 3 2.68,
C e  41.81
97 A 8.11 118.05 4.27 181.28 55.20 18.14
98 R 7.71 116.95 4.07 1.70
1.70
3.23
3.05
178.97 59.11 29.94 27.84 43.78
99 Y 7.94 118.52 3.98 3.02
2.89
6.79 177.73 62.75 38.03 132.27 H e * 6.81,
C e * 118.66
100 Y 7.73 116.41 3.24
2.86
7.14 176.77 60.02 38.14 133.28 H e * 6.54,
C e * 117.59
101 T 7.59 108.97 4.52 4.48 1.31 174.94 61.95 70.66 21.65
102 G 7.93 108.47
102 G 3.84
4.13
173.53 45.62
103 N 7.85 120.33 4.91 2.47
2.64
6.82
7.40
173.88 51.71 38.92 38.69 N d 2 112.47
104 E 8.43 122.49 3.83 1.87
1.87
2.22
2.22
174.04 55.74 28.74 36.48
105 P
106 T 8.88 113.00 60.11
106 T 4.54 4.66 1.30 176.06 59.99 72.18 21.82
107 K 9.03 120.60 3.93 1.90 1.40
1.33
1.72
1.68
178.49 60.50 31.99 25.48 29.56 H e 2 2.95,
H e 3 2.95,
C e  41.81
108 D 7.95 117.36 4.35 2.46
2.60
179.06 57.76 40.41
109 D 7.80 122.23 4.42 2.56
3.05
179.54 57.58 40.93
110 L 8.10 121.05 3.79 1.53
1.76
1.75 0.87
0.72
179.16 58.04 41.09 26.94 25.60
23.59
111 K 26.00
112 A 7.97 120.28 181.10 55.41 18.05
113 S 7.93 116.21 4.33 3.73
3.98
181.12 63.19 63.18
114 V 8.11 121.74 3.49 2.31 0.91
1.07
177.50 67.26 31.32 23.88
115 K 8.43 119.64 3.77 2.00 1.52
1.54
1.59
1.62
178.58 60.83 32.29 25.91 29.74 H e 2 2.79,
H e 3 2.79,
H e a 2.73,
H e b 2.80,
C e  41.78
116 E 7.69 118.47 4.04 2.20
2.24
2.37
2.22
178.99 59.60 29.41 35.74
117 V 7.74 120.05 3.58 2.18 1.08
0.88
177.88 67.27 31.85 23.33
118 L 8.53 119.26 4.06 1.51 1.83 0.73
0.73
179.15 58.17 41.55 26.95 22.67
22.67
119 K 8.44 119.53 3.77 1.86
2.00
1.20
1.20
178.27 60.93 32.48 26.96 30.29 H e a 2.72,
H e b 2.80,
C e  42.01
120 L 3.97 1.62
2.33
1.95 0.87
0.87
179.07 57.61 42.07 26.51 22.76
22.76
121 Y 8.26 120.88 2.77 2.58
2.30
6.06 177.35 61.48 37.32 133.36 H e * 6.47,
C e * 116.70
122 K 8.22 115.92 3.42 1.82
1.82
1.82
1.99
1.65
1.51
1.51
1.52
1.66
1.66
177.66 58.96 32.36 25.74 29.44 H e 2 2.94,
H e 3 2.94,
C e  41.95
123 A 7.18 117.92 4.08 1.38 178.12 52.41 19.07
124 M 7.08 117.75 4.15 2.03
1.71
2.45
2.45
176.91 57.71 37.48 32.06
125 S 9.61 117.87 4.26 174.93 58.53 64.74
126 D 8.86 121.35 4.19 2.63
2.63
179.16 58.04 39.60
127 A 8.25 122.82 4.17 1.44 180.99 55.24 18.27
128 G 8.11 111.69 4.03
3.64
176.08 47.29
129 K 8.30 121.31 3.76 1.77 1.68
1.17
1.62
1.71
180.26 60.95 33.06 27.02 29.59 H e 2 2.69,
H e 3 2.69,
C e  42.44
130 A 8.25 123.17 4.14 1.48 180.09 54.92 17.94
131 D 7.98 120.01 4.41 2.91
3.04
177.86 57.48 42.70
132 F 8.58 117.17 4.23 3.16
3.28
7.37 177.72 62.76 39.97 131.74 H e * 6.93,
C e * 131.02
133 G 8.51 104.18 3.60
3.78
174.41 46.51
134 K 7.55 119.59 4.06 2.01 1.43
1.43
1.73
1.67
178.54 58.67 32.51 25.30 29.08 H e 2 2.96,
H e 3 2.96,
C e  41.87
135 Q 6.74 113.07 4.17 1.57
1.65
2.42
2.43
174.67 55.25 29.83 32.45 N e 2 112.75,
H e 2a  6.66,
H e 2b  7.57
136 F 8.20 115.59 4.61 2.68
2.57
171.41 55.14 39.26 H e * 6.93,
C e * 132.50
137 P 4.34 2.33
1.86
1.95
1.95
3.62
2.86
65.63 31.68 27.43 50.15
138 F
139 L 3.38 1.97
0.97
1.97 0.73
0.73
178.60 57.70 41.54 26.97 22.74
22.74
140 A 8.93 119.02 3.86 1.60 178.94 56.15 19.09
141 K 7.32 117.23 3.89 1.73
1.68
1.73
1.79
1.38
1.38
1.66
1.66
180.17 58.96 33.57 24.80 28.95 H e 2 2.95,
H e 3 2.95,
C e  41.82
142 V 3.60 2.23 1.16
1.11
67.44 31.66 22.38
23.74
143 F 4.21 2.80
3.44
7.22 61.74 37.27 133.20 H e * 7.21,
C e * 131.39
144 E
145 S 4.36 4.09
3.99
59.86 64.27
146 G
147 K 4.02 1.81
1.68
1.62
1.43
1.68
1.68
178.79 59.13 32.45 25.27 29.06 H e 2 2.96,
H e 3 2.96,
C e  41.88
148 A 7.73 120.87 3.96 1.38 178.28 55.37 18.45
149 A 7.63 119.73 3.91 1.45 180.10 55.02 18.02
150 K 7.92 118.29 4.06 1.71
1.87
1.46
1.41
1.65
1.65
179.31 58.72 32.30 25.07 29.14 H e 2 2.94,
H e 3 2.94,
C e  42.12
151 F 7.86 120.03 4.25 3.07
3.20
7.14 176.24 60.47 39.54 131.44
152 A 7.96 117.76 3.94 1.41 177.34 53.20 19.31
153 G 7.58 104.45 3.85
3.96
174.26 45.31
154 E 8.00 120.34 4.29 1.79
2.03
2.15
2.23
175.37 56.28 30.80 36.30
155 N 7.97 124.78 4.38 2.68
2.57
6.72
7.40
179.42 54.87 40.53 N d 2 112.61
H N aH bH gH dH C aC bC gC dC
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-13 G
-12 S
-11 S
-10 H
-9 H
-8 H
-7 H
-6 H
-5 H
-4 S
-2 G
-1 H
0 M
1 F 4.54 2.93
2.94
7.11 57.81 40.79 131.98 H e * 7.10,
C e * 131.38
2 K 4.46 1.64
1.84
1.30
1.33
1.63
1.63
176.19 54.46 34.90 24.32 28.92 H e a 2.90,
H e b 2.91,
C e  41.78
3 Y 8.86 123.81 3.86 2.90
2.82
6.85 176.31 61.72 38.74 133.52 H e * 6.60,
C e * 118.99
4 E 9.01 113.67 3.67 1.86
2.09
2.36
2.20
175.98 58.82 28.57 37.55
5 D 7.76 118.19 4.39 2.64
2.73
177.38 55.58 41.24
6 I 7.61 121.73 3.97 1.66 0.91
1.86
0.95
0.82 177.35 59.85 38.25 28.21
17.64
13.76
7 P
8 A 3.74 1.44 178.14 56.21 18.73
9 D 8.86 112.76 4.29 2.55
2.38
177.84 56.05 39.12
10 Y 7.55 116.27 4.13 6.85 177.97 60.20 38.63 132.88 H e * 6.60,
C e * 118.29
11 R 7.99 119.30 3.80 1.81
2.02
1.59
1.60
3.34
3.15
178.65 60.55 30.62 28.07 43.76
12 D 8.10 115.93 4.44 2.63
2.56
176.74 56.37 40.65
13 L 7.31 116.62 4.31 2.03
1.55
1.80 0.82
0.81
177.69 54.92 43.70 26.50 22.83
14 M 7.36 117.57 3.88 2.01
1.73
15 P
16 P 4.01 2.33
1.94
2.02
2.18
3.84
3.79
178.17 65.82 31.88 27.72 50.77
17 E 10.20 116.77 4.05 1.85 180.12 60.39 29.41 37.25
18 A 7.41 119.58 4.16 1.36 177.75 54.27 19.24
19 R 7.66 118.51 3.80 1.82
1.82
1.47
1.22
3.18
3.23
177.61 60.56 30.46 28.50 43.63
20 D 8.35 116.66 4.09 2.63
2.49
177.94 57.29 41.60
21 F 7.13 116.78 4.14 3.33
3.04
6.99 176.68 60.19 39.78 132.29 H e * 7.01,
C e * 131.11
22 L 7.90 115.39 3.69 1.25
1.71
0.85
0.86
178.67 57.11 43.11 25.83 25.80
23 Q 8.36 117.09 3.41 1.93
1.93
176.60 58.50 28.76 34.07 N e 2 112.40,
H e 2a  6.88,
H e 2b  7.47
24 N 4.68 2.58
2.81
7.65
6.87
174.32 53.15 39.81 N d 2 116.09
25 L 6.61 121.65 4.23 1.43
1.52
1.58 0.49
0.49
176.59 55.56 42.39 25.22 25.29
25.29
26 S 9.35 124.98 4.70 3.99
4.34
175.42 56.70 66.66
27 D
28 G 3.84
3.84
176.43 47.09
29 D 7.95 123.45 4.33 2.44
3.03
178.30 57.22 41.84
30 K 7.94 118.39 3.78 2.03
1.85
1.66 178.30 60.92 32.35 25.60 29.76 H e a 2.68,
H e b 2.80,
C e  41.35
31 T 7.95 115.93 3.87 4.39 1.25 176.14 67.20 68.72 21.98
32 V 7.85 122.49 3.71 2.21 1.08
0.87
177.81 66.89 31.43 22.32
23.27
33 L 8.20 118.97 3.82 1.29
2.07
2.05 0.89
0.89
178.51 58.86 41.76 26.34 24.13
34 K 7.98 117.90 3.91 1.97
1.97
1.30
1.30
1.75
1.75
178.30 60.64 32.68 25.96 29.70 H e a 2.88,
H e b 2.95,
C e  41.96
35 E 8.43 119.05 3.94 2.04
2.25
2.53
2.53
180.49 59.74 29.69 36.72
36 V 8.64 119.52 3.72 2.16 0.84
1.02
180.16 66.72 31.58 23.98
37 F 8.68 122.48 4.31 3.22
3.29
7.06 179.20 62.85 39.29 132.02 H e * 7.15,
C e * 132.51
38 K 8.80 119.87 4.05 1.81
2.00
1.70
1.61
1.44
1.42
176.26 59.03 32.35 25.67 29.03 H e a 2.77,
H e b 2.99,
C e  41.91
39 A 7.27 119.94 4.08 1.50 176.87 51.94 18.73
40 G 7.15 104.20 3.83
3.83
43.80
41 P
42 Y
42 Y 4.61 3.16
2.59
7.09 56.80 40.70 133.23 H e * 6.65,
C e * 117.41
43 K 3.89 1.77
1.65
1.41 1.52 176.37 59.04 33.66 25.19 29.33 H e a 2.94,
H e b 3.01,
C e  41.94
44 N 7.32 108.45 4.69 3.21
3.29
7.05
6.69
175.94 51.61 39.56 N d 2 110.84
45 T 3.89 3.81 0.83 65.94 68.23 22.69
45 T
46 E 3.65 2.06
1.88
2.21
2.38
179.29 61.53 28.28 37.71
47 E 8.48 120.90 4.06 2.23
2.09
2.35
2.50
179.05 59.53 30.17 37.47
48 S 7.54 117.76 3.94 3.50
3.41
61.31 62.73
49 I 7.78 123.25 3.38 1.72 0.43
0.59
0.76
0.43 177.57 65.43 37.44 17.48
30.11
13.78
50 A 7.95 123.50 3.91 1.41 180.56 55.31 17.68
51 A 7.62 121.19 3.99 1.30 180.70 55.03 18.04
52 L 7.81 120.13 3.96 1.49
2.05
1.44 0.92
0.92
177.69 57.95 41.90 27.01 24.36
24.35
53 K 8.60 117.79 3.76 1.75
1.85
1.25
1.56
1.54
1.54
177.62 59.74 32.82 27.26 30.04 H e a 2.62,
H e b 2.69,
C e  41.87
54 K 7.28 115.39 3.96 1.85 1.56
1.42
1.66
1.75
1.66
1.68
178.02 58.62 32.66 25.38 29.43 H e 2 2.95,
H e 3 2.95,
C e  42.18
55 K 7.08 116.88 4.24 1.75
1.74
1.45
1.45
1.64
1.64
177.40 57.28 33.94 25.35 28.91 H e 2 2.94,
H e 3 2.94,
C e  42.06
56 S 8.52 111.31 4.83 3.68
3.76
177.41 54.68 62.86
57 P 4.34 2.40
1.97
2.15
2.15
3.96
3.49
179.82 66.19 32.29 27.24 50.25
58 E 8.77 118.17 4.08 1.95
2.03
2.28
2.28
179.12 59.96 29.37 36.84
59 L 7.70 121.75 4.19 1.71
1.71
1.62 0.93
0.97
179.78 57.74 41.89 27.26 25.88
23.67
60 G 8.94 104.15 3.36
3.55
174.30 47.65
61 A 8.02 122.86 4.22 1.53 180.58 55.14 18.32
62 K 7.57 117.89 4.06 2.20
1.89
1.38
1.65
179.76 60.02 33.51 26.22 30.63 H e 2 2.93,
H e 3 2.93,
C e  42.06
63 V 8.14 118.97 3.28 1.99 0.75
0.87
177.11 66.87 31.23 24.16
22.06
64 E 8.59 121.45 3.94 2.23
2.09
2.24
2.24
178.63 60.32 30.16 36.59
65 K 7.58 118.59 4.13 1.92
1.93
1.47
1.61
1.70
1.70
179.58 59.40 32.34 25.35 29.19 H e 2 2.95,
H e 3 2.95,
C e  42.19
66 L 7.61 120.45 4.01 1.75
1.28
1.63 0.33
0.59
178.11 58.09 41.97 26.74 23.25
25.01
67 H 8.73 119.93 4.05 2.92
3.26
176.58 60.63 31.38
68 A 8.23 120.45 3.81 1.50 180.70 55.25 17.85
69 M 7.89 119.07 4.06 2.00
2.00
2.77
2.25
178.73 58.88 32.36 31.24 H e * 1.86
70 V 8.13 119.84 3.33 1.91 0.40
0.58
67.36 31.06 21.96
23.08
71 K 8.37 119.18
72 S 8.06 115.61 4.16 3.93
3.93
176.63 61.74 62.86
73 K 7.63 123.95 3.89 1.06
1.71
1.66
1.74
178.39 60.01 34.94 25.18 29.42 H e a 2.90,
H e b 3.08,
C e  41.56
74 I 8.13 117.12 3.80 1.91 2.24
1.06
0.98
0.87 178.36 65.36 38.14 17.38
30.10
14.20
75 A 7.69 118.27 4.06 1.45 178.20 54.21 18.31
76 A 7.16 118.41 4.30 1.39 178.15 52.10 19.18
77 L 7.44 120.27 4.37 2.15
1.74
1.22 1.06 177.96 55.32 43.25 26.85 23.52
25.49
78 G 10.53 112.53 3.86
4.32
178.02 44.35
79 P 4.15 2.36
1.96
2.17
2.04
3.71
3.71
179.84 66.35 32.14 27.64 48.94
80 E 8.31 120.30 4.06 2.02 2.13
2.23
179.33 59.75 29.68 35.98
81 A 9.68 124.26 4.61 1.94 179.55 55.19 19.68
82 K 9.33 120.51 3.97 1.93
1.73
1.54
1.43
178.70 60.33 32.52 25.56 29.74 H e a 2.99,
H e b 3.06,
C e  42.09
83 G 8.02 106.28 3.95
3.64
176.52 47.12
84 F 7.60 123.52 4.37 3.28
3.43
6.83 177.62 60.36 39.78 131.89 H e * 6.83
85 A 8.66 125.17 3.34 1.44 179.10 55.48 17.78
86 E 8.87 116.14 3.87 2.19
2.01
2.56
2.56
180.30 60.07 29.48 36.89
87 K 8.21 120.77 4.05 1.84
1.91
1.50
1.42
1.70
1.70
179.73 59.22 32.52 25.38 28.99 H e 2 2.92,
H e 3 2.92,
C e  41.89
88 S 7.98 117.63 3.93 175.89 63.65 62.53
89 I 8.39 122.88 3.51 1.92 0.89
0.89
1.79
0.78 177.65 65.64 37.76 17.47
30.52
13.52
90 E 7.84 120.79 4.04 2.02
2.18
2.35
2.35
179.99 59.70 29.25 35.74
91 I 7.79 122.06 3.73 2.04 0.90
1.66
1.66
0.80 179.49 65.45 37.77 17.55
30.22
13.98
92 A 8.00 123.16 3.95 1.48 179.02 55.59 18.45
93 R 9.07 118.52 3.80 179.50 60.62 30.40 25.64 41.29
94 G 8.05 107.30 3.97
3.97
176.41 47.08
95 I 7.53 122.70 3.83 2.20 1.39
1.65
0.95
0.80 177.76 63.57 36.84 27.86
18.16
11.56
96 K 8.17 120.28 3.76 1.86 1.47
1.47
1.67
1.73
177.41 60.56 32.58 25.87 29.74 H e 2 2.68,
H e 3 2.68,
C e  41.81
97 A 8.11 118.05 4.27 181.28 55.20 18.14
98 R 7.71 116.95 4.07 1.70
1.70
3.23
3.05
178.97 59.11 29.94 27.84 43.78
99 Y 7.94 118.52 3.98 3.02
2.89
6.79 177.73 62.75 38.03 132.27 H e * 6.81,
C e * 118.66
100 Y 7.73 116.41 3.24
2.86
7.14 176.77 60.02 38.14 133.28 H e * 6.54,
C e * 117.59
101 T 7.59 108.97 4.52 4.48 1.31 174.94 61.95 70.66 21.65
102 G 7.93 108.47
102 G 3.84
4.13
173.53 45.62
103 N 7.85 120.33 4.91 2.47
2.64
6.82
7.40
173.88 51.71 38.92 38.69 N d 2 112.47
104 E 8.43 122.49 3.83 1.87
1.87
2.22
2.22
174.04 55.74 28.74 36.48
105 P
106 T 8.88 113.00 60.11
106 T 4.54 4.66 1.30 176.06 59.99 72.18 21.82
107 K 9.03 120.60 3.93 1.90 1.40
1.33
1.72
1.68
178.49 60.50 31.99 25.48 29.56 H e 2 2.95,
H e 3 2.95,
C e  41.81
108 D 7.95 117.36 4.35 2.46
2.60
179.06 57.76 40.41
109 D 7.80 122.23 4.42 2.56
3.05
179.54 57.58 40.93
110 L 8.10 121.05 3.79 1.53
1.76
1.75 0.87
0.72
179.16 58.04 41.09 26.94 25.60
23.59
111 K 26.00
112 A 7.97 120.28 181.10 55.41 18.05
113 S 7.93 116.21 4.33 3.73
3.98
181.12 63.19 63.18
114 V 8.11 121.74 3.49 2.31 0.91
1.07
177.50 67.26 31.32 23.88
115 K 8.43 119.64 3.77 2.00 1.52
1.54
1.59
1.62
178.58 60.83 32.29 25.91 29.74 H e 2 2.79,
H e 3 2.79,
H e a 2.73,
H e b 2.80,
C e  41.78
116 E 7.69 118.47 4.04 2.20
2.24
2.37
2.22
178.99 59.60 29.41 35.74
117 V 7.74 120.05 3.58 2.18 1.08
0.88
177.88 67.27 31.85 23.33
118 L 8.53 119.26 4.06 1.51 1.83 0.73
0.73
179.15 58.17 41.55 26.95 22.67
22.67
119 K 8.44 119.53 3.77 1.86
2.00
1.20
1.20
178.27 60.93 32.48 26.96 30.29 H e a 2.72,
H e b 2.80,
C e  42.01
120 L 3.97 1.62
2.33
1.95 0.87
0.87
179.07 57.61 42.07 26.51 22.76
22.76
121 Y 8.26 120.88 2.77 2.58
2.30
6.06 177.35 61.48 37.32 133.36 H e * 6.47,
C e * 116.70
122 K 8.22 115.92 3.42 1.82
1.82
1.82
1.99
1.65
1.51
1.51
1.52
1.66
1.66
177.66 58.96 32.36 25.74 29.44 H e 2 2.94,
H e 3 2.94,
C e  41.95
123 A 7.18 117.92 4.08 1.38 178.12 52.41 19.07
124 M 7.08 117.75 4.15 2.03
1.71
2.45
2.45
176.91 57.71 37.48 32.06
125 S 9.61 117.87 4.26 174.93 58.53 64.74
126 D 8.86 121.35 4.19 2.63
2.63
179.16 58.04 39.60
127 A 8.25 122.82 4.17 1.44 180.99 55.24 18.27
128 G 8.11 111.69 4.03
3.64
176.08 47.29
129 K 8.30 121.31 3.76 1.77 1.68
1.17
1.62
1.71
180.26 60.95 33.06 27.02 29.59 H e 2 2.69,
H e 3 2.69,
C e  42.44
130 A 8.25 123.17 4.14 1.48 180.09 54.92 17.94
131 D 7.98 120.01 4.41 2.91
3.04
177.86 57.48 42.70
132 F 8.58 117.17 4.23 3.16
3.28
7.37 177.72 62.76 39.97 131.74 H e * 6.93,
C e * 131.02
133 G 8.51 104.18 3.60
3.78
174.41 46.51
134 K 7.55 119.59 4.06 2.01 1.43
1.43
1.73
1.67
178.54 58.67 32.51 25.30 29.08 H e 2 2.96,
H e 3 2.96,
C e  41.87
135 Q 6.74 113.07 4.17 1.57
1.65
2.42
2.43
174.67 55.25 29.83 32.45 N e 2 112.75,
H e 2a  6.66,
H e 2b  7.57
136 F 8.20 115.59 4.61 2.68
2.57
171.41 55.14 39.26 H e * 6.93,
C e * 132.50
137 P 4.34 2.33
1.86
1.95
1.95
3.62
2.86
65.63 31.68 27.43 50.15
138 F
139 L 3.38 1.97
0.97
1.97 0.73
0.73
178.60 57.70 41.54 26.97 22.74
22.74
140 A 8.93 119.02 3.86 1.60 178.94 56.15 19.09
141 K 7.32 117.23 3.89 1.73
1.68
1.73
1.79
1.38
1.38
1.66
1.66
180.17 58.96 33.57 24.80 28.95 H e 2 2.95,
H e 3 2.95,
C e  41.82
142 V 3.60 2.23 1.16
1.11
67.44 31.66 22.38
23.74
143 F 4.21 2.80
3.44
7.22 61.74 37.27 133.20 H e * 7.21,
C e * 131.39
144 E
145 S 4.36 4.09
3.99
59.86 64.27
146 G
147 K 4.02 1.81
1.68
1.62
1.43
1.68
1.68
178.79 59.13 32.45 25.27 29.06 H e 2 2.96,
H e 3 2.96,
C e  41.88
148 A 7.73 120.87 3.96 1.38 178.28 55.37 18.45
149 A 7.63 119.73 3.91 1.45 180.10 55.02 18.02
150 K 7.92 118.29 4.06 1.71
1.87
1.46
1.41
1.65
1.65
179.31 58.72 32.30 25.07 29.14 H e 2 2.94,
H e 3 2.94,
C e  42.12
151 F 7.86 120.03 4.25 3.07
3.20
7.14 176.24 60.47 39.54 131.44
152 A 7.96 117.76 3.94 1.41 177.34 53.20 19.31
153 G 7.58 104.45 3.85
3.96
174.26 45.31
154 E 8.00 120.34 4.29 1.79
2.03
2.15
2.23
175.37 56.28 30.80 36.30
155 N 7.97 124.78 4.38 2.68
2.57
6.72
7.40
179.42 54.87 40.53 N d 2 112.61
H N aH bH gH dH C aC bC gC dC
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-13 G
-12 S
-11 S
-10 H
-9 H
-8 H
-7 H
-6 H
-5 H
-4 S
-2 G
-1 H
0 M
1 F 4.54 2.93
2.94
7.11 57.81 40.79 131.98 H e * 7.10,
C e * 131.38
2 K 4.46 1.64
1.84
1.30
1.33
1.63
1.63
176.19 54.46 34.90 24.32 28.92 H e a 2.90,
H e b 2.91,
C e  41.78
3 Y 8.86 123.81 3.86 2.90
2.82
6.85 176.31 61.72 38.74 133.52 H e * 6.60,
C e * 118.99
4 E 9.01 113.67 3.67 1.86
2.09
2.36
2.20
175.98 58.82 28.57 37.55
5 D 7.76 118.19 4.39 2.64
2.73
177.38 55.58 41.24
6 I 7.61 121.73 3.97 1.66 0.91
1.86
0.95
0.82 177.35 59.85 38.25 28.21
17.64
13.76
7 P
8 A 3.74 1.44 178.14 56.21 18.73
9 D 8.86 112.76 4.29 2.55
2.38
177.84 56.05 39.12
10 Y 7.55 116.27 4.13 6.85 177.97 60.20 38.63 132.88 H e * 6.60,
C e * 118.29
11 R 7.99 119.30 3.80 1.81
2.02
1.59
1.60
3.34
3.15
178.65 60.55 30.62 28.07 43.76
12 D 8.10 115.93 4.44 2.63
2.56
176.74 56.37 40.65
13 L 7.31 116.62 4.31 2.03
1.55
1.80 0.82
0.81
177.69 54.92 43.70 26.50 22.83
14 M 7.36 117.57 3.88 2.01
1.73
15 P
16 P 4.01 2.33
1.94
2.02
2.18
3.84
3.79
178.17 65.82 31.88 27.72 50.77
17 E 10.20 116.77 4.05 1.85 180.12 60.39 29.41 37.25
18 A 7.41 119.58 4.16 1.36 177.75 54.27 19.24
19 R 7.66 118.51 3.80 1.82
1.82
1.47
1.22
3.18
3.23
177.61 60.56 30.46 28.50 43.63
20 D 8.35 116.66 4.09 2.63
2.49
177.94 57.29 41.60
21 F 7.13 116.78 4.14 3.33
3.04
6.99 176.68 60.19 39.78 132.29 H e * 7.01,
C e * 131.11
22 L 7.90 115.39 3.69 1.25
1.71
0.85
0.86
178.67 57.11 43.11 25.83 25.80
23 Q 8.36 117.09 3.41 1.93
1.93
176.60 58.50 28.76 34.07 N e 2 112.40,
H e 2a  6.88,
H e 2b  7.47
24 N 4.68 2.58
2.81
7.65
6.87
174.32 53.15 39.81 N d 2 116.09
25 L 6.61 121.65 4.23 1.43
1.52
1.58 0.49
0.49
176.59 55.56 42.39 25.22 25.29
25.29
26 S 9.35 124.98 4.70 3.99
4.34
175.42 56.70 66.66
27 D
28 G 3.84
3.84
176.43 47.09
29 D 7.95 123.45 4.33 2.44
3.03
178.30 57.22 41.84
30 K 7.94 118.39 3.78 2.03
1.85
1.66 178.30 60.92 32.35 25.60 29.76 H e a 2.68,
H e b 2.80,
C e  41.35
31 T 7.95 115.93 3.87 4.39 1.25 176.14 67.20 68.72 21.98
32 V 7.85 122.49 3.71 2.21 1.08
0.87
177.81 66.89 31.43 22.32
23.27
33 L 8.20 118.97 3.82 1.29
2.07
2.05 0.89
0.89
178.51 58.86 41.76 26.34 24.13
34 K 7.98 117.90 3.91 1.97
1.97
1.30
1.30
1.75
1.75
178.30 60.64 32.68 25.96 29.70 H e a 2.88,
H e b 2.95,
C e  41.96
35 E 8.43 119.05 3.94 2.04
2.25
2.53
2.53
180.49 59.74 29.69 36.72
36 V 8.64 119.52 3.72 2.16 0.84
1.02
180.16 66.72 31.58 23.98
37 F 8.68 122.48 4.31 3.22
3.29
7.06 179.20 62.85 39.29 132.02 H e * 7.15,
C e * 132.51
38 K 8.80 119.87 4.05 1.81
2.00
1.70
1.61
1.44
1.42
176.26 59.03 32.35 25.67 29.03 H e a 2.77,
H e b 2.99,
C e  41.91
39 A 7.27 119.94 4.08 1.50 176.87 51.94 18.73
40 G 7.15 104.20 3.83
3.83
43.80
41 P
42 Y
42 Y 4.61 3.16
2.59
7.09 56.80 40.70 133.23 H e * 6.65,
C e * 117.41
43 K 3.89 1.77
1.65
1.41 1.52 176.37 59.04 33.66 25.19 29.33 H e a 2.94,
H e b 3.01,
C e  41.94
44 N 7.32 108.45 4.69 3.21
3.29
7.05
6.69
175.94 51.61 39.56 N d 2 110.84
45 T 3.89 3.81 0.83 65.94 68.23 22.69
45 T
46 E 3.65 2.06
1.88
2.21
2.38
179.29 61.53 28.28 37.71
47 E 8.48 120.90 4.06 2.23
2.09
2.35
2.50
179.05 59.53 30.17 37.47
48 S 7.54 117.76 3.94 3.50
3.41
61.31 62.73
49 I 7.78 123.25 3.38 1.72 0.43
0.59
0.76
0.43 177.57 65.43 37.44 17.48
30.11
13.78
50 A 7.95 123.50 3.91 1.41 180.56 55.31 17.68
51 A 7.62 121.19 3.99 1.30 180.70 55.03 18.04
52 L 7.81 120.13 3.96 1.49
2.05
1.44 0.92
0.92
177.69 57.95 41.90 27.01 24.36
24.35
53 K 8.60 117.79 3.76 1.75
1.85
1.25
1.56
1.54
1.54
177.62 59.74 32.82 27.26 30.04 H e a 2.62,
H e b 2.69,
C e  41.87
54 K 7.28 115.39 3.96 1.85 1.56
1.42
1.66
1.75
1.66
1.68
178.02 58.62 32.66 25.38 29.43 H e 2 2.95,
H e 3 2.95,
C e  42.18
55 K 7.08 116.88 4.24 1.75
1.74
1.45
1.45
1.64
1.64
177.40 57.28 33.94 25.35 28.91 H e 2 2.94,
H e 3 2.94,
C e  42.06
56 S 8.52 111.31 4.83 3.68
3.76
177.41 54.68 62.86
57 P 4.34 2.40
1.97
2.15
2.15
3.96
3.49
179.82 66.19 32.29 27.24 50.25
58 E 8.77 118.17 4.08 1.95
2.03
2.28
2.28
179.12 59.96 29.37 36.84
59 L 7.70 121.75 4.19 1.71
1.71
1.62 0.93
0.97
179.78 57.74 41.89 27.26 25.88
23.67
60 G 8.94 104.15 3.36
3.55
174.30 47.65
61 A 8.02 122.86 4.22 1.53 180.58 55.14 18.32
62 K 7.57 117.89 4.06 2.20
1.89
1.38
1.65
179.76 60.02 33.51 26.22 30.63 H e 2 2.93,
H e 3 2.93,
C e  42.06
63 V 8.14 118.97 3.28 1.99 0.75
0.87
177.11 66.87 31.23 24.16
22.06
64 E 8.59 121.45 3.94 2.23
2.09
2.24
2.24
178.63 60.32 30.16 36.59
65 K 7.58 118.59 4.13 1.92
1.93
1.47
1.61
1.70
1.70
179.58 59.40 32.34 25.35 29.19 H e 2 2.95,
H e 3 2.95,
C e  42.19
66 L 7.61 120.45 4.01 1.75
1.28
1.63 0.33
0.59
178.11 58.09 41.97 26.74 23.25
25.01
67 H 8.73 119.93 4.05 2.92
3.26
176.58 60.63 31.38
68 A 8.23 120.45 3.81 1.50 180.70 55.25 17.85
69 M 7.89 119.07 4.06 2.00
2.00
2.77
2.25
178.73 58.88 32.36 31.24 H e * 1.86
70 V 8.13 119.84 3.33 1.91 0.40
0.58
67.36 31.06 21.96
23.08
71 K 8.37 119.18
72 S 8.06 115.61 4.16 3.93
3.93
176.63 61.74 62.86
73 K 7.63 123.95 3.89 1.06
1.71
1.66
1.74
178.39 60.01 34.94 25.18 29.42 H e a 2.90,
H e b 3.08,
C e  41.56
74 I 8.13 117.12 3.80 1.91 2.24
1.06
0.98
0.87 178.36 65.36 38.14 17.38
30.10
14.20
75 A 7.69 118.27 4.06 1.45 178.20 54.21 18.31
76 A 7.16 118.41 4.30 1.39 178.15 52.10 19.18
77 L 7.44 120.27 4.37 2.15
1.74
1.22 1.06 177.96 55.32 43.25 26.85 23.52
25.49
78 G 10.53 112.53 3.86
4.32
178.02 44.35
79 P 4.15 2.36
1.96
2.17
2.04
3.71
3.71
179.84 66.35 32.14 27.64 48.94
80 E 8.31 120.30 4.06 2.02 2.13
2.23
179.33 59.75 29.68 35.98
81 A 9.68 124.26 4.61 1.94 179.55 55.19 19.68
82 K 9.33 120.51 3.97 1.93
1.73
1.54
1.43
178.70 60.33 32.52 25.56 29.74 H e a 2.99,
H e b 3.06,
C e  42.09
83 G 8.02 106.28 3.95
3.64
176.52 47.12
84 F 7.60 123.52 4.37 3.28
3.43
6.83 177.62 60.36 39.78 131.89 H e * 6.83
85 A 8.66 125.17 3.34 1.44 179.10 55.48 17.78
86 E 8.87 116.14 3.87 2.19
2.01
2.56
2.56
180.30 60.07 29.48 36.89
87 K 8.21 120.77 4.05 1.84
1.91
1.50
1.42
1.70
1.70
179.73 59.22 32.52 25.38 28.99 H e 2 2.92,
H e 3 2.92,
C e  41.89
88 S 7.98 117.63 3.93 175.89 63.65 62.53
89 I 8.39 122.88 3.51 1.92 0.89
0.89
1.79
0.78 177.65 65.64 37.76 17.47
30.52
13.52
90 E 7.84 120.79 4.04 2.02
2.18
2.35
2.35
179.99 59.70 29.25 35.74
91 I 7.79 122.06 3.73 2.04 0.90
1.66
1.66
0.80 179.49 65.45 37.77 17.55
30.22
13.98
92 A 8.00 123.16 3.95 1.48 179.02 55.59 18.45
93 R 9.07 118.52 3.80 179.50 60.62 30.40 25.64 41.29
94 G 8.05 107.30 3.97
3.97
176.41 47.08
95 I 7.53 122.70 3.83 2.20 1.39
1.65
0.95
0.80 177.76 63.57 36.84 27.86
18.16
11.56
96 K 8.17 120.28 3.76 1.86 1.47
1.47
1.67
1.73
177.41 60.56 32.58 25.87 29.74 H e 2 2.68,
H e 3 2.68,
C e  41.81
97 A 8.11 118.05 4.27 181.28 55.20 18.14
98 R 7.71 116.95 4.07 1.70
1.70
3.23
3.05
178.97 59.11 29.94 27.84 43.78
99 Y 7.94 118.52 3.98 3.02
2.89
6.79 177.73 62.75 38.03 132.27 H e * 6.81,
C e * 118.66
100 Y 7.73 116.41 3.24
2.86
7.14 176.77 60.02 38.14 133.28 H e * 6.54,
C e * 117.59
101 T 7.59 108.97 4.52 4.48 1.31 174.94 61.95 70.66 21.65
102 G 7.93 108.47
102 G 3.84
4.13
173.53 45.62
103 N 7.85 120.33 4.91 2.47
2.64
6.82
7.40
173.88 51.71 38.92 38.69 N d 2 112.47
104 E 8.43 122.49 3.83 1.87
1.87
2.22
2.22
174.04 55.74 28.74 36.48
105 P
106 T 8.88 113.00 60.11
106 T 4.54 4.66 1.30 176.06 59.99 72.18 21.82
107 K 9.03 120.60 3.93 1.90 1.40
1.33
1.72
1.68
178.49 60.50 31.99 25.48 29.56 H e 2 2.95,
H e 3 2.95,
C e  41.81
108 D 7.95 117.36 4.35 2.46
2.60
179.06 57.76 40.41
109 D 7.80 122.23 4.42 2.56
3.05
179.54 57.58 40.93
110 L 8.10 121.05 3.79 1.53
1.76
1.75 0.87
0.72
179.16 58.04 41.09 26.94 25.60
23.59
111 K 26.00
112 A 7.97 120.28 181.10 55.41 18.05
113 S 7.93 116.21 4.33 3.73
3.98
181.12 63.19 63.18
114 V 8.11 121.74 3.49 2.31 0.91
1.07
177.50 67.26 31.32 23.88
115 K 8.43 119.64 3.77 2.00 1.52
1.54
1.59
1.62
178.58 60.83 32.29 25.91 29.74 H e 2 2.79,
H e 3 2.79,
H e a 2.73,
H e b 2.80,
C e  41.78
116 E 7.69 118.47 4.04 2.20
2.24
2.37
2.22
178.99 59.60 29.41 35.74
117 V 7.74 120.05 3.58 2.18 1.08
0.88
177.88 67.27 31.85 23.33
118 L 8.53 119.26 4.06 1.51 1.83 0.73
0.73
179.15 58.17 41.55 26.95 22.67
22.67
119 K 8.44 119.53 3.77 1.86
2.00
1.20
1.20
178.27 60.93 32.48 26.96 30.29 H e a 2.72,
H e b 2.80,
C e  42.01
120 L 3.97 1.62
2.33
1.95 0.87
0.87
179.07 57.61 42.07 26.51 22.76
22.76
121 Y 8.26 120.88 2.77 2.58
2.30
6.06 177.35 61.48 37.32 133.36 H e * 6.47,
C e * 116.70
122 K 8.22 115.92 3.42 1.82
1.82
1.82
1.99
1.65
1.51
1.51
1.52
1.66
1.66
177.66 58.96 32.36 25.74 29.44 H e 2 2.94,
H e 3 2.94,
C e  41.95
123 A 7.18 117.92 4.08 1.38 178.12 52.41 19.07
124 M 7.08 117.75 4.15 2.03
1.71
2.45
2.45
176.91 57.71 37.48 32.06
125 S 9.61 117.87 4.26 174.93 58.53 64.74
126 D 8.86 121.35 4.19 2.63
2.63
179.16 58.04 39.60
127 A 8.25 122.82 4.17 1.44 180.99 55.24 18.27
128 G 8.11 111.69 4.03
3.64
176.08 47.29
129 K 8.30 121.31 3.76 1.77 1.68
1.17
1.62
1.71
180.26 60.95 33.06 27.02 29.59 H e 2 2.69,
H e 3 2.69,
C e  42.44
130 A 8.25 123.17 4.14 1.48 180.09 54.92 17.94
131 D 7.98 120.01 4.41 2.91
3.04
177.86 57.48 42.70
132 F 8.58 117.17 4.23 3.16
3.28
7.37 177.72 62.76 39.97 131.74 H e * 6.93,
C e * 131.02
133 G 8.51 104.18 3.60
3.78
174.41 46.51
134 K 7.55 119.59 4.06 2.01 1.43
1.43
1.73
1.67
178.54 58.67 32.51 25.30 29.08 H e 2 2.96,
H e 3 2.96,
C e  41.87
135 Q 6.74 113.07 4.17 1.57
1.65
2.42
2.43
174.67 55.25 29.83 32.45 N e 2 112.75,
H e 2a  6.66,
H e 2b  7.57
136 F 8.20 115.59 4.61 2.68
2.57
171.41 55.14 39.26 H e * 6.93,
C e * 132.50
137 P 4.34 2.33
1.86
1.95
1.95
3.62
2.86
65.63 31.68 27.43 50.15
138 F
139 L 3.38 1.97
0.97
1.97 0.73
0.73
178.60 57.70 41.54 26.97 22.74
22.74
140 A 8.93 119.02 3.86 1.60 178.94 56.15 19.09
141 K 7.32 117.23 3.89 1.73
1.68
1.73
1.79
1.38
1.38
1.66
1.66
180.17 58.96 33.57 24.80 28.95 H e 2 2.95,
H e 3 2.95,
C e  41.82
142 V 3.60 2.23 1.16
1.11
67.44 31.66 22.38
23.74
143 F 4.21 2.80
3.44
7.22 61.74 37.27 133.20 H e * 7.21,
C e * 131.39
144 E
145 S 4.36 4.09
3.99
59.86 64.27
146 G
147 K 4.02 1.81
1.68
1.62
1.43
1.68
1.68
178.79 59.13 32.45 25.27 29.06 H e 2 2.96,
H e 3 2.96,
C e  41.88
148 A 7.73 120.87 3.96 1.38 178.28 55.37 18.45
149 A 7.63 119.73 3.91 1.45 180.10 55.02 18.02
150 K 7.92 118.29 4.06 1.71
1.87
1.46
1.41
1.65
1.65
179.31 58.72 32.30 25.07 29.14 H e 2 2.94,
H e 3 2.94,
C e  42.12
151 F 7.86 120.03 4.25 3.07
3.20
7.14 176.24 60.47 39.54 131.44
152 A 7.96 117.76 3.94 1.41 177.34 53.20 19.31
153 G 7.58 104.45 3.85
3.96
174.26 45.31
154 E 8.00 120.34 4.29 1.79
2.03
2.15
2.23
175.37 56.28 30.80 36.30
155 N 7.97 124.78 4.38 2.68
2.57
6.72
7.40
179.42 54.87 40.53 N d 2 112.61
H N aH bH gH dH C aC bC gC dC
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-13 G
-12 S
-11 S
-10 H
-9 H
-8 H
-7 H
-6 H
-5 H
-4 S
-2 G
-1 H
0 M
1 F 4.54 2.93
2.94
7.11 57.81 40.79 131.98 H e * 7.10,
C e * 131.38
2 K 4.46 1.64
1.84
1.30
1.33
1.63
1.63
176.19 54.46 34.90 24.32 28.92 H e a 2.90,
H e b 2.91,
C e  41.78
3 Y 8.86 123.81 3.86 2.90
2.82
6.85 176.31 61.72 38.74 133.52 H e * 6.60,
C e * 118.99
4 E 9.01 113.67 3.67 1.86
2.09
2.36
2.20
175.98 58.82 28.57 37.55
5 D 7.76 118.19 4.39 2.64
2.73
177.38 55.58 41.24
6 I 7.61 121.73 3.97 1.66 0.91
1.86
0.95
0.82 177.35 59.85 38.25 28.21
17.64
13.76
7 P
8 A 3.74 1.44 178.14 56.21 18.73
9 D 8.86 112.76 4.29 2.55
2.38
177.84 56.05 39.12
10 Y 7.55 116.27 4.13 6.85 177.97 60.20 38.63 132.88 H e * 6.60,
C e * 118.29
11 R 7.99 119.30 3.80 1.81
2.02
1.59
1.60
3.34
3.15
178.65 60.55 30.62 28.07 43.76
12 D 8.10 115.93 4.44 2.63
2.56
176.74 56.37 40.65
13 L 7.31 116.62 4.31 2.03
1.55
1.80 0.82
0.81
177.69 54.92 43.70 26.50 22.83
14 M 7.36 117.57 3.88 2.01
1.73
15 P
16 P 4.01 2.33
1.94
2.02
2.18
3.84
3.79
178.17 65.82 31.88 27.72 50.77
17 E 10.20 116.77 4.05 1.85 180.12 60.39 29.41 37.25
18 A 7.41 119.58 4.16 1.36 177.75 54.27 19.24
19 R 7.66 118.51 3.80 1.82
1.82
1.47
1.22
3.18
3.23
177.61 60.56 30.46 28.50 43.63
20 D 8.35 116.66 4.09 2.63
2.49
177.94 57.29 41.60
21 F 7.13 116.78 4.14 3.33
3.04
6.99 176.68 60.19 39.78 132.29 H e * 7.01,
C e * 131.11
22 L 7.90 115.39 3.69 1.25
1.71
0.85
0.86
178.67 57.11 43.11 25.83 25.80
23 Q 8.36 117.09 3.41 1.93
1.93
176.60 58.50 28.76 34.07 N e 2 112.40,
H e 2a  6.88,
H e 2b  7.47
24 N 4.68 2.58
2.81
7.65
6.87
174.32 53.15 39.81 N d 2 116.09
25 L 6.61 121.65 4.23 1.43
1.52
1.58 0.49
0.49
176.59 55.56 42.39 25.22 25.29
25.29
26 S 9.35 124.98 4.70 3.99
4.34
175.42 56.70 66.66
27 D
28 G 3.84
3.84
176.43 47.09
29 D 7.95 123.45 4.33 2.44
3.03
178.30 57.22 41.84
30 K 7.94 118.39 3.78 2.03
1.85
1.66 178.30 60.92 32.35 25.60 29.76 H e a 2.68,
H e b 2.80,
C e  41.35
31 T 7.95 115.93 3.87 4.39 1.25 176.14 67.20 68.72 21.98
32 V 7.85 122.49 3.71 2.21 1.08
0.87
177.81 66.89 31.43 22.32
23.27
33 L 8.20 118.97 3.82 1.29
2.07
2.05 0.89
0.89
178.51 58.86 41.76 26.34 24.13
34 K 7.98 117.90 3.91 1.97
1.97
1.30
1.30
1.75
1.75
178.30 60.64 32.68 25.96 29.70 H e a 2.88,
H e b 2.95,
C e  41.96
35 E 8.43 119.05 3.94 2.04
2.25
2.53
2.53
180.49 59.74 29.69 36.72
36 V 8.64 119.52 3.72 2.16 0.84
1.02
180.16 66.72 31.58 23.98
37 F 8.68 122.48 4.31 3.22
3.29
7.06 179.20 62.85 39.29 132.02 H e * 7.15,
C e * 132.51
38 K 8.80 119.87 4.05 1.81
2.00
1.70
1.61
1.44
1.42
176.26 59.03 32.35 25.67 29.03 H e a 2.77,
H e b 2.99,
C e  41.91
39 A 7.27 119.94 4.08 1.50 176.87 51.94 18.73
40 G 7.15 104.20 3.83
3.83
43.80
41 P
42 Y
42 Y 4.61 3.16
2.59
7.09 56.80 40.70 133.23 H e * 6.65,
C e * 117.41
43 K 3.89 1.77
1.65
1.41 1.52 176.37 59.04 33.66 25.19 29.33 H e a 2.94,
H e b 3.01,
C e  41.94
44 N 7.32 108.45 4.69 3.21
3.29
7.05
6.69
175.94 51.61 39.56 N d 2 110.84
45 T 3.89 3.81 0.83 65.94 68.23 22.69
45 T
46 E 3.65 2.06
1.88
2.21
2.38
179.29 61.53 28.28 37.71
47 E 8.48 120.90 4.06 2.23
2.09
2.35
2.50
179.05 59.53 30.17 37.47
48 S 7.54 117.76 3.94 3.50
3.41
61.31 62.73
49 I 7.78 123.25 3.38 1.72 0.43
0.59
0.76
0.43 177.57 65.43 37.44 17.48
30.11
13.78
50 A 7.95 123.50 3.91 1.41 180.56 55.31 17.68
51 A 7.62 121.19 3.99 1.30 180.70 55.03 18.04
52 L 7.81 120.13 3.96 1.49
2.05
1.44 0.92
0.92
177.69 57.95 41.90 27.01 24.36
24.35
53 K 8.60 117.79 3.76 1.75
1.85
1.25
1.56
1.54
1.54
177.62 59.74 32.82 27.26 30.04 H e a 2.62,
H e b 2.69,
C e  41.87
54 K 7.28 115.39 3.96 1.85 1.56
1.42
1.66
1.75
1.66
1.68
178.02 58.62 32.66 25.38 29.43 H e 2 2.95,
H e 3 2.95,
C e  42.18
55 K 7.08 116.88 4.24 1.75
1.74
1.45
1.45
1.64
1.64
177.40 57.28 33.94 25.35 28.91 H e 2 2.94,
H e 3 2.94,
C e  42.06
56 S 8.52 111.31 4.83 3.68
3.76
177.41 54.68 62.86
57 P 4.34 2.40
1.97
2.15
2.15
3.96
3.49
179.82 66.19 32.29 27.24 50.25
58 E 8.77 118.17 4.08 1.95
2.03
2.28
2.28
179.12 59.96 29.37 36.84
59 L 7.70 121.75 4.19 1.71
1.71
1.62 0.93
0.97
179.78 57.74 41.89 27.26 25.88
23.67
60 G 8.94 104.15 3.36
3.55
174.30 47.65
61 A 8.02 122.86 4.22 1.53 180.58 55.14 18.32
62 K 7.57 117.89 4.06 2.20
1.89
1.38
1.65
179.76 60.02 33.51 26.22 30.63 H e 2 2.93,
H e 3 2.93,
C e  42.06
63 V 8.14 118.97 3.28 1.99 0.75
0.87
177.11 66.87 31.23 24.16
22.06
64 E 8.59 121.45 3.94 2.23
2.09
2.24
2.24
178.63 60.32 30.16 36.59
65 K 7.58 118.59 4.13 1.92
1.93
1.47
1.61
1.70
1.70
179.58 59.40 32.34 25.35 29.19 H e 2 2.95,
H e 3 2.95,
C e  42.19
66 L 7.61 120.45 4.01 1.75
1.28
1.63 0.33
0.59
178.11 58.09 41.97 26.74 23.25
25.01
67 H 8.73 119.93 4.05 2.92
3.26
176.58 60.63 31.38
68 A 8.23 120.45 3.81 1.50 180.70 55.25 17.85
69 M 7.89 119.07 4.06 2.00
2.00
2.77
2.25
178.73 58.88 32.36 31.24 H e * 1.86
70 V 8.13 119.84 3.33 1.91 0.40
0.58
67.36 31.06 21.96
23.08
71 K 8.37 119.18
72 S 8.06 115.61 4.16 3.93
3.93
176.63 61.74 62.86
73 K 7.63 123.95 3.89 1.06
1.71
1.66
1.74
178.39 60.01 34.94 25.18 29.42 H e a 2.90,
H e b 3.08,
C e  41.56
74 I 8.13 117.12 3.80 1.91 2.24
1.06
0.98
0.87 178.36 65.36 38.14 17.38
30.10
14.20
75 A 7.69 118.27 4.06 1.45 178.20 54.21 18.31
76 A 7.16 118.41 4.30 1.39 178.15 52.10 19.18
77 L 7.44 120.27 4.37 2.15
1.74
1.22 1.06 177.96 55.32 43.25 26.85 23.52
25.49
78 G 10.53 112.53 3.86
4.32
178.02 44.35
79 P 4.15 2.36
1.96
2.17
2.04
3.71
3.71
179.84 66.35 32.14 27.64 48.94
80 E 8.31 120.30 4.06 2.02 2.13
2.23
179.33 59.75 29.68 35.98
81 A 9.68 124.26 4.61 1.94 179.55 55.19 19.68
82 K 9.33 120.51 3.97 1.93
1.73
1.54
1.43
178.70 60.33 32.52 25.56 29.74 H e a 2.99,
H e b 3.06,
C e  42.09
83 G 8.02 106.28 3.95
3.64
176.52 47.12
84 F 7.60 123.52 4.37 3.28
3.43
6.83 177.62 60.36 39.78 131.89 H e * 6.83
85 A 8.66 125.17 3.34 1.44 179.10 55.48 17.78
86 E 8.87 116.14 3.87 2.19
2.01
2.56
2.56
180.30 60.07 29.48 36.89
87 K 8.21 120.77 4.05 1.84
1.91
1.50
1.42
1.70
1.70
179.73 59.22 32.52 25.38 28.99 H e 2 2.92,
H e 3 2.92,
C e  41.89
88 S 7.98 117.63 3.93 175.89 63.65 62.53
89 I 8.39 122.88 3.51 1.92 0.89
0.89
1.79
0.78 177.65 65.64 37.76 17.47
30.52
13.52
90 E 7.84 120.79 4.04 2.02
2.18
2.35
2.35
179.99 59.70 29.25 35.74
91 I 7.79 122.06 3.73 2.04 0.90
1.66
1.66
0.80 179.49 65.45 37.77 17.55
30.22
13.98
92 A 8.00 123.16 3.95 1.48 179.02 55.59 18.45
93 R 9.07 118.52 3.80 179.50 60.62 30.40 25.64 41.29
94 G 8.05 107.30 3.97
3.97
176.41 47.08
95 I 7.53 122.70 3.83 2.20 1.39
1.65
0.95
0.80 177.76 63.57 36.84 27.86
18.16
11.56
96 K 8.17 120.28 3.76 1.86 1.47
1.47
1.67
1.73
177.41 60.56 32.58 25.87 29.74 H e 2 2.68,
H e 3 2.68,
C e  41.81
97 A 8.11 118.05 4.27 181.28 55.20 18.14
98 R 7.71 116.95 4.07 1.70
1.70
3.23
3.05
178.97 59.11 29.94 27.84 43.78
99 Y 7.94 118.52 3.98 3.02
2.89
6.79 177.73 62.75 38.03 132.27 H e * 6.81,
C e * 118.66
100 Y 7.73 116.41 3.24
2.86
7.14 176.77 60.02 38.14 133.28 H e * 6.54,
C e * 117.59
101 T 7.59 108.97 4.52 4.48 1.31 174.94 61.95 70.66 21.65
102 G 7.93 108.47
102 G 3.84
4.13
173.53 45.62
103 N 7.85 120.33 4.91 2.47
2.64
6.82
7.40
173.88 51.71 38.92 38.69 N d 2 112.47
104 E 8.43 122.49 3.83 1.87
1.87
2.22
2.22
174.04 55.74 28.74 36.48
105 P
106 T 8.88 113.00 60.11
106 T 4.54 4.66 1.30 176.06 59.99 72.18 21.82
107 K 9.03 120.60 3.93 1.90 1.40
1.33
1.72
1.68
178.49 60.50 31.99 25.48 29.56 H e 2 2.95,
H e 3 2.95,
C e  41.81
108 D 7.95 117.36 4.35 2.46
2.60
179.06 57.76 40.41
109 D 7.80 122.23 4.42 2.56
3.05
179.54 57.58 40.93
110 L 8.10 121.05 3.79 1.53
1.76
1.75 0.87
0.72
179.16 58.04 41.09 26.94 25.60
23.59
111 K 26.00
112 A 7.97 120.28 181.10 55.41 18.05
113 S 7.93 116.21 4.33 3.73
3.98
181.12 63.19 63.18
114 V 8.11 121.74 3.49 2.31 0.91
1.07
177.50 67.26 31.32 23.88
115 K 8.43 119.64 3.77 2.00 1.52
1.54
1.59
1.62
178.58 60.83 32.29 25.91 29.74 H e 2 2.79,
H e 3 2.79,
H e a 2.73,
H e b 2.80,
C e  41.78
116 E 7.69 118.47 4.04 2.20
2.24
2.37
2.22
178.99 59.60 29.41 35.74
117 V 7.74 120.05 3.58 2.18 1.08
0.88
177.88 67.27 31.85 23.33
118 L 8.53 119.26 4.06 1.51 1.83 0.73
0.73
179.15 58.17 41.55 26.95 22.67
22.67
119 K 8.44 119.53 3.77 1.86
2.00
1.20
1.20
178.27 60.93 32.48 26.96 30.29 H e a 2.72,
H e b 2.80,
C e  42.01
120 L 3.97 1.62
2.33
1.95 0.87
0.87
179.07 57.61 42.07 26.51 22.76
22.76
121 Y 8.26 120.88 2.77 2.58
2.30
6.06 177.35 61.48 37.32 133.36 H e * 6.47,
C e * 116.70
122 K 8.22 115.92 3.42 1.82
1.82
1.82
1.99
1.65
1.51
1.51
1.52
1.66
1.66
177.66 58.96 32.36 25.74 29.44 H e 2 2.94,
H e 3 2.94,
C e  41.95
123 A 7.18 117.92 4.08 1.38 178.12 52.41 19.07
124 M 7.08 117.75 4.15 2.03
1.71
2.45
2.45
176.91 57.71 37.48 32.06
125 S 9.61 117.87 4.26 174.93 58.53 64.74
126 D 8.86 121.35 4.19 2.63
2.63
179.16 58.04 39.60
127 A 8.25 122.82 4.17 1.44 180.99 55.24 18.27
128 G 8.11 111.69 4.03
3.64
176.08 47.29
129 K 8.30 121.31 3.76 1.77 1.68
1.17
1.62
1.71
180.26 60.95 33.06 27.02 29.59 H e 2 2.69,
H e 3 2.69,
C e  42.44
130 A 8.25 123.17 4.14 1.48 180.09 54.92 17.94
131 D 7.98 120.01 4.41 2.91
3.04
177.86 57.48 42.70
132 F 8.58 117.17 4.23 3.16
3.28
7.37 177.72 62.76 39.97 131.74 H e * 6.93,
C e * 131.02
133 G 8.51 104.18 3.60
3.78
174.41 46.51
134 K 7.55 119.59 4.06 2.01 1.43
1.43
1.73
1.67
178.54 58.67 32.51 25.30 29.08 H e 2 2.96,
H e 3 2.96,
C e  41.87
135 Q 6.74 113.07 4.17 1.57
1.65
2.42
2.43
174.67 55.25 29.83 32.45 N e 2 112.75,
H e 2a  6.66,
H e 2b  7.57
136 F 8.20 115.59 4.61 2.68
2.57
171.41 55.14 39.26 H e * 6.93,
C e * 132.50
137 P 4.34 2.33
1.86
1.95
1.95
3.62
2.86
65.63 31.68 27.43 50.15
138 F
139 L 3.38 1.97
0.97
1.97 0.73
0.73
178.60 57.70 41.54 26.97 22.74
22.74
140 A 8.93 119.02 3.86 1.60 178.94 56.15 19.09
141 K 7.32 117.23 3.89 1.73
1.68
1.73
1.79
1.38
1.38
1.66
1.66
180.17 58.96 33.57 24.80 28.95 H e 2 2.95,
H e 3 2.95,
C e  41.82
142 V 3.60 2.23 1.16
1.11
67.44 31.66 22.38
23.74
143 F 4.21 2.80
3.44
7.22 61.74 37.27 133.20 H e * 7.21,
C e * 131.39
144 E
145 S 4.36 4.09
3.99
59.86 64.27
146 G
147 K 4.02 1.81
1.68
1.62
1.43
1.68
1.68
178.79 59.13 32.45 25.27 29.06 H e 2 2.96,
H e 3 2.96,
C e  41.88
148 A 7.73 120.87 3.96 1.38 178.28 55.37 18.45
149 A 7.63 119.73 3.91 1.45 180.10 55.02 18.02
150 K 7.92 118.29 4.06 1.71
1.87
1.46
1.41
1.65
1.65
179.31 58.72 32.30 25.07 29.14 H e 2 2.94,
H e 3 2.94,
C e  42.12
151 F 7.86 120.03 4.25 3.07
3.20
7.14 176.24 60.47 39.54 131.44
152 A 7.96 117.76 3.94 1.41 177.34 53.20 19.31
153 G 7.58 104.45 3.85
3.96
174.26 45.31
154 E 8.00 120.34 4.29 1.79
2.03
2.15
2.23
175.37 56.28 30.80 36.30
155 N 7.97 124.78 4.38 2.68
2.57
6.72
7.40
179.42 54.87 40.53 N d 2 112.61
H N aH bH gH dH C aC bC gC dC
